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ABSTRACT 
Leprosy is a chronic granulomatous condition principally affecting the skin and peripheral 
nerves. It is caused by infection with the obligate intracellular pathogen Mycobacterium 
leprae. The host immune response of an infected individual determines the disease 
phenotype. The borderline states of the disease are complicated by immunologically 
mediated Type 1 reactions in up to 30% of people. Type 1 reactions cause inflammation of 
the skin and peripheral nerves and can lead to permanent nerve function impairment. The 
treatment of Type 1 reactions is with oral corticosteroids but there are few data concerning 
the optimal dose and duration of corticosteroid treatment. Clinical trials have been 
hampered due to a lack of a valid measure of disease severity. 
A clinical severity scale was developed and tested in Bangladesh and Brazil. It was shown 
to be valid and able to discriminate between mild and moderate and moderate and severe 
Type 1 reactions. It was also shown to be reliable with excellent inter-observer agreement.  
A double blind randomized controlled clinical trial of high dose intravenous 
methylprednisolone and prednisolone (total dose equivalent to 6.15 g of prednisolone) was 
compared to placebo infusion and prednisolone (total dose 2.52 g of prednisolone). There 
were no significant differences in the rate of adverse effects between the two study groups. 
A large proportion, almost 50%, of individuals in both arms required additional 
prednisolone. Only 20% of individuals with nerve function impairment completely 
recovered although another 50% did improve. 
Skin biopsies were taken from participants before and at two time points during 
corticosteroid therapy. These biopsies were stained with monoclonal antibodies directed 
against toll-like receptors 1, 2, 4 and 9. Toll-like receptor 2 is highly expressed in skin 
lesions of Type 1 reaction but high expression of toll-like receptor 1, 2 and 4 was found in 
non-reactional patients with borderline lepromatous and lepromatous leprosy. The 
expression in the skin of the toll-like receptors 1, 2 and 4 fell during corticosteroid therapy. 
The gene expression of toll-like receptor 2 and 4 fell during treatment and this change in 
gene expression was associated with disease outcome. The human acidic ribosomal protein 
P0 was validated as a control gene in PCR assays in this group of patients. 
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1.1 Introduction 
Leprosy is a disease recorded in the writings of ancient civilisations in Egypt and India 
(Rastogi and Rastogi, 1984). It was and remains a highly stigmatizing disease. The first 
effective antimicrobial agent for the infection dapsone was introduced in the 1940s. 
Dapsone resistance became an increasing problem in the 1960s but the emergence of 
rifampicin and clofazimine resistance has not been a clinically significant problem. 
The surgeon Paul Brand drew attention to the deleterious effects of the neuropathy of 
leprosy and how this resulted in the disability and deformity of the disease (Brand, 1952). 
One aspect of leprosy that contributes to the deterioration in nerve function is the 
immunological reactions. 
The research contained in this thesis has three components each of which improves our 
ability to understand and study leprosy Type 1 reaction (T1R) and nerve function 
impairment (NFI). The three themes of the research are: 
 the quantification of the clinical severity of T1Rs  
 the treatment of T1Rs and NFI with corticosteroids 
 the expression of toll-like receptors (TLR) in the skin during T1R 
A detailed review of the literature is used to provide context and the rationale for this 
research.  
1.2 Literature review of leprosy 
Leprosy is a chronic granulomatous infection principally affecting the skin and peripheral 
nerves caused by the obligate intracellular organism Mycobacterium leprae (Lockwood, 
2004). The disease causes skin lesions and neuropathy. Complications secondary to the 
neuropathy can result in deformity and disability. Leprosy remains a stigmatising disease. 
The early detection of the disease and treatment with multidrug therapy (MDT) which 
cures the infection is the goal of leprosy control programmes (Britton and Lockwood, 
2004).  In many individuals leprosy can be effectively treated before disability develops 
(Britton and Lockwood, 2004). 
 
1.2.1 Epidemiology 
249 007 new cases of leprosy were diagnosed and reported to World Health Organization 
(WHO) in 2008 (WHO, 2009). It continues to be an important health problem worldwide 
with 121 countries reporting cases to WHO. The highest number of new cases detected are 
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in India, Brazil, the Democratic Republic of Congo, Bangladesh, Nepal, Myanmar and 
Ethiopia. The disease burden in India is 53.9% of all new cases worldwide. 134 184 cases 
were reported from India, 38 914 cases from Brazil and 4708 from Nepal in 2008 (WHO, 
2009). 
The epidemiological indices of leprosy used are the number of new cases detected and 
registered prevalence (WHO, 2009). The registered prevalence of leprosy is the number of 
patients receiving MDT during the reported year per 10000 of population. An accurate 
estimate of the actual prevalence of the disease is not possible because of the prolonged 
incubation period. The incubation period for tuberculoid leprosy (TT) disease  varied 
between 2.9 and 5.3 years and between 9.3 and 11.6 years for lepromatous disease in 
United States military personnel exposed for relatively short periods of time (Noordeen, 
1994). However the incubation period has been as long as 30 years in other individuals. 
The number of cases reported to WHO is dependent on operational factors and the political 
will of governments. The operational factors include the ascertainment and registration of 
cases, the appropriate training and deployment of staff  (Fine, 2008). The reported number 
of cases increases when active case detection strategies are employed. In 2007 in 
Maharashtra 254 active cases of undetected leprosy were diagnosed during one survey. The 
new case detection rate for the surveyed areas ranged from 1.9-9.42 per 10 000 population. 
This is much greater than the 0.9 cases per 10 000 reported by health posts. Children 
represented 35% of these cases indicating that active transmission was occurring (Shetty et 
al., 2009). The registered prevalence is reduced if the duration of treatment is reduced or if 
people are given a complete course of treatment at the time of diagnosis and discharged. 
The decline in the number of cases reported to WHO is dramatic from 719 219 in 2000 to 
249 007 in 2008 (WHO, 2002; WHO, 2009). This decline has been attributed to the lack of 
ascertainment and reporting of cases rather than a biologically plausible decrease in the 
actual number of cases (Fine, 2008; Penna and Penna, 2007).  The eradication of leprosy 
has not been achieved despite over 25 years of MDT. 
The proportion of women diagnosed with leprosy reported to WHO in 2008 varied widely 
between different geographical regions. The reported range is from 12% in the Philippines 
to 64.5% in Congo but mostly there is a male preponderance (WHO 2009). The male to 
female ratio of registered cases was 2:1 in Nepal in 2008. The imbalance has been 
attributed to social rather than biological factors (Varkevisser et al., 2009). 
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Figure 1.01. The reported prevalence rates of leprosy 2007 
(http://www.who.int/lep/situation/PrevStart2007a.pdf) 
1.2.2 Transmission 
Transmission of M. leprae is thought to be from untreated lepromatous patients to healthy 
individuals via inhalation of the organism. Immunosuppressed mice can be experimentally 
infected with M. leprae via the airborne route (Rees and McDougall, 1977). 48% of 
patients with lepromatous leprosy compared with 3% of borderline patients have nasal 
discharge containing M. leprae. The number of acid-fast bacilli (AFB) in a single nasal 
blow ranged from 1.4 x 10
6 
to 4.3 x 10
8
 (mean 1.1 x 10
8
) in a study of 17 of these patients 
(Davey and Rees, 1974). Contacts of leprosy patients are at higher risk of developing the 
disease that the general population. The risk for household contacts of multibacillary (MB) 
patients in Malawi is as much as eight times that of the general population and for 
household contacts of paucibacillary (PB) patients approximately two-fold. The risk was 
greatest for those household contacts residing in rather than simply visiting the household 
of MB patients. There was no such difference in the risk for the contacts of PB patients 
suggesting that the PB cases may not be the source of infection (Fine et al., 1997).Nasal 
carriage of M. leprae DNA was found in 8% of healthy subjects in a leprosy endemic 
region of Indonesia (Hatta et al., 1995). In Ethiopia the rate of M. leprae DNA carriage was 
5.7% in healthy subjects (Beyene et al., 2003). After entry via the nose M. leprae then 
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spreads to the skin and nerves via the circulation. It is hypothesised that in endemic areas 
most people have encountered M. leprae and have mounted an immune response against it 
(Hatta et al., 1995). 
There are case reports of leprosy occurring following presumed inoculation through the 
skin during surgical procedures, tattooing or accidental trauma (Brandsma et al., 2005). 
The organism can persist outside the body under various environmental conditions for up 
to five months (Desikan and Sreevatsa, 1995). M. leprae was demonstrated in the stratum 
corneum in 60% of untreated patients with borderline lepromatous (BL) leprosy and 
lepromatous leprosy (LL) in a small study from India. 17% of household contacts of 
untreated patients had M. leprae DNA detectable in washings from their skin (Job et al., 
2008).  
1.2.3 Mycobacterium leprae 
Armauer Hansen first identified M. leprae in 1873 in unstained tissue from the nodules of 
Norwegian patients (Hansen, 1874). M. leprae is the only bacterium that invades and 
multiplies in Schwann cells and this neurotropism is one of the hallmarks of the organism 
(Job, 1994). M. leprae is an obligate intracellular pathogen. Attempts to culture it in axenic 
media have failed. It can be obtained following prolonged growth in the mouse foot pad 
and from the nine-banded armadillo (Dasypus novemcinctus) which is a natural reservoir of 
the organism. In the footpad of the mouse M. leprae has a very slow doubling time of 
approximately 11 days (Levy, 1976). 
The organism is an acid-fast bacillus. It is best visualised using carbol-fuchsin based stains. 
The mycolic acids in the cell wall cause the retention of the dye and prevent 
decolourisation by acid. M. leprae has a peptidoglycan cell wall similar to other 
mycobacteria. The lipid rich capsule contains phenolic glycolipids (PGL) which are unique 
to M. leprae (Mehra et al., 1984). PGL-1 is the major surface glycolipid and binds 
complement (Schlesinger and Horwitz, 1991) 
In 2001 the genome of an armadillo derived M.leprae was sequenced (Cole et al., 2001). 
The organism appears to have undergone extensive reductive evolution with considerable 
downsizing of its genome compared to M. tuberculosis (Mtb). M. leprae has 1604 protein 
coding genes (1439 of which are common to both organisms). The superoxide dismutases 
are encoded in the genome of M. leprae and these allow it to combat reactive oxygen 
species produced within the macrophage. Almost half of the genome is occupied by 
pseudogenes which have intact counterparts in Mtb. M. leprae lacks the mbt operon which 
is required for the production of the mycobactin siderophore which chelates iron. It retains 
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many genes for haem and iron based proteins. The enzymes formate dehydrogenase, nitrate 
and fumarate reductase have been lost impairing anaerobic and microaerophilic electron 
transfer systems. The lack of intrinsic essential components of key biochemical pathways 
underlies the inability of the organism to grow in culture. It requires the host cell to provide 
these essential metabolic requirements. 
1.2.4 Genetics of susceptibility 
The host response to M. leprae is important in determining the nature of the disease. This 
has prompted investigators to examine potential genetic factors that predispose to or protect 
against developing clinical disease following exposure. There have been studies 
demonstrating higher concordance rates for leprosy among monozygotic compared to 
dizygotic twins (Chakravartti and Vogel, 1973).  
Various genes and regions in the human genome have been linked to or associated with 
susceptibility to leprosy per se or with a particular type of leprosy. The human leucocyte 
antigens (HLA) encoded by both class I and class II genes of the major histocompatibility 
complex (MHC) have been studied in a wide variety of populations. HLA DR2 has been 
associated with TT leprosy in patients from Thailand (n=32), Brazil (n=32) and India 
(n=28) (Schauf et al., 1985; Visentainer et al., 1997). The Indian patients had the 
DRB1*15 allele (Rani et al., 1993). In the same Indian study the association of 
lepromatous disease (BL (n=25) and LL (n=41)) and the same allele was even stronger. 
HLA DR2 was also associated with BL leprosy and LL in a study of 50 Turkish patients 
(Cem Mat et al., 1988). Sixty-nine Chinese multibacillary (MB) patients had a lower 
frequency of the HLA I genes HLA-B46 and MHC Class I chain-related A than 112 
healthy controls (Wang et al., 1999). The transporter associated with antigen-processing 
(TAP) is formed by two polypeptides TAP1 AND TAP2. The genes encoding these two 
polypeptides are located between HLA-DP and HLA-DQ in the HLA class II region on 
chromosome six. A study of 50 patients with TT leprosy from north India showed that 
these individuals were more likely to have a variant of the TAP2 gene than healthy controls 
(Rajalingam et al., 1997). 
Mira et al identified that certain alleles in the PARK2 and PACRG region on chromosome 6 
are associated with susceptibility to leprosy in 205 Vietnamese patients from 86 families 
and 587 unrelated Brazilian patients (Mira et al., 2004; Mira et al., 2003). The analysis did 
not examine any association with clinical type of leprosy. PARK2 is expressed by both 
Schwann cells and macrophages. It is an ubiquination E3 ligase and is involved in the 
delivery of polyubiquinated proteins to the proteosome complex involved in protein 
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degradation (Ciechanover, 2006). However this finding was not reproduced in a study of 
six single nucleotide polymorphisms (SNPs) in these regions in 286 Indian patients 
compared to 350 controls (Malhotra et al., 2006). 
An Indian cohort of 107 TT leprosy and 124 LL patients and 166 healthy controls were 
studied for the Taq1 polymorphism of the Vitamin D receptor (VDR) gene. TT leprosy 
patients were more likely to be homozygous for the polymorphism whereas the LL patients 
were less likely to have the Taq1 allele (Roy et al., 1999). This study suggests that the 
VDR gene may be implicated in the type of leprosy an individual develops. Upregulation 
of the VDR gene on macrophages is associated with increased intracellular killing of Mtb 
(Liu et al., 2006).  
The inflammatory cytokine tumour necrosis factor (TNF) α is essential for granuloma 
formation.  The SNP 308 G  A of the TNF promoter region was shown to be associated 
with increased susceptibility to LL (Roy et al., 1997) in a study of 121 patients. However 
in a cohort from southern Brazil the same allele was protective against leprosy per se 
(Santos et al., 2002). A study of Malawians who had predominantly PB disease did not find 
any association of this TNF promoter with leprosy (Fitness et al., 2004). 
Interleukin (IL) -10 is associated with the inhibition of TNFα and other T helper (Th) 1 
cytokines (Kontoyiannis et al., 2001). 297 Brazilian leprosy patients were compared to 283 
healthy controls for five SNPs in the IL10 promoter. No single SNP was associated with 
leprosy or leprosy type however one haplotype of three SNPs was protective (Moraes et al., 
2004). An extended haplotype in the IL10 promoter was more frequent in 266 healthy 
Indian controls than 282 leprosy patients (Malhotra et al., 2005). Another Brazilian study 
by the same group but using a different cohort of 300 patients showed that homozygosity 
for the SNP 819 C  T in the IL10 promoter was significantly more frequent in the 
patients than controls (Santos et al., 2002).  
Two TLR4 gene SNPs are associated with a lower risk of having leprosy in Ethiopians.  
SNP 896 G  A and SNP 1196 C  T result in a substitution of an aspartic acid with a 
glycine and a threonine with an isoleucine respectively (Bochud et al., 2009b).  
The differing and sometimes conflicting results of genetic studies may be attributed to 
differences in study design and sample size. It is also possible that different populations 
have distinct genetic susceptibilities (Fitness et al., 2002). 
 
 
23 
 
1.2.5 Pathology 
The pathology of leprosy is studied on biopsies taken from affected tissue, most commonly 
the skin. The tissue is fixed and embedded in paraffin. Standard staining with haematoxylin 
and eosin is performed along with a stain for AFB. The Fite-Faraco modification of the 
carbol-fuchsin stain is preferred to the standard Ziehl-Neelsen as it causes less 
decolourisation. The use of immunohistochemical stains such as anti-BCG and anti-S100 
antibodies may also aid histological diagnosis (Gupta et al., 2006).  
In biopsies the presence of granulomatous inflammation associated with infiltration and 
destruction of nerve fibres is characteristic of lesions of TT leprosy. The granulomas 
extend into the papillary dermis. AFB are not seen and fibrinoid necrosis or caseation are 
rare phenomena. 
The histology of indeterminate skin lesions does not show evidence of granuloma 
formation. There is a non-specific inflammatory infiltrate around skin appendages. 
The biopsies of skin lesions in LL have an atrophic epidermis with loss of the rete ridges 
histologically. The papillary dermis appears as a clear band (Grenz zone) (Martens and 
Klingmuller, 1984) whilst the deeper dermis is diffusely infiltrated with macrophages, 
lymphocytes and plasma cells. The macrophages have a granular cytoplasm but with 
increasing chronicity they become more foamy and vacuolated. There are abundant AFB 
both singly or in clumps (Job, 1994). 
The formation of small granulomas is characteristic of borderline leprosy. The granulomas 
becoming more diffuse from borderline tuberculoid (BT) to BL disease. AFB may not be 
visualised in BT leprosy but are seen in increasing numbers in borderline borderline (BB) 
leprosy and BL disease. 
The pathology of peripheral nerves associated with leprosy starts distally and affects more 
proximal parts of the nerve as it progresses. Inflammation is both intraneural and 
perineural. Demyelination and axonal degeneration occur (Scollard, 2008).  
In biopsies of peripheral nerves from patients with TT leprosy inflammation of a fascicle 
may be isolated or all the fascicles may be involved. The granuloma consists of epithelioid 
cells, lymphocytes and Langhan’s giant cells. There is a reactive proliferation of perineural 
cells. Nerve abscess formation is a well recognised complication of TT disease and is 
characterised by caseous necrosis which usually contains AFB (Shetty and Antia, 1997). 
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In LL the intracellular proliferation of the organism is associated with foamy degeneration 
of Schwann cells. The Schwann cells and axons degenerate. There is marked perineural 
thickening which is thought to contribute to ischaemia of the already damaged cells. The 
dead Schwann and axons are replaced by fibrous tissue (Job, 1994). 
M. leprae infects both Schwann cells and intraneural macrophages. The macrophages and 
possibly Schwann cells present antigen to T lymphocytes (Krutzik et al., 2005; Spierings et 
al., 2000). The macrophages secrete inflammatory cytokines such as TNFα.  
1.2.6 Immunology of leprosy  
Infection with M. leprae is followed by a subclinical phase during which an unknown 
proportion of individuals (but probably the majority) will clear the infection without ever 
showings signs of the disease (Harboe, 1994). Healthy contacts of leprosy patients have 
lymphocytes that in vitro are more greatly stimulated by M. leprae antigen than those of 
non-exposed controls. This suggests that these individuals have encountered the organism 
and mounted a successful response to it (Closs et al., 1982).  
Another group of individuals will pass through the subclinical phase and develop 
indeterminate leprosy. This can either heal spontaneously or progress to established clinical 
leprosy. The immunological response mounted by the host dictates the clinical phenotype 
that develops. People with leprosy show a spectrum of clinical types. The polar forms of 
the disease are said to conform to an immunological paradigm. Tuberculoid disease being 
the result of high cell mediated immunity (CMI) with a largely Th1 type immune response. 
These individuals who have strong CMI have none or very few organisms in the skin or 
nerves. Lepromatous disease however is characterised by an anergic response to M. leprae 
with a humoral Th2 response (Modlin, 1994). This lower CMI is associated with large 
numbers of proliferating bacilli.  
The macrophage is the predominant host cell for M. leprae. Murine macrophages infected 
with M. leprae are less responsive to IFNγ measured by their ability to restrict the growth 
of intracellular Toxoplasma gondii in culture in vitro (Sibley and Krahenbuhl, 1987). M. 
leprae is taken up by macrophages and dendritic cells. Phagocytosis of M. leprae by 
macrophages and other antigen presenting cells (APCs) is facilitated by C3 which is avidly 
fixed to PGL-1in a dose-dependent fashion in vitro (Schlesinger and Horwitz, 1991). Other 
surface components of M. leprae do not fix complement. In murine macrophages 
phagocytosis of M. leprae is regulated by protein kinases. The phagocytosis is blocked in 
vitro by protein kinase inhibitors (Prabhakaran et al., 2000). 
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Figure. 1.02. Ridley-Jopling Classification and features of the host 
immune response. (BB and BL images reproduced from www.aifo.it) 
 
In the phagosome M. leprae evades immune surveillance mechanisms and in individuals 
with lepromatous disease is able to proliferate in a lipid-rich environment. The survival of 
M. leprae within the macrophage is facilitated by components of the cell wall which inhibit 
the macrophage’s inherent killing mechanisms such as oxidative stress. APCs present 
mycobacterial antigen to T cells resulting in activation and proliferation of the T cells. 
Inflammatory cytokines are produced which further activate the APCs. M. leprae infected 
dendritic cells express PGL-1 on their cell surface. If this expression is blocked in vitro 
then there is increased T cell activation (Hashimoto et al., 2002). 
M. leprae peptide antigens are presented by either MHC I or II complexes. Antigen 
presentation also occurs via CD1 molecules which bind lipid or glycolipid antigens and 
pattern recognition receptors (PRR) of the innate immune system. Intracellular pathogens 
such as M. leprae are initially recognised by the innate immune system. The highly 
conserved toll-like receptors (TLRs) on the surface of monocytes and macrophages 
recognise mycobacterial lipoproteins and can lead to the production of IL12 and the 
expression of inducible nitric oxide (iNOS) (Brightbill et al., 1999). In the case of M. 
leprae this appears to takes place mainly through the TLR1/2 heterodimer and leads to 
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monocyte differentiation into macrophages and dendritic cells (Krutzik et al., 2003; 
Krutzik et al., 2005). The latter present antigen and cause the activation of naïve T-cells by 
IL12 secretion (Demangel and Britton, 2000). The IL12βR2 portion of the IL12 receptor is 
expressed more on Th1 lymphocytes, preferentially shifting the immune response further 
towards a Th1 response. TLR stimulation also activates the nuclear transcription factor 
NFκB which modulates the transcription of many immune response genes (Texereau et al., 
2005).  
The C-type lectin Dendritic Cell-Specific Intercellular adhesion molecule-3-Grabbing Non-
integrin (DC-SIGN) also known as CD209 is expressed on macrophages in the skin lesions 
of leprosy patients. This receptor recognises mannose containing carbohydrates including 
those found in the cell wall of M. leprae. DC-SIGN is upregulated following activation of 
the TLR1/2 heterodimer in vitro (Krutzik et al., 2005). Soilleux demonstrated that DC-
SIGN was highly expressed in cells in the skin of patients with LL but only sparsely in the 
skin of some individuals with BT disease (Soilleux et al., 2006). These authors also 
showed that DC-SIGN was expressed on nearly all cells infected with M. leprae. DC-SIGN 
expressing HeLa cells bind fluorescent  M. leprae, Mtb and M. smegmatis with greater 
affinity than HeLa cells which do not express this lectin (Barreiro et al., 2006). The binding 
of M. leprae is increased eight-fold. However polymorphisms in the DC-SIGN gene did not 
appear to alter susceptibility to leprosy in 194 Pakistani patients compared to 78 matched 
controls. 
The receptor for advanced glycation endproducts (RAGE) which is a member of the 
immunoglobulin superfamily binds advanced glycation endproducts (AGE) which are non-
enzymatically altered proteins and also damage-associated molecular patterns (DAMPs) 
(Sparvero et al., 2009). This receptor and an associated ligand EN-RAGE (S100A12) have 
been shown (using polyclonal rabbit and goat antibodies) to be expressed on the surface of 
macrophages and endothelial cells in the skin of patients with PB leprosy and patients with 
MB leprosy (Kim et al., 2006). Activation of RAGE leads to increased expression of 
inflammatory cytokines and vascular endothelial growth factor (VEGF). 
The Th1 /Th2 model of CD4 lymphocyte subsets is used to explain the occurrence of the 
polar forms of leprosy (TT and LL). The first work to support this was performed on eight 
patients with TT leprosy and eight with LL (Yamamura et al., 1991). Using PCR of cDNA 
reverse transcribed from RNA extracted from skin lesions they were able to show that the 
products when electrphoresed on 2% agarose gel were different in the two groups. The TT 
patients had bands of greater intensity for IL2, IFNγ and lymphotoxin compatible with a 
Th1 cytokine pattern. The LL patients had bands for IL4, IL5 and IL10 but these were 
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much weaker in intensity than the Th1 products. Yamamura et al also showed that mRNA 
expression for TNFα and TGFβ was greater in TT patients. The group had previously 
shown that in patients with TT leprosy IFNγ and IL2 protein expressing cells are more 
abundant in the granulomas of skin lesions than in patients with LL (Modlin et al., 1984).  
The borderline part of the spectrum is immunologically dynamic and movement between 
the two polar forms occurs. These shifts in the immunological response underlie the T1Rs 
that are a feature of the borderline states. The Th1 /Th2 model is not able to precisely 
explain this important aspect of the immunology of leprosy because it is dichotomous. 
There has also been a practice of grouping patients into “tuberculoid” and “lepromatous” 
categories for the purpose of experiments and this may lead to oversimplification of 
conclusions and less data about the borderline states. 
Macrophages under the influence of cytokines, particularly TNFα together with 
lymphocytes form granulomas. TNFα is essential for the formation of granulomas (Algood 
et al., 2005).The granuloma envelops infected macrophages and APCs (Russell, 2007). 
CD4+ cells are found mainly within the granuloma and CD8 cytotoxic T cells in the mantle 
area surrounding it (Modlin et al., 1988). T lymphocytes in tuberculoid granulomas 
produce the anti-microbial protein granulysin (Ochoa et al., 2001). Lepromatous disease is 
characterised by poor granuloma formation. mRNA production is predominantly for 
cytokines IL4, IL5 and IL10 (Yamamura et al., 1991). IL4 has been shown to down 
regulate TLR2 on monocytes (Brightbill et al., 1999) and IL10 will suppress production of 
IL12 (Libraty et al., 1997). There is a preponderance of CD8 cells in LL skin lesions. 
Lepromatous patients (LL and BL) were shown to produce greater amounts of IgA, IgG 
and IgM antibodies to M. leprae than BT and TT patients (Melsom et al., 1982). The role 
of specific antibodies directed against M. leprae in the pathogenesis of leprosy is unclear. 
Anti-PGL-1 antibodies of the IgA, IgG and IgM subtypes are found in the serum of leprosy 
patients. The detection of the IgM antibody raised against the terminal trisaccharride of 
PGL-1 forms the basis of the lateral flow test which is an additional tool for classifying but 
not diagnosing leprosy (Oskam et al., 2003). The test is not sensitive in individuals with PB 
disease as only 15–40 % of these patients have detectable antibodies. Patients with LL also 
have increased production of immunoglobulins and antibodies that are not specific for M. 
leprae such as rheumatoid factor, anti-cardiolipin antibodies and cryoglobulins (Bullock et 
al., 1970). 
The balance and complex interaction of cytokines, chemokines, adhesion molecules, their 
receptors and the cells of the innate and adaptive immune system all play a role in 
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ultimately determining the particular immune response of the individual to the organism 
and the resultant immunopathology. 
1.2.7 Clinical Features 
Patients commonly present with skin lesions, numbness or weakness caused by peripheral 
nerve involvement or more rarely a painless burn or ulcer in an anaesthetic hand or foot. A 
leprosy reaction may be a presenting feature of the disease (Pfalzgraff and Ramu, 1994). In 
non-endemic areas the diagnosis is frequently delayed because leprosy is not considered 
and patients may present to a wide range of specialists (Lockwood and Reid, 2001). 
1.2.7.1 Cutaneous 
Early skin lesions may be rather poorly defined hypopigmented or erythematous macules. 
Sensation in these early stages may be unaltered.  
TT leprosy is characterised by a single or very few lesions. These are macules or plaques 
with well defined edges. In dark skin hypopigmentation predominates over the erythema or 
copper colour more usually seen in lighter skin. The lesions are frequently anaesthetic. The 
anaesthesia is due to destruction of dermal nerve fibres. Anaesthesia may not be present in 
facial lesions. Involvement of autonomic fibres is often marked and results in dry lesions 
with a tendency to scale due to loss of sweating. Hairs are reduced in number or may be 
completely absent. The TT form carries a good prognosis and lesions will often self-heal.  
Individuals with BT leprosy have similar lesions to those with TT leprosy but the margins 
of lesion are less pronounced and less infiltrated. BT lesions tend to be more numerous and 
larger (fig.1.03a). TT lesions tend to heal before enlarging to greater than 10cm whereas 
BT lesions may involve a large part of a limb or the trunk. The BT lesions of an affected 
individual may vary in size and shape. 
BB leprosy is very unstable immunologically. Patients may have macular or papular or 
plaque-like skin lesions or even a combination. Larger lesions may have a geographic 
appearance and some lesions have an ill-defined outer margin with a well-defined 
(“punched-out”) inner margin. 
BL leprosy usually starts with a few macular lesions which become more widespread and 
symmetrically distributed. The macules become progressively more infiltrated. Papular and 
nodular lesions may develop and are more defined than those seen in LL.  Skin lesions at 
the lepromatous (BL/LL) end of the spectrum may not have demonstrable sensory loss. 
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Lepromatous disease may be present for many years before diagnosis. The early skin 
changes are widely and symmetrically distributed macules. They are poorly defined with 
mild hypopigmentation and erythema. Flesh coloured or occasionally erythematous papules 
and nodules may be present. The skin if left untreated thickens due to dermal infiltration 
giving rise to the “leonine facies” (fig.1.03b).  
 
 
Figures 1.03a. BT leprosy and  1.03b. LL 
Hair is lost from affected skin notably from eyelashes and eyebrows (madarosis). M. leprae 
have been demonstrated in hair follicles located in the dermal papilla and the outer root 
sheaf during anagen and telogen in untreated lepromatous patients. The formative process 
of the hair shafts, root sheaths and pigmentation was not affected but the authors postulated 
that changes in the biochemical environment of the dermal papilla may be responsible for 
hair loss (Gummer et al., 1983).  
The nail changes observed in leprosy result from the peripheral neuropathy and are not 
specific to the disease. Trauma, vascular impairment and infection all contribute in varying 
degrees (Patki and Baran, 1991).  
1.2.7.2 Neural 
Nerve involvement in leprosy affects sensory, motor and autonomic function of peripheral 
nerves. Sensory loss is the earliest and most frequently affected modality but a 
predominantly motor loss can also occur. Enlarged nerves can also be damaged due to 
entrapment within fibro-osseous tunnels. Reactions cause further nerve damage. The 
a b 
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presence of a skin lesion overlying a major nerve trunk is associated with a significantly 
increased risk of impairment in that nerve (van Brakel et al., 2005b). Silent neuropathy is 
an insidious deterioration in sensory or motor function without signs or symptoms of 
inflammation (van Brakel and Khawas, 1994). 
The effect of the disease on nerves leads to disability and deformity such as clawing of the 
hand. Deformity also occurs through impaired sensation leading to trauma and secondary 
infection (including osteomyelitis) which causes tissue damage. The increased dryness of 
the involved skin makes it more vulnerable to damage. 
At enrolment in the Bangladesh Acute Nerve Damage Study (BANDS), a prospective 
cohort study of 2664 patients with leprosy, 6.46% of posterior tibial nerves were impaired 
(Croft et al., 1999). In the same study 3.23% of the ulnar, 2.2% of the median, 1.18% of the 
lateral popliteal, 0.79% of the facial and 0.09% of the radial nerves were impaired. Other 
nerves affected by the disease include the greater auricular, radial and the radial cutaneous 
nerves. The majority of (83.33%) patients in this cohort had PB disease. The MB patients 
of the ILEP Nerve Function Impairment and Reaction (INFIR) recruited in India had much 
higher rates of NFI with 29.9% of posterior tibial nerves and 12.9% of ulnar nerves 
impaired (van Brakel et al., 2005a). 
In TT leprosy damage to peripheral nerves is limited. However in BT leprosy damage to 
peripheral nerves may be marked and enlargement and tenderness are features. Nerve pain 
misdiagnosed as joint pain may result in a person being labelled as having arthritis. Nerve 
involvement results in sensory and/or motor impairment. Nerve function may deteriorate 
rapidly. Tenderness is less of a feature in BL leprosy. In LL the destruction of dermal 
nerves leads to a glove and stocking neuropathy, peripheral nerve involvement tends to 
occur late and is usually symmetrical.  
Pure neuritic leprosy (PNL) affects peripheral nerve trunks in the absence of cutaneous 
signs. PNL may be any disease type (Pannikar et al., 1983; Uplekar and Antia, 1986). PNL 
accounts for approximately 5% of cases of leprosy in India and Bangladesh (Croft et al., 
1999; van Brakel et al., 2005b). The prevalence of PNL in an Ethiopian cohort was 0.5% 
(Saunderson et al., 2000b).  
The presence or absence of anti-PGL-1 antibodies in the serum has been shown to predict 
which patients are at greatest risk of NFI when used in conjunction with the WHO 
classification in Bangladesh (Schuring et al., 2008). Seronegative PB patients are at lowest 
risk of NFI with a cumulative incidence of 3.5%. Seropositive PB and seronegative MB 
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patients have a medium risk of NFI of 13% and seropositive MB patients have a high 
cumulative risk of 53%. 
1.2.7.3 Ocular 
A compilation of 47 surveys conducted between 1983 and 1994 in 24 countries with 4772 
patients with leprosy showed that the disease had caused of blindness in 3.2% of those 
studied (Ffytche, 1998). Blindness can have devastating consequences for those who 
probably already have sensory loss of the hands and feet. The disease compromises the eye 
through nerve damage and by inflammation due to direct bacillary invasion of the skin or 
eye itself. These factors can occur in combination and result in the four main causes of 
visual loss: lagophthalmos (an inability to close the eyes normally), corneal ulceration, 
acute or chronic iridocyclitis and secondary cataract. 
Lagophthalmos results from damage to the zygomatic and temporal branches of the facial 
(VIIth) nerve. It gives rise to exposure keratopathy. Reduced corneal and conjunctival 
sensation due to involvement of the ophthalmic branch of the trigeminal (Vth) nerve 
predisposes to corneal ulceration. 
1.2.7.4 Nasal  
Involvement of the nasal mucosa in LL gives rise to nasal stuffiness which is an early 
symptom and later epistaxis may occur (Barton, 1976). Infiltration of nasal structures may 
lead to a saddle deformity due to septal perforation and destruction of the anterior nasal 
spine (Pfalzgraff and Ramu, 1994). Nasal deformity contributes significantly to the stigma 
associated with leprosy (Schwarz and Macdonald, 2004). 
Laryngeal involvement although extremely rare nowadays, was life threatening before 
effective chemotherapy was available. 
1.2.7.5 Systemic 
The involvement of other systems seen in LL and BL disease is due to bacillary infiltration 
of structures and organs. M. leprae is found in lymph nodes, bone marrow, the liver, 
spleen, kidneys and adrenal glands. The lungs do not appear to be affected (Chinen et al., 
1997). 
Testicular atrophy results from bacillary infiltration in LL and also the acute orchitis of 
erythema nodosum leprosum (ENL, Type 2 reactions). In a small study of 30 Indian 
patients with  BL leprosy and LL 30% had reduced testicular volume and 10% had 
gynaecomastia (Abraham et al., 1990). In a study from Japan of 86 men (with a mean age 
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of 65.5 years), who had previously been treated for leprosy, 43% had lower than normal 
bone mineral density compatible with osteoporosis. These individuals had significantly 
lower free testosterone than those who did not have osteoporosis. Unfortunately the authors 
did not include any data concerning the type of leprosy these individuals had had (Ishikawa 
et al., 2001). 
1.2.8 Disability 
The WHO classifies leprosy disability into three grades (WHO, 1988): 
WHO Disability Grade Criteria 
0 No disability 
1 Loss of sensation in the hands or feet 
2 Visible damage or disability 
Table 1.01.  WHO Leprosy Disability classification 
A complete motor and sensory neurological assessment is carried out to ensure that nerve 
function is not deteriorating especially as this can be asymptomatic. 40.9% of the newly 
diagnosed Indian INFIR cohort had WHO disability grade one and 9.6% grade two at 
enrolment (van Brakel et al., 2005b). The BANDS cohort had a prevalence of grade one 
and grade two disability of 9.61 and 5.97% overall (PB and MB patients) at enrolment. 
However the rate of grade one disability was 28.48% and grade two 18.24% in the MB 
patients (Croft et al., 1999). In Brazil almost 6% of the new cases reported to WHO in 
2008 had grade two disability at presentation (WHO, 2009). 
1.2.9 Classification of leprosy 
The classification of patients is important to determine the appropriate treatment. 
Classification also enables the clinician to predict those at risk of complications and to give 
as accurate a prognosis as possible. There are two systems used to classify leprosy patients.  
 The Ridley-Jopling System (Ridley and Jopling, 1966) was developed to help improve the 
understanding of the disease and was intended for research purposes. The system uses 
clinical and histopathological features and the bacteriological index to classify patients. It 
categorises leprosy patients into a spectrum with polar TT and LL forms and middle types 
of BT, BB and BL leprosy. Patients with different disease types exhibit different 
immunological responses to M. leprae (Modlin et al., 1988) (fig.1.02). It is useful as the 
borderline states are unstable immunologically and can be complicated by reactions. 
Following the introduction of MDT it was used to decide which patients received PB or 
MB MDT. 
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The definition of a PB case was originally any individual with indeterminate leprosy or TT 
or BT leprosy. MB cases were defined as individuals with a BI ≥ 2 at any site (WHO, 
1982). The PB and MB categories were changed slightly in 1988 when an MB case was 
defined as any individual with a positive slit skin smear (WHO, 1988). It was subsequently 
acknowledged that high quality slit skin smear facilities were not widely available (WHO, 
1994). A simpler classification based on the number of skin lesions was introduced for use 
in the field when slit-skin smears are unavailable (WHO, 1998). It is a quick and useful 
tool which can be employed by a wide variety of health care providers.  
Leprosy type Number of 
skin lesions 
Paucibacillary (PB) 1-5 
Multibacillary (MB) 6 or more 
Table 1.02.  WHO Operational Classification of leprosy 
 
The MB group as it is currently defined is very heterogeneous. It includes some individuals 
with BT leprosy and all those with BB, BL and LL. In the INFIR study approximately 60% 
of the cohort of MB patients had a negative bacterial index (BI) (van Brakel et al., 2005b). 
A similar figure of 63.29% was reported for the BANDS cohort (Croft et al., 1999). The 
Ridley-Jopling classification is the recommended classification system for use in studies 
examining immunological processes or genetic susceptibility to leprosy or its 
complications (Lockwood et al., 2007). 
1.2.10 Diagnosis and investigations 
The diagnosis of leprosy remains a principally clinical one. It is important to take a history 
to determine risk factors for the disease and the type of symptoms being experienced. The 
patient should be examined in a quiet room with good light. 
The presence of the cardinal signs of leprosy: skin lesions with definite sensory loss or 
thickened peripheral nerves or the demonstration of M. leprae on slit-skin smears or on 
histology of tissue (skin or nerve) is diagnostic. (Table 1.03).  
Cardinal signs of leprosy 
 
Skin lesions with definite sensory loss 
 
Thickened peripheral nerves 
 
Acid-fast bacilli on skin smears or tissue biopsy 
 
Table 1.03. Cardinal features of leprosy  
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Sensory loss is not a feature of the skin lesions affecting patients with BL leprosy or LL. In 
the Ethiopian ALERT MDT Field Evaluation Study (AMFES) sensory loss in skin lesions 
was present in 70% of the 594 individuals with leprosy (Saunderson and Groenen, 2000). 
In a population survey in Karonga district in Malawi anaesthesia was found in only 48.5% 
of leprosy skin lesions confirmed by histopathology (Ponnighaus and Fine, 1988). The 
majority of the Malawians found to have leprosy had PB disease. In a study of 225 
suspected and definite cases of leprosy in India three examiners identified skin patches 
with sensory loss in 70.5%, 85.5 % and 86.9% of the cases (Gupte et al., 1990). 
A cohort study of MB patients in Mumbai found that 85% (302 of 357) of patients had 
nerve enlargement on palpation. This was graded on a four point scale as: “no 
enlargement”, “slightly enlarged”, “moderately enlarged” and “very enlarged” (Khambati 
et al., 2009). The ulnar nerve was most commonly enlarged as determined by clinical 
examination in both this study and the INFIR cohort (van Brakel et al., 2005b). The 
investigators of the Mumbai study reported that 74% of ulnar nerves were thickened 
clinically compared to 61.3% of ulnar nerves being definitely thickened. The proportion of 
thickened posterior tibial nerves in both studies was 50% and 46.4% respectively. In 
Malawi enlarged nerves were more common in patients who self reported compared to 
those who were actively detected (Ponnighaus and Fine, 1988).  
The cardinal signs elicited by clinical examination are variable in their sensitivity and 
specificity. The diagnosis may be supported by slit-skin smears (Pfalzgraff and Ramu, 
1994). The BI is a logarithmic scale (1-6) quantifying the density of M. leprae on a slit-skin 
smear and is used to assess response to treatment. The proportion of patients enrolled into 
BANDS that were slit-skin smear negative was 92.83%. Bangladesh appears to have much 
more PB leprosy than other countries and the reason for this is not clear. In the Ethiopian 
AMFES cohort the proportion of slit-skin smear negative individuals was much lower at 
55%.  
The histological examination of a skin biopsy is the gold standard for diagnosis of leprosy 
and rarely a nerve biopsy may be needed to confirm the diagnosis. A nerve biopsy is 
performed on a purely sensory nerve (e.g. radial cutaneous or sural nerve). 
 
1.2.11 Nerve function assessment  
The assessment of nerve function is done by testing sensation and motor function in the 
face, hands and feet. Motor function is assessed by using the MRC grading system of 
muscle power (Brain, 2000). The muscles tested in the hand are the abductor digiti minimi 
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and the first dorsal interosseous innervated by the ulnar nerve. Abductor pollicis brevis and 
extensor carpi ulnaris innervated by the median nerve and radial nerve respectively. The 
lateral popliteal nerve in the lower limb which supplies the tibialis anterior and extensor 
hallucis longus and orbicularis oculi in the face are tested. It is important to ensure that the 
muscle being tested is isolated by careful positioning. The effect of other muscles is thus 
removed so that they are unable to provide the movement being tested and give an 
erroneous result for a muscle that may be paralysed. This may occur if the extrinsic 
extensor and flexor muscles are allowed to abduct the little finger when abductor digiti 
minimi is affected (van Brakel et al., 1996).  
The method of sensory testing used depends on the availability of equipment and personnel 
trained to use it. The use of a ball-point pen at four sites on each hand and foot is 
recommended in the Global Strategy for Further Reducing the Leprosy Burden and 
Sustaining Leprosy Control Activities (2006-2010) (WHO, 2006). The ball-point pen is 
used to gently depress the skin such that a dimple of approximately 1 cm across is created 
at each test site (Anderson and Croft, 1999). The ball-point pen has been shown to be 
reliable (Anderson and Croft, 1999) and was used in BANDS. Semmes-Weinstein 
monofilaments (SWM) are able to detect more subtle loss than the ball-point pen 
(Koelewijn et al., 2003) but require more training of personnel and are less widely 
available. SWM are standardised graded nylon filaments attached to a handle. The stimulus 
is applied to the test site until the thread just bends and the patient is asked to indicate 
where they felt the stimulus (Brandsma, 1981). Three test points are used for each nerve 
(median and ulnar) in the hand and four for the posterior tibial on the foot (fig. 2.01) 
(Roberts et al., 2007).The graded weights used in leprosy studies are 200 mg, 2 g, 4 g, 10 g 
and 300 g. SWM are very reliable when used by trained personnel (Anderson and Croft, 
1999). The level of agreement was high but it is important to ensure that training is 
regularly repeated and inconsistencies associated with technique are corrected (Roberts et 
al., 2007). SWM have been shown to have good concordance with sensory nerve 
conduction and quantitative sensory testing (QST) such as thermal thresholds but are less 
sensitive (van Brakel et al., 2005a). 
1.2.12 Differential Diagnosis  
The manifestations of leprosy are protean and the differential diagnosis is therefore wide. 
The lesions of vitiligo are depigmented rather than hypopigmented. The hypopigmented 
lesions of pityriasis alba can be difficult to distinguish from early disease. Pityriasis 
versicolor and dermatophyte infection may both cause diagnostic difficulty; tinea corporis 
and faceii because lesions are erythematous plaques. Other granulomatous conditions such 
36 
 
as sarcoid, granuloma multiforme, cutaneous tuberculosis and granuloma annulare may 
resemble leprosy. In countries where Leishmania donovani is endemic post-kala-azar 
dermal leishmaniasis is a differential diagnosis in LL. The lesions of cutaneous T cell 
lymphoma may also mimic borderline types of leprosy. 
Nerve thickening is a feature of the rare neurological conditions such as hereditary sensory 
motor neuropathy Type III and Refsum’s disease. Amyloid which itself can complicate 
leprosy can cause nerve thickening.  
 
1.2.13 Treatment of the infection 
The WHO recommends that patients diagnosed as having leprosy should receive a 
multidrug combination. MDT was introduced in 1982 following the emergence of 
resistance to dapsone-only regimes (WHO, 1982). The first-line agents are rifampicin, 
clofazimine and dapsone. Between 1985 and 2005 14 million individuals received MDT 
(WHO, 2005).
 
PB patients are treated with rifampicin and dapsone for six months and the 
recommendation for individuals with MB disease is three drugs for 12 months (Table 
1.04). 
 
Type of leprosy 
Drug treatment Duration of 
treatment (months) 
Monthly supervised Daily, self 
administered 
Paucibacillary Rifampicin 600mg Dapsone 100mg 6 
Multibacillary Rifampicin 600mg, 
clofazimine 300mg 
Clofazimine 50mg, 
dapsone 100mg 
12 
Table 1.04 WHO-recommended MDT regimes 
Rifampicin is the only bactericidal agent in the regimen. M. leprae are rapidly killed by 
rifampicin.  The infectivity of M. leprae in the mouse footpad is lost after three to four days 
of rifampicin (Shepard et al., 1974).  The infectivity of patients is markedly reduced within 
four days of a single dose of rifampicin (Hogerzeil and Rees, 1975). The public health risk 
posed by lepromatous patients is thought to cease to be significant within a “few” days of 
starting rifampicin (Waters et al., 1978). However no studies have been performed to 
examine how quickly M. leprae loses its viability following the treatment of patients with 
WHO MDT. 
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The relapse rates following MDT are low. In PB disease reported rates of relapse are 
between 0.19 and 2.4% (Boerrigter et al., 1991; Chopra et al., 1990). In MB disease the 
published rates of relapse are between 0 and 7.7% (Fajardo et al., 2009; Girdhar et al., 
2000). The highest reported relapse rate was in 20 of 260 (7.7%) Indian multibacillary 
patients who were treated with 24 months of MB MDT and all but two had a BI ≥ 4 
(Girdhar et al., 2000).  
WHO reduced the recommended treatment period for multibacillary disease from 24 to 12 
months (WHO, 1994) but many clinicians advocate 24 months for patients with a BI > 4 at 
the time of diagnosis because Girdhar et al demonstrated that 90% of relapses occurred in 
patients with a BI greater than 4 (Girdhar et al., 2000). Individuals in this study who were 
treated until they were smear negative had a lower relapse rate. 
MDT appears to be generally well tolerated but there is little prospective data concerning 
the rate of adverse effects requiring omission of a component of the three drug regimen.  
An orange-red discolouration of body fluids occurs for 48 hours after ingestion of 
rifampicin. It may also cause hepatitis.  
Clofazimine treatment causes red-brown skin and conjunctival discolouration and 
darkening of involved skin which can range from red through to purple or black (Jopling, 
1976). This unpleasant effect may make the drug unacceptable to some patients particularly 
if cosmetically sensitive sites are affected. The discolouration fades slowly on withdrawal 
of the drug. Clofazimine also causes an ichthyosis on the shins and forearms (Jopling, 
1976). Clofazimine crystals may be deposited in other tissues – and in the bowel can cause 
an enteropathy (Atkinson et al., 1967). 
In a retrospective study of 194 Brazilian patients 43.8% experienced adverse effects 
attributed to dapsone (Deps et al., 2007). Dapsone causes haemolysis which may be severe 
especially in individuals with glucose-6-phosphate dehydrogenase deficiency (Degowin et 
al., 1966)
 
and is associated with a severe hypersensitivity syndrome (Lowe and Smith, 
1949; Pandey et al., 2007).
   
Dapsone therapy may also cause hepatitis. 
In individuals unable to take clofazimine or dapsone then other agents such as minocycline, 
clarithromycin, ofloxacin or pefloxacin are active against M. leprae (Britton and 
Lockwood, 2004) and can all be used as second line agents. Minocycline causes slate grey 
skin discolouration in some individuals (Simons and Morales, 1980). 
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1.2.14 Prevention of disability 
The early detection of deterioration in nerve function and the rapid introduction of 
corticosteroid therapy are essential to minimise nerve damage and thus prevent disability.  
Secondary damage to neuropathic areas must be prevented. It is important to make the 
patient aware of activities that put these areas at risk and to give advice about orthotics and 
protective footwear. Individuals should be taught self-examination and to recognise any 
areas of trauma. It has been demonstrated in Nepal that training people in self care can 
reduce the requirement for admission to hospital with plantar ulceration (Cross and 
Newcombe, 2001). 254 patients were taught self-examination and compared to the same 
number of randomly selected control patients who had not undergone the training. The OR 
of admission to hospital for a plantar ulcer for individuals who did not receive training was 
1.8 (95% CI = 0.15-0.01). 
Damaged neuropathic areas should be protected from further damage by resting the area 
and any secondary infection treated with appropriate antibiotics. Surgical intervention may 
be required to debride necrotic tissue and allow drainage of any collection. Reconstructive 
surgery may have a role in trying to improve function if contractures occur, there is foot 
drop or when there is eye involvement. 
1.2.15 Leprosy and human immunodeficiency virus (HIV) infection 
In 1991 approximately 10 years after the recognition of the HIV epidemic an editorial in 
the International Journal of Leprosy stated that there was:  
“Sparse but tantalizing evidence…HIV may increase the incidence of leprosy…..either 
through shortening the incubation period or by increasing disease penetrance” (Miller, 1991) 
 The hypothesis that advanced HIV infection would increase susceptibility to M. leprae and 
increase the proportion of patients developing LL was not substantiated nor does leprosy 
appear to develop more quickly. A case-control study from Uganda did not detect a 
significant difference in the proportion of HIV positive individuals diagnosed with leprosy 
and matched controls (Kawuma et al., 1994). 
The skin biopsies from individuals with both HIV and M. leprae infection (co-infected) 
have the typical histopathological changes of leprosy. The proportion of CD4+ 
lymphocytes in the granulomas of BT patients with HIV in Brazil was similar to that of 
HIV negative BT patients despite the fact that the HIV positive patients had low CD4 
counts ranging from (0-379 cells/mm
3
) (Sampaio et al., 1995). The response to MDT is 
also similar to that of HIV negative individuals. M. leprae does not appear to accelerate the 
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decline in immune function in HIV disease which tuberculosis (TB) does (Aaron et al., 
2004).  
The reported series of co-infected patients show that all Ridley-Jopling types are seen but 
there appears to be an overrepresentation of patients from the tuberculoid end of the 
spectrum. Fifteen of 22 co-infected individuals were classified as either TT or BT leprosy 
in a retrospective study from Brazil. Only one individual had LL (Pereira et al., 2004). 
Three individuals had indeterminate leprosy. The Ridley-Jopling classification was not 
reported for three individuals. Ten individuals had HIV as their initial diagnosis. Five were 
diagnosed with leprosy first and seven were diagnosed with both simultaneously. Two 
individuals developed a T1R during the first six months of antiretroviral therapy (ART). 
Deps and Lockwood suggested that the occurrence of leprosy or a T1R during the first six 
months of ART be part of the definition of leprosy as an immune reconstitution 
inflammatory syndrome (IRIS) (Deps and Lockwood, 2008). Eight individuals developed 
leprosy in a cohort of 1002 HIV+ patients started on ART in Pune, India between 2003 and 
2006 (Vinay et al., 2009).  The incidence of leprosy after starting ART in this retrospective 
study was 5.22 per 1000 person years. Four of these Indian patients were diagnosed with 
leprosy in the first six months of ART but the authors state that the two individuals they 
regarded as having had IRIS presented 28 and 43 months after the initiation of ART. 
A retrospective study of 1026 leprosy patients from Brazil found that a greater proportion 
of the 54 patients with HIV co-infection had BT leprosy compared with HIV negative 
leprosy patients. The HIV positive group had a significantly greater number of reactions 
(type not specified) at diagnosis than the HIV negative group but the cumulative rate of 
reactions in the two groups was similar overall (Sarno et al., 2008). T1Rs have been 
increasingly reported in individuals with HIV co-infection as part of an immune 
reconstitution inflammatory syndrome following the commencement of anti-retroviral 
therapy (Deps and Lockwood, 2008).  
A Ugandan study of  nine HIV positive patients with T1Rs reported a similar response to 
steroids to individuals in the HIV negative group (Bwire and Kawuma, 1994). This small 
study was not well designed in terms of outcome measures or comparability of severity of 
the two groups. The current treatment of T1Rs in HIV infected individuals is with 
corticosteroids just as in uninfected patients. The reported cases of T1Rs in co-infected 
individuals, whether ART related or not, have all used corticosteroids. One individual 
required the introduction of azathioprine to control repeated relapses of his steroid 
dependent T1R (Lawn et al., 2003). The adverse effect of additional immunosuppression in 
HIV positive patients with T1Rs is unknown. 
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The influence of CD4 counts, viral load and ART on T1Rs and associated neuropathy 
requires investigation in prospective cohort studies. The contrast between the interaction of 
M. leprae and HIV and that of Mtb and HIV is striking and may provide important insights 
into all three diseases.   
1.2.16 Pregnancy  
The interaction between leprosy and pregnancy is well recognised. The development of 
T1Rs and neuritis is increased in the postpartum period when cell-mediated immunity 
returns to the pre-pregnant level  (Duncan and Pearson, 1982; Lockwood and Sinha, 1999). 
ENL reactions occur throughout pregnancy and lactation and the onset of nerve damage is 
earlier than in those who are not pregnant (Duncan and Pearson, 1984). There is little 
evidence that pregnancy promotes infection or relapse of the disease.  
 
1.3 Literature review of leprosy reactions 
Leprosy reactions are immunologically mediated complications of the disease which can 
occur before, during or after successful completion of MDT. T1Rs, ENL and neuritis are 
immune mediated. Lucio’s phenomenon which is regarded as a reaction is probably a result 
of vascular occlusion rather than immune activation. The main focus of this thesis is T1Rs 
and associated or isolated NFI. The other types of reaction are discussed briefly first. 
1.3.1 Erythema nodosum leprosum (Type 2 reactions) 
In a retrospective study of 481 BL and LL patients conducted in Hyderabad ENL occurred 
in approximately 50% of LL and 10% of BL leprosy cases (Pocaterra et al., 2006).  The 
OR for developing ENL was 8.4 for individuals with LL and 5.2 for individuals with a BI  
≥ 4. A retrospective study of 563 Nepali patients with BL leprosy and LL found that 19% 
experienced ENL. The greater the infiltration of the skin and BI > 4 significantly increase 
the risk of developing ENL (Manandhar et al., 1999).  
The histology of ENL lesions classically shows an intense perivascular infiltrate of 
neutrophils throughout the dermis and subcutis (Job, 1994). However in a study of ENL 
lesions from Pakistani patients neutrophils were not seen in 36% (Hussain et al., 1995). 
Tissue oedema and vessels exhibiting fibrinoid necrosis may also be present. ENL is an 
immune complex mediated disease. Direct immunofluorescence studies have demonstrated 
granular deposits of immunoglobulin and complement in the dermis in ENL lesions but not 
in those of uncomplicated LL disease (Wemambu et al., 1969). There is evidence of T 
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lymphocyte and macrophage activation and expression of mRNA for TNFα and IL12 in the 
skin (Moraes et al., 1999). The ratio of CD4:CD8 cells is increased in ENL compared to 
uncomplicated LL (Kahawita and Lockwood, 2008). High levels of circulating TNFα have 
been demonstrated in the plasma of some individuals with ENL (Sarno et al., 1991). In 
vitro peripheral blood mononuclear cells (PBMC) from individuals with ENL secrete 
increased amounts of TNFα following stimulation by M. leprae or M. leprae antigens 
compared to individuals with other forms of leprosy
 
(Barnes et al., 1992).  
ENL is a systemic disorder affecting many organ systems. The onset is acute but it may 
pass into a chronic phase and it can be recurrent.  ENL produces fever and in the skin 
painful and tender red papules or nodules (fig.1.04) occur in crops often affecting the face 
and extensor surfaces of the limbs. The lesions may be superficial or deep causing a 
panniculitis. Bullous ENL has been described
 
(Rijal et al., 2004) and lesions may ulcerate. 
Subcutaneous tissue involvement may lead to tethering and fixation to joints causing loss 
of function. ENL reactions may also produce uveitis, neuritis, arthritis, dactylitis, 
lymphadenitis and orchitis. The recurrent inflammation of eyes can lead to blindness and 
the testes to sterility. 
 
Figure 1.04 Cutaneous ENL 
The majority of ENL reactions require immunosuppression. The more severe ones require 
high doses of corticosteroids, usually starting with prednisolone 60mg daily. This controls 
the acute episode but the recurrent nature of the condition means that steroid-induced side 
effects may become a significant problem. Thalidomide 300-400mg daily has a dramatic 
effect in controlling ENL and preventing recurrences (Walker et al., 2007). Its use is 
limited due to teratogenicity (phocomelia) and possible neurotoxicity (although 
neurotoxicity does not appear to be a problem in leprosy patients). 
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Clofazimine and pentoxifylline have both been used in ENL but they are less effective than 
prednisolone or thalidomide (Iyer and Ramu, 1976; Moreira et al., 1998). Colchicine and 
chloroquine have also been used with limited effect. TNFα blockade with the biological 
drug infliximab has been used to treat a woman with ENL (Faber et al., 2006).  In leprosy 
endemic settings the risk of TB may be a contraindication to the use of these drugs. The 
current cost of these agents will also limit their use. 
The use of thalidomide and pentoxifylline have been shown to reduce the levels of TNFα in 
vivo in subjects whose ENL has shown clinical improvement (Moreira et al., 1998; 
Sampaio et al., 1998) . However a study by Haslett et al has demonstrated low TNFα levels 
in individuals with milder ENL reactions and paradoxically these levels increased during 
therapy with thalidomide (Haslett et al., 2005). This effect has been noted in toxic 
epidermal necrolysis as well as other diseases (Wolkenstein et al., 1998). The authors 
postulate that ENL with systemic involvement may produce the high circulating TNFα 
levels previously seen and that this may not be the case in milder forms of the condition. 
Thalidomide has costimulatory effects on lymphocytes as well as inhibiting macrophage 
TNFα production which may explain the increase in TNFα during treatment in this setting. 
1.3.2 Lucio’s phenomenon 
This is a very rare reactional state occurring in lepromatous disease which presents as 
painful irregular patches. They become purpuric and bullae form. The bullae breakdown 
leaving widespread areas of ulceration (Moschella, 1968; Rea and Jerskey, 2005). Healing 
is with scarring. Lucio’s phenomenon is associated with severe systemic upset and may be 
fatal. The mechanism is a cutaneous vasculopathy which is thought to be due to infiltration 
of the skin causing an inflammatory microthromboembolic occlusion of the dermal 
vasculature
  
(Azulay-Abulafia et al., 2006; Sehgal et al., 1987). Other authors have 
described a predominantly vasculitic process in the skin biopsies of patients (Rea and 
Ridley, 1979). Lucio’s phenomenon was first described in Mexico and was thought to be 
confined to the western hemisphere but cases from India have been reported (Kaur et al., 
2005). 
1.3.3 Neuritis and silent neuropathy 
Neuritis is present if an individual has any of the following:  spontaneous nerve pain, 
paraesthesia, tenderness, or new sensory or motor impairment (van Brakel et al., 2005b).  It 
indicates inflammation in the nerve. Nerve pain, paraesthesia or tenderness may precede 
nerve function impairment (NFI), which, if not treated rapidly and adequately becomes 
permanent.  
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van Brakel and Khawas proposed the term “Silent Neuropathy” (SN) to describe the 
phenomenon of nerve function impairment occurring in the absence of symptoms of 
inflammation. Other authors had used terms such as “quiet nerve paralysis” (Srinivasan et 
al., 1982) and “silent neuritis” (Duncan and Pearson, 1982). It is therefore only detected if 
health workers perform a careful examination of the peripheral nervous system. In Nepal 
13% of patients developed SN including 6.8% of new patients who presented with SN. The 
majority of SN was present at diagnosis or developed during the first year of MDT (van 
Brakel and Khawas, 1994). In the Mumbai cohort study 3% of participants had SN which 
had been present for less than six months at the time of enrolment (Khambati et al., 2008). 
The BANDS investigators reported a cumulative incidence of SN of 28% in MB cases after 
five years follow-up (Richardus et al., 2004). 
SN can occur in isolation from other types of reaction but may precede or be preceded by 
T1R (van Brakel and Khawas, 1994). They postulated that SN may be due to Schwann cell 
degeneration or possibly increased CMI (as happens in T1R) however it remains unclear if 
this is the case why the skin is not affected at the same time. The treatment of SN is the 
same as for T1R. The duration of SN cannot always be ascertained from the history and so 
a trial of prednisolone is usually given. 
1.3.4 Type 1 (reversal) reactions 
T1Rs are a major cause of NFI in leprosy and affect up to 30% of susceptible individuals 
(Ranque et al., 2007). T1Rs may be a presenting feature of leprosy or occur during MDT or 
even after it has been successfully completed.  
1.3.4.1 Epidemiology 
There have been relatively few epidemiological studies of T1Rs or neuritis in leprosy. 
Tables 1.05 and 1.06 summarise some of the reports of the frequency of T1Rs. The large 
variation in these rates is due to the different methodologies used and the changing 
definitions of PB and MB categories. 
30.1% of individuals with borderline leprosy in Nepal develop a T1R (van Brakel et al., 
1994). Half of these individuals had demonstrable new NFI. These figures are from a 
retrospective study conducted at a leprosy referral centre and similar studies conducted in 
India have reported T1R rates of 8.9% in a cohort from Hyderabad presenting in one year 
(1985) and followed for almost 6 years, 10.7% in Orissa between 1992 and 2002 and 
24.1% in Chandigarh over 15 years (Kumar et al., 2004; Lockwood et al., 1993; Santaram 
and Porichha, 2004). The cumulative rate in Hyderabad was 24% for PB (tuberculoid and 
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borderline tuberculoid) patients in the five year period 1982 to 1987 (Hogeweg et al., 
1991). 19.8% (60 of 303) of INFIR cohort had a T1R at recruitment (van Brakel et al., 
2005b). Thirty-nine per cent (74 of 188) experienced a reaction or NFI during the two year 
follow-up period. A T1R occurred in 10% (19 of 188) of individuals during the study 
period (van Brakel et al., 2008). 35.7% of a cohort of MB patients in Malawi experienced a 
T1R or a deficit in nerve function (Ponnighaus and Boerrigter, 1995). 19.9% of individuals 
enrolled in a prospective study from a referral centre in Thailand developed a T1R, each 
patient was followed for a minimum of three years after being diagnosed with leprosy 
(Scollard et al., 1994). A prospective hospital based study from Vietnam demonstrated a 
prevalence of T1Rs of 29.1% in 237 patients with mainly BB and BL leprosy (Ranque et 
al., 2007). A retrospective study conducted in the field in Bangladesh identified T1Rs in 
8.8% of individuals (Richardus et al., 1996). A prospective study in Bangladesh with five 
years follow-up demonstrated a cumulative incidence of T1Rs of 17% in MB patients 
(Richardus et al., 2004). A prospective field study of 594 individuals with up to 10 years 
follow-up from Ethiopia reported a rate of T1Rs of 16.5% (Saunderson et al., 2000a).    
Location of study 
Type of 
study 
Number of 
patients 
Type of leprosy 
Duration of 
follow-up 
(years) 
Frequency of Type 
1 reactions and/or 
nerve function 
impairment (%) 
 PROSPECTIVE STUDIES   
Ethiopia 
(Saunderson et al., 2000a) 
Cohort study 594 New patients 6-11 16.5 
Bangladesh 
(Richardus et al., 2004) 
Cohort study 2664 
Paucibacillary (PB) 
and Multibacillary 
(MB) 
PB 3 
MB 5 
PB 0.9 
MB 17 
Naini and Faizabad, India 
 (van Brakel et al., 2005b) 
Cohort study 303 Multibacillary 2 19.8 
Thailand 
(Scollard et al., 1994) 
Cohort study 176 
All newly diagnosed 
types 
3 minimum 19.9 
Vietnam 
(Ranque et al., 2007) 
Case-control 
study 
237 
All types except 
indeterminate 
Not clear. 29.1 
Malawi* 
(Ponnighaus and Boerrigter, 1995) 
Randomized 
trial of MB 
MDT 
305 
Multibacillary 
BI ≥2 at any site 
Mean follow- 
up 3 years 
35.7 
Table 1.05. The frequency of Type 1 reactions. *These prospective studies used definitions of 
PB and MB leprosy which differ from the current WHO definitions. 
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Location of study 
Type of 
study 
Number of 
patients 
Type of leprosy 
Duration of 
follow-up 
(years) 
Frequency of Type 
1 reactions and/or 
nerve function 
impairment (%) 
RETROSPECTIVE STUDIES 
Hyderabad, India 
(Lockwood et al., 1993) 
Leprosy 
research 
centre clinic 
records 
review 
494 All types ≤6 8.9 
Orissa, India 
(Santaram and Porichha, 2004) 
Regional 
leprosy 
centre 
records 
review 
942 
Patients registered 
between 1992-2002 
Not clear 10.7 
Hyderabad, India* 
(Hogeweg et al., 1991) 
Leprosy 
research 
centre clinic 
records 
review 
1226 
Paucibacillary 
(Tuberculoid and 
borderline 
tuberculoid 1982-87) 
Not clear 24 
Chandigarh, India 
(Kumar et al., 2004) 
Tertiary 
referral 
clinic 
records 
review 
2867 
All types except pure 
neuritic leprosy 
3-13 
24.1 at presentation. 
33 overall. 
Brazil 
(Nery et al., 1998) 
Leprosy 
clinic 
records 
review 
162 
Untreated slit skin 
smear positive 
patients 
Not clear 25.9 
Nepal 
(van Brakel et al., 1994) 
Leprosy 
hospital 
clinic 
records 
review 
386 
Untreated patients 
except those with 
pure neuritic leprosy 
Mean 1.73 30.1 
Table 1.06. The frequency of Type 1 reactions. *These retrospective studies used definitions of 
PB and MB leprosy which differ from the current WHO definitions. 
The prospective study from Bangladesh suggests that nerve function impairment and T1Rs 
occur more than 1.7 times more frequently in men than women (Croft et al., 2000a). This 
finding needs further confirmation in other studies. 
Indian and Ethiopian cohort studies show that patients continue to experience reactions and 
neuropathy in the third year after diagnosis and beyond (Saunderson et al., 2000a; van 
Brakel et al., 2008).   
 
Figure 1.05. Number of episodes of neuropathy by year after diagnosis in 
the AMFES cohort (n=594) (Saunderson et al., 2000c) 
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1.3.4.2 Risk factors 
 
Borderline disease is a strong risk factor for the occurrence of T1Rs (Ranque et al., 2007) 
but small numbers of patients with the polar forms of leprosy may also experience T1Rs 
(Kumar et al., 2004). Older patients (≥ 15 years) may be at increased risk of T1R than 
children with leprosy (Ranque et al., 2007). Individuals who have WHO disability grades 1 
and 2 at diagnosis are significantly more likely to have severe T1Rs (Schreuder, 1998a). 
T1Rs can occur at any time but are frequently seen after starting MDT or during the 
puerperium (Lockwood and Sinha, 1999). 
Borderline patients with positive slit-skin smears were more likely to experience a T1R 
(Roche et al., 1991). A study of Brazilian patients with slit-skin smear negative single 
lesion paucibacillary leprosy showed that individuals with M. leprae DNA detectable by 
PCR in the skin were more likely to experience a T1R than those in whom M. leprae DNA 
was undetectable (Sousa et al., 2007). Individuals with borderline forms of leprosy who are 
seropositive for anti-PGL-1 antibodies have an increased risk of T1R (Roche et al., 1991). 
Of the 188 participants of the INFIR cohort (n=303) who did not have a T1R or NFI at 
baseline 69 experienced a T1R and five ENL during the two year follow-up period (Smith 
et al., 2009). Abnormality in sensory nerve conduction in the ulnar and radial cutaneous 
nerves at baseline was predictive of a future T1R or ENL. An abnormality in any nerve 
sensory conduction (except the median nerve) at the assessment immediately prior to the 
event was predictive. 
1.3.4.3 Genetic susceptibility  
Ethiopian patients with a microsatellite polymorphism in the TLR2 gene had an increased 
frequency of T1R. However individuals with the SNP 597 C  T in the TLR2 gene had a 
lower frequency of T1R (Bochud et al., 2008).  
The SNP 1805 T  G in the TLR1 gene has been associated with a decreased risk of 
leprosy T1R in Nepali patients (Misch et al., 2008). This polymorphism appears to lead to 
a loss of expression of the receptor on the surface of peripheral blood monocytes (Johnson 
et al., 2007).  
1.3.4.4 Pathology 
The histological features of a T1R are oedema with disorganisation of the granuloma and 
widespread inflammatory cells largely lymphocytes but also including neutrophils 
occasionally. The number of AFB may be significantly reduced in BL lesions (Job, 1994). 
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The diagnosis is usually made clinically but a skin biopsy is sometimes used to help 
support the diagnosis. Interestingly, even experienced pathologists may under diagnose 
reaction in skin sections from patients with clinically apparent T1R (Lockwood et al., 
2008). Four pathologists were asked to examine the skin sections from 99 patients with a 
clinical diagnosis of T1R and 52 controls. The agreement between the histological and 
clinical diagnosis of T1R was low at approximately 50%. The proportion of T1R diagnoses 
made by the four pathologists ranged between 32-62% of the patients with a clinical 
diagnosis of T1R. Important diagnostic features appear to be epithelioid cell granuloma 
oedema, dermal oedema, the presence of plasma cells and granuloma fraction and 
epidermal expression of HLA-DR.  
1.3.4.5 Immunology 
T1Rs are delayed hypersensitivity reactions that occur predominantly in borderline forms 
of leprosy (Job, 1994). M. leprae antigens have been demonstrated in the nerves and skin 
of patients experiencing T1Rs. The antigens were localised to Schwann cells and 
macrophages (Lockwood et al., 2002). Human Schwann cells express TLR2 (Oliveira et 
al., 2003). M. leprae infection may lead to the expression of MHC II on the surface of the 
cells and this may give rise to antigen presentation which triggers CD4 lymphocyte killing 
of the cell mediated by cytokines such as TNFα (Ochoa et al., 2001).  
A small study from Brazil showed that three patients with BL leprosy who experienced a 
T1R had a greater number of CD80 positive staining cells in their skin biopsy than the one 
BL leprosy patient and the two LL patients who did not experience a reaction. The 
reactional patients also had a greater number of CD80 positive PBMCs identified by flow 
cytometry than non-reactional individuals (Santos et al., 2007). 
There was increased TNFα protein detectable in the skin and nerves of 14 patients during 
T1Rs. The assessment was made by counting the proportion of cells positively stained 
using a anti-TNFα mouse antibody (Khanolkar-Young et al., 1995). The results of the 
immunhistochemistry experiment were supported by TNFα mRNA expression determined 
using in-situ hybridisation. BT patients had greater levels of staining and mRNA 
expression than BL leprosy patients. 
T1Rs appear to be mediated via Th1 type cells and lesions in reaction express the pro-
inflammatory IFNγ, IL12 and the oxygen free radical producer iNOS (Little et al., 2001). 
This study was performed on serial skin biopsies taken from 15 Indian patients with T1R at 
baseline, day 7, day 28 and day 180 of treatment with prednisolone. Cytokine expression 
and cellular infiltration persisted at pretreatment levels until at least day 7. The levels 
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gradually fell in the majority but some individuals showed persistence of infiltration and 
cytokine expression even at six months.  The expression of mRNA of various chemokines 
including IL-8, monocyte chemoattractant protein 1 and CCL5 (or RANTES) is higher in 
the skin during reaction (Kirkaldy et al., 2003). Stefani and colleagues recently showed that 
10 smear negative newly diagnosed BT patients with T1R had significantly elevated levels 
of plasma CXCL10 and IL-6 compared to BT non-reactional controls. None of these 
individuals had neuritis (Stefani et al., 2009). 
The levels of circulating cytokines do not reflect the local changes taking place in the skin 
during T1Rs. Treatment of the reaction causes clinical improvement but changes in the 
inflammatory cytokines lag behind by some considerable time and in some may remain 
unchanged (Andersson et al., 2005). A similar seemingly paradoxical finding has also been 
demonstrated in tuberculous meningitis (TBM) (Simmons et al., 2005). This variation in 
the inflammatory activity within different compartments may help to explain why 
treatment is not always effective. The inflammatory cytokines produced during a T1R may 
affect local conversion of endogenous corticosteroids (the cortisol-cortisone shuttle) in the 
lesional skin of leprosy patients with T1Rs (Andersson et al., 2007). The gene expression 
of the enzyme 11β-hydroxysteroid dehydrogenase type 2 which converts the active cortisol 
back to inactive cortisone is decreased in the skin of patients with T1R compared to non-
reactional controls. This supports the hypothesis that local endogenous active 
glucocorticoid levels are increased during T1R in response to the marked inflammation that 
has been triggered but are insufficient to suppress it. In patients with untreated pulmonary 
TB there is an increase in the urinary metabolites of cortisol compared to successfully 
treated and healthy controls (Baker et al., 2000). 
1.3.4.6 Clinical features 
A T1R is characterised by acute inflammation in skin lesions or nerves or both. T1Rs 
predominantly affect the borderline states of leprosy. Skin lesions become acutely inflamed 
and oedematous and may ulcerate (fig. 1.06). Oedema of the hands, feet and face can also 
be a feature of a reaction but systemic symptoms are unusual.  
T1Rs are frequently recurrent and this can lead to further nerve damage (van Brakel et al., 
1994). The detection of NFI is done clinically. Graded SWM (or a ball-point pen) are used 
to detect sensory loss. Voluntary muscle testing is used to assess motor nerve function. A 
recent study by van Brakel et al, using nerve conduction studies and quantitative sensory 
testing, has demonstrated that individuals experiencing neuritis, NFI or reactional episodes 
either alone or in combination have evidence of sub-clinical neuropathy up to 12 weeks 
prior to clinically detectable changes (van Brakel et al., 2008).  
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Figure 1.06. Inflamed skin and peripheral oedema in patients experiencing leprosy T1R 
 
In the INFIR Cohort study the 12 individuals who were diagnosed with a T1R limited to 
the skin had demonstrable sub-clinical nerve involvement using sensory nerve conduction 
and/or warm detection thresholds (P. Nicholls, personal communication). Sub-clinical 
changes in nerve function are predictive of further nerve impairment (Smith et al., 2009). 
1.3.4.7 Treatment of Type 1 reactions  
The use of adrenocorticotrophic hormone in the management of leprosy reactions was first 
reported by Roche et al in 1951 (Roche et al., 1951). The response of NFI to 
corticosteroids is highly variable with 33-73% of nerves recovering (Croft et al., 2000b; 
Saunderson et al., 2000c). There are few good data for making evidence-based treatment 
decisions about managing T1Rs or NFI. This was highlighted by the Cochrane systematic 
review “Corticosteroids for treating nerve damage in leprosy” by van Veen et al (van Veen 
et al., 2007). Three randomized controlled trials were included in the review. The sole trial 
which examined the effect of corticosteroids in T1R did not fulfil the initial inclusion 
criteria of the review.  
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Country, Year 
and Type of 
study 
Criteria for 
review 
Number 
analysed 
Measures Conclusion 
India 
(Santaram and 
Porichha, 2004) 
 
All reactions 101 Type 1 
reactions of 942 
cases 
“Satisfactory 
response” 
95.2% of all 
reactions had 
satisfactory 
response 
Indonesia 
(Bernink and 
Voskens, 1997) 
Field study 
Nerve function 
impairment in 
all types of 
reaction 
154 Improvement, the 
same or worse 
75% of nerves 
improved in all 
types of reaction. 
Nepal 
(van Brakel and 
Khawas, 1996) 
Nerve function 
impairment 
168 Comparison of 
nerve function at 3 
and 6 months after 
steroids 
Up to 47% showed 
no functional 
improvement 
India 
(Lockwood et al., 
1993) 
All cases from 
1985 
Type 1 reaction 44 Type 1 
reaction of 494 
cases 
Improvement in 
symptoms and 
signs 
93% 0f skin lesions 
and 50% of neuritic 
episodes responded 
Ethiopia 
(Becx-Bleumink 
and Berhe, 1992) 
All reactions 365 Type 1 
reactions 
Recurrent reaction 
Nerve function 
loss 
Approx a third of 
BL patients relapse 
as steroids cut. 25% 
of nerves do not 
improve 
India 
(Kiran et al., 
1991) 
≤6 months of 
facial nerve 
damage with 
lagophthalmos 
27 
(36 eyes) 
Degree of eyelid 
lag in mm 
64% had a good 
response 
Ethiopia 
(Naafs et al., 
1979) 
Neuritis of 
selected 
patients 
48 VMT deficit A longer course is 
better than a short 
one. 
Table 1.07. Retrospective reports of steroids in Type 1 reactions and/or nerve 
function impairment 
 
Table 1.07 summarises reports of retrospective studies of the effect of corticosteroids on 
T1Rs and/or nerve function impairment in patient series from Ethiopia, India, Nepal and 
Indonesia. Only limited conclusions can be drawn from these series. These studies suggest 
more favourable responses to corticosteroids than the prospective data from the more 
rigorous studies in Tables 1.08 and 1.09. Despite this they clearly indicate a less than 
satisfactory response of T1Rs or isolated nerve function impairment to corticosteroids. 
Tables 1.08 and 1.09 summarise the published studies of prospective cohorts in which 
systemic corticosteroids or other immunosuppressants were used to treat T1Rs and/or nerve 
involvement due to leprosy. Studies that were not formal clinical trials were included if 
there was a clearly stated clinical outcome. There are only five randomized studies four of 
which were conducted in south Asia.  
The trial from Brazil (Garbino et al., 2008) is difficult to interpret in a meaningful way 
because the authors used a scoring system which had not been validated and grouped 
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individuals with T1R and ENL together. The amount of prednisone used by each individual 
varied but was not stated. 
Country, Year 
and Type of 
study 
Entry 
criteria 
No. Intervention 
Outcome 
measures 
Conclusion 
Brazil 
(Garbino et al., 
2008) 
Randomised, 
controlled 
 
Type 1 
reactions or 
ENL 
associated 
with ulnar 
neuropathy 
21 Prednisone 120mg 
daily initially 
compared with 60mg 
daily initially for 
controls. Tapered 
variably. 
Clinical Score and 
motor nerve 
conduction  
Difficult to compare 
groups. Clinical Score was 
not validated. 
Both types of reaction 
analysed together. 
“Significant improvement 
over time” 
India 
(Rao et al., 
2006) 
Double-blind 
randomised 
controlled, 
parallel group 
“Severe” 
Type 1 
reactions 
334 3 prednisolone 
regimes: 
3.5g over 5 months 
2.31g over 5 months 
2.94g over 3 months 
 
Amount of extra 
prednisolone 
required 
The 5 month regimes were 
equally effective and less 
additional prednisolone 
was required by these two 
groups than by the 3 month 
group 
Nepal 
(Marlowe et al., 
2004) 
Randomised, 
controlled 
Type 1 
reactions 
skin or skin 
and nerve 
40 12 weeks azathioprine 
and 8 weeks 
prednisolone 
compared to 12 weeks 
prednisolone alone 
Skin signs, nerve 
tenderness, 
sensory and motor 
testing and amount 
of extra 
prednisolone 
required 
Equally effective 
Nepal, 
Bangladesh 
(Richardus et 
al., 2003b) 
Randomised 
placebo 
controlled, 
double blind 
NFI of 6-24 
months 
duration. 
92 16 week standard 
prednisolone regime 
Sensory and motor 
test scores 
No difference 
Nepal, 
Bangladesh 
(van Brakel et 
al., 2003) 
Randomised 
placebo 
controlled, 
double blind 
Isolated mild 
sensory 
impairment 
75 16 week standard 
prednisolone regime 
Improvement in 
monofilament 
scores. 
No difference between 
treated and untreated 
groups. 
Table 1.08. Prospective randomised studies using steroids in Type 1 reactions and/or nerve 
function impairment.  
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Country, Year 
and Type of 
study 
Entry 
criteria 
No. Intervention 
Outcome 
measures 
Conclusion 
Ethiopia, 
Nepal 
(Marlowe et al., 
2007)  
Open, 
uncontrolled 
Severe acute 
Type 1 
reactions 
43 12 weeks ciclosporin 
5mg/kg and 
prednisolone 40mg 
for first 5 days 
Ciclosporin increased 
to 7.5mg/kg if 
deterioration 
Skin and nerve 
score 
Improvement in 
clinical outcomes 
and relapse 
Variable improvement in skin 
and nerve signs. 
High levels of recurrence of 
reaction particularly in 
Ethiopian patients. 
Ethiopia 
(Saunderson et 
al., 2000c) 
Prospective 
observation 
field study 
Neuropathy 
including 
nerve 
tenderness 
594 Steroid regimes for 
PB (12 weeks) and 
MB (24 weeks) 
patients 
Motor and 
sensory testing 
and symptom 
improvement 
73% of all neuropathy given 
steroids responded fully in 73 
patients with no impairment 
at diagnosis 
Bangladesh 
(Croft et al., 
2000b) 
Prospective, 
open, 
uncontrolled 
NFI 132 16 week standard 
prednisolone regime 
Improvement 33% of motor nerves and 
37% of sensory nerves fully 
recovered at 12 months. 
67% of nerves improved 
Thailand 
(Schreuder, 
1998b) 
Observation 
study 
Newly 
diagnosed 
leprosy 
patients 
640 Not clear Nerve function Nerve damage at presentation 
improves in only 44% 
compared to 82% 
improvement in damage 
developing whilst on 
treatment 
Nepal 
(Wilder-Smith 
and Wilder-
Smith, 1997) 
Skin signs - 
obligatory 
Nerve signs -
optional 
Oedema or 
fever - 
optional 
18 Prednisolone starting 
at 40mg and tapered 
according to 
individual response 
Nerve function 21.2% improved sensory 
function and 1.3% improved 
motor function 
India 
(Kiran et al., 
1985) 
?Prospective 
Open.  
Impaired 
VMT or ST 
33 Semi-standardized 
prednisolone regime 
Nerve score Good result in 74% of nerves 
(No controls) 
Ethiopia 
(Touw-
Langendijk et 
al., 1984)  
Open, 
uncontrolled 
Recent nerve 
function loss 
36 6 month course of 
prednisolone 
Sensory and 
motor function 
63% of affected nerves 
(59/93) “improved” 
Table 1.09. Non-randomised prospective studies using steroids in Type 1 reactions and/or 
nerve function impairment.  
Different methodologies employing different entry criteria and outcome measures have 
made it difficult to compare studies. The grouping together of all individuals with T1R 
regardless of whether new NFI is a feature of the reaction makes it difficult to assess the 
impact on nerve function of the treatments being studied. Studies have also used different 
features of nerve involvement such as nerve function impairment and neuritis as entry 
criteria and outcome measures.  
It is difficult to compare studies that use improvement as an outcome with those that use 
the more stringent criterion of recovery. Some published studies have even looked at T1Rs 
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and ENL together despite their different aetiology, clinical presentation and response to 
treatment. 
Several studies have indicated that some nerve function impairment will improve without 
steroid therapy. This improvement may be spontaneous or  attributable to MDT (Croft et 
al., 2000b; Saunderson et al., 2000c; Schreuder, 1998b). The BANDS cohort included 69 
individuals with NFI who should have received prednisolone but did not. In these patients 
33% of involved motor nerves and 62% of sensory nerves had some degree of 
improvement at 12 months follow-up (Croft et al., 2000b).  The AMFES cohort included 
141 individuals with NFI at the time of enrolment which had been present for longer than 
six months and so were not treated with steroids. Between a quarter and a third of nerves 
with this longstanding impairment fully improved during the long period of follow-up 
(Saunderson et al., 2000c).  
The effective killing of M. leprae by MDT may improve neuropathy which is due to direct 
bacillary invasion of nerves and allow some axonal regeneration. The phenomenon of 
spontaneous improvement in nerve function is another confounder in determining the size 
of the effect of any intervention being studied. It would now be unethical to conduct a trial 
of the effect of steroids compared to inactive placebo. 
The treatment of T1Rs is aimed at controlling the acute inflammation, easing pain and 
reversing nerve damage. MDT is initiated in those presenting with a T1R or continued in 
those who develop a reaction whilst on it. Individuals with inflamed skin plaques, neuritis 
or nerve function impairment are treated with oral corticosteroids. Different regimes have 
been employed in the management of T1Rs.  
A randomized study of three different prednisolone regimes suggested that duration of 
treatment, rather than the starting dose of prednisolone, may be more important in 
controlling T1Rs (Rao et al., 2006). This was an Indian multicentre study of 334 patients 
treated with prednisolone. Prednisolone 30 mg tapered slowly to zero over 20 weeks (total 
dose = 2.31 g) was superior to prednisolone 60 mg tapered over 12 weeks (total dose 2.94 
g). There was no significant difference between prednisolone 30 mg or 60 mg (total dose 
3.5 g) tapered over 20 weeks. Individuals both with and without nerve involvement were 
enrolled into the study. The primary outcome measures were failure to respond to treatment 
and physician determined requirement for additional prednisolone rather than improvement 
in nerve function or skin signs. 
The Trials In Prevention of Disability (TRIPOD) were three randomized controlled trials of 
MB patients conducted in Nepal and Bangladesh. The first and largest of these TRIPOD 1 
54 
 
examined the role of a four month course of prophylactic prednisolone in the prevention of 
reactional episodes, neuritis and nerve function impairment (Smith et al., 2004). 636 
individuals were enrolled and received either prednisolone 20mg for 12 weeks and tapered 
to zero over a further four weeks (total dose 1.96 g) or placebo. The prednisolone had a 
protective effect whilst patients were taking it but at 12 month follow-up this effect had 
been lost 
The current WHO document: The Global Strategy for Further Reducing the Leprosy 
Burden and Sustaining Leprosy Control Activities (2006-2010) states that “Severe reversal 
reactions should be treated with a course of steroids, usually lasting 3-6 months” (WHO, 
2006). Only 60% of individuals will show improvement in nerve function with 12 weeks of 
oral prednisolone (van Brakel and Khawas, 1996). Skin lesions will readily respond.  
The TRIPOD 3 study randomized 92 MB patients with NFI that had been present for 
between 6 and 24 months to either a 16 week course of prednisolone (total dose 2.52 g) or 
placebo (Richardus et al., 2003b). There was no significant improvement in this 
longstanding NFI.  
A trial in which individuals with ulnar neuritis were randomized to either six weeks 
prednisolone or medial epicondylectomy and six weeks prednisolone demonstrated 
improvement in nerve function in both groups but did not show any added benefit of 
surgery (Pannikar et al., 1984). A study from Senegal in 31 patients with neuritis who were 
treated with prednisone for six months did not demonstrate any additional benefit of early 
surgery in those nerves randomized to receive a decompression procedure and 
epineurotomy (Boucher et al., 1999).  
Azathioprine in combination with an eight week course of prednisolone was as effective as 
a 12 week course of prednisolone in the management of T1Rs in a pilot study in Nepal 
(Marlowe et al., 2004). Ciclosporin has been used in pilot studies in Nepal and Ethiopia 
with some success (Marlowe et al., 2007). 
1.3.4.8 Aim and hypothesis 1 
I have shown that although the clinical entity of T1R and NFI is well recognised, the 
assessment of the clinical severity of these complications of leprosy is not currently 
possible due to a lack of a validated tool. This has made the interpretation of the small 
number of controlled trials and cohort studies difficult. These and future studies are 
diminished in their clinical relevance because of this. 
 AIM 1: To develop and validate a severity scale for T1Rs. 
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 HYPOTHESIS 1: The development of a reliable and valid severity scale for T1Rs 
and leprosy associated NFI can be done using symptoms and signs assessed on 
clinical examination 
1.4 Literature review of the actions of corticosteroids 
Corticosteroids bind to specific glucocorticoid receptors (GR) in the cytoplasm of the cell. 
The receptors then may dissociate from their chaperone proteins (such as heat shock 
protein (hsp)-90) and this exposes sites on the receptor necessary for transport of the GR-
steroid complex across the nuclear membrane. In human embryonic cells made to express 
mouse-GR reduced acetylation of hsp90 is associated with less stables steroid binding 
capacity (Murphy et al., 2005). The relocation is under the control of nuclear import 
proteins such as importin α and importin β (fig.1.07) (Pratt et al., 2004). Alternatively 
active transport of the chaperone-GR steroid complex may occur along cytoplasmic 
microtubules but it is not clear whether hsp90 is still bound to the GR at the point of entry 
into the nucleus (Grad and Picard, 2007).  
Once in the nucleus the GR-steroid complexes form dimers and bind to the promoter region 
of steroid responsive genes known as glucocorticoid response elements (GRE). Activation 
of GRE leads to the transcription of genes encoding anti-inflammatory mediators such as 
annexin-1, MAP kinase phosphatase-1, IκBα, secretory leukocyte protease inhibitor and 
glucocorticoid-induced leucine zipper (GILZ) (Barnes, 2006; Perretti and D'Acquisto, 
2006). 
Activated GR-steroid complexes may also interact with the coactivator molecules and 
transcription factor complexes in the nucleus. This inhibits the activity of histone 
acetyltransferases (HATs), preventing chromatin remodelling and thus reducing the 
production of proinflammatory cytokines. It has been shown in vitro by 
immunoprecipitation that the corticosteroid dexamethasone when bound to GR recruits 
histone deacetylases to reverse chromatin remodelling in a dose-dependent fashion (Ito et 
al., 2000). The activity of HATs requires the steroid receptor coactivator 3 and has been 
shown to increase the expression of cathelicidin mRNA in normal human epidermal 
keratinocytes in response to Vitamin D (Schauber et al., 2008).  
In higher concentrations (such as is the case with pulsed methylprednisolone (MP) therapy) 
corticosteroids may also have nongenomic effects such as inhibiting transcription factors 
and destabilising mRNA by binding to adenine/uridine rich elements (Barnes, 2006). There 
is some indirect evidence to support this post-transcriptional effect of corticosteroids. In an 
alveolar carcinoma cell line (A549) IL1β induced cyclo-oxygenase 2 mRNA expression 
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increases until three hours and then gradually declines over the following three hours 
whereas the addition of dexamethasone results in a rapid decline of mRNA to almost 
undetectable levels (Newton et al., 1998). The addition of an RNA polymerase II blocker 
to the system instead of dexamethasone had no appreciable effect. 
 
Figure 1.07. Cellular mechanism of action of corticosteroids 
1.4.1 Corticosteroid resistance 
A proportion of individuals with inflammatory conditions such as asthma, rheumatoid 
arthritis (RA) and inflammatory bowel disease who are non responsive to corticosteroid 
therapy are described as “resistant” (Barnes and Adcock, 2009). The molecular 
mechanisms that have been postulated to underlie this include reduced corticosteroid-
corticosteroid receptor binding, defective nuclear translocation and reduced histone 
acetylation. It is not known how common the phenomenon of corticosteroid resistance due 
to such physiological factors is in patients with leprosy reactions. 
1.4.2 Adverse effects of corticosteroids 
The risks associated with the administration of any drug are a concern. The use of potent 
immunosuppressants is potentially problematic in areas endemic for severe infectious 
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diseases such as TB. Immunosuppression may also cause potentially fatal hyperinfection 
with Strongyloides stercoralis (Leang et al., 2004). 
The First European Workshop on Glucocorticoid Therapy designated doses of prednisone 
between > 30mg and ≤ 100mg as “high doses” which are associated with severe side 
effects if used long term. This group also considers that side effects are considerable and 
dose dependent at “medium doses” of between > 7.5mg and ≤ 30mg (Buttgereit et al., 
2002). There are few data concerning the long term sequelae of corticosteroids used to treat 
patients with T1Rs.  
Taking corticosteroids may cause bone demineralization leading to osteoporosis. This is a 
dose dependent phenomenon and the rate of loss of bone mineral density is considerable in 
the first six months of corticosteroid therapy. Men with leprosy are at increased risk of 
osteoporosis and this is associated with hypogonadism (Ishikawa et al., 1999). The role of 
previous corticosteroid therapy in exacerbating the osteoporosis affecting people who have 
had leprosy has not been assessed. Osteoporosis may become increasingly important if 
longer courses or higher doses of corticosteroids are conclusively proven to be superior in 
the management of T1Rs. There are no studies of the extent of bone demineralization in 
leprosy patients treated with steroids or interventions that might improve or prevent it. 
Diabetes and hyperglycaemia may occur during treatment with low doses of 
corticosteroids. A case-controlled study of patients in a Medicaid programme in the USA 
showed that at low steroid doses hypoglycaemic agents may be required (Gurwitz et al., 
1994). In a large, retrospective series of 581 Indian patients with T1R, 2.2% developed 
diabetes requiring an oral hypoglycaemic agent during the initial phase of treatment with 
corticosteroids (Sugumaran, 1998). 
The formation of cataracts is a recognised complication of corticosteroid therapy but may 
also complicate leprosy (particularly smear positive disease) per se (Daniel and Sundar 
Rao, 2007). Cataract was identified in 4% of individuals treated for T1R by Sugumaran but 
all of these patients had been on steroids for more than 12 months (Sugumaran 1998). Age-
related cataract is now the commonest cause of blindness in leprosy affected people 
(Hogeweg and Keunen, 2005). 
Analysis of the adverse events attributable to prednisolone in the three TRIPOD trials 
suggests that the drug is safe when used under field conditions in standardised regimens 
(Richardus et al., 2003a). The trials used a total prednisolone dose of 1.96 g and 2.52 g. 
The steroid treated group were significantly more likely to experience minor adverse events 
but there was no difference in the likelihood of major adverse events between the 
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prednisolone and placebo groups. Three hundred of the 815 patients enrolled in the three 
studies were followed for 24 months and none developed TB or hypertension during that 
time. It should be noted that these 815 patients represent a very small proportion of leprosy 
patients treated with corticosteroids and lack of data concerning the rate of adverse events 
in people treated under field conditions where monitoring may be absent due to a lack of 
suitably trained staff. 
1.4.3 Pulse methylprednisolone therapy 
High dose intravenous (IV) methylprednisolone is beneficial when used in the early phase 
of an exacerbation of Th1 cytokine mediated relapsing chronic diseases. These conditions 
include RA (Weusten et al., 1993) and multiple sclerosis (MS) (Filippini et al., 2000).  
In 18 patients with MS treated with IV methylprednisolone 1 g for three days there was  a 
significant suppression  of mitogen stimulated  IFNγ, TNFα and IL2 production by blood 
leucocytes ex vivo after treatment (Wandinger et al., 1998). Methylprednisolone has also 
been shown to reduce serum levels of TNFα in RA (Youssef et al., 1997). Eleven patients 
given 1 g intravenously showed significantly reduced serum levels of TNFα at 4 and 24 
hours. In a comparative study of lymphocyte-suppressive potency between prednisolone 
and methylprednisolone in 44 individuals with RA the latter was more effective in those 
with greater disease activity as defined by rheumatoid factor titres (Hirano et al., 2000).  
IL10 is an anti-inflammatory cytokine produced by blood monocytes and its levels rise 
during T1R or relapse of reactions. It has been postulated that this is a response to the 
release of TNFα (Lockwood et al., 2002). Methylprednisolone in vitro up-regulates 
monocyte IL10 in whole blood in addition to suppression of the pro-inflammatory 
cytokines involved in T1Rs namely TNFα, IFNγ and IL2 (Hodge et al., 1999).  
The ex vivo effect of dexamethasone on PBMCs from an unspecified number of healthy 
volunteers has been studied using DNA microarray analysis.  Dexamethasone down 
regulated the expression of pro-inflammatory cytokine genes such as IL1β, IL1α, IL8, IFNγ 
and pro-inflammatory chemokine genes MCP2 and MCP3 whilst up-regulating the 
expression of anti-inflammatory cytokines TGFβ3 and IL10 (Galon et al., 2002). One of 
the genes most strongly down-regulated was IL1Ra, a soluble receptor antagonist released 
during inflammation. 
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A Phase III study to investigate the difference in effect of oral versus IV 
methylprednisolone in MS (Oral Megadose Corticosteroid Therapy of Acute Exacerbations 
of Multiple Sclerosis (OMEGA)) is currently underway (Burton et al., 2009). 
1.4.4 Aim and hypothesis 2 
Systemic corticosteroids are the mainstay of treatment of T1Rs and NFI although 
conclusive evidence of their efficacy is lacking. The optimal dose and duration of treatment 
with corticosteroids is unclear. Physicians working in leprosy endemic areas are 
experienced in using systemic corticosteroids to manage leprosy reactional states. 
Methylprednisolone is an affordable and readily available corticosteroid in many leprosy 
endemic areas. The drug is available as an IV preparation facilitating the administration of 
larger doses of steroid in a relatively short time - pulse therapy. Methylprednisolone has 
been used with success in disorders with similar immunological features to T1Rs. These 
factors make it an appropriate drug to study in the management of T1Rs. 
 AIM 2: To assess the safety and effect of high dose IV methylprednisolone in 
leprosy T1Rs and NFI in a leprosy endemic setting. 
 
 HYPOTHESIS 2: High dose IV methylprednisolone and oral prednisolone is not 
associated with a significantly greater rate of adverse events compared to oral 
prednisolone alone.  
1.5 Literature review of innate immunity and toll-like receptors 
The innate immune system protects the host organism and responds to pathogens by 
triggering inflammation via complement activation, the recruitment of inflammatory cells 
and initiation of adaptive immunity. 
TLRs and other PRRs play a vital role in the activation of the innate immune system. 
1.5.1 Toll-like receptors 
TLRs are membrane bound PRRs which are highly conserved throughout the plant and 
animal kingdoms. They were originally discovered in Drosophila melanogaster (Anderson 
et al., 1985) and shown to be important in the fly’s resistance to fungal infection by 
Aspergillus fumigatus  (Lemaitre et al., 1996). Homologous mammalian TLRs were 
subsequently discovered. 
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Ten human TLRs have been identified to date and these are located either on the cell 
surface or intracellular endosomal membranes.  
1.5.2 Structure of toll-like receptors 
TLRs are type I integral membrane glycoproteins. The extracellular component is 
comprised of an N-terminal leucine-rich repeat (LRR) domain, there are between 19 and 25 
repeats of 24 to 29 leucine residues (Matsushima et al., 2007). There is a short 
transmembrane portion and a C-terminal intracellular portion which has a high degree of 
homology with the IL-1R domain and is referred to as the Toll-IL-1R (TIR) (Gay and 
Keith, 1991). TLRs are therefore classed as members of the IL1R superfamily. 
1.5.3 Pathogen-associated molecular patterns (PAMPs) 
TLRs bind distinct groups of ligands which are highly conserved on and by pathogenic 
organisms. These are known as PAMPs. These bind to the LRR domain of the TLRs. The 
LRR domain creates a large concave binding surface which has a high affinity for its 
ligand. 
TLR2 forms heterodimers with TLR1 and TLR6 in order to recognise and bind with certain 
PAMPs (Weber et al., 2003). 
The human TLRs and their ligands are shown in Table 1.10. 
Receptor Cellular 
location 
Immune cell 
type 
Microbial ligands Micro-organisms 
recognised 
TLR1/TLR2 Cell membrane Macrophages 
Dendritic cells 
B lymphocytes 
Triacylated lipopeptides Bacteria and mycobacteria 
TLR2 Cell membrane Macrophages 
Dendritic cells 
Mast cells 
 
Lipoteichoic acid 
Porins 
Peptidoglycan 
Lipoaribinomannan 
Gram-positive bacteria 
Gram-negative bacteria 
Gram-positive and negative 
Mycobacteria 
TLR3 Endosomal Dendritic cells 
B lymphocytes 
Double-stranded RNA Viruses 
TLR4 Cell membrane Macrophages 
Dendritic cells 
B lymphocytes 
Lipopolysaccharides 
Heat shock proteins 
Gram-negative bacteria 
Bacterial and host 
TLR5 Cell membrane Macrophages 
Dendritic cells 
Flagellin Flagellated bacteria 
TLR6/TLR2 Cell membrane Macrophages 
Dendritic cells 
Diacylated lipopeptides 
Lipoteichoic acid 
Mycoplasma 
Group B Streptococci 
TLR7 Endosomal Macrophages 
Dendritic cells 
B lymphocytes 
Single-stranded RNA 
(Imidazoquinoline) 
Viruses 
TLR8 Endosomal Monocytes  
Neutrophils 
?Single stranded RNA Unknown 
TLR9 Endosomal Macrophages 
Dendritic cells 
B lymphocytes 
Hypomethylated  
CpG DNA 
Gram-positive and negative 
bacteria and mycobacteria 
TLR10 Cell membrane Macrophages 
B lymphocytes 
Unknown Unknown 
Table 1.10. Human toll-like receptors, cellular location and ligands 
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1.5.4 Damage-associated molecular patterns (DAMPs) 
The recognition of PAMPs by TLRs does not explain why commensal organisms do not 
trigger inflammation via TLRs and other PRRs of the innate immune system. Matzinger 
postulated that the innate immune system also recognises danger signals or DAMPs 
(Matzinger, 1998).  
DAMPs such as heat shock proteins, S100 proteins, the products of cellular damage by 
reactive oxygen species and the chromatin associated protein high-mobility group box 1 
(HMGB1) commonly occur in infections because of tissue damage. DAMPs have also been 
implicated in autoimmunity and inflammation as mammalian host DNA and uric acid can 
trigger inflammation via PRRs. Genomic double-stranded DNA from lysed fibroblasts 
induced maturation of murine APCs indicated by an increase in CD11c cells expressing 
CD40  (Ishii et al., 2001).Treating the cell lysates with proteinase K and DNase I prevented 
this maturation. Uric acid crystals activated the NALP3 inflammasome to release IL1β in 
THP1 cells ( a human leukaemia cell line) (Martinon et al., 2006). The innate immune 
system binds ligands expressed on invading pathogens and also recognises the products of 
inflammation and cellular damage. 
1.5.5 Toll-like receptor signal transduction 
Once a ligand has bound to its TLR, the receptor dimerises and activates an orchestrated 
proinflammatory response via a signalling cascade (Gay and Gangloff, 2007). The 
signalling may proceed via one of two pathways. These pathways are Myeloid 
differentiation primary response gene (88) (MyD88)-dependent (Tauszig-Delamasure et 
al., 2002) or MyD88-independent (Fitzgerald et al., 2003) and both lead to the production 
of proinflammatory cytokines and type I interferons. All TLRs except TLR3 signal via 
MyD88. TLR3 utilises TIR-domain-containing adaptor protein inducing IFNβ (TRIF, also 
known as TICAM1) (Yamamoto et al., 2003).  
The MyD88 dependent pathway is activated by homophilic association of the TLR 
cytoplasmic IL1R domain with the IL1R like portion of MyD88 (fig. 1.07). A further 
adaptor molecule TIR-domain-containing-adaptor (TIRAP) is also recruited to this 
complex (Gay and Gangloff, 2007). This is followed by the recruitment of IL1R-associated 
kinase 4 (IRAK-4) and IRAK1. IRAK4 is then activated via phosphorylation and 
subsequently phosphorylates and activates IRAK1. Phosphorylated IRAK1 associates with 
TNF receptor-associated factor 6 (TRAF6). TRAF6 activates transforming growth factor 
(TGF)-β-activating kinase 1 (TAK1) which phosphorylates the inhibitor of IκB kinase-2 
(IKK) and mitogen-activated protein (MAP) kinase kinase 6 (MKK 6). 
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The activated inhibitor of IκB, IKK, then phosphorylates IκB. IκB is bound to NFκB in the 
cytoplasm, once phosphorylated it dissociates from NFκB. The free NFκB is then able to 
enter the nucleus and exert its effect on proinflammatory gene transcription (Barnes, 2006).  
The signalling cascade initiated by TLR bound ligand can also result in the activation of 
the interferon regulatory factors (IRF), c-Jun N-terminal kinases (JNKs) and other kinases 
such as p38. The signalling cascade for TLR3 is MyD88-independent and is mediated by 
TRIF and results in the activation of IRF3. TLR4 can also use a MyD88-independent 
pathway by recruiting TRIF-related adaptor molecule (TRAM) which then activates TRIF. 
Figure 1.08. MyD88-dependent toll-like receptor signal transduction 
In the nucleus NFκB associates with AP-1 and large coactivator molecules such as cyclic 
AMP response element binding (CREB) binding protein (CBP). The coactivator molecules 
have histone acetyltransferase activity. Reversible acetylation of histones causes chromatin 
remodelling. The remodelling of chromatin results in the normally closed structure of the 
chromatin opening up and allowing the binding of RNA polymerase II to the DNA and 
thus activating transcription of genes coding for proinflammatory agents (Barnes, 2006). 
Other molecules such as CD14, a glycosylphosphatidylinositol protein expressed on the 
cell surface amplifies TLR2 specific responses and the recognition of lipopolysaccharide 
by TLR4. It can also act as a transporter of microbial ligands to TLRs (Akashi-Takamura 
and Miyake, 2008). 
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1.5.6 Toll-like receptors and disease 
TLR are expressed in tissues during mycobacterial diseases, in the skin during infectious 
and primary inflammatory dermatoses and also in neural tissue in central and peripheral 
nervous system disorders. 
1.5.7 Toll-like receptors and mycobacterial diseases 
Nine HIV negative individuals with pulmonary TB expressed a wide variety of TLRs in 
lung tissue granulomas whereas two control patients with pulmonary neoplasia did not. The 
TLR receptor expression was identified using rabbit polyclonal anti-human TLR 
antibodies. TLR1, TLR2, TLR4 and TLR9 were expressed most frequently (Fenhalls et al., 
2003). TLR2 and TLR4 were expressed on alveolar macrophages and epithelioid 
macrophages and giant cells associated with the tuberculous granulomas. 
TLR2 deficient mice are markedly susceptible to infection with Mtb and this susceptibility 
to infection is much less marked in TLR9 deficient mice. However mice deficient in both 
TLR2 and TLR9 are much more susceptible to Mtb than mice which are deficient in only 
one of these TLRs. This suggests that in mice, at least, TLR9 may play a role in combating 
infection with Mtb (Bafica et al., 2005). TLR9 deficient mice form larger granulomas 
following pulmonary infection with Mtb but these are associated with decreased production 
of cytokines such as IFNγ and IL12 (Ito et al., 2007). The immunopathology associated 
with infection may be reduced although granuloma formation is preserved. Human myeloid 
precursors in vitro are converted to competent CD1 expressing APCs following infection 
with live Mtb or exposure to lipid components of the mycobacterial cell wall. This 
conversion is TLR2 dependent (Roura-Mir et al., 2005).Human monocytes infected with 
Mtb and then activated via TLR2 up-regulate the VDR and produce cathelicidin. 
Cathelicidin is an antimicrobial which is active against Mtb (Liu et al., 2006).Macrophages 
derived from healthy donors and stimulated with lipid fractions from different strains of 
Mtb show up and down regulation of TLR2 and TLR4. TLR2 is upgraded by the Canetti 
strain and down regulated by H37Rv and Beijing strains. The same holds for TLR4 
although the results for the H37Rv strain conflicted depending on the polarity of the lipids 
(Rocha-Ramirez et al., 2008). 
The apoptosis of peripheral morphonuclear neutrophils (PMNs) in patients with pulmonary 
TB occurs following the interaction of Mtb with TLR2 and is mediated via the kinase p38. 
In pleural effusions such PMNs take on a dendritic cell phenotype and express CD83, so-
called transdifferentiation. Monocytes in tuberculous pleural fluid show increased 
expression of TLR2 and TLR4 compared to their counterparts in the peripheral blood 
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(Prabha et al., 2008). Peripheral CD4+ T lymphocytes show increased expression of TLR2 
in patients with pulmonary TB compared to healthy donors. In individuals with pleural 
disease the expression of TLR2 was significantly greater on CD4+ cells from pleural fluid 
than from the peripheral blood in patients with uncomplicated TB. 
Individuals with latent TB (tuberculin skin test positive but no clinical symptoms, signs or 
radiological signs of TB) and co-existent filarial infection show reduced mRNA expression 
of TLR2 and TLR9 (Babu et al., 2009). The expression of mRNA of these receptors was 
also reduced in TB infected individuals with filarial infection following stimulation with 
either PPD or Mtb-culture filtrate protein compared to similar individuals who did not have 
filarial infection.   
In 151 Turkish patients with TB (pulmonary, pleural, lymph node, bone and renal) the SNP 
753 GA in the TLR2 gene which results in a substitution of arginine to glutamine was 
associated with an increased risk of TB compared to 116 controls (Ogus et al., 2004). The 
microsatellite polymorphisms with shorter GT repeats within intron II of the TLR2 gene 
were associated with an increased risk of developing pulmonary or extra-pulmonary TB in 
Korean subjects (n=176) and confirmed in a further 82 patients used as a validation cohort 
(Yim et al., 2006). This polymorphism was also associated with an increased risk of  non-
tuberculous mycobacteria pulmonary disease with Mycobacterium avium-intracellulare 
complex or Mycobacterium abscessus in another cohort of 193 HIV negative Korean 
patients (Yim et al., 2008). In a study of  Tanzanian patients with HIV and pulmonary TB, 
the 24 individuals with TB were nearly three times more likely to have the SNP 896 A  
G of the TLR4 gene than 80 HIV positive controls without active TB (Ferwerda et al., 
2007). This SNP encodes a glycine instead of an aspartic acid residue. 
Two studies have shown that individuals with the SNP 558 C  T in the gene encoding 
TIRAP are more likely to have TBM (Dissanayeke et al., 2009; Hawn et al., 2006). In the 
study by Hawn et al of 175 Vietnamese individuals with TBM the odds ratio of having the 
SNP was 3.02 (95% CI 1.79 – 5.09) compared to that of the controls. The blood of 
individuals homozygous for the thymidine allele produced significantly less IL6 when 
stimulated with bacterial lipopeptides (Hawn et al., 2006). Khor and colleagues reported 
that individuals from West Africa and Algeria who were heterozygous for the SNP 539 C 
T in the TIRAP gene were protected against TB. The same TIRAP gene polymorphism 
was found significantly less frequently in controls than in a UK cohort with invasive 
pneumococcal disease (the isolation of Streptococcus pneumoniae from a normally sterile 
site). This polymorphism results in a leucine substitution of serine at position 180 in the 
TIRAP protein. The leucine variant TIRAP results in less activation of NFκB and it is 
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hypothesised that the reduced host inflammatory response may result in less severe disease 
(Khor et al., 2007). However this association was not reproduced in similar studies of 
individuals from Russia, Ghana and Indonesia (Nejentsev et al., 2008).  
The SNP 336 A  G in the gene CD209 which encodes DC-SIGN was present more 
frequently in 914 control subjects than 1262 individuals with pulmonary TB from West 
Africa and Malawi (OR 0.86, 95%CI 0.77–0.96) (Vannberg et al., 2008) this 
polymorphism results in reduced expression of DC-SIGN in vitro (Sakuntabhai et al., 
2005). 
In a Taiwanese study of eight children who had Mycobacterium bovis bacilli Calmette-
Guerin (BCG) infection following BCG vaccination none had any abnormality of TLR2 
signalling (Lee et al., 2009b).In Mycobacterium ulcerans disease (MUD) TLR9 is 
expressed on the surface of plasmacytoid dendritic cells. M. ulcerans is a largely 
extracellular pathogen and it is not clear what might cause this expression of TLR9 which 
is expressed intracellularly (Peduzzi et al., 2007). In vitro M. ulcerans induces TLR2 and 
TLR4 expression on HaCaT cells and Dectin-1 in both HaCat cells and primary 
keratinocytes (Lee et al., 2009a). 
In mycobacterial infections there is evidence from human and mouse studies that TLRs are 
important in recognising pathogen and instituting an immune response. However there is 
also evidence that TLR expression may be associated with more severe disease. The 
evidence supporting their role in such immunopathology is that they are associated with 
increase cytokine activity and more severe disease in mouse models (Ito et al., 2007). In 
human mycobacterial disease such as TBM an immunopathological component has been 
implicated in the high rates of mortality and neurological complications (Green et al., 
2009). This is supported by the fact that dexamethasone reduces mortality in these patients 
(Thwaites et al., 2004). Polymorphisms in genes encoding TLRs or molecules involved in 
TLR signal transduction may reduce TLR induced inflammation (Khor et al., 2007).  
1.5.8 Toll-like receptors and cutaneous diseases 
TLRs are expressed by human skin cells in vitro and in vivo. The expression of TLRs 
occurs in skin diseases associated with infection or colonisation by micro-organisms and 
immunologically mediated diseases such as psoriasis. 
Human keratinocytes express TLR2 and TLR4. Activation of these TLRs was associated 
with the production of inflammatory cytokines which led to microbial killing (Pivarcsi et 
al., 2003). The mRNA of all TLRs except TLR7, TLR8 and TLR9 was shown to be 
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expressed in human epidermis, cultured primary foreskin keratinocytes and HaCaT cells 
(Kollisch et al., 2005). Exposure of primary human keratinocytes in vitro to 
Staphylococcus aureus is associated with TLR2-dependent increased expression of the 
antibacterial agent human β-defensin 3 (Menzies and Kenoyer, 2006; Sumikawa et al., 
2006). Human Langerhans cells stimulated via TLR2 acquire migratory capacity and 
stimulate the proliferation of allogeneic CD4+ T lymphocytes (Peiser et al., 2008).  Human 
melanocytes express functional TLR4 (Ahn et al., 2008). 
In acne lesions TLR2 is expressed on macrophages surrounding the pilosebaceous unit. In 
acne inversa lesions, the expression of both TLR2 mRNA and protein is increased in the 
dermis compared to normal skin (Hunger et al., 2008). The TLR2 was expressed on cells 
that also expressed DC-SIGN. Propionibacterium acnes triggers the release of 
inflammatory cytokines via TLR2 in vitro (Kim et al., 2002). The expression of both TLR2 
and TLR4 was increased in the epidermis of acne lesions compared with normal skin 
(Jugeau et al., 2005). Zinc is used topically in mild to moderate acne and has mild 
antimicrobial effects against P. acnes and also anti-inflammatory properties (Bojar et al., 
1994). Incubation of extracts of P. acnes stimulated cultured primary foreskin 
keratinocytes with zinc has been shown to reduce the expression of TLR2 (Jarrousse et al., 
2007). This suggests that zinc may improve acne by reducing TLR2 induced inflammation.  
Seborrhoeic dermatitis is associated with the presence of Malassezia furfur in affected skin. 
Human keratinocytes when infected experimentally with Malassezia furfur increase their 
expression of TLR2 mRNA (Baroni et al., 2006). Lithium gluconate which is used 
topically in the treatment of seborrhoeic dermatitis reduces TLR2 and TLR4 expression in 
lipopolysaccharide stimulated cultured normal human epidermal keratinocytes (Ballanger 
et al., 2008). These findings support an analogous role in reducing TLR mediated 
inflammation for lithium in seborrhoeic dermatitis as for zinc in acne. 
In mice infected with the protozoan Leishmania braziliensis MyD88 deficient animals 
experienced more severe and prolonged illness than wild type animals. Interestingly TLR2 
deficient animals demonstrated enhanced resistance to infection despite a similar parasite 
burden to wild type animals (Vargas-Inchaustegui et al., 2009). This finding suggests that 
TLR2 may contribute to the clinical phenotype of cutaneous ulceration in this murine 
model.  
TLR3 and TLR9 are expressed in the lesions of viral warts and molluscum contagiosum 
and the expression of  mRNA of these TLRs is greater than in normal skin (Ku et al., 
2008).  
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Epidermal keratinocytes in normal human skin constitutively express TLR1, TLR2 and 
TLR5. In the epidermis of lesions of psoriasis TLR2 staining is greatest at the top of the 
epidermis, the site of least proliferation of keratinocytes (Baker et al., 2003). Curry also 
reported increased staining of TLR2 as well as TLR1 and TLR4 in psoriasis lesions (Curry 
et al., 2003). TLR2 staining was markedly increased in the affected skin of individuals with 
plaque psoriasis (Begon et al., 2007). TLR9 protein and mRNA expression was greater in 
22 individuals with lichen planus compared to normal controls (Li et al., 2007). 
In mycosis fungoides epidermal keratinocytes show increased expression of TLR2, TLR4 
and TLR9 protein. It was postulated that they may facilitate the persistence of clonal 
lymphocytes within the epidermis (Jarrousse et al., 2006). 
In a small study of 24 individuals with pulmonary sarcoidosis there was a greater degree of 
TLR2 and TLR4 expression on peripheral blood mononuclear cells than healthy controls 
(Wiken et al., 2009). 
1.5.9 Toll-like receptors and peripheral nerve disorders 
TLRs are expressed by the specialised cells of the peripheral and central nervous systems 
including microglial cells, astrocytes, oligodendrocytes and Schwann cells and neurons 
(Okun et al., 2009). 
Wallerian (traumatic) degeneration of peripheral nerves may cause the release of proteins 
which activate TLR4 and lead to the release of monocyte chemoattractant  protein-1 by rat 
Schwann cells in vitro (Karanth et al., 2006). TLR2 and TLR4 activation is associated with 
recovery of locomotor function following experimental sciatic nerve injury in mice (Boivin 
et al., 2007). Transection of L5 spinal nerves in rats leads to increased mRNA expression 
of TLR4 in the spinal cord (Tanga et al., 2004). 
Rat and mouse Schwann cells are activated following incubation with necrotic neuronal 
cells. The inflammatory response produced is attenuated in TLR2 and TLR3 knockout 
mice (Lee et al., 2006). 
Anti-ganglioside-like lipo-oligosaccharides antibody which is associated with Guillain-
Barré syndrome enhances the expression of TLR4 on rat Schwann cells and the production 
of IL-1β and TNFα (Hao et al., 2009). In experimental autoimmune neuritis (a rat model of 
Guillain-Barré syndrome) there is increased expression of TLR2 and CD14 on 
inflammatory cells in sciatic nerves (Zhang et al., 2009). 
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TLR4 knockout mice experience reduced pain hypersensitivity compared to wild type 
animals when subjected to an experimental sciatic nerve injury which induces neuropathic 
pain (Bettoni et al., 2008). TLR2 knockout mice experience less nerve injury induced 
allodynia than C57BL/6 mice (Kim et al., 2007). It has been postulated that HMGB-1 may 
be the ligand responsible for activating TLRs following insults which result in neuropathic 
pain (Kim et al., 2009). There is increasing recognition of the complication of neuropathic 
pain in individuals with leprosy (Hietaharju et al., 2000; Saunderson et al., 2008; Stump et 
al., 2004). 
There is an association between SNPs in the TLR4 gene and peripheral neuropathy 
complicating Type 2 diabetes mellitus (Rudofsky et al., 2004). SNP 896 A  G and SNP 
1196 C  T which result in a glycine substituted for an aspartic acid and a threonine for an 
isoleucine respectively. 
1.5.10 The effect of corticosteroids on toll-like receptor expression 
Corticosteroids have marked effects on gene expression. In healthy subjects treated with 
dexamethasone DNA Microarray experiments showed that of the 9182 genes studied 9% 
were considered down-regulated and 12% up-regulated in PBMCs (Galon et al., 2002). 
PBMCs from these dexamethasone treated healthy volunteers showed increased gene 
expression of TLR2 and TLR4 whilst TLR3 gene expression was downregulated (Galon et 
al., 2002). Dendritic cells increase their expression of TLR2 and TLR4 following 
incubation with corticosteroids (dexamethasone, methylprednisolone and prednisone) 
although the cells showed reduced functional capabilities (Rozkova et al., 2006). Human 
epidermal keratinocytes show increased TLR2 mRNA expression following incubation 
with budesonide (Kis et al., 2006) or dexamethasone (Shibata et al., 2009). Primary human 
corneal epithelial cells express less TLR3 following incubation with dexamethasone (Hara 
et al., 2009). Dexamethasone acts synergistically in the presence of TNFα to increase the 
expression of TLR2 on respiratory epithelial cells (Homma et al., 2004) and IL1β in HeLa 
cells (Sakai et al., 2004). 
Corticosteroids increase GILZ mRNA expression by human monocytes and in mice. GILZ 
gene expression in a monocytic cell line was associated with a reduced expression of TLR2 
following ligand stimulation (Berrebi et al., 2003). 
The monocytes of patients with systemic lupus erythematosus treated with pulsed 
corticosteroids showed reduced expression of CD14 compared with patients who did not 
receive corticosteroid therapy (Sumegi et al., 2005). 
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TLR2 and TLR4 are expressed on human adrenal cortex cells but not medulla (Bornstein et 
al., 2004). TLR2 deficient mice produce less corticosterone than wild type mice even in the 
unstressed state. It is postulated that there is an interaction which is bidirectional between 
the innate immune system via TLRs and the hypothalamic-pituitary axis (Bornstein et al., 
2006). 
Corticosteroids up-regulate TLR expression in in vitro experiments and in healthy subjects 
but their effect in individuals during pathological processes may be different. Galon and 
colleagues showed that although TLR4 gene expression was up-regulated by 
dexamethasone in healthy subjects when they activated isolated immune cells by 
incubating with anti-human CD3 and anti-CD28 antibodies TLR4 gene expression was 
down regulated (Galon et al., 2002). 
1.5.11 Aim and hypothesis 3 
 AIM 3: To quantitatively measure TLR gene and protein expression during 
corticosteroid treatment and validate a housekeeping gene for PCR assays in 
individuals with T1R who receive prednisolone and MDT. 
 HYPOTHESIS 3: The expression of  TLR1, TLR2, TLR4 and TLR9 in skin 
lesions is associated with T1Rs and declines during corticosteroid therapy. 
1.6 Summary 
Leprosy T1Rs are a complication of infection by M. leprae. The delayed hypersensitivity 
exhibited affects the skin and nerves and may lead to permanent loss of nerve function. The 
treatment of T1R is with corticosteroids but not all patients’ nerve function will fully 
recover. The design of clinical trials has been limited by difficulties in defining outcome 
measures for T1Rs. 
TLRs are expressed in normal and diseased skin and nerves. The expression of certain 
TLRs is increased during infections and inflammatory processes of the skin and nerves in 
both the end organ and immune cells.  
1.7 Aims 
1. To develop and validate a severity scale for T1Rs.  
2. To assess the safety and effect of high dose IV methylprednisolone in leprosy 
T1Rs and NFI in a leprosy endemic setting. 
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3. To quantitatively measure TLR gene and protein expression during corticosteroid 
treatment and validate a housekeeping gene for PCR assays in individuals with 
T1R who receive prednisolone and MDT. 
 
1.8 Hypotheses 
1. The development of a reliable and valid severity scale for T1Rs and leprosy 
associated NFI is possible using symptoms and signs determined by clinical 
examination 
2. High dose IV methylprednisolone and oral prednisolone is not associated with a 
significantly greater rate of adverse events compared to oral prednisolone alone.  
3. TLR1, TLR2, TLR4 and TLR9 expression in skin lesions is associated with T1Rs 
and declines during corticosteroid therapy. 
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2.1 Introduction 
Clinical trials with appropriate outcome measures are needed to determine the most 
effective treatment regimens for T1Rs (van Brakel et al., 2007b). It has proved difficult to 
compare the small number of studies because of the different outcome measures used. 
There are also difficulties in comparing the severity of T1Rs between different cohorts and 
even between different arms of clinical trials. 
A tool which enables clinicians to accurately assess the severity of leprosy T1Rs would be 
useful in defining outcomes for clinical trials. It would facilitate the even distribution of 
patients with similar disease severity between the arms of clinical trials. A measure of 
reaction severity could also be used in treatment guidelines to indicate the need for therapy. 
A quantitative measure of reaction severity may be a useful prognostic tool. 
A scale devised as part of the INFIR Cohort study examined 21 items for the basis of a 
severity scale of both types of leprosy reactions and retrospectively assessed the 
performance of this scale (van Brakel et al., 2007a). There was good agreement between 
items in the scale.  
A different scale (with 24 items) was used by Marlowe et al in a different INFIR study of 
azathioprine and prednisolone in T1Rs but it was not validated (Marlowe et al., 2004). 
An “indice névritique” – a composite scale using various assessments of nerves including 
electrophysiological studies – was developed by Naafs and colleagues but has not been 
validated (Naafs and Dagne, 1977; Naafs et al., 1979). 
Garbino compiled a Clinical Score for ulnar neuropathy complicating Type 1 and ENL 
reactions (Garbino et al., 2008). This was a composite of an assessment of spontaneous 
nerve pain with a visual analogue score, graded clinical assessment of nerve enlargement, 
monofilament sensory testing and voluntary muscle testing. The score was not validated. 
Using the INFIR scales as a starting point we decided to develop and validate a scale to 
measure the severity of T1Rs and NFI in leprosy. This was initially based on 24 items with 
a final version based on 21 items. 
2.2 Participants and Methods 
2.2.1 Expert opinion 
To establish content validity a questionnaire was sent to eight leprologists who were not 
involved in the development of the current scale. The questionnaire used open questions to 
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ascertain the signs they believed to be important in T1R, which signs indicated a more 
severe reaction and how they categorised T1R severity.  
2.2.2 Scale development 
The severity scale for leprosy T1Rs was developed by modifying the two previous scales 
used in the INFIR studies and informed by the responses of the leprologists to the 
questionnaire. 
The scale that was developed and tested had 24 items grouped into three parts (see 
Appendix A): 
Section A contained six items each of which scored between 0 and 3 depending on the 
assessment of their severity by the examiner using the scale. 
Section B was an assessment of sensory function of each of the trigeminal, ulnar, median 
and posterior tibial nerves. Cotton wool was used to assess the trigeminal nerve. Graded 
SWM were used for the ulnar, median and posterior tibial nerves.  
The ulnar and median nerves were examined using a 2 g and 10 g monofilament at three 
sites on the palmar aspect of the hand for each nerve (ulnar and median) and the posterior 
tibial nerves were assessed using 10 g and 300 g at four sites on the sole of the foot (fig. 
2.01).  
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A score from 0 to 6 was assigned depending on the ability of the patient to successfully 
recognise the weighted monofilaments and the number of sites in which they were felt. For 
Figure 2.01. Sites of sensory testing on the palms and soles 
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example, on the hand if a person could feel the 2 g monofilament at the three sites 
innervated by the ulnar nerve then a score of zero was recorded. If the 2 g was felt at two 
sites and the 10 g at the third site a score of one was recorded. If however the 10 g 
monofilament was not felt at one site then a score of 4 was recorded even if the patient was 
able to feel the 2 g monofilament at the other two sites. 
Section C measured motor function of ten nerves (facial, ulnar, median, radial, posterior 
tibial) by voluntary muscle testing (VMT) using the Medical Research Council (MRC) 
grading system (Brain, 2000). Normal muscle power (MRC Grade 5) scored zero on the 
scale. Active movement against gravity and resistance (Grade 4) scored one and active 
movement against gravity (Grade 3) scored two. An MRC grade of less than three scored 
three on the severity scale.  
The sum of the total for each section gives the overall severity scale score which ranged 
from 0-96, the lower the score the less severe the reaction. 
2.2.3 Scale testing 
The assessment of the severity scale was performed at the specialist leprosy referral centres 
of DBLM Hospital, Nilphamari, Bangladesh and Oswaldo Cruz Institute, Rio de Janeiro, 
Brazil between June 2006 and November 2007. 
Ethical approval was granted for the external validation of the scale and the assessment of 
inter-observer agreement by the Ethics Committee of the London School of Hygiene and 
Tropical Medicine (4021), the Bangladesh Medical Research Council and the Institutional 
Review Board of the Oswaldo Cruz Institute. 
Patients attending the centres with evidence of a T1R or nerve function impairment of less 
than 6 months duration were eligible. Eligible individuals were invited to participate by the 
attending physician. 
Written informed consent was obtained from individuals who participated in the external 
validation of the scale and also from those enrolled in the study of inter-observer 
agreement.   
2.2.4 Validation of the scale 
Individuals were examined independently by a worker who was trained to use the scale and 
experienced leprologists (> 20 years experience) who categorized the reaction as mild or 
moderate or severe. Neither assessor (nor the patient) was aware of the result of the others 
examination. All of the demographic and clinical data were recorded on a standard form. 
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The Ridley-Jopling classification was used to classify the type of leprosy each patient had 
(Ridley and Jopling, 1966). 
2.2.5 Inter-observer agreement  
Inter-observer agreement was tested at the two centres in a subsequent stage of the study 
using the same eligibility criteria. Two assessors independently used the scale to assess 
individuals diagnosed as having T1Rs. The scale was applied in the same way as in the 
validation part of the study. The time interval between the two assessments was kept as 
short as was practicable. Four pairs of assessors were used. 
2.2.6 Data management 
The data were entered into an Access database. The data were analysed using the Statistical 
Package for the Social Sciences (SPSS version 14. SPSS Inc, Illinois, Chicago). 
2.2.7 Statistical Methods 
The item to total score correlation was examined using Spearman rank correlation.  
The internal consistency or reliability was assessed using Cronbach’s alpha. An alpha 
between 0.7 and 0.9 was considered acceptable (Streiner and Norman, 2003). The 
contribution of each item in the scale was assessed by calculating Cronbach’s alpha for the 
scale if that item were removed. 
The ability of the scale to discriminate between different clinical severity categories was 
determined using analysis of variance. The threshold for accepting statistical significance 
was p < 0.05. 
Inter-observer reliability was evaluated using Intra-Class Correlation of the total score of 
each examiner using a two-way analysis of variation (5% level of significance) and the 
strength of agreement criteria of Landis and Koch (Landis and Koch, 1977). A Bland 
Altman plot of the difference between pairs of observations and the mean of those pairs 
was used to highlight any potential systematic differences between raters.  
Receiver operating characteristic curves were used to determine cut off points for mild, 
moderate and severe reactions by calculating the sensitivity and specificity of the scale 
scores for mild and moderate groups and moderate and severe groups respectively. 
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2.3 Results 
2.3.1 Expert opinion 
The questionnaire sent to eight leprologists was returned by seven. The features of T1R 
that were considered important indicators of severity were extent and degree of 
inflammation of skin lesions, the presence of peripheral oedema, nerve tenderness and 
nerve function impairment. These items are all part of the clinical severity scale we have 
developed and thus gives our scale face validity. 
Question 1: What clinical signs would be important to include in an attempt to objectively 
measure a Type 1 reaction? 
The responders listed between three and 10 clinical signs they regarded as important when 
measuring a T1R. These are shown in Table 2.01 with the number of leprologists who 
included them in their response to question 1. 
Clinical sign Number 
(n=7) 
Skin lesion oedema 5 
Skin lesion erythema 4 
Skin lesion ulceration 4 
              Number or percentage of skin lesions involved 4 
Body surface area involved 1 
Peripheral oedema 4 
Fever 2 
Neuritis 7 
Nerve function impairment 6 
Nerve enlargement 5 
Patient discomfort 2 
Ridley-Jopling Classification 1 
Table 2.01. Important signs of T1R –expert opinion  
 
Question 2: How would you measure these signs? 
Six of the respondents stated that they would use VMT and monofilament sensory testing. 
There was less agreement concerning the measurement of other signs but categories such 
as; mild or moderate or severe and absent or present were given by three respondents. 
Question 3: Which signs, if any, are more likely to indicate a more severe Type 1 reaction? 
Nerve function impairment, nerve tenderness, peripheral oedema and ulceration of skin 
lesions were reported as indicating a severe reaction by the majority of leprologists who 
responded to the questionnaire (Table 2.02). 
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Signs associated with more severe 
reaction 
Number 
(n=7) 
Skin ulceration 4 
Peripheral oedema 5 
Nerve function impairment 5 
Nerve pain or tenderness 5 
Speed of onset 1 
Fever 2 
Ridley-Jopling classification 1 
Duration 
Large number of patches 
New patches 
1 
1 
1 
 
Table 2.02.  Signs indicative of a severe T1R –expert 
opinion  
 
Question 4: How do you categorise the severity of a Type 1 reaction? 
Four respondents categorise T1Rs as mild or moderate or severe. Two classify reaction 
severity on the basis of whether an individual requires corticosteroids or does not require 
corticosteroids. One leprologist used mild or severe to categorise T1R severity. 
2.3.2 Scale testing 
2.3.2.1 Validity 
81 individuals were recruited (56 from Bangladesh and 25 from Brazil). 64 (79%) were 
male and 17 (21%) female. The clinical features are summarised in Table 2.03. 
 Study of Validity 
Number (%) 
 
Number enrolled 81  
Male 
Female 
64 (79) 
17 (21) 
 
Mean Age in years 
(range) 
39.5 (11-86)  
Type of leprosy 
BT 
BB 
BL 
LL 
PNL 
 
56(69.1) 
6 (7.4) 
18 (22.2) 
4 (4.9) 
1 (1.2) 
 
First episode of Type 
1 reaction 
52 (64.2)  
Type of reaction 
 
  
Skin and nerves 56 (69.1)  
Skin only 18 (22.2)  
Nerves only 7 (8.6)  
Table 2.03. 
Description of 
individuals 
enrolled in the 
validation 
study 
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The median severity score for the 81 individuals was 10. The range was 59, with a 
minimum of two and a maximum of 61. The distribution of scores was right skewed (fig. 
2.02). 
 
Figure 2.02. Distribution of scores for the validation study (n=81) 
 
The range of the item to total score correlation was -0.09 to +0.73. Nerve pain and nerve 
tenderness appeared to show no correlation with the total score. 
The internal consistency of the scale was assessed using Cronbach’s alpha. The Cronbach’s 
alpha was 0.819. Removal of the following individual items resulted in an increase in the 
alpha: the degree of inflammation of skin lesions, the number of raised inflamed lesions, 
nerve pain, nerve tenderness, fever, function of right trigeminal nerve, function of the left 
trigeminal nerve, motor function of the right and left radial nerves (Table 2.04). This 
indicates that removal of one or more of these items might improve the remaining items 
ability to measure the severity of T1Rs. 
 
 
 
 
79 
 
Type of item Item 
Cronbach's 
Alpha if Item 
Deleted 
Skin and oedema signs Degree of inflammation of skin .822 
Number of raised and/or inflamed lesions .824 
Peripheral oedema due to reaction .814 
Nerve symptom Nerve pain and/or paraesthesia .826 
Nerve sign Nerve tenderness (worst affected nerve only) .825 
Systemic sign Fever (°C) .820 
Sensory function of nerve Right trigeminal .821 
Left trigeminal .821 
Right ulnar .799 
Left ulnar .789 
Right median .795 
Left median .803 
Right posterior tibial .797 
Left posterior tibial .800 
Motor function of nerve Right facial  .817 
Left facial .816 
Right ulnar .810 
Left ulnar .807 
Right median .809 
Left median .808 
Right radial .821 
Left radial .821 
Right lateral popliteal .809 
Left lateral popliteal  .816 
Table 2.04.  Cronbach α for the scale when individual item indicated is removed.  
 An increase in α indicates that removal of the item is improving agreement of the remaining 
scale items. (The overall α for the original 24 item scale was 0.819) 
 
Principal component analysis (PCA) identified a general factor or component to which all 
but nerve pain, nerve tenderness and the number of inflamed lesions contributed 
accounting for 23.5% of total variance. 
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  Component 
  1 2 3 4 5 6 7 
SKIN   
Degree of inflammation of skin 
lesions 
.036 .151 .593 .229 -.290 -.282 -.122 
Number of raised or inflamed 
skin lesions 
-.006 .074 .658 .014 -.473 .006 .012 
Peripheral oedema due to 
reaction  
.300 -.043 .671 -.131 -.225 .283 .087 
NERVES  
Nerve pain -.190 -.050 .401 -.335 .190 .482 .349 
Nerve tenderness -.201 .182 .550 -.204 .305 .491 .104 
SYSTEMIC SIGN  
Fever .148 -.207 .437 .309 -.080 .202 -.123 
SENSORY  
Right trigeminal .022 .789 .060 .252 .446 .125 -.241 
Left trigeminal .022 .789 .060 .252 .446 .125 -.241 
Right ulnar .690 -.099 .083 -.381 .280 -.302 -.031 
Left ulnar .851 -.191 .030 .204 .035 .044 -.070 
Right median .725 -.103 .201 -.097 .218 -.254 -.207 
Left median .683 -.343 .133 .376 .203 -.014 -.239 
Right posterior tibial .683 .286 -.173 -.285 -.235 .204 -.240 
Left posterior tibial .631 .381 -.056 -.274 -.160 .167 -.311 
MOTOR  
Right facial .304 .644 -.025 .149 -.230 -.191 .509 
Left facial .331 .647 .006 .166 -.123 -.260 .467 
Right ulnar .632 -.092 -.356 .188 -.015 .277 .393 
Left ulnar .587 -.078 .068 -.424 .193 -.160 .157 
Right median .698 -.259 .119 .475 .076 .171 .178 
Left median .685 -.061 .277 .002 .102 -.279 .167 
Right radial .147 -.266 -.249 .552 .198 .313 .156 
Left radial .041 -.117 .039 -.407 .563 -.091 .275 
Right lateral popliteal .563 .094 -.214 -.268 -.269 .272 -.170 
Left lateral popliteal .396 .106 -.482 -.191 -.281 .351 .055 
            Extraction Method: Principal Component Analysis. 7 components extracted. 
Table 2.05.  Loadings for each item by component (factor) 
 
The important variables in the second factor accounting for 11.6% of the total variance 
were those related to the eye, namely, trigeminal nerve sensation and facial nerve motor 
function. The third factor which accounted for 10.7% contrasted individuals with skin signs 
and no NFI with those who only had NFI. 
The second factor explains the amount of variance that remains unaccounted for after the 
first component has been extracted. The second component is not correlated with the first 
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component, they are orthogonal. This is true of the relationship of the third factor to the 
second and so on. 
The contribution of the different scale variables to each component are shown in Table 
2.05. 
The Scree plot shows the eigenvalue for each component. The eigenvalue is an index of the 
variance accounted for by each component. The PCA identified seven components with an 
eigenvalue greater than one accounting for 73.8% of the total variance. 
Figure 2.03. Scree plot of eigenvalues for each component (factor)  
The expert assessment of the severity of the T1Rs was categorized as mild in 19 
individuals (23.5%), moderate in 40 (49.4%) and severe in 12 (14.8%). The severity was 
not recorded in 10 cases. 
The median scores for each category of reaction severity are shown in the box plot in fig. 
2.04 with the inter-quartile range (IQR).  
Outliers are indicated by either a circle or an asterisk which is labelled with the individuals 
unique study identifier. A circle indicates a result is 1.5 to 3 times the IQR. An asterisk is a 
more extreme outlier at > 3 times the IQR. 
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Figure 2.04. Severity scores and expert assessment of severity of T1R 
 
The median scores for each category were: mild = 5.0 (IQR=11), moderate = 10.5 
(IQR=13) and severe = 18.0 (IQR=29). 
The differences between the mild and moderate group and the moderate and severe groups 
did not reach statistical significance (p=0.053 and 0.052 respectively). The performance of 
the scale was not materially affected by excluding the seven individuals who did not have 
skin involvement.  
2.3.2.2 Inter-observer agreement 
Thirty nine individuals (27 from Bangladesh and 12 from Brazil) were recruited to the 
second stage of the study to assess inter-observer agreement. The details of these 
participants are presented in Table 2.06. 
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Study of Interobserver Agreement 
 Number (%) 
Number enrolled 39 
 
Male  29 (74.4) 
Female  
 
10 (25.6) 
Mean Age in years 
(range) 
40.9 (11-95) 
Type of leprosy 
 
 
BT 
BB 
BL 
LL 
PNL 
17 (43.6) 
3 (7.7) 
15 (38.5) 
4 (10.3) 
0 (0) 
First episode of Type 
1 reaction 
19 (48.7) 
Type of reaction 
 
 
Skin and nerves 28 (71.8) 
Skin only 9 (23.1) 
Nerves only 7 (5.1) 
Table 2.06. Description of 
participants in the reliability study 
 
The Intra-Class Correlation coefficient based on a two-way analysis of variance with 
random effects is 0.994. The strength of agreement is very good (Landis and Koch, 1977). 
A Bland and Altman plot (Bland and Altman, 1995) (fig.2.05) of the difference between 
the scores for pairs of observers plotted against the mean of the scores shows good 
agreement between observers with 95% of differences less than two standard deviations 
from the mean. 
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                    Figure 2.05. Plot using scores for each individual from both examiners. 
 
2.3.2.1 The Final scale 
The scale was adjusted and the analysis repeated in the light of the data obtained.  
The items nerve pain, nerve tenderness and fever were removed (see Appendix 4). The 
rationale for removing these items was that nerve pain and nerve tenderness performed 
least well of all the items in the scale (in terms of Cronbach’s alpha). Fever was removed 
because it occurred in only four of the 120 participants in the study as a whole.  
We felt it was important to retain the cutaneous signs and trigeminal and radial nerve 
function items as these are important clinical features of T1Rs. 
The scores for the sensory testing (using SWM and cotton wool) were reduced by 50% to 
make the maximum score possible for each sensory nerve three. This is the maximum score 
possible for each of the motor and cutaneous items. 
These adjustments result in the final scale which consists of 21 items and has a range of 0-
63. The maximum score possible for sections A, B and C are 9, 24 and 30 respectively. 
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The severity score for each of the 71 participants who had been categorised as mild or 
moderate or severe was recalculated using the final scale.  
For this adjusted version of the scale Cronbach’s alpha remained satisfactory at 0.833.  
The median scores for each severity group were: mild = 5.0, moderate = 7.5 and severe = 
15.25. The differences between the mild and moderate groups (p=0.038) and the moderate 
and severe groups (p=0.048) reached statistical significance. 
 
Figure 2.06. Final severity scores and expert assessment of severity of T1R 
 
Receiver operating characteristic (ROC) curves can be used to determine cut off points 
between two groups (Streiner and Norman, 2003).  
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Figure 2.07. ROC Curves (A) mild and moderate, (B) moderate and severe 
B 
A 
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ROC curves for the final scale scores was plotted for individuals identified as mild or 
moderate by the expert raters and for those categorized as moderate or severe (fig.2.07). 
This facilitates the determination of cut off scores for each category. 
Using the ROC curves in conjunction with a consideration of the clinical meaning of a 
given score we determined the following cut off points. This was done by choosing scores 
with a high sensitivity and reasonable specificity. 
 
Final Scale 
(Mild or 
Moderate) 
Scores Sensitivity 1 - Specificity 
MILD 
SCORES 
 
1.0000 1.000 1.000 
2.5000 1.000 .895 
3.5000 .875 .579 
MODERATE 
SCORES 
 
4.5000 .800 .526 
5.2500 .725 .368 
5.7500 .725 .316 
6.5000 .600 .263 
7.2500 .525 .263 
8.0000 .475 .263 
  8.7500 .450 .263 
  9.2500 .400 .211 
  10.0000 .375 .211 
  11.0000 .325 .211 
  11.7500 .275 .158 
  12.5000 .250 .158 
  13.5000 .175 .105 
  14.5000 .175 .053 
  15.2500 .150 .053 
  15.7500 .125 .053 
  17.2500 .100 .053 
  19.5000 .075 .053 
  21.2500 .075 .000 
  24.7500 .050 .000 
  32.7500 .025 .000 
 39.0000 .000 .000 
Table 2.07. Scores and cut offs for mild and moderate 
 
A mild T1R is characterized using the final scale by a score of 4 or less (see Table 2.07). A 
moderate reaction is a score of between 4.5 and 8.5.  
A severe reaction is a score of 9 or more (see Table 2.08).  
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Final Scale 
(Moderate or 
Severe) 
Scores Sensitivity 1 - Specificity 
 1.5000 1.000 1.000 
 2.7500 .917 1.000 
 3.5000 .917 .878 
MODERATE 
SCORES 
4.5000 .917 .805 
5.5000 .917 .732 
6.5000 .917 .610 
7.2500 .917 .537 
7.7500 .833 .488 
8.2500 .750 .488 
 8.7500 .750 .463 
SEVERE 
SCORES 
9.2500 .750 .415 
10.0000 .750 .390 
10.7500 .750 .341 
11.2500 .667 .341 
11.7500 .583 .293 
12.5000 .583 .268 
14.0000 .583 .171 
15.2500 .500 .146 
15.7500 .417 .122 
16.5000 .417 .098 
17.2500 .333 .098 
18.0000 .250 .098 
20.2500 .250 .073 
24.7500 .250 .049 
29.0000 .250 .024 
32.2500 .167 .024 
36.0000 .083 .024 
40.5000 .083 .000 
44.0000 .000 .000 
Table 2.08. Scores and cut offs for moderate and severe 
 
The area under the curve for mild and moderate categories is 0.701 for the final scale 
(0.688 for the original scale). The area under the curve for the moderate and severe 
categories is 0.734 for the final scale (0.731 for the original scale). These values indicate 
that the final scale is a fair discriminator between the severity categories traditionally used 
by clinicians. 
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2.4 Discussion 
In many branches of medicine a single test or diagnostic criterion is either not available or 
insufficient to adequately measure or describe a clinical syndrome. This has led to 
difficulties in measuring the severity and prognosis of conditions. The response by 
researchers has been to develop composite measurement scales. 
Psychologists have for many years been concerned with accurately measuring and 
predicting behaviour and there is a large literature on how to develop and test such 
measures (Cronbach and Meehl, 1955; Streiner and Norman, 2003).  
The use of unpublished scales to measure outcome has been shown to be a significant 
source of bias in psychiatry (Marshall et al., 2000). The lack of clear descriptions of scales 
and familiarity with them make clinical research difficult to interpret. 
A reliable 21 item severity scale to measure leprosy T1Rs has been developed and 
prospectively validated.  
The scale requires the examiner to be proficient in recognising the cutaneous signs of T1R, 
the assessment of VMT and the use of SWM. These skills are not widely practised even in 
many leprosy endemic countries and it is anticipated that the main use of this tool, at least 
initially, will be in research and referral settings. 
The scale is easy to use and requires little additional training or equipment for workers 
based in referral centres. Using a standard assessment form the additional time required to 
use the scale is minimal. 
T1Rs are a significant cause of nerve function impairment and this is the major concern of 
the physician managing a patient with this condition. The scale we have developed reflects 
the importance of NFI in the severity of T1Rs.  
VMT and SWM in the assessment of NFI have been shown to be reliable (Anderson and 
Croft, 1999). Monofilaments have been shown to be concordant with other sensory 
function tests (van Brakel et al., 2005a). These factors undoubtedly contribute to the 
robustness of the current scale but careful training and assessment of examiners is required 
(Roberts et al., 2007).  
In Nepal, Kets and colleagues reported monofilament touch sensibility thresholds in 136 
healthy volunteers to be 200 mg for the hand and 2 g for the sole of the foot (Kets et al., 
1996). These findings were supported by those of Anderson and van Brakel who reported 
similar findings in 600 healthy Nepalis. In addition they reported that the normal threshold 
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for the heel was 10 g (Anderson and van Brakel, 1998). These thresholds were used in the 
scoring system developed for the INFIR studies in which five monofilaments were used. 
The use of two monofilaments on the hands (2 g and 10 g) and feet (10 g and 300 g) 
simplifies the system used in the INFIR Cohort Study. However this also results in a higher 
sensory threshold before an individual’s NFI impacts on their T1R severity scale score.  
The rationale for using 2 g and 10 g on the hand is that thresholds of more than 2 g were 
associated with a loss of functional capability in leprosy patients in Nepal. Individuals 
unable to recognise a 2 g monofilament were not able to detect a 0.5 mm Braille-like dot in 
the corner of a smooth aluminium sheet. The majority of these individuals were also unable 
to differentiate between five different textures (smooth vinyl, sandpaper and textiles) (van 
Brakel et al., 1997). 
An inability to detect a 10 g monofilament on the foot is associated with an increase in 
plantar ulceration in leprosy patients in the United States (Birke and Sims, 1986). In a 
study conducted in Ethiopia a 10 g monofilament was a sensitive screening tool for 
detecting individuals with leprosy who were at risk of developing a plantar ulcer (Feenstra 
et al., 2001). 
In a study conducted in the United Kingdom an inability to feel a 10 g monofilament is an 
independent risk factor for ulceration in individuals with diabetes mellitus. The 10 g 
monofilament is recommended as a screening tool by the American Diabetes Association 
(American Diabetes Association, 2008).  
The INFIR Cohort study also used a single monofilament test site for the purely sensory 
radial cutaneous and sural nerves (van Brakel et al., 2005b). These two nerves are not 
commonly tested in routine clinical practice and are not included in the severity scale.  
The radial cutaneous and sural nerves may be assessed using various forms of quantitative 
sensory testing before new impairment identified by monofilaments is demonstrable. 
Recently published data analysing 188 individuals from the INFIR Cohort who did not 
present with reaction or nerve involvement  has shown that impairment identified using 
monofilaments occurred in the radial cutaneous nerve in 7% of individuals and in the sural 
nerve in 6.1% (van Brakel et al., 2008). However the definition of impairment in the radial 
cutaneous nerve was the inability to feel monofilaments less than 10 g or in the sural nerve 
less than 300 g (van Brakel et al., 2005b).  
The lack of a gold standard measure of T1Rs has resulted in us having to compare the scale 
with the variable and somewhat vague clinical categories of severity as mild, moderate or 
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severe. This has undoubtedly led to a degree of heterogeneity of T1R severity within these 
categories but despite this the scale has performed well. 
The final scale has a high degree of inter-observer reliability. We were unable to test intra-
observer reliability because of the effect of treatment on the signs of reaction. It would be 
unethical to withhold treatment. The assessment of intra-observer variation is desirable but 
not absolutely necessary in scales with a high level of inter-observer reliability (Streiner 
and Norman, 2003). This is because the sources of error that contribute to intra-observer 
variation will also contribute to inter-observer variation. There will also be additional 
sources of difference in inter-observer variation. The assessment of intra-observer variation 
has not been possible in the development of valid scales in other fields such as neurology 
(Wijdicks et al., 2005). 
Severity scales are widely used to quantify the severity of inflammatory dermatoses and 
neurological diseases. The Psoriasis Area Severity Index (PASI) was introduced 
(Fredriksson and Pettersson, 1978) without formal validation (Berth-Jones et al., 2006) as 
an outcome measure in the first trial of the retinoid etretinate in psoriasis. It has become the 
most widely used severity measure of psoriasis and clinicians are required to use it to 
assess the severity of psoriasis in individuals being considered for biological therapies in 
the UK (Smith et al., 2005).  
The PASI does show good reliability in terms of inter- and intra-observer agreement (the 
intra-class correlation coefficient for each being > 0.81) (Berth-Jones et al., 2006). The 
PASI has been criticised for not being a linear scale and for being difficult to use. A self 
administered version of the scale, the SAPASI, has been tested and declared valid although 
in order to test its validity it was compared to the PASI (Feldman et al., 1996). 
In atopic dermatitis it has been recognised that there are too many outcome measures used 
in clinical trials (Schmitt et al., 2007). Twenty measures of severity were identified but 
only three had undergone sufficient validation. The authors recommended that future 
studies use the Eczema Area Severity Index, the Patient-oriented Eczema Measure and the 
Severity Scoring of Atopic Dermatitis index (SCORAD). 
The most common neurological complication of HIV infection is a painful sensory 
neuropathy. The Subjective Peripheral Neuropathy Screen (SPNS) was developed to try 
and detect HIV-induced peripheral neuropathy or neuropathy secondary to antiretroviral 
therapy. This used self reported symptoms of neuropathy and was shown to be reliable 
(with a Cronbach alpha of 0.86) and valid. The SPNS differentiated between those who had 
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symptoms of neuropathy and controls. It also showed good agreement with objective 
quantitative sensory testing (McArthur, 1998). 
The use of valid severity scales to measure inflammatory skin disease and peripheral 
neuropathy demonstrate that the development of quantitative approaches to such disorders 
is possible. Leprosy T1Rs combine features of inflammatory skin disease and peripheral 
neuropathy. 
In its final form the adjusted severity scale for leprosy T1Rs and NFI is valid and sensitive. 
Neurological items are well represented and reflect the importance of nerve function 
impairment.  The addition of weighting of the different components of the scale would add 
to its complexity. An important issue that requires further work is that of determining the 
Minimally Important Difference (MID) from a patient perspective in scores derived from 
the scale before and after treatment. This is important because it provides a meaningful 
patient centred outcome measure of change. This is discussed further in the final chapter. 
The ability of the scale to reflect change following corticosteroid treatment of T1R and NFI 
is examined in Chapter 3 using a Nepali cohort. 
A consideration that has not been addressed is the performance of the scale in individuals 
who have nerve damage of greater than 6 months duration. The treatment of nerve damage 
present for this length of time with corticosteroids is not associated with significant clinical 
benefit compared to placebo (Richardus et al., 2003b). Nerve damage greater than six 
months duration should not be included in the severity score. The issue of longstanding 
NFI can be problematic as patients who are presenting for the first time may be unsure as 
to the duration of the NFI and may have some acute NFI in a nerve which already has some 
pre-existing permanent impairment. 
Longstanding nerve damage in an individual who experiences a T1R would lead to a higher 
score than an individual with an identical reaction but who has no pre-existing nerve 
damage. The severity of the T1R in the two individuals is presumably the same. However it 
could be argued that individuals who already have some degree of permanent nerve 
damage have less neurological reserve and are thus more at risk from even a mild reaction. 
This however needs to be formally tested.  
This is the first prospective validation of a severity scale for leprosy T1Rs. It is hoped that 
this scale will prove a useful tool in more accurately assessing T1Rs particularly in clinical 
trials where the ability to accurately compare the severity of T1Rs in different patients is 
vital.  
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3.1 Overview of trial 
Oral corticosteroids are the mainstay of treatment of leprosy T1R. However treatment with 
a  standardised 12 week course of oral prednisolone (total dose 1.68 g) which had been 
used in a previous pilot study in Nepal resulted in 37% of  individuals requiring additional 
prednisolone (Marlowe et al., 2004). The randomized controlled treatment trials TRIPOD 2 
and TRIPOD 3 that were reported during the design of this study had both used a 16 week 
course of oral prednisolone (total dose 2.52 g) (Richardus et al., 2003b; van Brakel et al., 
2003). It was decided to compare pulsed methylprednisolone and oral prednisolone with a 
16 week course of oral prednisolone (total dose 2.52 g) alone. High dose IV MP had not 
been used previously in a trial of treatment of leprosy T1R so a Phase 2 trial was needed to 
confirm safety before considering whether to proceed to a larger Phase 3 trial of clinical 
efficacy.  
A Phase 2 trial made it possible to assess the adverse effect profile of methylprednisolone 
when used in leprosy patients and patient tolerability for methylprednisolone in the Nepali 
setting. 
We wished to recruit 60 individuals in total. This number was felt to be feasible in the time 
available. The recruitment started on 7
th
 December 2005 and ended on 31
st
 December 2007. 
The final assessment was completed and the data entered into the Access database on 5
th
 
November 2008.  
3.2 Aims of trial 
1. To assess the safety and tolerability of high dose methylprednisolone in patients 
with leprosy T1Rs and patients with leprosy associated acute neuritis with nerve 
function impairment in Nepal. 
2. To assess the effect of high dose methylprednisolone on the clinical outcome of 
leprosy T1Rs and leprosy associated acute neuritis with nerve function impairment. 
3.3 Methods 
A double blind randomised placebo controlled trial was designed to compare early high 
dose IV methylprednisolone, followed by oral prednisolone (P) with oral prednisolone 
alone as the control. It is not ethical to use an inactive agent as placebo on its own. 
Individuals received IV normal saline placebo and oral prednisolone. The participants were 
treated with corticosteroids for 16 weeks. The total period of follow-up was 48 weeks from 
entry into the trial.  
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3.3.1 Participants  
Participants in the trial were recruited from the leprosy service of Anandaban Hospital, 
Kathmandu, Nepal.  
3.3.2 Study location  
Nepal is a landlocked country situated between India and China with a population of 
approximately 23 million. It is one of the poorest countries in the South Asia region (only 
Afghanistan and Bhutan have lower purchasing power parity gross national incomes).  
Skin disease is common in Nepal particularly in rural areas (Walker et al., 2008). 4708 new 
cases of leprosy were reported in 2008. The overall leprosy prevalence rate of 2.0 per 10 
000 population but this is higher in rural areas such as the Terai (Jain, 2008; WHO, 2009). 
Anandaban Hospital is the leprosy referral centre for the central region of Nepal. The 
hospital provides a weekly outpatient clinic and a full range of inpatient services to leprosy 
affected people free of charge. Anadaban Hospital is funded by The Leprosy Mission 
Nepal. 
3.3.3 Ethical Approval  
The study was approved by the Nepal Health Research Council and the Ethics Committee 
of the London School of Hygiene and Tropical Medicine (Number 4022). 
3.3.4 Consent 
Informed consent was obtained by a native Nepali speaker after s/he had fully explained 
the trial and answered any questions. The trial consent forms and information leaflets were 
available in Devanagari script. The consent forms were signed by all participants (if they 
were unable to sign, a mark or thumb print was used instead and witnessed by the person 
obtaining the consent).  
3.3.5 Good Clinical Practice  
The study adhered to the guidelines of the International Conference on Harmonisation of 
Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) Good 
Clinical Practice. The trial monitors were Dr K V Krishna Moorthy, Blue Peter Research 
Centre, Hyderabad, India and Dr P S S Sundar Rao, The Leprosy Mission, Delhi, India. 
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3.3.6 International Standard Randomised Controlled Trial Number 
The trial was registered with Current Controlled Trials Ltd (www.controlled-trials.com) in 
accordance with the policy of the International Committee of Medical Journal Editors 
(Moher et al., 2001) and was assigned the unique identifier ISRCTN31894035.  
3.3.7 Diagnosis of leprosy 
A person was diagnosed as having leprosy if they had hypopigmented, anaesthetic skin 
patches and/or thickened nerves and/or acid-fast bacilli on slit skin smears. Individuals 
were also diagnosed as having leprosy if the histological features of the disease were 
present in a skin or nerve biopsy. All participants in the study had a confirmatory skin 
biopsy. 
3.3.8 Definitions of terms used in the study  
A T1R was present if an individual with leprosy experienced the acute development of 
erythema and oedema of skin lesions and/or inflammation of nerves and/or oedema of the 
hands, feet and face.  
New NFI is defined as less than 6 months duration of reduction in sensory, motor or 
autonomic function on history or examination.  
Neuritis is the presence of spontaneous nerve pain, tenderness or paraesthesia. 
Deterioration in symptoms or re-reaction was defined as a sustained deterioration for a 
period of at least two weeks of nerve function, the development of nerve pain unresponsive 
to analgesics, palpable swelling of skin patches or new erythematous and raised skin 
patches. Any decline in nerve function which the study doctors believed required 
immediate additional prednisolone was also regarded as deterioration.  
3.3.9 Eligibility 
Two groups of individuals were eligible for entry into the trial: 
1. Individuals diagnosed as having leprosy with clinical evidence of Type 1 reaction 
of less than six months duration.  
2. Individuals diagnosed with leprosy with new (less than six months duration) nerve 
function impairment without inflammation of skin lesions (if skin lesions were 
present). 
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Participants with any type of leprosy of the Ridley-Jopling Classification (Ridley and 
Jopling, 1966) were eligible. 
Participants had to be adults aged between 16-65 years and weigh more than 30 kg. 
One criterion for an individual’s eligibility for the study was modified in September 2006 
following a review of the study by the trial committee (Dr Susmita Dhakal, Dr Rachel 
Hawksworth, Professor Diana Lockwood, Dr Peter Nicholls and Dr Stephen Walker).  
At the time the committee met the trial had been recruiting for nine months. In that time 
only 14 participants had been enrolled. It was determined that recruitment had been optimal 
by reviewing a random sample of clinical records from the leprosy clinic. 
At first, enrolment into the study required individuals with clinical evidence of a T1R to 
have associated nerve function impairment. This was changed so that individuals with 
T1Rs involving the skin only would also be eligible for enrolment. 
The change to this eligibility criterion was approved by the two Ethics committees. 
3.3.10 Exclusion criteria 
Individuals unwilling to give consent or return for follow-up were excluded. 
Individuals who had taken systemic steroids within three months of enrolment were 
excluded.  
Individuals who had received other immunosuppressant therapy including thalidomide 
within three months of enrolment were excluded. 
Individuals with severe active infection such as tuberculosis or severe intercurrent disease 
were not enrolled into the trial.  
Individuals with a contraindication to high dose methylprednisolone such as peptic ulcer 
disease, diabetes mellitus, glaucoma and uncontrolled hypertension or known allergy to 
methylprednisolone were also excluded.  
Pregnant women were excluded and females of child bearing capacity were not recruited 
unless they had at least one month of adequate contraception.  
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3.3.11 Randomisation 
Block randomisation in groups of four using a table of random numbers generated by Dr 
Peter Nicholls was used. A standard envelope system was used for allocation concealment. 
The envelopes were pre-packed in London by Dr Claire Watson. 
The allocation procedure was decentralized and operated solely by the chief pharmacist at 
Anandaban Hospital who kept a separate record of the allocation.  The pharmacist had no 
contact with the study participants during their inpatient stay. 
The participants were randomly allocated to the methylprednisolone/prednisolone or the 
prednisolone alone arm and so had an equal chance of being in either arm of the study. 
All study participants, physicians, ward staff and other assessors (physio-technicians) were 
blinded to the allocation. Only Dr Peter Nicholls had access to the study data and the 
randomisation code. The allocation code was revealed to the researchers once recruitment, 
follow-up, data collection and laboratory analyses had been completed (March 2009). 
3.3.12 Treatment regimen 
Individuals were randomly allocated to receive 1 gram of IV methylprednisolone in normal 
saline infused (over one hour) daily for 3 days plus eight placebo tablets (Comprehensive 
Medical Services India, Chennai India) daily or an identical normal saline infusion plus 
eight prednisolone 5 mg tablets daily for three days. 
Methylprednisolone (as the sodium succinate) was supplied as a powder in vials containing 
1 g. It was reconstituted with water for injection, mixed thoroughly and added to 500 ml of 
Normal saline by the chief pharmacist.   
The infusions were administered in hospital by the enrolling physician or the nursing staff. 
The participants were given the tablets by the nursing staff who observed them being taken. 
 The study participants stayed in hospital until at least the second assessment. This was 
conducted on day 4 of the study; the day after the third infusion had been completed.  
Individuals in the two groups from day 4 continued treatment with identical tablets in a 
standard reducing schedule of oral prednisolone until they had received a total of 16 weeks 
of treatment with corticosteroids (Table 3.01.).   
An individual allocated to the methylprednisolone group received a total dose of 
corticosteroid equivalent to 6.15 g of prednisolone. Individuals in the prednisolone alone 
group received 2.52 g of prednisolone in total. 
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Assessment 
Number 
Time 
point 
Prednisolone alone 
arm 
(Total corticosteroid 
dose = 2.52 g 
of prednisolone) 
Methylprednisolone/Prednisolone 
arm 
(Total corticosteroid dose equivalent 
to 6.15 g of prednisolone) 
1 Day 1 
Placebo infusion + 
Prednisolone 40 mg 
Methylprednisolone 1 g IV 
+ 8 placebo tablets 
 Day 2 
Placebo infusion + 
Prednisolone 40 mg 
Methylprednisolone 1 g IV 
+ 8 placebo tablets 
 Day 3 
Placebo infusion + 
Prednisolone 40 mg 
Methylprednisolone 1 g IV 
+ 8 placebo tablets 
2 
Days  
4-7 
Prednisolone 40 mg Prednisolone 40 mg 
3 
Days  
8-14 
Prednisolone 40 mg Prednisolone 40 mg 
4 
Days 
15- 21 
Prednisolone 35 mg Prednisolone 35 mg 
 
Days 
22- 28 
Prednisolone 35 mg Prednisolone 35 mg 
5 
Day  
29-35 
Prednisolone 30 mg Prednisolone 30 mg 
 
Days 
36-42 
Prednisolone 30 mg Prednisolone 30 mg 
 
Days 
43-49 
Prednisolone 25 mg Prednisolone 25 mg 
 
Days 
50-56 
Prednisolone 25 mg Prednisolone 25 mg 
6 
Days 
57-63 
Prednisolone 20 mg Prednisolone 20 mg 
 
Days 
64-70 
Prednisolone 20mg Prednisolone 20mg 
 
Days 
71-77 
Prednisolone 15 mg Prednisolone 15 mg 
 
Days 
78-84 
Prednisolone 15 mg Prednisolone 15 mg 
7 
Days 
85-91 
Prednisolone 10 mg Prednisolone 10 mg 
 
Days 
92-98 
Prednisolone 10 mg Prednisolone 10 mg 
 
Days 
99-105 
Prednisolone 5 mg Prednisolone 5 mg 
 
Days 
106-112 
Prednisolone 5 mg Prednisolone 5 mg 
8 Day 113 No corticosteroids No corticosteroids 
Table 3.01. Treatment regimen for the methylprednisolone study 
 
Deterioration in nerve function or skin signs was treated with further prednisolone. 
Individuals deteriorating on a dose of prednisolone less than 20 mg daily had the dose 
increased back to 20 mg and reduced as per the above regimen. The exception to this was if 
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they had a T1R involving a facial patch. Individuals taking a dose of prednisolone greater 
than 20 mg had their dose increased to 40 mg and tapered as per the above protocol. 
All participants in the study were given the anti-helminthic agent albendazole 400 mg daily 
for the first three days of the study. This was done to minimise the risk of helminth 
infections and in particular hyperinfection by Strongyloides stercoralis (Leang et al., 
2005). The histamine H2-receptor antagonist famotidine 40mg daily was prescribed to all 
individuals whilst they were taking corticosteroids. 
Standard, appropriate WHO MDT was commenced in individuals who were newly 
diagnosed with leprosy and continued in those who had not received a full course of either 
six or 12 months for PB or MB disease respectively. 
3.3.13 Baseline demographic and clinical data 
The patients name, age, occupation and level of literacy were recorded. Details about the 
time since leprosy symptoms first developed, the Ridley-Jopling classification of their 
disease and treatment with MDT were all recorded. Each participant was assigned a unique 
trial number. 
Nerve function impairment present for more than six months was recorded. The nerve 
involved and the functional modality affected (sensory or motor) was also documented. 
A detailed history of their skin and nerve symptoms was taken. The number and 
morphology of skin lesions, the presence of peripheral oedema, nerve tenderness, 
paraesthesia or nerve pain were recorded. 
The individual’s weight, height, temperature and blood pressure were recorded.  
The skin was examined and the features of the skin signs including number and 
morphology of lesions and the presence of erythema or ulceration were recorded. 
Sensory testing (ST) was performed using two SWM (Sorri-Bauru, Bauru, São Paulo, 
Brazil) at designated test sites on the hands and feet (see fig. 2.01, Chapter 2). The ulnar 
and median nerves were tested with 2 g and 10 g monofilaments. The posterior tibial nerve 
was tested with the 10 g and 300 g monofilaments. Trigeminal nerve sensation was tested 
using cotton wool.  
VMT was assessed using the modified Medical Research Council grading of power (Brain, 
2000). The facial nerve was tested by assessing forced eye closure. The median nerve was 
tested using resisted thumb abduction, the ulnar nerve by resisted little finger abduction and 
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the radial nerve by resisted wrist extension. The lateral popliteal nerve was tested by 
resisted foot dorsiflexion.  
ST and VMT assessments were carried out by trained physio-technicians and if necessary 
repeated by the study physicians. 
The results of the examination findings were recorded and a Clinical Severity Score 
calculated using the severity scale that was undergoing validation testing in Bangladesh 
and Brazil (see Chapter 2). 
3.3.14 Baseline laboratory investigations  
All participants in the study had the following investigations performed on entry into the 
trial: 
A full blood count, serum creatinine and random blood glucose were taken. A stool sample 
was examined for ova, cysts and parasites. A chest radiograph was performed. On the first 
three days of the study a daily sputum specimen was examined for the presence of AFB. A 
pregnancy test was performed on all females of childbearing capacity. 
The investigations were performed at Anandaban Hospital and had to be normal or 
negative prior to commencement of the trial drugs. Any parasites identified on stool 
microscopy that were not sensitive to albendazole were treated appropriately. Chest 
radiograph abnormalities were reviewed by two physicians and a decision made as to 
whether the participant could continue in the study. 
Slit skin smears were taken from four sites to determine the mean BI if the participant had 
not had one done in the three months prior to enrolment in the trial. This investigation is 
also performed at Anandaban Hospital. 
A skin biopsy (6mm punch, Stiefel Laboratories Ltd, High Wycombe, UK) was performed 
to determine the Ridley-Jopling classification in those individuals who had not already had 
a biopsy. The skin was fixed in formalin and examined by an experienced leprosy 
histopathologist at one of two Leprosy Mission Hospitals in India, Dr Lakshmi Rajan 
(Delhi) or Dr Joyce Ponnaiya (Karigiri). 
3.3.15 Clinical assessments during the study 
Participants were assessed by a study physician prior to treatment and then at day 4 (after 
the three IV infusions) and then days 8, 15, 29, 57, 85, 113, 141, 169, 197, 225, 253, 281, 
309 and 337. A total of 15 assessments during the 48 week follow-up period. 
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The assessments were standardised. Participants were questioned about skin and nerve 
symptoms and potential adverse effects related or attributable to corticosteroids.  
The same skin and nerve function assessments were performed as at baseline. The 
individual’s weight, temperature and blood pressure were recorded. The participant’s urine 
was tested with urine test strips at each visit to screen for glycosuria. 
The assessor recorded the total amount of prednisolone that was prescribed at that visit and 
whether there was any need for additional prednisolone. 
3.3.16 Study specimens  
All participants provided a skin biopsy (6mm punch) at baseline, day 4 or day 29 and week 
17. These specimens were bisected. One half was snap frozen in liquid nitrogen. The other 
half was immersed in RNAlater
TM 
(Ambion
 
Inc., Austin, Texas, USA) and kept at 4°C 
overnight. The following day the RNAlater
TM
 was discarded and the skin sample stored at  
-80°C.  
These samples were transported to the UK in a liquid nitrogen Dewar flask (CP100 Jencons 
(Scientific) Ltd.) and stored at the London School of Hygiene and Tropical Medicine in 
liquid nitrogen. 
3.3.17 Data recording and management 
All data were recorded at each assessment on standardised forms. The study forms were 
kept in a separate set of case notes from the ordinary hospital record. All study records 
were kept in a locked area to which access was limited. The data were entered into a secure 
anonymised Microsoft Office Access database by Dr Walker.  
3.3.18 Statistical analysis 
The data were analysed using the Statistical Package for the Social Sciences (SPSS version 
16. SPSS Inc., Chicago, Illinois). 
An intention to treat analysis was used for calculating the effects of treatment on 
individuals in each group. 
3.3.19 Outcome measures 
The primary outcome measure was the frequency of adverse events in the two treatment 
arms. Adverse events were enquired about at each assessment. Study form 6 (see Appendix 
3.11) contained a list of adverse events attributable to corticosteroids which participants 
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were asked if they had experienced. There was also a free text space available where other 
symptoms mentioned by the study participants or identified by the physician could be 
recorded. 
Adverse events were defined as major or minor in accordance with the classification used 
in the TRIPOD studies (Richardus et al., 2003a). 
Minor adverse events were defined as moon face, dermatophyte fungal or yeast infections, 
acne and gastric pain requiring an antacid (in addition to the famotidine each individual 
was prescribed whilst on corticosteroids). Individuals were questioned about the symptoms 
of nocturia, polyuria and polydipsia as a method of screening for diabetes mellitus in 
addition to urinalysis.  
Major adverse events were defined as psychosis, peptic ulcer, glaucoma, cataract, diabetes 
mellitus, severe infections (including tuberculosis), infected neuropathic ulcers and 
hypertension. 
Secondary outcomes measures were:  
 change in clinical nerve function impairment and Clinical Severity Score at 
days 4, 29, 113 and 337.  
 time to the next steroid requiring reactional episode or acute nerve function 
impairment  
 the amount of supplementary prednisolone required in addition to the reducing 
16 week regimen.  
A post-hoc physician assessment of neurological outcome was determined in those 
individuals who had nerve function impairment and had completed the course of treatment. 
The designated outcomes were one of: recovered, improved, unchanged or worse.  
Recovery was defined as the ability to feel the 2 g monofilament at all test sites on the 
hands, the 10 g at all sites on the feet and have grade 5 power in all tested muscles. 
The assessment was done by comparing participants’ baseline sensory and motor 
examinations with that of their last recorded assessment. The clinical severity score was not 
used to determine this outcome.  
3.3.20 Power calculation 
The proportion of Nepali individuals experiencing a major adverse effect in the 
prednisolone treated groups in the three TRIPOD studies was 2.4% (4 of 167) and the rate 
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of minor adverse effects in the prednisolone groups in the three TRIPOD studies was 8.4% 
(14 of 167) (Richardus et al., 2003a). The figure for the major adverse effects reported in 
the paper cited was a combined figure for Bangladesh and Nepal. A figure for the Nepali 
participants was calculated from the original TRIPOD data (supplied by Dr P. Nicholls). 
This was done because there was an appreciable difference in the adverse effects rates for 
the two countries. The rate of minor adverse effects for oral prednisolone in the three 
studies was 28% in Bangladesh compared to 8.4% in Nepal. 
The prednisolone treated groups received a total dose of prednisolone of either 1.96 g 
(TRIPOD 1 (n=636)) or 2.52 g (TRIPOD 2 and TRIPOD 3 (n = 179)). In this study we 
planned to compare methylprednisolone 1 g IV and oral prednisolone with a 2.52 g total 
dose 16 week course of oral prednisolone. The combined major adverse effect rate for the 
Nepali participants who received prednisolone in TRIPOD 2 and TRIPOD 3 was 
calculated. Two individuals out of a total of 47 who received prednisolone experienced a 
major adverse effect (4.3%). 
In order to have 80% power to show that methylprednisolone was not associated with a 
significantly greater (α < 0.05) rate of major adverse effects it was calculated that the study 
would need 201 participants in each group based on a higher rate of 7%. Using this same 
assumption but with the TRIPOD data for all the Nepali participants (major adverse effect 
rate of 2.4%) then 64 individuals would be needed to be enrolled in each arm. 
3.4 Results 
3.4.1 Participants 
42 patients were enrolled into the trial between 7
th
 December 2005 and 31
st
 December 
2007. 33 males and nine females were recruited.  
22 individuals were randomized to the prednisolone only group. There were no statistically 
significant differences between the groups with respect to gender, age, Ridley-Jopling 
classification, or treatment with MDT. 
  
105 
 
  
Study Number Gender Age Occupation 
Classification 
Reaction Type Ridley 
Jopling  WHO  
AN01 Male   36 Farmer BL MB Nerves Only     
AN02 Male   28 Carpet weaver BT MB Skin and Nerves 
AN03 Male   23 Labourer BT MB Skin and Nerves 
AN04 Male   49 Farmer BL MB Skin and Nerves 
AN05 Male   64 Farmer LL MB Skin and Nerves 
AN06 Male   24 Student BL MB Skin and Nerves 
AN07 Male   16 Student TT MB Skin and Nerves 
AN08 Male   24 Shop worker BT MB Skin and Nerves 
AN09 Male   42 Technician BT MB Nerves Only     
AN10 Male   65 Farmer BL MB Nerves Only     
AN11 Female 17 Student BL MB Skin and Nerves 
AN12 Male   55 Farmer BL MB Nerves Only     
AN13 Male   63 Farmer BL MB Skin and Nerves 
AN14 Female 18 Unemployed BT PB Skin and Nerves 
AN15 Female 35 Housewife BT MB Nerves Only     
AN16 Female 39 Farmer BT PB Nerves Only     
AN17 Female 42 Farmer BB MB Skin and Nerves 
AN18 Male   41 Farmer BL MB Skin and Nerves 
AN19 Male   54 Farmer BL MB Skin and Nerves 
AN20 Female 54 Farmer BT MB Skin and Nerves 
AN21 Male   53 Driver LL MB Nerves Only     
AN22 Male   16 None BT MB Nerves Only     
AN23 Male   29 Barber BT PB Skin and Nerves 
AN24 Male   33 Labourer BT PB Nerves Only     
AN25 Male   44 Labourer BT MB Skin and Nerves 
AN26 Male   28 Carpenter BT MB Skin and Nerves 
AN27 Male   40 Silver industry BB MB Skin Only       
AN28 Male   59 Farmer BL MB Skin Only       
AN29 Male   28 Driver BT MB Skin Only       
AN30 Male   35 Farmer BT MB Nerves Only     
AN31 Male   18 House servant BB MB Skin Only       
AN32 Male   36 Weaver BT MB Nerves Only     
AN33 Female 35 Housewife BT MB Skin Only       
AN34 Male   40 Farmer BL MB Nerves Only     
AN35 Male   27 
 
BT MB Skin Only       
AN36 Male   62 Farmer BT MB Skin and Nerves 
AN37 Female 17 Housewife BT MB Skin and Nerves 
AN38 Male   55 Driver BT MB Nerves Only     
AN39 Female 40 Housewife BT MB Skin Only       
AN40 Male   41 Farmer BL MB Skin and Nerves 
AN41 Male   23 Waiter BL MB Skin Only       
AN42 Male   22 Farmer BT MB Nerves Only     
Table 3.02. Description of MP study participants 
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Analyzed (n=22) 
 
 Excluded from analysis 
(n=0) 
Lost to follow-up 
(n=5) 
 
Discontinued 
intervention (n=1) 
    
Prednisolone alone (n=22) 
Received prednisolone 
(n=22) 
Did not receive 
prednisolone (n= 0) 
Lost to follow-up (n=3) 
 
Discontinued 
intervention (n=1) 
 
   
Methylprednisolone (n=20) 
 
Received MP (n=20) 
 
Did not receive MP (n=0) 
 
Analyzed (n= 20) 
 
Excluded from analysis 
(n=0) 
    
Allocation 
Analysis 
Follow-Up 
42 individuals randomly allocated to treatment 
Figure 3.01. CONSORT flow diagram for the pilot study of individuals randomized to either 
intravenous methylprednisolone and oral prednisolone or oral prednisolone alone. 
107 
 
Table 3.03. Description of study participants in each arm 
 
The two groups did not differ significantly in terms of the nature of the reaction, the type of 
nerve function impairment at baseline or the  pattern of old (> 6 months) nerve function 
impairment.  
 
Table 3.04. Reaction type and nerve involvement of study participants 
 
A majority (69%) of participants had negative slit-skin smears. The preponderance of 
smear negative cases is similar to that in the INFIR Cohort study where 63.7% of the MB 
patients were smear negative (van Brakel et al., 2005b). The number of participants in each 
arm of the study and their mean bacterial indices is shown in Table 3.05. 
Sex Female 5 4
Male 17 16
Median Age Female 39 (19;35-54) 17.5 (25;17-42)
[years (Range;Min-Max)] Male 40 (43;22-65) 28.5 (48;16-64)
Ridley-Jopling Classification TT 0 1
BT 11 12
BB 0 3
BL 10 3
LL 1 1
Multi-drug Therapy status Started at enrolment 3 5
Current 14 10
Completed 5 5
Prednisolone 
(n=22)
Methylprednisolone 
(n=20)
Prednisolone Methylprednisolone p value
(n=22) (n=20)  (Significance p<0.05)
Reaction Type Skin Only 4 4
Skin and Nerves 8 13
Nerves Only 10 3 0.87
Baseline Nerve Status No loss 3 4
New 10 14
Old 1 0
Old and new 8 2 0.149
Type of nerve involvement None 3 4
Sensory 3 3
Motor 3 4
Mixed 13 9 0.821
Old nerve  impairment pattern None 13 18
Sensory 3 1
Motor 1 0
Mixed 5 1 0.145
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Mean bacterial index 
Prednisolone (n=22) 
(%) 
Methylprednisolone  
(n=20) (%) 
 
     
 
0 13 (59.1) 16 (80) 
 
 
Up to and including 1 1 (4.5) 2 (10) 
 
 
Up to and including 2 3 (13.6) 1 (5) 
 
 
Up to and including 3 4 (18.2) 0 
 
 
Up to and including 4 1 (4.5) 1 (5) 
 
 
Up to and including 5 0 0 
 
 
Up to and including 6 0 0 
 Table 3.05. Mean bacterial index of participants in study 
 
  
3.4.2 Incomplete follow-up  
    Study 
Number 
Arm Number of 
assessments 
Number of days in the 
trial 
AN12 P 4 19 
AN15 P 9 147 
AN18 P 13 281 
AN19 MP 12 202 
AN20 P 13 272 
AN26 MP 8 119 
AN37 MP 4 14 
AN42 P 13 299 
Table 3.06. Participants who did not complete follow-up 
Eight participants (19%) did not complete the full schedule of follow-up. Five were 
randomised to the prednisolone arm and three received methylprednisolone. Efforts were 
made to get these individuals to attend by telephoning or writing to them but without 
success. Two of these individuals stopped attending whilst on corticosteroids.  
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3.4.3. Nerve impairment greater than six months at baseline 
Eleven (26.2%) participants had nerve function impairment which they reported as being 
present for more than six months. In the INFIR cohort 26.1% of individuals had 
longstanding NFI (van Brakel et al., 2005b) and 24.6% in a Bangladeshi cohort studied 
retrospectively (Richardus et al., 1996). 
A total of 26 out of 504 (5.2%) nerves were affected. Twenty-one out of 336 (6.3%) 
sensory nerves and 15 out 420 (3.6%) motor nerves had detectable nerve function 
impairment reported to be of greater than six months duration. The ulnar and median 
nerves have both sensory and motor functions.  
One individual (AN18) had six different nerves involved. Figure 3.02 shows the number 
and pattern of impairment for each individual. Table 3.07 shows each individuals impaired 
nerves and how their monofilament or motor scores differed between enrolment and the 
last assessment. 
 
 
Figure 3.02 Individuals with NFI greater than 6 months duration at baseline 
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Figure 3.03 shows the frequency of involvement of each peripheral nerve. The posterior 
tibial and ulnar nerves were the most commonly affected. Longstanding nerve impairment 
was more frequently sensory which is in keeping with previous studies of nerve 
involvement in leprosy (Croft et al., 1999; van Brakel et al., 2005a).  
 
 
Sixteen (76.2%) sensory nerves and 6 (40%) motor nerves showed some improvement in 
monofilament score or VMT score respectively during corticosteroid therapy. 
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Fig. 3.03 Number of nerves impaired for more than six months
(Total number of nerves in study)
Sensory nerves (n=336) Motor nerves (n=420)
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Study 
number 
Arm Nerve  Baseline score 
Last recorded 
score 
AN8 P 
Left posterior tibial 3 2 
Right posterior tibial* 3 3 
AN10 P Left facial nerve 1 0 
AN15 P Left ulnar* 3 3 
Left ulnar (motor)* 3 3 
Right ulnar* 3 3 
Right ulnar (motor)* 3 3 
Left median* 3 3 
Left median (motor)* 3 3 
Right median* 3 3 
Right median (motor) 2 3 
AN16 P Left ulnar (motor)* 3 3 
Right ulnar (motor) 1 0 
AN18 P Left facial (motor) 2 2 
Right facial (motor) 2 2 
Left ulnar 1.5 2.5 
Left median 2 2.5 
Left posterior tibial* 3 3 
Right posterior tibial 1.5 3 
AN24 P Right median 2 2 
AN30 P Left ulnar* 3 3 
Left ulnar (motor)* 3 3 
Right ulnar (motor)  1 0 
Left median* 3 3 
Left median (motor)* 3 3 
Left posterior tibial* 3 3 
Right posterior tibial 3 2.5 
AN34 P Left posterior tibial 2.5 2 
Right posterior tibial 1.5 0 
AN36 MP Left posterior tibial 2.5 2.5 
Right posterior tibial 0.5 1 
AN38 MP Left ulnar* 3 3 
Left ulnar (motor)* 3 3 
Left median* 3 3 
Left median (motor)* 3 3 
AN39 P Right ulnar (motor) 1 0 
(*indicates complete loss with no change) 
Table 3.07. Nerves reported to have been affected for more than six months 
and their scores at the beginning and end of treatment 
  
In contrast to what was seen during corticosteroid therapy at the last recorded assessment 
only one (4.8%) sensory nerve (posterior tibial AN34) had recovered, three (14.3%) 
posterior tibial nerves had improved by a median monofilament score of 0.5. Thirteen 
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(61.9%) were unchanged (including 11 nerves with a maximum monofilament score of 
three) and four sensory nerves had deteriorated by a median score of 0.75. 
Four (26.7%) motor nerves recovered but all had the mildest possible deficit at baseline; a 
VMT score of one (equivalent to MRC grade 4 power). Ten (66.7%) motor nerves were 
unchanged, including eight that had a maximal VMT score of three. One motor nerve 
(median AN15) deteriorated from a VMT score of two to three. 
3.4.4 Adverse Events 
Table 3.08 shows the number of individuals who experienced a particular adverse event. 
Twenty-three participants experienced at least one adverse event, twelve (54.5%) in the 
prednisolone arm and 11 (55%) in the methylprednisolone arm. Seven individuals 
experienced more than one adverse event. There were no statistically significant 
differences in the number of individuals experiencing a given adverse event between the 
two groups of the study. 
Two individuals (one from each arm of the study) experienced a major adverse event. One 
was diagnosed with glaucoma and the other with infected neuropathic ulcers. None of the 
participants developed hypertension, tuberculosis or diabetes mellitus. 
 
Table 3.08. Minor and major adverse events in both arms of the study 
    
The risk ratio of having an adverse event (of any type; major or minor) given that the 
participant received methylprednisolone was 1.0083 (95% CI: 0.5817 to 1.7480; p=0.9764) 
compared to prednisolone.  
 
Adverse Event Prednisolone Methylprednisolone
chi square
(Fisher's exact)
Minor
Moon Face 2 6 0.123
Acne 5 5 1
Fungal infection 0 1 0.476
Gastric pain 5 2 0.414
NPP 2 2 1
Weight gain 1 0 1
Major Glaucoma 1 0 1
Infected ulcers 0 1 0.476
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Study 
Number 
Arm Adverse events Timing 
of 
adverse 
events 
(days) 
Additional 
corticosteroids 
AN01 P Acne 56 No 
AN03 MP Acne 77 Yes 
AN04 P Glaucoma 305 Yes 
AN05 MP Moon face 138 Yes 
AN06 P Acne 14 Yes 
AN07 MP Moon face 85 No 
AN08 P Acne 57 Yes 
AN09 MP Acne 14 Yes 
  Fungal infection 14  
  Moon face 57  
  NPP 204  
AN10 P NPP 7 Yes 
  Gastric pain 29  
  Moon face 57  
AN13 MP NPP 4 No 
  Moon face 29  
AN14 MP Acne 27 No 
  Moon face 55  
AN16 P Gastric pain 26 Yes 
  Moon face 55  
AN17 MP Moon face 83 Yes 
AN21 P NPP 7 No 
  Weight gain 259  
AN22 MP Acne 54 No 
AN24 P Acne 56 Yes 
AN29 MP Acne 3 Yes 
  Gastric pain 3  
AN32 P Acne 83 Yes 
AN33 P Gastric pain 21 Yes 
     
AN36 MP Infected ulcers 170 No 
AN37 MP Gastric pain 3 No 
AN39 P Gastric pain 13 No 
AN42 P Gastric pain 243 Yes 
Table 3.09. Timing of adverse events for each individual 
 
Table 3.09 shows the timing of adverse events experienced by each individual. AN36 was 
randomized to the methylprednisolone arm of the study and developed infected neuropathic 
ulcers. This adverse event occurred at day 170. AN04 developed glaucoma at day 305 
following additional courses of prednisolone for ENL. 
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There was no significant association between the occurrence of adverse events and the 
prescribing of additional prednisolone. 
 
 
Figure 3.04 Time to first adverse event 
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Figure 3.05 Tinea cruris (AN9) 
 
Individuals were most likely to experience an adverse event whilst taking the first course of 
corticosteroids between days 1 and 112. Fig 3.04 is a Kaplan-Meier survival curve showing 
the cumulative “survival” probability (i.e.  not having an adverse event) for individuals in 
each group. There was no significant difference between the two groups (Log Rank 
(Mantel-Cox) 0.945).  
Four individuals had their first adverse event after the initial study intervention had been 
completed (post day 112). Two others had a new adverse event after the intervention 
period. AN21 and AN36 were the only two to experience an adverse event, weight gain 
and infected neuropathic ulcers respectively, whilst not taking corticosteroids. 
Baseline visual acuity was recorded in 24 individuals. Fifteen individuals had unchanged or 
normal visual acuity at the end of the study. There were five individuals (two had received 
MP) who experienced deterioration in their visual acuity. Four of these individuals had 
received additional prednisolone and of these two had ENL.  
Twelve individuals did not have their visual acuity measured during the study. In 22 
individuals it was not possible to determine change in visual acuity because data were 
missing. 
The only individual who reported weight gain on direct questioning was AN21. However 
22 individuals had objective evidence of weight gain during the study (11 from each 
group). 
The mean weight gain was 0.8 kg. There was no significant difference between the two 
groups. AN04 who was randomized to the prednisolone only arm had the largest weight 
gain of 7.5 kg after receiving a total of 4.08 g of prednisolone. 
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There was no correlation between weight gain and the total quantity of corticosteroid 
prescribed during the study (r
2 
= 5.89x10
-6
).
 
 
Figure 3.06. Increase in weight plotted against total amount of corticosteroid prescribed 
 
Five individuals had abnormal urinalysis. Two individuals had a trace of albumin detected 
at baseline prior to the administration of steroids. The serum creatinine of both were 
normal. Another individual had a trace of albumin detected by urinalysis at day 237. Her 
serum creatinine was normal and all subsequent urinalysis was normal.  
AN6 had glycosuria of +2 at day 309, this had resolved at the following visit. AN24 had an 
episode of +1 glycosuria and albuminuria at day 287. His serum creatinine was normal and 
subsequent urinalysis did not demonstrate any abnormality. Both these individuals were 
asymptomatic, neither complained of nocturia, polyuria and polydipsia.  
One individual had a dermatophyte fungal infection. 
3.4.5 Change in clinical status during the study 
The total clinical severity scores, calculated using the validated scale, for each arm of the 
study at day 1 (enrolment) and days 4, 29,113 and 337 are shown using boxplots in 
fig.3.07.  
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There is a downward trend in the total clinical severity scores of both groups. There were 
no statistically significant differences between the prednisolone and methylprednisolone 
groups at any time point. 
 
Figure 3.07. Total severity score at days 1, 4, 29, 113, 337 
3.4.5.1 Skin signs  
There was a significant difference between skin scores at baseline (p=0.014). This occurred 
despite allocation to the groups being randomized. The median skin score at baseline in the 
MP group was 4 (IQR =8) and in the P group was 0.5 (IQR =7). 
The median skin scores were zero at the end of the study for both groups. 
The Kaplan-Meier in fig.3.10 shows the cumulative probability of no deterioration in skin 
at a given time point. There is no statistical difference between the two groups (Log Rank 
(Mantel-Cox) = 0.838). 
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Figure 3.08 Skin score at days 1, 4, 29, 113, 337.  
 
Figure 3.09 Facial T1R a. before and b. after corticosteroid treatment (AN19)                   
(Image 3.09a Dr R A Hawksworth) 
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Figure 3.10 Time to deterioration of the skin 
3.4.5.2 Sensory scores 
There was no significant difference between the sensory scores (corrected for impairment  
> 6 months) of the two groups at baseline. A downward trend is visible for both groups but 
there are no differences at any of the pre-specified time points. 
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Figure 3.11 Monofilament score at days 1, 4, 29, 113, 337 
The Kaplan-Meier survival analyses of deterioration in sensory score during the study to 
days 29, 113 and 337 demonstrate that there is no difference between the groups at day 29  
but at day 113 there is a significant difference in the probability of  monofilament 
deterioration between MP and P arms (p=0.046). The prednisolone group were more likely 
to experience deterioration in sensation. This effect is not maintained at the end of the 
study follow-up period at day 337. 
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Figure 3.12 Time to deterioration of sensory function 
 
3.4.5.3 Motor scores 
The motor scores of the two groups at baseline are not significantly different. They show a 
downward trend during the course of the study. There are no significant differences 
between the scores of the group at any of the time points. 
There were no significant differences between the groups in the probability of an individual 
experiencing a deterioration in motor function at days 29, 113 or 337. 
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Figure 3.13 Motor score at days 1, 4, 29, 113, 337 
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Figure 3.14 Time to deterioration of motor function 
 
3.4.6 Additional prednisolone requirements of participants 
Figure 3.14 is a Kaplan-Meier estimate of the survival curve for the two groups showing 
the event when additional steroid was prescribed and censoring individuals who were 
unavailable for further assessment or who received prednisolone either inappropriately or 
for ENL. There was no significant difference in the probability of being prescribed 
additional prednisolone between the two groups (Log Rank (Mantel Cox) p=0.126).  
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Figure 3.15 Time to requiring first course of additional prednisolone 
 
The events that resulted in additional prednisolone being prescribed are shown in Table 
3.09 for each individual. Four individuals subsequently required a further course of 
prednisolone.  
The amount of additional prednisolone required by individuals randomized to either the 
MP or P alone treatment group did not differ significantly. The mean amount of additional 
prednisolone prescribed during the study was 1252.5 mg (SD±1862.0) for the MP group 
and 1432.7 mg (SD±1245.9) for the P group (p=0.718). 
Individuals and events leading to the prescribing of additional prednisolone 
Twenty individuals (47.6%) required additional prednisolone because they experienced a 
deterioration of nerve function (n= 11) or a recurrence of a T1R (n= 6) or both (n= 3). In 
addition two individuals received additional prednisolone inappropriately and two (AN04 
and AN40) developed ENL requiring prednisolone. 
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Study 
Number 
Arm Time of event 
(Days after 
enrolment) 
Event Approp-
riate 
Further additional 
prednisolone required 
AN03 MP 336 Deterioration in sensation right 
and left median and right and 
left ulnar power 
Yes No 
AN04 P 111 ENL Yes Yes 
AN05 MP 313 Deterioration both posterior 
tibial nerves 
Yes No 
AN06 P 266 Deterioration right lateral 
popliteal power 
Yes No 
AN08 P 176 Deterioration in skin and right 
and left median sensation 
Yes No 
AN09 MP 175 Deterioration left ulnar 
sensation 
Yes No 
AN10 P 140 Left facial, right and left ulnar 
weakness 
Yes Yes, day 183 for skin flare 
AN15 P 15 No change in skin or nerves No No 
AN16 P 96 Deterioration left ulnar 
sensation 
Yes No 
AN17 MP 152 Deterioration both posterior 
tibial nerves 
Yes No 
AN18 P 105 Deterioration in skin, sensation 
both ulnar and median nerves 
and power both ulnar nerves 
Yes No 
AN19 MP 125 Skin flare Yes No 
AN20 P 21 Deterioration right posterior 
tibial sensation 
Yes Yes, day 160 for skin flare 
AN23 MP 142 Skin flare Yes No 
AN24 P 14 Deterioration in sensation and 
power right ulnar 
Yes Yes, day 147 deterioration 
sensation and power right ulnar 
AN25 P 245 No change in skin or nerves No No 
AN27 P 124 Skin flare and deterioration left 
posterior tibial 
Yes Yes, day 280 for skin flare and 
deterioration sensation left 
ulnar, right and left median and 
left posterior tibial 
AN28 MP 61 Skin flare Yes Yes developed ENL 
AN29 MP 114 Skin flare Yes No 
AN32 P 195 Deterioration right ulnar 
sensation 
Yes No 
AN33 P 146 Skin flare Yes No 
AN35 MP 152 Skin flare Yes No 
AN40 P 306 ENL Yes No 
AN42 P 243 Left ulnar weakness Yes No 
Table 3.10. Indication for and timing of additional prednisolone 
  
Five of the 20 individuals (appropriately prescribed additional prednisolone for a trial 
indication) required prednisolone before day 112, the last day of the intervention period. 
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The median time to requiring additional prednisolone was 61 days when individuals were 
receiving prednisolone 20 mg daily. 
The other 75% had finished the prednisolone before experiencing a deterioration requiring 
further treatment. The median number of days between finishing the study intervention and 
requiring additional prednisolone was 63 days (range = 2-224). 
Physician assessment of neurological outcome 
The physician assessment of neurological outcome demonstrated that 7 (20.6%) individuals 
who had nerve damage at baseline (of less than six months duration) and completed a 16 
week course of corticosteroid therapy recovered (fig. 3.15). Seventeen individuals of 34 
(50%) had an improvement in their nerve function. However nine participants (26.5%) had 
nerve function that was unchanged and one individual’s nerve function had deteriorated. 
Six individuals were excluded from this analysis because throughout the study they only 
had cutaneous involvement and two individuals did not complete the 16 week course of 
corticosteroid therapy. 
 
Table 3.11 shows the physician assessment of neurological outcome by individual and the 
difference between the neurological components of the clinical severity score at their last 
recorded assessment and baseline. A negative value indicates that the value of the 
neurological component of the clinical severity score increased. 
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Figure 3.16. Comparison of nerve impairment at final recorded assessment in 
individuals (n=34) who completed initial steroid course
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Study Number Outcome Arm 
Change in nerve 
score 
AN20 Recovered P 5.5 
AN42 Recovered P 3 
AN39 Recovered P 1 
AN40 Recovered P 1 
AN05 Recovered MP 10 
AN07 Recovered MP 3 
AN13 Recovered MP 2 
AN08 Improved P 10.5 
AN25 Improved P 10 
AN01 Improved P 5 
AN32 Improved P 5 
AN21 Improved P 4 
AN24 Improved P 4 
AN34 Improved P 3 
AN16 Improved P 1.5 
AN06 Improved P 1 
AN10 Improved P 0 
AN11 Improved MP 21.5 
AN22 Improved MP 12.5 
AN03 Improved MP 9 
AN09 Improved MP 2.5 
AN17 Improved MP 2.5 
AN02 Improved MP 1.5 
AN19 Improved MP 1 
AN04 Unchanged P 1.5 
AN30 Unchanged P 1.5 
AN15 Unchanged P 0 
AN18 Unchanged P 0 
AN26 Unchanged MP 9.5 
AN14 Unchanged MP 1.5 
AN36 Unchanged MP 0.5 
AN38 Unchanged MP 0.5 
AN23 Unchanged MP 0 
AN27 Worse P -2.5 
AN33 Skin only P 0 
AN41 Skin only P 0 
AN28 Skin only MP 0 
AN31 Skin only MP 0 
AN29 Skin only MP 0 
AN35 Skin only MP 0 
AN12 Lost P 1 
AN37 Lost MP 0 
Table 3.10. Physician assessment of neurological outcome and 
change in nerve score. (Shaded area indicates participants not 
included in this assessment) 
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Figure 3.17 Change in nerve score and clinical outcome in those completing 
corticosteroid course (n=34) 
 
Individuals were grouped according to their status with respect to the physician assessment 
of neurological outcome as shown in fig.3.17. The median change in nerve score between 
the baseline and the final recorded assessments were significantly different (Mann Whitney 
p=0.003). 
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3.5 Discussion 
3.5.1 Adverse events 
In this small study the occurrence and timing of minor and major adverse events did not 
differ significantly between the prednisolone and the methylprednisolone treated groups. 
Twenty-one (50%) individuals experienced at least one minor adverse event and two 
(4.8%) a major adverse outcome. 
In the TRIPOD trials 8.4% (14/167) of the prednisolone treated Nepali cohorts experienced 
a minor adverse event. This was not significantly different from the placebo treated group. 
The individuals in these groups were treated with either 1.96 or 2.52 g of prednisolone 
depending on which of the three trials they were enrolled into.  
The commonest minor adverse event in this study of methylprednisolone was acne. Ten 
(23.8%) participants developed acne which was relatively uniform, a characteristic feature 
of corticosteroid-induced acne (Monk et al., 1993).  
The TRIPOD cohorts included people from Bangladesh as well as Nepal. Two per cent of 
the 401 corticosteroid treated participants had acne. Interestingly only 89 individuals in 
these trials received 2.52 g of prednisolone (the same amount as the prednisolone only arm 
in this study) and none developed acne. In contrast nine (of 312) of those who received the 
smaller total dose of 1.96 g and three (of 414) who received placebo did. These differences 
were not statistically significant overall. The involvement of dermatologists in the 
methylprednisolone study may have facilitated the diagnosis of acne.  
The self-reported prevalence of acne was between 10-20% in 2040 respondents to a survey 
of individuals in the United States of America who were taking long-term (≥ 60days) oral 
glucocorticoid therapy (Curtis et al., 2006).  
Conn and Poynard performed a large meta-analysis of adverse events during corticosteroid 
therapy (Conn and Poynard, 1994). The purpose of this study was to assess the putative 
link between peptic ulceration and systemic corticosteroid therapy. 
The meta-analysis analysed 93 double blind randomised controlled trials in which more 
than 8700 patients had participated. These patients received a mean daily dosage of 
prednisolone 35 mg (or its equivalent) for a mean duration of 64 days. The mean total dose 
received was 2.2 g. 
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In the meta-analysis acne, moon face, buffalo hump and truncal obesity were grouped 
together as “cosmetic” and “dermatologic” adverse events. They are reported as being four 
times more common in the corticosteroid treated group.  
Increased fat deposition causes the “moon face” associated with Cushing’s disease and 
Cushing’s syndrome. This adverse event affected 19% of individuals in the study. In the 
TRIPOD cohorts 3% of corticosteroid treated individuals developed this problem 
(Richardus et al., 2003a).  
A French prospective study examined 88 patients started on corticosteroid therapy            
(≥ 20 mg) for longer than three months. The mean dose of prednisone was 42 mg/day in the 
first three months. Ten of these individuals received pulse therapy.  Sixty-one per cent 
(±8%) were adjudged to have corticosteroid-induced lipodystrophy (CIL) of the face or 
dorsocervical region at three months (Fardet et al., 2007b). 
Shubin reported the adverse effects of triamcinolone 4-12mg in 47 patients with pulmonary 
disease treated for a period of 5-8 years. Sixty-six per cent developed moon facies (Shubin, 
1965). 
Fardet and colleagues also demonstrated that individuals with CIL were more likely to 
exhibit features suggestive of the metabolic syndrome such as higher fasting blood glucose, 
triglyceride levels and total cholesterol concentrations (Fardet et al., 2007a).  
The metabolic syndrome is a group of risk factors including insulin resistance, 
hyperinsulinaemia, hypertension, increased triglycerides, reduced high-density lipoprotein 
cholesterol, abdominal obesity and hypercoagulability. The metabolic syndrome confers an 
increased risk of Type 2 diabetes mellitus and cardiovascular disease. This would suggest 
that CIL is not simply a cosmetic problem.  
Only one individual complained of weight gain despite the fact that five individuals had 
gained weight by the end of the study of 4 kg or more.  
One individual (AN09) experienced two episodes of tinea cruris. The initial episode 
occurred at day 14 and was successfully treated with oral fluconazole and topical 1% 
clotrimazole cream. The second episode (diagnosed on day 113) responded to clotrimazole 
cream alone. This man’s tinea cruris was symptomatic. It caused pruritus and so likely to 
be reported early. It is possible that either a pre-existing infection deteriorated or he 
acquired the infection after starting corticosteroid therapy. The full physical examination at 
enrolment makes the latter possibility more likely. The second episode is likely to have 
been a further infection as he had complete resolution of his symptoms following oral and 
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topical treatment of the first episode and because of the considerable time interval between 
the two events. 
Fungal infections were uncommon in the TRIPOD studies (Richardus et al., 2003a). Five 
individuals (1.2%) who were treated with prednisolone developed a fungal infection, which 
were defined as “severe fungal skin infections”. All of these infections occurred in the 
prednisolone treated group of TRIPOD 1 who received 1.96 g of prednisolone over 16 
weeks (Smith et al., 2004). 
Seven (16.7%) participants experienced gastric pain. There were no cases of peptic 
ulceration detected in this study. Gastric pain occurred in 18% of the prednisolone treated 
individuals in the TRIPOD studies.  
Conn and Poynard found an increased number of peptic ulcers in the corticosteroid treated 
group but this did not reach statistical significance. 
The symptoms of nocturia, polyuria and polydipsia were reported by four (9.5%) of 
individuals. The two individuals who had glycosuria did not complain of these symptoms. 
Their glycosuria was not persistent and therefore not considered to be clinically significant. 
The two individuals were both receiving additional prednisolone at the time but neither had 
received methylprednisolone. There were no individuals in the study diagnosed with 
diabetes mellitus. 
TRIPOD 1 study reported one individual from the prednisolone treated group who 
developed glycosuria. This was considered a major adverse event in this study but the 
authors did comment whether this patient was diagnosed with diabetes mellitus (Smith et 
al., 2004). Three individuals in the steroid treated groups of the three TRIPOD studies 
developed diabetes mellitus compared with one in the placebo group but this difference 
was not significant (Richardus et al., 2003a). 
The meta-analysis found a rate of diabetes mellitus four times greater in the steroid treated 
group which was statistically significant (Conn and Poynard, 1994). 
One individual developed glaucoma. He had concomitant ENL which like corticosteroid 
therapy is a recognised cause of secondary glaucoma. This man developed glaucoma at day 
305 of the study. He required additional prednisolone at day 111 because he developed 
painful, tender skin lesions typical of ENL. He required continuous oral prednisolone 
(receiving a total additional dose of 2.87 g of prednisolone between days 111 and 305) 
despite treatment of his ENL with high dose (300 mg daily) clofazimine. The majority of 
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individuals who develop ENL require long term treatment and many become corticosteroid 
dependent (Pocaterra et al., 2006).  
There were no cases of glaucoma in any of the TRIPOD participants. The meta-analysis 
does not contain any reference to glaucoma. The methylprednisolone study and TRIPOD 
studies would have been unable to detect any asymptomatic elevations in intra-ocular 
pressure.  There are no good data concerning the incidence of glaucoma in individuals 
treated with systemic corticosteroids. Thirty-four per cent of individuals taking systemic 
corticosteroids in an Israeli study had intra-ocular pressure >20 mmHg compared with 6% 
of those not taking corticosteroids. However 71.7% of these individuals had received 
corticosteroid for longer than one year (Godel et al., 1972). 
Infected neuropathic ulcers affected one individual treated with methylprednisolone. This 
occurred 58 days after this man (AN36) completed the trial intervention.  
Two individuals in the TRIPOD studies (one from the prednisolone treated group) 
developed infected ulcers. It is not reported whether the prednisolone treated person was 
taking the drug at the time the infection was diagnosed. 
There were no episodes of hypertension in this cohort which was also the case in the 
TRIPOD studies. The meta-analysis of Conn and Poynard found that the frequency of 
hypertension was increased in patients treated with corticosteroids and that this difference 
was significant. 
There were no episodes of mental illness reported by the participants or identified by the 
study physicians. This was also the case in the TRIPOD studies. The reported findings of 
Conn and Poynard are somewhat conflicting. The difference between the numbers of 
steroid treated individuals was significant using the sign test but not when odds ratio 
methods (fixed and random effects models) were employed.  
Tuberculosis or other severe infections were not observed in the study. It is possible that 
the individuals who did not complete follow-up may have been unable to do so because of 
a severe illness such as TB. It is also possible that the duration of follow-up was not 
sufficient to identify any infections that might have occurred after 48 weeks. The TRIPOD 
studies included 300 individuals treated with corticosteroids who were followed for 24 
months; none of these individuals were diagnosed with TB (Richardus et al., 2003a).  
TB was a rare occurrence in the meta-analysis with only five cases reported in 2056 
individuals treated with steroids. However there were none in the placebo group. The odds 
ratio for this adverse event was not significant.  
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The size of the study limited our ability to detect rare adverse events however a much 
higher rate of acne and moon face was recorded than the TRIPOD studies. Another factor 
that might have reduced our estimation of adverse events is the duration of follow-up 
which may have been too short, however most studies have assumed that adverse events 
will occur during the treatment phase predominantly. We were also unable to examine the 
effect of our interventions on bone density which may be significantly affected by 
corticosteroid therapy in the doses and durations commonly used to manage leprosy T1R 
and NFI. 
Very large randomised trials would be required to identify accurately the risk of rare 
adverse events such as peptic ulceration in individuals receiving corticosteroids. This is 
unlikely to be possible due to financial and logistical constraints. However it remains 
important to monitor individuals for adverse events. The establishment of registries of 
steroid treated patients at specialised centres such as Anandaban could facilitate the 
collection of reliable data without the need to resort to more costly randomised controlled 
trials.  
3.5.2 Clinical outcomes 
The use of a validated scale to measure leprosy Type 1 reactions and nerve function 
impairment allows the comparison of the two groups in this study. There are no significant 
differences in terms of the total severity score or the sensory or motor scores between the 
prednisolone and methylprednisolone treated groups at any of the pre-defined time points.  
The difference in the total scores of all the participants taken together were significantly 
different at the pre-defined time points (ANOVA p=0.003) compared with baseline. This 
appears to be due to the change in the skin scores with time. The sensory and motor scores 
did not differ significantly at later time points from baseline. However there was a trend 
towards improvement in sensory and motor scores during the study. This is demonstrated 
by the change in nerve score between baseline and last recorded assessment in Table 3.10. 
Participants in the prednisolone treated group were significantly more likely to have a 
decrease in sensory function than the methylprednisolone treated group by the end of the 
16 week course of treatment (fig. 3.12). However this difference is not sustained to the end 
of the study. This phenomenon is similar to the outcome in the TRIPOD 1 study of 
prophylactic prednisolone to prevent the occurrence of reactions and nerve function 
impairment. It demonstrated a protective effect of prednisolone (total dose 1.96 g) 
compared with placebo during the 16 weeks of treatment which was lost by 48 weeks. The 
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higher dose may have a greater effect whilst an individual is receiving corticosteroids but 
not once they are no longer taking the drug.  
This effect may have occurred by chance as it was not reproduced in the skin or in motor 
function. The number of participants contributing to all of the survival analyses towards the 
end of the study is small and the results therefore less reliable.  
The physician assessment of neurological outcome although a less stringent outcome 
reveals the high rates of neurological impairment even after individuals have completed at 
least one prolonged course of steroids. Overall in this cohort only 70.6% (24/34) of those 
treated with at least 16 weeks of corticosteroid improved or recovered. This is consistent 
with data from Bangladesh where 67% of nerves improved after a 16 week course of 
prednisolone (Croft et al., 2000b). The small study conducted in Nepal by Marlowe et al of 
prednisolone and a combination of azathioprine and prednisolone reported improvement in 
sensory function in 57.1% of individuals with sensory impairment present for less than six 
months (Marlowe et al., 2004). The figure was identical for those with motor impairment 
before the start of treatment. 
There was no significant improvement in NFI present for longer than six months at 
enrolment. Nineteen per cent of sensory nerves improved or recovered. The improvement 
was modest at best with a median decrease in monofilament score of 0.5 which equates to 
an individual sensing a finer monofilament at a single test site.  
In the TRIPOD 3 study of treatment of  longstanding nerve function impairment there was 
no significant difference between prednisolone (total dose of 2.52 g) treatment of 
longstanding nerve function impairment compared to placebo (Richardus et al., 2003b). It 
is striking that 51% of individuals in the placebo arm (n=52) experienced improvement in 
longstanding nerve impairment compared with 54% in the prednisolone treated group 
(n=40). The authors do not report the change in the scores for the nerves and even if they 
did it would be difficult to compare the scoring system they used with that used as part of 
the validated Clinical Severity Scale. Five monofilaments were used in the TRIPOD 
studies compared to two in this study. The sensory thresholds that were considered 
acceptable were also different.   
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3.5.3 Additional prednisolone  
Forty-five per cent of the methylprednisolone group and 50% of the prednisolone group 
were prescribed additional prednisolone appropriately. Of the 20 individuals that required 
additional prednisolone 12 did not do so until at least 28 days after completing the trial 
intervention. The clinical nature of the deterioration (skin or nerves or both) did not differ 
significantly between those who experienced it whilst receiving the study intervention and 
those who experienced deterioration after completing it (χ2=0.292). 
The delay in deterioration in the majority of individuals requiring additional prednisolone 
is similar to that seen in the TRIPOD 1 study when prednisolone 20 mg daily for 12 weeks 
was used as a prophylaxis to try and prevent nerve damage in newly diagnosed leprosy 
patients (Smith et al., 2004).  
The requirement for extra prednisolone was used as the sole outcome measure in the multi-
centre double blind randomised controlled trial of three different prednisolone regimens 
conducted in India (Rao et al., 2006). The proportion of individuals requiring additional 
prednisolone in the three groups was 24%, 31% and 46% respectively. Individuals who 
received prednisolone for five months were significantly less likely to require additional 
steroid. However this does not necessarily reflect clinical improvement. 
The inclusion criteria were individuals with evidence of severe T1R which was defined as 
nerve tenderness or any motor or sensory impairment of less than three months duration or 
severely inflamed skin lesions. These criteria are broadly similar to those of the 
methylprednisolone study.  
A pragmatic design was used by Rao and colleagues. The decision to use additional 
prednisolone was left to the individual clinician’s judgement at each of the six centres. It is 
not clear how consistency was ensured between individual physicians or at different stages 
of the trial.  
The shorter duration of nerve function impairment compared with the other studies in 
Table 3.12 may in part account for the lower rates of additional prednisolone being 
prescribed to individuals.  
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Number 
%age 
requiring 
Study Inclusion criteria Arm in 
extra 
prednisolone 
   
arm at 48 weeks 
TRIPOD 2 
Mild sensory Prednisolone 2.52 g 41 27 
impairment of the 16 weeks 
  
TRIPOD 2 
(van Brakel et al., 2003) 
ulnar or post tib Placebo 34 18 
nerves <6 months 16 weeks 
  
     
Marlowe 
 
Prednisolone 1.68 g 19 37 
 
Severe Type 1 12 weeks 
  
Marlowe reaction Prednisolone 1.33 g* 21 48 
(Marlowe et al., 2004) 
 
8 weeks 
  
     
Rao 
 
Prednisolone 3.5 g 113 24 
 
Severe Type 1 
20 weeks 
  
Rao 
reaction or 
Prednisolone 2.31  g 113 31 
 
NFI 
20 weeks 
  
Rao 
 
Prednisolone 2.94 g 108 46 
(Rao et al., 2006) 
 
12 weeks 
  
     
Methylprednisolone 
Severe Type 1 
Prednisolone 2.52 g 22 50 
 
reaction or 
16 weeks 
  
Methylprednisolone 
NFI MP  
(Prednisolone equivalent = 6.15 g) 20 45 
  
16 weeks 
  
*this group received azathioprine as well for a period of 12 weeks 
Table 3.12 Studies of T1R and NFI (including current study) and the requirement for extra 
prednisolone 
The protocol of the MP study was stringent in treating NFI. Mild deterioration in NFI and 
NFI of short duration were both treated. This may in part account for the high proportion of 
individuals who received additional prednisolone. Any sustained (as little as one week) 
deterioration in monofilament testing at even a single test site. On the hand deterioration in 
sensation, at a single point, from being able to sense the 2 g monofilament to only being 
able to sense the 10 g would score 0.5 using the validated Clinical Severity Scale and be 
equivalent to a change of two points using van Brakel’s sensory scoring system      
(TRIPOD 2) (van Brakel et al., 2003). In the TRIPOD 2 study a two point increase in the 
score of a particular nerve was classified as “unchanged”. However an individual unable to 
feel the 10g at a single site on the hand would score two using the Clinical Severity Scale 
but at least three using the TRIPOD system which the authors defined in those studies as 
deterioration. This illustrates the lower threshold used in the methylprednisolone for 
defining deterioration. 
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It is possible that some of the change labelled as deterioration was due to test response 
variability. 
In the TRIPOD 2 cohort 27% of prednisolone treated individuals with mild sensory 
impairment experienced deterioration necessitating additional prednisolone. A group with 
mild isolated sensory impairment would be expected to require less additional prednisolone 
than a group that included severe nerve impairment both sensory and motor and marked 
skin involvement. 
The results of this small study should be interpreted with caution but it would appear that 
given the available data methylprednisolone does not result in an increase in the number or 
severity of adverse events in individuals with leprosy in Nepal. However close detailed 
adverse event recording would still be required in any future studies of methylprednisolone 
in this setting. 
The clinical outcome of patients in the two arms of this study was not significantly 
different in terms of the validated clinical severity scale or a physician assessment of 
neurological outcome. The methylprednisolone treated group had significantly less 
deterioration in sensory function during the 16 weeks of corticosteroid therapy but this was 
not maintained to the end of the 48 week follow-up period. This may be a reflection of the 
small numbers in the study, particularly towards the end of follow-up. A much larger study 
would be required to examine this potential effect further. 
The study has also highlighted that corticosteroid treatment for T1R and NFI is sub-optimal 
even when given in large doses for 16 weeks. It adds further support to the argument that 
treatment should be given for longer durations. At present there is convincing evidence for 
at least 20 weeks but some would argue for 24 (Walker and Lockwood, 2008) and even 
longer (Naafs, 2003). The development of more prolonged treatment protocols would 
require further monitoring of adverse events and in particular the long term sequelae of 
corticosteroid therapy.  
3.6 Summary 
 There were no significant differences in the rate of minor or major adverse effects 
between the methylprednisolone and prednisolone treated groups. 
 20.6% of individuals with NFI recovered, 50% improved and 26.5% were 
unchanged. One individual was worse. 
 All eight individuals who only had a cutaneous T1R recovered but 50% required 
additional prednisolone. 
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 The methylprednisolone group were significantly less likely to have a deterioration 
in sensory function during the 16 week treatment period but this was not sustained 
to the end of the follow-up period 
 The proportion of individuals receiving additional prednisolone was high in both 
groups. In the MP group it was 45% and in the prednisolone group 50%. There was 
no significant difference between the two groups in the requirement for additional 
prednisolone. 
 There was no significant improvement in longstanding NFI in either group. 
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4.1 Introduction 
The role of the innate immune system in the immunopathology of leprosy skin lesions has 
received much less attention than that of the adaptive immune system. The role of TLRs in 
the initiation and promotion of inflammatory and infectious disease in a wide variety of 
systems has been investigated but there is a paucity of in vivo data from experiments 
performed with skin.  
The intracellular niche occupied by M. leprae and the immunological inflammatory 
complications associated with leprosy provide evidence for the role of pattern recognition 
receptors in both primary infection and its sequelae. There are few in vivo data concerning 
the expression of TLRs in patients with leprosy and leprosy reactional states. Krutzik et al 
used immunoperoxidase and immunofluorescence methods to stain skin biopsies from 
leprosy patients (Krutzik et al., 2003). The skin biopsies from 10 patients reported to have 
T-lep and 10 L-lep disease. This is a nomenclature this group uses in their published 
reports. Patients are classified using the Ridley-Jopling classification and they report that 
these groups of patients, T-lep and L-lep, have tuberculoid and lepromatous leprosy 
respectively. Using murine monoclonal antibodies and the avidin-biotin method they 
reported that patients with T-lep had greater amounts of TLR1 and TLR2 staining than 
individuals with L-lep. They used confocal microscopy to show these two TLRs were 
expressed together on cells predominantly of the macrophage/monocyte lineage.  
In vitro data also support the hypothesis that TLRs play a role in leprosy 
immunopathology. Transfected human embryonic kidney 293 cells that have been made to 
transiently express TLRs are activated by killed M. leprae via TLR1/2 heterodimer or 
TLR2 in vitro. Peritoneal macrophages from TLR2 knockout mice do not produce TNF 
following stimulation with killed M. leprae.  The TNF production by these cells from 
TLR1 knockout mice is reduced compared to wild type mice (Krutzik et al., 2003). The 
TLR1/2 heterodimer recognises bacterial triacylated lipopeptides including the 
mycobacterial 19-kDa lipoprotein. Mycobacterial lipomannan has been shown to activate 
the secretion of TNFα by murine macrophages events via TLR2 and TLR4 (Doz et al., 
2007). TLR9 recognises bacterial CpG motifs. TLR9 has been shown to contribute to the 
recognition of Mycobacterium bovis BCG by showing that TNFα, IL12p40 and IL6 was 
not produced by bone marrow derived dendritic cells from  TLR2/4/9 deficient mice but 
was by TLR2/4 deficient mice (but at a lower level than cells from wild type mice) (von 
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Meyenn et al., 2006). The TLR9 deficient murine dendritic cells did not up-regulate 
costimulatory molecules such as CD86 either. 
Individuals with polymorphisms in TLR1 have a reduced risk of acquiring leprosy (Johnson 
et al., 2007; Schuring et al., 2009). Two SNPs in the TLR4 gene  have also been shown to 
be associated with a lower risk of leprosy (Bochud et al., 2009a). A polymorphism in TLR1 
has been shown to be associated with protection against T1Rs (Misch et al., 2008). A SNP 
in TLR2 is associated with protection against T1R and a microsatellite polymorphism with 
increased risk (Bochud et al., 2008). This further implicates TLRs in the immunopathology 
of T1Rs. 
Activation of TLR leads to cytokine production and the expression of co-stimulatory 
molecules which result in activation of adaptive immune system cells. This results in an 
increased cellular immunity which is the hallmark of T1Rs (Job, 1994). 
TLR2 has been studied in leprosy skin lesions and Schwann cells and so was felt to be an 
interesting focus for its expression during T1R in this study. TLR2 forms a heterodimer 
with TLR1 and so this receptor was included for study. The expression of TLR4 is 
increased in TB, sarcoid and experimental neuropathy and so its role in T1Rs which may 
exhibit cutaneous and neural pathology is warranted. T1R often occur after the initiation of 
MDT. The killing of M. leprae may release bacterial DNA which is recognised by TLR9 
and lead to the activation of inflammatory pathways. 
4.2 Aims 
 To compare the expression of TLRs according Ridley-Jopling classification in non 
reactional control patients and patients with T1R. 
 To compare the cellular infiltration during T1Rs and nerve function impairment in 
the skin of leprosy patients with that of untreated non-reactional leprosy controls. 
 To compare the expression of selected TLRs during T1Rs and NFI in the skin of 
leprosy patients with that of untreated non-reactional leprosy controls. 
 To assess the effect of corticosteroid therapy on the cellular infiltration in skin 
lesions in individuals with leprosy T1Rs or NFI. 
 To assess the effect of corticosteroid therapy on the expression of TLRs in skin 
lesions in individuals with leprosy T1Rs or NFI.  
 To determine the cellular sub-types expressing TLRs in skin lesions of individuals 
with T1R. 
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 To validate a quantitative method of gene expression in corticosteroid treated 
individuals. 
 To determine the gene expression of TLRs in skin lesions of individuals with T1R 
and NFI. 
4.3 Participants, materials and methods 
4.3.1 Participants 
The study subjects were leprosy patients with evidence of T1R or NFI of less than six 
months duration enrolled in the randomised controlled trial of IV methylprednisolone 
versus prednisolone at Anandaban Hospital in Nepal (see Chapter 3).  
Control subjects were untreated newly diagnosed leprosy patients who presented to 
Anandaban Hospital during the period of recruitment and follow-up of the 
methylprednisolone study.  
4.3.2 Ethical Approval  
The study was approved by the Nepal Health Research Council and the Ethics Committee 
of the London School of Hygiene and Tropical Medicine (Number 4022). 
4.3.3. Consent 
Informed consent was obtained by a native Nepali speaker after s/he had fully explained 
the trial and answered any questions. The trial consent forms and information leaflets were 
available in Devanagari script. The consent forms were signed by all participants (if they 
were unable to sign, a mark or thumb print was used instead and witnessed by the person 
obtaining the consent). Control subjects gave similar written informed consent before a 
study biopsy was performed. 
4.3.4 Diagnosis and classification 
Study and control subjects were diagnosed in accordance with the method described in 
Chapter 3.  The Ridley-Jopling classification was used to classify both study subjects and 
controls. All participating individuals had a skin biopsy taken from a typical skin lesion. 
This was fixed in formalin and sent for histopathological examination for confirmation of 
diagnosis and Ridley-Jopling classification (Ridley and Jopling, 1966). This was performed 
at one of two Leprosy Mission Hospitals in India by either Dr Lakshmi Rajan (Delhi) or Dr 
Joyce Ponnaiya (Karigiri). 
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4.3.5 Study specimens  
All participants in the randomised controlled trial provided a skin biopsy (6mm punch) at 
baseline, day 4 or day 29 and day 113. The three biopsies were taken from the same site. A 
skin biopsy was taken from control subjects at the time of diagnosis prior to starting MDT.  
The specimens were bisected. One half was snap frozen in liquid nitrogen. The other half 
was immersed in RNAlater
TM 
(Ambion
 
Inc., Austin, Texas, USA) and kept at 4°C 
overnight. The following day the RNAlater
TM
 was discarded and the skin sample stored at  
-80°C.  
These samples were transported to the UK in a liquid nitrogen Dewar flask (CP100 Jencons 
(Scientific) Ltd. Lutterworth, UK) and stored at the London School of Hygiene and 
Tropical Medicine in liquid nitrogen. 
4.3.6 Immunohistochemistry (IHC) 
Skin biopsies were embedded in FSC 22
TM
 (Surgipath, Richmond, Illinois).  Cryosections 
(6µm) were cut on a Leica CM1100 Cryostat (Leica Microsystems, Germany) and adhered 
to a polysine coated glass slides (VWR International Ltd, Lutterworth, United Kingdom). 
The sectioning of skin biopsies was performed in a Category 3 laboratory. 
The slides were stored at -20ºC. 
The antibodies used in the study were directed against human CD1a, CD3, CD68 and 
human TLR1, TLR2, TLR4 and TLR9. 
Table 4.01 shows the source, isotype and dilutions of the primary antibodies. 
Immunohistochemistry was performed using the peroxidise-anti-peroxidase (PAP) and the 
labelled streptavidin-biotin (LSAB) horseradish peroxidise methods. The staining protocols 
were performed in a humidified chamber at room temperature. 
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Antibody 
Specificity 
 
Source Isotype 
Immunoglobulin 
concentration 
(mg/ml) 
Working 
dilution 
Supplier (Cat. 
No.) 
Method 
       
CD1a Mouse IgG1 1.383 1:100 Dako (M3571) PAP 
       CD3 Mouse IgG1 0.273 1:100 Dako (M7254) PAP 
CD68 Mouse IgG1 0.53 1:200 Dako (M0718) PAP 
TLR1 Mouse IgG1 0.5 1:20 eBioscience 
(14-9911) 
LSAB 
TLR2 Mouse IgG2a 0.5 1:200 eBioscience 
(14-9029) 
LSAB 
TLR4 Rabbit Polyclonal 0.2 1:200 Santa Cruz 
(SC-10741) 
LSAB 
TLR9 Mouse IgG2a 0.1 1:500 
 
Hycult 
Biotechnology 
(HM2087) 
LSAB 
       
Table 4.01. Primary antibodies, source and isotype 
 
4.3.6.1 Peroxidase-anti-peroxidase method 
Slides were defrosted for 60 minutes and then fixed in acetone for 15 minutes and air dried. 
Each section was circumscribed using a hydrophobic barrier pen (ImmEdge™ Pen, Vector 
Laboratories Inc., Burlingame, California). 
The slides were washed in phosphate buffered saline (PBS) for five minutes. Non-specific 
background staining was minimised by incubating each section with PBS containing 10% 
rabbit serum (Dako, X0902, Glostrup, Denmark), the same species as the secondary 
antibody for 30 minutes.  
The primary antibody was diluted in antibody diluent (Dako, S3022) and applied to the 
sections for 60 minutes. Negative controls were performed using the same antibody isotype 
directed against non-human antigens (Mouse IgG1 Dako, X0931). 
The slides were then washed in PBS before addition of the secondary antibody (polyclonal 
rabbit anti-mouse immunoglobulins Dako, Z0259) diluted to 1:100 in antibody diluent for 
30 minutes. This was followed by a wash in PBS for 10 minutes. 
The sections were then incubated for 30 minutes with the antibody detection reagent mouse 
monoclonal PAP (Dako, P0850) at 1:100 dilution in antibody diluents. 
The slides were then washed in PBS and the enzymatic reaction was developed using the 
chromagen 3, 3’ diaminobenzidine (DAB) (Sigma, St. Louis, Missouri) as the substrate. 
The reaction was assessed using a light microscope and stopped in water. 
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The sections were then counterstained with Harris haematoxylin (Sigma) for two minutes 
followed by washing in running water. The sections were decolourised by brief immersion 
in 1% acid alcohol and washed in running water. The sections were dehydrated in an 
alcohol gradient of: 70% ethanol, 100% ethanol, 100% ethanol, xylene and xylene for two 
minutes each.  
The slides were then mounted with a cover slip using DPX (Fluka, St. Louis, Missouri).  
4.3.6.2 Labelled streptavidin-biotin horseradish peroxidise method 
The sections were thawed, fixed and marked as in the PAP method. After the first PBS 
wash the sections were then incubated in 0.3% hydrogen peroxide in methanol for 10 
minutes. This was followed by a further PBS wash. 
A non-specific background blocking step was performed using PBS containing 10% goat 
serum (Dako, X0907 from the same species as the biotinylated secondary antibodies) for 
30 minutes.  
The sections were then incubated with primary antibodies diluted in antibody diluent for 60 
minutes. Negative controls were used (Mouse IgG1 Dako, X0931 and Mouse IgG2a Dako, 
X0943) depending on the isotype of the primary antibody. The negative control for TLR4 
was PBS. 
The sections were washed with PBS and then incubated with the biotinylated goat anti-
mouse/rabbit secondary antibody (Dako Real™ Detection System, Peroxidase/DAB+, 
Rabbit/Mouse, Dako, K5001) for 15 minutes. A further PBS wash was performed. 
The sections were then incubated with the streptavidin conjugated to horseradish 
peroxidase (Dako, K5001) for 15 minutes. 
The slides were then washed in PBS and the enzymatic reaction was developed using the 
chromagen DAB (Dako, K5001) as the substrate. The reaction was assessed using a light 
microscope and stopped in water. Counterstaining, dehydration and mounting of the slides 
was identical to that used in the PAP method. 
4.3.6.3 Optimisation of staining 
Each primary antibody was tested on sections at concentrations ranging from 0.1µg/ml to 
100µg/ml using the PAP method for CD1a, CD3 and CD68, the PAP and LSAB method 
for TLR2 and the LSAB method for TLRs 1, 4 and 9. 
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4.3.6.4 Assessment of staining 
Sections were assessed using a light microscope (Nikon, Kingston-upon-Thames, UK) with 
x50, x200 and x400 magnification. Photographs of representative sections were taken using 
a Leica DFC420 digital camera (Leica, Milton Keynes, UK). 
The degree of cellular infiltration of the sections and the intensity of staining were 
assessed. Positive staining cells were determined by the presence of brown intra- or 
extracellular staining due to the chromagen DAB. Negative cells lacked staining. 
4.3.6.5 Quantification of staining 
The degree of cellular infiltration and intensity of staining of sections was evaluated by two 
independent assessors once the slides had been re-coded with a unique number. This 
ensured that neither assessor knew which slides were from study participants and which 
from controls. It also blinded the assessors to the timing of the biopsies in study 
participants.  
The percentage of positive staining cells was graded 0-5 using a semi-quantitative scoring 
system. The degree of cellular infiltration was scored from 0-3. The criteria used for 
scoring are shown in Table 4.02. 
Intensity of staining Cellular Infiltration 
Grade %age of positive cells Grade Cellular infiltration 
0 None 0 No cellular infiltrate 
1 <10%   
2 10-30% 1 Few small granulomas/group of 
cells 
3 30-50% 2 Medium-sized granulomas/ 
moderate cellular infiltrate 
4 50-80%   
5 80-100% 3 Large granulomas/extensive 
cellular infiltration 
Table 4.02 Criteria for grading of cellular infiltration and intensity of staining. 
 
The grading of the immunohistochemical staining was with a semi-quantitive scale and so 
non-parametric methods were used for analysis. The level of staining of biopsies from 
controls was compared with those of the study participants at baseline using the Mann-
Whitney U test. The analysis of the level of staining in biopsies from study participants at 
different time points was by the Wilcoxon signed rank test. The threshold for accepting 
statistical significance was p < 0.05. 
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4.3.7 Double Fluorescent Immunostaining 
The primary antibodies used for double immunofluorescent staining were directed against 
the same target antigens as in the IHC experiments. In addition to the polyclonal rabbit 
anti-TLR4 antibody a mouse monoclonal anti-TLR4 IgG2a antibody (Santa Cruz, SC-
13593) was also used. A fluorescein isothiocyanate (FITC) conjugated mouse monoclonal 
anti-TLR9 IgG2a antibody (Hycult HM2087F) was also used. 
The fluorochrome conjugated secondary (or tertiary) antibodies used are shown in Table 
4.03. 
Antibody Fluorochrome 
Laser 
(wavelength, nm) 
Excitation/Emission (nm) 
Working 
dilution 
Supplier 
(Cat.No.) 
Target 
      
Goat anti-
mouse IgG1 
Fluorescein Argon (488)  
494/519 
1:200 Molecular 
Probes 
(A10530) 
CD1a, CD3, 
CD68, TLR1 
Goat anti-
mouse IgG2a 
Alexa Fluor® 546 Helium-Neon-1 (543) 
556/573 
1:200 Molecular 
Probes 
(A21133) 
TLR2, TLR4, 
TLR9 
Goat anti-
rabbit 
Alexa Fluor® 350 Diode (405)  
346/442 
1:200 Molecular 
Probes 
(A11046) 
TLR4 
(polyclonal) 
Streptavidin 
(Tertiary) 
Alexa Fluor® 350 Diode (405)  
346/442 
1:100 Molecular 
Probes 
(S11249) 
Biotin 
conjugated 
goat anti-
mouse/rabbit 
(1:100) 
Table 4.03. Labelled secondary and tertiary reagents used in immunofluorescence studies 
4.3.7.1 Double immunostaining methods 
Skin biopsies were embedded in FSC 22
TM
 (Surgipath, Richmond, Illinois).  Cryosections 
(6µm) were cut on a Leica CM1100 Cryostat (Leica Microsystems, Germany) and adhered 
to polysine coated glass slides (VWR International Ltd, Lutterworth, United Kingdom). 
The sectioning of skin biopsies was performed in a Category 3 laboratory. 
The staining protocols were performed in a humidified chamber at room temperature. 
Following the addition of fluorochrome conjugated antibodies all further incubations and 
washes were performed in the dark. 
In all staining methods the sections were thawed at room temperature for 60 minutes and 
then fixed in acetone for 15 minutes and air dried.  Each section was circumscribed using a 
hydrophobic barrier pen (ImmEdge™ Pen, Vector Laboratories Inc., Burlingame, 
California). The slides were washed in PBS for five minutes.  
Sections were fluorescently double stained using one of the following protocols: 
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1. Primary murine antibody isotypes IgG1/IgG2a staining. Non-specific background staining 
was minimised by incubating each section with PBS containing 10% goat serum (Dako, 
X0907 from the same species as the secondary antibody) for 30 minutes. The sections were 
then incubated with both primary antibodies diluted together in antibody diluent for 60 
minutes. Negative controls were performed using isotype specific antibodies. The sections 
were then washed in PBS for 10 minutes. The sections were then incubated with a mixture 
of the fluorochrome conjugated isotype specific goat anti-mouse secondary antibodies in 
antibody diluent for 30 minutes.  
2. Polyclonal rabbit anti-human TLR4 antibody staining. Non-specific background staining 
was minimised by incubating each section with PBS containing 10% rabbit serum (Dako, 
X0902, the same species as the secondary antibody) for 30 minutes. The sections were then 
incubated with the primary antibody diluted in antibody diluent for 60 minutes. Negative 
controls were performed using PBS. The sections were then washed in PBS for 10 minutes. 
The sections were then incubated with Alexa Fluor® 350 conjugated goat anti-rabbit 
secondary antibody in diluent for 30 minutes.  
3. Primary murine antibody isotypes IgG1/IgG2a staining. Non-specific background staining 
was minimised by incubating each section with PBS containing 10% goat serum (Dako, 
X0907 from the same species as the secondary antibody) for 30 minutes. The sections were 
then incubated with a primary antibody diluted in antibody diluent for 60 minutes. 
Negative controls were performed using isotype specific antibodies. The sections were then 
washed in PBS for 10 minutes. The sections were then incubated with the appropriate 
biotinylated secondary antibody, either goat anti-mouse IgG1 (Molecular Probes, A10519, 
1:100) or goat anti-mouse IgG2a (Caltag Laboratories M32215, 1:100). The sections were 
then washed in PBS for 10 minutes and then incubated for 30 minutes with Alexa Fluor® 
350 conjugated streptavidin diluted in antibody diluent.  
4. FITC-conjugated anti-TLR9 antibody staining. The sections were incubated with this 
antibody for 60 minutes. 
In all of the fluorescent staining methods the sections remained shielded from light and 
were washed in PBS for 10 minutes and then equilibrated in water for 5 minutes. The slides 
were then mounted with a cover slip using Vectashield® Hard Set™ (Vector Laboratories 
Inc., Burlingame, California). All of the slides were stored at 4ºC in the dark and examined 
within 24 hours. 
4.3.7.2 Optimisation of fluorescent staining 
The optimisation of fluorescent staining was achieved by staining with each primary 
antibody in the concentration used in the IHC methods. If this concentration did not result 
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in adequate and specific fluorescence the concentration of primary antibody was increased, 
in some cases undiluted. 
This approach was also used to achieve the optimal concentrations of the fluorochrome 
conjugated secondary antibodies and the biotinylated isotype specific secondary antibodies 
and Alexa Fluor® 350 conjugated streptavidin. 
4.3.7.3 Confocal laser microscopy 
Immunofluorescent labelled sections were examined using a confocal microscope 
(LSM510, Zeiss, Welwyn Garden City, UK) fitted with diode, argon and helium-neon 
lasers. The excitation wavelengths used are shown in Table 4.03. A 505-550 band-pass 
emission filter was used for fluorescein and FITC conjugated antibodies. A 585nm long-
pass emission filter was used for Alexa Fluor® 546 conjugated goat anti-mouse IgG2a 
antibody. A 420-480 band pass filter was used for Alexa Fluor® 350 conjugated 
antibodies.  
The images were superimposed for colocalisation analysis. Staining with negative control 
antibodies was recorded using the same settings as the test antibodies to check for non-
specific fluorescence. 
4.3.8 Real-time Polymerase Chain Reaction (PCR) Assays 
4.3.8.1 RNA extraction  
RNA was isolated from skin stored in RNAlater™ (Ambion, Austin, Texas) using the 
RNeasy Fibrous Tissue Kit (Qiagen, Crawley, UK) according to the manufacturer’s 
protocol. Tissue from half of a 6 mm punch biopsy (approximately 10 mg) was disrupted 
using a disposable pellet pestle (Anachem, Luton, UK) and homogenised with a 
Qiashredder (Qiagen, Crawley, UK). DNA was digested with DNase I (Qiagen, Crawley, 
UK). The isolation of RNA was performed in a Category 3 laboratory. RNA samples were 
stored at -80 ºC. 
RNA concentration and quality was confirmed using a NanoDrop 1000, spectrophotometer 
(Thermo Scientific, Epsom, UK). The concentration of each sample was calculated in 
triplicate according to the Beer Lambert Law. The mean 260/280 ratio was also calculated. 
4.3.8.2 cDNA synthesis 
cDNA was synthesised from RNA using the Omniscript Reverse Transcriptase Kit 
(Qiagen). Reactions were performed using 1x RT buffer, 0.5 mM dNTP, 1 µM Oligo-dT 
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primer (Invitrogen, Paisley, UK), 0.5 units/µl RNase inhibitor (Invitrogen, Paisley, UK), 
0.2 units/µl reverse transcriptase, 80 ng template RNA and nuclease free water to a total 
volume of 20 µl. Reactions were incubated in an ABI 9700 Programmable Thermal Cycler 
(Applied Biosystems, Foster City, California) for 60 minutes at 37 ºC followed by 5 
minutes at 95 ºC and cooling to 4 ºC for 5 minutes and then 15 ºC. 
4.3.8.3 Choice of the control gene 
human Acidic Ribosomal Phosphoprotein P0 (hARP-P0) has been used previously in PCR 
experiments examining TLR gene expression in vitro (Renn et al., 2006).  
4.3.8.4 Primers 
Primers for hARP-P0 and TLR1, TLR2, TLR4 and TLR9 were obtained from previously 
published reports (Renn et al., 2006). Predicted primer binding specificities and fragment 
sizes were tested by PCR in silico using the AmpliFx software (Nicholas Jullien, Institut 
Jean Roche, Université de la Mediterranée Marseilles, France) against sequences obtained 
from the European Molecular Biology Laboratory (EMBL) Nucleotide databases.   
Oligonucleotide primers were synthesised and desalted by Sigma-Genosys (Gillingham, 
UK). Working stocks of 12.5 µM were kept at 4 °C. These primers could not amplify 
genomic DNA targets and functioned with cDNA templates only as they spanned exon 
boundaries.  
Table 4.04 shows the primer sequences, primer melting temperatures, amplicon size and 
melting temperature. 
Primer 
(F, sense; R, 
antisense) 
Sequence 
 
Tm 
(ºC) 
Amplicon  
size 
 (bp) 
Amplicon 
 Melt  
(ºC) 
hARP-P0(F) 
hARP-P0(R) 
5 CCACgCTgCTgAACATgCT 
5 TCgAACACCTgCTggATgAC 
67.7 
66.4 
67 81.0 
TLR1(F) 
TLR1(R) 
5 TCTAgTgTgCTgCCAATTgCTC 
5 AAAgTCTTgAAggCCCTCAgg 
66.5 
65.6 
102 79.8 
TLR2(F) 
TLR2(R) 
5 CAT TCC CTC Agg gCT CAC Ag 
5 TTgTTggACAggTCAAggCTT 
67.1 
65.8 
51 76.8 
TLR4(F) 
TLR4(R) 
5 AggATgAggACTgggTAAggAAT 
5 TgAAggCAgAgCTgAAATggA 
64.8 
67.1 
76 78.0 
TLR9(F) 
TLR9(R) 
5 CTCTgAAgACTTCAggCCCAACT 
5 CACggTCACCAggTTgTTCC 
66.8 
67.8 
76 82.2 
Table 4.04. Primer sequences, melting temperatures (Tm) and amplicon size 
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4.3.8.5 Real-time quantitative PCR 
Real-time quantitative PCR of all the genes was performed on the Rotor-Gene™ 3000 
programmable thermal cycler (Corbett Life Science (Qiagen), Crawley, UK) using the 
QuantiTect
®
 SYBR
®
 Green PCR Kit (Qiagen, Crawley, UK).  
Reactions consisted of 1x QuantiTect SYBR Green PCR Master Mix, 0.3 µM forward 
primer, 0.3 µM reverse primer, 1 µl cDNA and nuclease free water to a total volume of 25 
µl. The master mix contains HotStarTaq DNA polymerase, PCR buffer, dNTP mix, SYBR 
Green I, ROX (passive reference dye) and 5 mM magnesium chloride. 
The Rotor-Gene conditions were as follows: polymerase activation was achieved by 
incubating at 95 ºC for 15 minutes; and 45 cycles of denaturation at 94 ºC for 10 seconds, 
annealing at 60 ºC for 15 seconds, extension at 72 ºC for 20 seconds, and fluorescence 
acquisition for five seconds at 72 ºC. 
Melting point data were obtained by increasing the temperature from 72 ºC to 95 ºC by      
1 ºC on each step. The interval between increases in temperature was 45 seconds for the 
first step and then five seconds for subsequent steps. 
Negative and no template controls were included in all experiments. 
The size of the PCR products was confirmed for each gene by electrophoresis of the 
amplicon products in 3% agarose gel with ethidium bromide and photographed under UV 
transillumination. This was only done during standardisation and not performed on each 
specimen. 
Relative gene expression was analysed using the 2
-ΔΔCT
 method (Livak and Schmittgen, 
2001). The CT value is the threshold number for the amplification of the target gene. The 
threshold cycles for the target gene and control gene at each time point are measured. The 
difference in the threshold, ΔCT, between the two genes was calculated. The difference 
between the ΔCT of the second time point and that of baseline was calculated (the ΔΔCT). 
The fold change in gene expression from baseline is given by the expression 2
-ΔΔCT
.  
4.3.8.6 Validation of hARP-P0 as the control gene 
The expression of the control gene in relative gene expression experiments must not vary 
significantly under the conditions being studied. Corticosteroids are well recognised to 
affect gene expression of most genes (Nishimura et al., 2006). The choice of control gene 
was influenced by the effect of corticosteroids on gene expression. The control gene hARP-
P0 was amplified. 
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RNA extracted from skin biopsies taken from three of the study individuals at each of the 
three time points was diluted to a concentration of 20 ng/µl and reversed transcribed to 
cDNA. These were then amplified in triplicate with hARP-P0 and the cycle threshold 
determined. 
4.3.8.7 Validation of the 2
-ΔΔCT
 method for hARP-P0 
The 2
-ΔΔCT
 method is only valid if the efficiency of amplification of the target gene does not 
differ significantly from that of the control gene (in this case hARP-P0). The ΔCT was 
calculated for different dilutions (ranging from 1 to 1:128) of cDNA in triplicate for each 
TLR gene and for hARP-P0, the control gene. 
4.3.8.8 Analysis  
The data were analysed using the Statistical Package for the Social Sciences (SPSS version 
16. SPSS Inc., Chicago, Illinois) or GraphPad Prism (version 4.02 for Windows, 
GraphPad Software, San Diego, California). 
The threshold for accepting statistical significance was <0.05. The level of statistical 
significance between a group and its baseline results are indicated in figures as follows: p< 
0.05 (*), p≤0.01 (**), and p≤0.001 (***). 
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4.4 Results 
4.4.1 Study and control subjects 
Forty-two individuals were enrolled into the randomized controlled trial and 23 control 
subjects were recruited. The clinical data for the controls and participants are shown in 
Tables 4.05 and 4.06 respectively. 
Non-reactional 
controls 
Gender Age 
Ridley Jopling 
Classification 
BI 
C3 Female 41 LL 3.5 
C4 Male 34 LL 3.75 
C5 Male 29 LL 4.25 
C9 Male 20 BT 1 
C10 Male 20 BT 0 
C11 Male 16 BT 0 
C12 Female 67 TT 0.25 
C15 Male 26 BL 1.75 
C16 Male 24 BL 2.75 
C17 Female 45 BT 0 
C18 Male 25 BT 0 
C19 Male 21 BT 0 
C20 Female 47 I 0 
C22 Female 51 BT 0 
C23 Male 21 BT 0 
Table 4.05. Control subjects. 
 
Eight controls were rejected. One individual (Control 1) had a histological diagnosis of 
cutaneous leishmaniasis. The label on the vial of Control 2 became illegible and so this 
specimen was used in some of the optimisation experiments. Control 6 had no evidence of 
leprosy on her skin biopsy. Controls 7, 8 and 13 all received oral prednisolone immediately 
after their skin biopsy was performed. The biopsy of Control 14 did not stain appropriately 
with any antibody used in the immunohistochemical analysis and was felt to have been 
compromised during transit or storage. The specimen of Control 21 was too small to 
section.  
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Study 
Number 
Gender Age 
Ridley Jopling 
Classification 
BI MDT Status Reaction Type Study Arm 
AN01 Male   36 BL 1.5 Completed  Nerves Only     Prednisolone 
AN02 Male   28 BT 0 None  Skin and Nerves MP 
AN03 Male   23 BT 0 None  Skin and Nerves MP 
AN04 Male   49 BL 0 Started     Skin and Nerves Prednisolone 
AN05 Male   64 LL 0 Completed  Skin and Nerves MP 
AN06 Male   24 BL 0 Started     Skin and Nerves Prednisolone 
AN07 Male   16 TT 0 Started     Skin and Nerves MP 
AN08 Male   24 BT 0.75 Started     Skin and Nerves Prednisolone 
AN09 Male   42 BT 0 Completed  Nerves Only     MP 
AN10 Male   65 BL 2.5 Completed  Nerves Only     Prednisolone 
AN11 Female 17 BL 0 Started     Skin and Nerves MP 
AN12 Male   55 BL 0 Completed  Nerves Only     Prednisolone 
AN13 Male   63 BL 0 Started     Skin and Nerves MP 
AN14 Female 18 BT 0 Completed  Skin and Nerves MP 
AN15 Female 35 BT 0 Completed  Nerves Only     Prednisolone 
AN16 Female 39 BT 0 Completed  Nerves Only     Prednisolone 
AN17 Female 42 BB 1 None  Skin and Nerves MP 
AN18 Male   41 BL 2.5 None  Skin and Nerves Prednisolone 
AN19 Male   54 BL 1.25 Started     Skin and Nerves MP 
AN20 Female 54 BT 3.25 Started     Skin and Nerves Prednisolone 
AN21 Male   53 LL 0 Started     Nerves only Prednisolone 
AN22 Male   16 BT 0.5 Started     Nerves Only     MP 
AN23 Male   29 BT 0 Completed  Skin and Nerves MP 
AN24 Male   33 BT 0 Started     Nerves Only     Prednisolone 
AN25 Male   44 BT 0 Started     Skin and Nerves Prednisolone 
AN26 Male   28 BT 0 None  Skin and Nerves MP 
AN27 Male   40 BB 0 Started     Skin Only       Prednisolone 
AN28 Male   59 BL 1.75 None  Skin Only       MP 
AN29 Male   28 BT 0 Completed  Skin Only       MP 
AN30 Male   35 BT 0 None  Nerves Only     Prednisolone 
AN31 Male   18 BB 3.75 None  Skin Only       MP 
AN32 Male   36 BT 0 Started     Nerves Only     Prednisolone 
AN33 Female 35 BT 0 Started     Skin Only       Prednisolone 
AN34 Male   40 BL 2 Started     Nerves Only     Prednisolone 
AN35 Male   27 BT 0 Started     Skin Only       MP 
AN36 Male   62 BT 0 Started     Skin and Nerves MP 
AN37 Female 17 BT 0 Started     Skin and Nerves MP 
AN38 Male   55 BT 0 Started     Nerves Only     MP 
AN39 Female 40 BT 0 Started     Skin Only       Prednisolone 
AN40 Male   41 BL 2.5 Started     Skin and Nerves Prednisolone 
AN41 Male   23 BL 3 Started     Skin Only       Prednisolone 
AN42 Male   22 BT 0 Started     Nerves Only     Prednisolone 
        
Table 4.06. Study subjects.
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4.4.2 Immunostaining by Ridley-Jopling classification 
The controls and study patients were grouped by Ridley-Jopling classification. Controls 
diagnosed with TT and BT leprosy were grouped together and those with BL or LL 
classifications were grouped together. The same was done for study participants. For the 
purposes of this analysis the control patient with indeterminate leprosy was excluded as were 
the three study participants with BB leprosy. This analysis compared the grade of staining of 
biopsies from control patients and biopsies from the study participants taken at enrolment. 
There were no significant differences between the TT/BT and BL/LL control groups or 
between a control group and its corresponding study group in terms of cellular infiltration, 
dermal CD1a or CD68 staining. This was also true for CD3 staining with the exception of 
the TT/BT control group which had significantly higher staining (p = 0.043) than the 
corresponding study group with median grades of CD3 staining of 4 and 2.5 respectively. 
The grade of TLR staining for the control and study groups is shown in fig. 4.01.  
TLR1 staining was significantly higher in BL/LL controls compared to TT/BT controls       
(p = 0.002). The median grade of staining for the BL/LL control group was the maximum 5 
and for the TT/BT control group 2. The BL/LL control group TLR1 grade of staining was 
also significantly higher than that of both the BL/LL and TT/BT study groups at baseline    
(p = 0.005 and p = 0.01 respectively). There were no significant differences TLR1 staining 
between the other groups. 
The grade of TLR2 staining was not significantly different between any of the groups except 
the BL/LL control group and the TT/BT study group (p = 0.037). The median TLR2 grade 
of the BL/LL controls was the maximum 5 and that of the BL/LL study group 3 but this was 
not significant (p = 0.057). 
The grade of TLR4 staining was significantly higher in BL/LL control subjects than in their 
TT/BT counterparts. The median score for the former was the maximum 5 and for the 
TT/BT controls 1.5 (p = 0.045). There were no other significant differences between the 
groups. 
The results were not affected by excluding study subjects with only nerve involvement. 
TLR9 was not analysed in this way (see 4.4.11). 
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Figure 4.01. TLR1, TLR2 and TLR4 
staining for controls and study 
participants by Ridley-Jopling 
classification. 
p< 0.05 (*), p≤0.01 (**) and p≤0.001 (***) 
** 
** ** 
 * 
 * 
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4.4.3 Cellular infiltration in the skin during corticosteroid treatment. 
The degree of cellular infiltration was similar in both control subjects and study participants 
at baseline (p=0.053) and then was significantly reduced at days 4 and 133 (p=0.03 and 
p=0.001 respectively). There was no significant difference in the cellular infiltration in the 
skin of study participants at baseline and day 29. 
The 14 individuals in the study who had nerve involvement only, had significantly lower 
cellular infiltration than controls (p=0.007) but not the 28 study participants with skin (with 
or without NFI) involvement (p=0.105). 
4.4.4 CD3 staining in the skin during corticosteroid treatment. 
The number of CD3 positive cells was significantly higher in control subjects compared to 
study participants (p=0.016). This is accounted for by the individuals with isolated nerve 
involvement who had significantly lower scores for CD3 staining than controls (p=0.003) 
but not those study participants with skin involvement (p=0.190). The individuals with 
clinical evidence of T1R in the skin did not have significantly different CD3 scores 
compared to controls (p=0.099). 
The degree of CD3 staining was significantly reduced in study participants at all time points 
compared with baseline. 
4.4.5 CD68 staining in the skin during corticosteroid treatment. 
CD68 staining was similar in controls and study participants (p=0.356) and was significantly 
reduced in study participants by day 29 (p= 0.006) and this was maintained at day 113 (p < 
0.001). 
4.4.6 Dermal CD1a staining in the skin during corticosteroid treatment. 
Overall the level of staining of dermal CD1a was less than that of CD3 or CD68. The 
maximum level of staining recorded was 3 regardless of an individual’s status (control or 
study participant) or the timing of the biopsy. 
There was no significant difference between the number of dermal CD1a positive staining 
cells in the controls and study participants (p=0.722). There were significant reductions in 
the dermal CD1a of study participants staining at days 4 (p=0.002) and days 29 (p=0.025) 
but not day 113 (p=0.171). 
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Figure 4.02 Grade of cellular infiltration and staining for CD3, CD68 and CD1a 
4.4.7 The relationship between clinical skin inflammation and cellular 
infiltration and cellular expression of CD1a, CD3 and CD68 before 
treatment 
There were no significant differences in the grade of cellular infiltration or the number of 
cells staining positive for CD1a, CD3 and CD68 between individuals with signs of T1R 
reaction cutaneous inflammation and those without prior to starting treatment. 
 *  ***   *   *   *   * 
 **   *** 
 **   * 
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CD3
CD68
CD1a
Negative controls
Figure 4.03. Representative staining of CD3, CD68 and CD1a in study subjects at baseline 
with their negative controls 
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4.4.8 The cellular expression of toll-like receptor 1 in the skin during 
corticosteroid treatment 
There was no statistically significant difference in the level of staining of TLR1 in controls 
compared to study participants at baseline (p=0.061). In the study participants the only 
significant decline, compared to baseline in staining for TLR1, occurred at day 113 
(p=0.009). 
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Figure 4.04. Cellular expression of TLR1 by controls and 
MP study participants days 1, 4, 29 and 113 
 
4.4.9 The cellular expression of toll-like receptor 2 in the skin during 
corticosteroid treatment 
There was no significant difference in the level of TLR2 staining between controls and study 
participants (p=0.349). The subgroup with only nerve involvement showed significant 
differences in the degree of staining for TLR2. This group not only had significantly less 
TLR2 staining than controls (p=0.043) but also significantly less than those individuals in 
the study with clinical features of skin inflammation due to T1R (p=0.015). There was no 
significant difference between the latter group and controls. 
 ** 
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The level of TLR2 staining had declined significantly by day 29 (p = 0.001) and remained 
significantly reduced at day 113 (p < 0.001) compared to baseline. The reductions in TLR 2 
staining during corticosteroid therapy at days 29 and 113 remained significant for the 
subgroup with cutaneous features of T1R. 
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Figure 4.05 Cellular expression of TLR2 by controls and 
MP study participants days 1, 4, 29 and 113 
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Figure 4.06. Representative staining of TLR1, TLR2, TLR4 and TLR9 in study subjects at 
baseline with their negative controls. 
  
Negative controls
Toll-like receptor 1
Toll-like receptor 2
Toll-like receptor 4
Toll-like receptor 9
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4.4.10 The cellular expression of toll-like receptor 4 in the skin during 
corticosteroid treatment 
There was no significant difference in the level of staining for TLR4 between controls and 
study subjects (p = 0.797).  TLR4 staining was significantly reduced at days 4 (p = 0.011) 
and days 133 (p = 0.01) compared to baseline. 
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Figure 4.07 Cellular expression of TLR4 by controls and 
MP study participants days 1, 4, 29 and 113 
 
Excluding individuals who received additional corticosteroids before day 113 did not 
significantly alter the findings of the analysis of the immunohistochemistry data for the 
cellular markers or the TLRs. 
4.4.11 The cellular expression of toll-like receptor 9 in the skin during 
corticosteroid treatment 
Skin sections TLR9 staining was less intense than other antibody stains.  Sections were 
therefore assessed as either positive or negative. It was not possible to perform a positive 
control. 
 
  * 
 ** 
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 Toll-like receptor 9 staining 
 Positive Negative 
   
Controls 9 6 
Steroid treated individuals (Day 1) 9 32 
Table 4.07. TLR9 staining 
The control subjects were more likely to have skin that stained positive for TLR9 (Chi-
squared, Fisher’s exact test p=0.011). 
None of the nine corticosteroid treated individuals who had TLR9 positive staining cells in 
the baseline skin biopsy had evidence of it in subsequent biopsies. Two individuals AN07 
and AN29 who had negative day 1 biopsies had TLR9 staining of skin sections at day 4 
(AN07), day 28 (AN29) and day 113 (both AN07 and AN29).  
4.4.12 The relationship between skin inflammation and cellular expression of 
toll-like receptor 1 
The median grade for individuals with clinical signs of T1R in the skin was three. This was 
greater than the median scores of individuals who did not have clinical signs of skin reaction 
which was two but lower than controls whose median score was four. However these 
differences were not statistically significant. 
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Figure 4.08. TLR1 expression by controls and individuals with and without skin T1R at baseline 
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4.4.13 The relationship between skin inflammation and cellular expression of 
toll-like receptor 2 
Individuals with clinical evidence of cutaneous involvement due to T1R had significantly 
different scores from those individuals with no skin involvement (p = 0.015). The median 
score of the inflamed group was higher than that of the controls but this was not statistically 
significant. 
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Figure 4.09. TLR2 expression by controls and individuals with and without skin T1R at baseline  
4.4.14 The relationship between skin inflammation and cellular expression of 
toll-like receptor 4 
There were no significant differences between any of the three groups with respect to TLR4 
although the median score for the inflamed group was higher than that of the controls and 
individuals with no skin inflammation. 
    [ --------*----------] 
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Figure 4.10. TLR4 expression by controls and individuals with and without skin T1R at baseline  
4.4.15 Comparison of the effect of methylprednisolone and prednisolone on 
cellular infiltration in the skin 
There were no significant difference between the cellular infiltration in biopsies from 
controls and those from either of the study arms. The degree of cellular infiltration did not 
differ significantly between the two study groups at any time point. However both the 
prednisolone and the methylprednisolone groups had significantly less cellular infiltration in 
biopsies taken at day 113 than was present at baseline (p = 0.005 and p = 0.036 
respectively).  
4.4.16 Comparison of the effect of methylprednisolone and prednisolone on 
CD3 staining in the skin 
The level of staining for CD3 was significantly higher in the control group than the 
prednisolone treated group (p = 0.008). There was no significant difference between the 
control group and the methylprednisolone treated group. There were no significant 
differences in the level of CD3 staining between the two study groups at any of the time 
points. 
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The number of CD3 positive cells was significantly reduced at day 113 in the prednisolone 
treated group compared to baseline (p = 0.013). The methylprednisolone group had 
significant reductions in CD3 positive staining cells at day 4 (p = 0.041) and day 113          
(p = 0.003). 
4.4.17 Comparison of the effect of methylprednisolone and prednisolone on 
CD68 staining in the skin 
There were no significant differences between the control group and either of the study 
groups, or between the study groups at any of the four time points. The number of CD68 
positive cells was significantly reduced at day 29 (p = 0.031) and day 113 (p = 0.007) 
compared to baseline in the prednisolone treated group. The methylprednisolone group only 
had a significant reduction in CD68 positive staining cells on day 113 (p = 0.001). 
4.4.18 Comparison of the effect of methylprednisolone and prednisolone on 
dermal CD1a staining in the skin 
There were no significant differences between the control group and the study groups with 
respect to the dermal staining of CD1a positive cells. There were no significant differences 
between the study groups at any of the time points. The only significant reduction in CD1a 
positive staining compared to baseline was seen in the methylprednisolone group at day 4    
(p = 0.005) but this significant reduction was not sustained. 
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4.4.19 Comparison of the effect of methylprednisolone and prednisolone on toll-
like receptor 1 expression in the skin 
There were no significant differences between the control group and either of the study 
groups with respect to cellular staining of TLR1. The level of staining of TLR1 was not 
significantly different between the study groups at any of the time points. 
There were no significant changes in TLR1 staining in the prednisolone group at any of the 
time points. However the methylprednisolone group showed a significant reduction in TLR1 
staining compared to baseline at day 4 (p = 0.041) and day 113 (p = 0.012). 
Figure 4.11.  Cellular infiltration and grade of staining of CD3, CD68 and CD1a for controls 
and individuals by study treatment arms. p< 0.05 (*), p≤0.01 (**) and p≤0.001 (***). 
  
 * 
 ** 
        [**] 
 *  ** 
 *** 
  * 
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Figure 4.12. TLR1 staining for controls and individuals in the study treatment arms 
4.4.20 Comparison of the effect of methylprednisolone and prednisolone on toll-
like receptor 2 expression in the skin 
The grading of TLR2 staining did not differ significant between the control group and the 
study groups. The study groups were not significantly different from each other. 
The prednisolone group showed a significant reduction in TLR2 staining at day 113 (p = 
0.004). At day 29 the level of staining was reduced but this was not statistically significant 
(p = 0.051). The methylprednisolone group showed a reduction in TLR2 staining at all time 
points. This was not statistically significant at day 4 (p = 0.066) but was at day 29 (p = 
0.011) and day 113 (p = 0.001). These findings were not altered by analysing individuals 
with only nerve involvement and cutaneous involvement separately.  
  * 
  * 
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Figure 4.13. TLR2 staining for controls and individuals in the study treatment arms 
4.4.21 Comparison of the effect of methylprednisolone and prednisolone on toll-
like receptor 4 expression in the skin 
There were no significant differences in the level of TLR4 staining between controls and 
either of the study groups. There were no significant differences between the two study 
groups at any of the time points. 
The prednisolone group did not have a significant change in the level of TLR4 staining at 
any of the time points. The methylprednisolone group showed a reduction in TLR4 staining 
at all time points. This was significant at day 4 (p = 0.026) and day 113 (p = 0.008) but not 
at day 29 (p = 0.058). 
 ***   ** 
   * 
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Figure 4.14. TLR4 staining for controls and individuals in the study treatment arms 
4.4.22 Comparison of the effect of methylprednisolone and prednisolone on toll-
like receptor 9 expression in the skin 
Further sub-division and analysis of the small numbers of TLR9 positive biopsies was not 
performed. 
4.4.23 Co-localisation of toll-like receptors and cell surface markers during 
Type 1 reaction and corticosteroid therapy 
The labelling of CD1a, CD3, CD68 and TLR2 was successful. There were no differences in 
the pattern of staining between study subjects and BT or BL leprosy controls. 
TLR2 was closely associated with both CD3 and CD68 positive cells and co-localised with 
these cells in some areas of the sections examined. 
There is marked CD1a staining of the epidermis but there are also CD1a positive staining 
cells within the dermis which are closely associated with but not co-localised to cells 
expressing TLR2. 
 **   * 
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Figure 4.15. Confocal microscopy images of fluorescent 
staining of TLR2 and a. CD3, b. CD68 and c. CD1a. The 
images are merged in the final panel 
a. 
b. 
     c. 
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Despite using different techniques no positive staining was achieved for TLR1, TLR4 or 
TLR9. TLR1 primary antibody was used at various concentrations (including undiluted) 
with Alexa Fluor® 350 and fluorescein anti-IgG1 secondary antibodies. Visualisation was 
also attempted using biotinylated secondary and an Alexa Fluor® 350 conjugated 
streptavidin tertiary antibody. Two different primary antibodies were used to try and label 
TLR4, the rabbit polyclonal antibody that was used in the immunohistochemical experiment 
and an IgG2a murine monoclonal (Santa Cruz SC-13593). These were used in various 
concentrations with appropriate secondary conjugated antibodies. The antibodies were also 
used with a biotinylated secondary and the Alexa Fluor® 350 conjugated streptavidin 
tertiary antibody. None of these were successful. TLR 9 was not visualised using 
immunofluorescent techniques. These included those outlined above for other IgG2a 
antibodies. The FITC conjugated anti-TLR9 antibody did fluoresce but background 
fluorescence was such that it was not possible to determine if the labelling was specific.  
4.4.24 Validation of control gene hARP-P0 for PCR assays 
There was no significant difference in the transcriptional activity of hARP-P0 before and 
during corticosteroid therapy (One way ANOVA p=0.058). 
 The primers for the reference gene hARP-P0 were used to amplify cDNA and compared 
with each pair of primers for the four TLR genes under investigation.  
The ΔCT (CT, TLR gene- CT, hARP-P0) was calculated for each of the eight dilutions of template 
cDNA (see Appendix 5.3).  
The data fit using least squares linear regression. All four study TLR amplicons had similar 
efficiencies as hARP-P0. The slopes of ΔCT plotted against log(concentration) are close to 
zero. R
2 
is the proportion of the total variance in ΔCT explained by the regression model i.e. 
relative concentration. 
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Figure 4.16. ΔCt for each TLR gene and hARP-P0 at dilutions ranging from 1 to 1:128 
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4.4.25 Toll-like receptor 1 gene expression during corticosteroid treatment 
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Figure 4.17. TLR1 gene expression days 1, 4, 29 and 113 
The median fold change of TLR1 gene expression decreased at all time points after baseline 
but none were significant. At day 113 the methylprednisolone group had a significant 
reduction in gene expression (p = 0.043). 
4.4.26 Toll-like receptor 2 gene expression during corticosteroid treatment 
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Figure 4.18. TLR2 gene expression days 1, 4, 29 and 113 
 ***     * 
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There was a significant fall in TLR2 gene expression at day 29 (p < 0.001) and day 113      
(p = 0.043) compared to day 1. There was no significant difference between the study 
groups. 
The prednisolone (p = 0.004) and methylprednisolone (p = 0.037) groups showed significant 
decreases in gene expression at day 29 from their respective day 1 levels. The fold change 
difference was not significant at day 113 for either group. 
4.4.27 Toll-like receptor 4 gene expression during corticosteroid treatment 
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Figure 4.19. TLR4 gene expression days 1, 4, 29 and 113 
There was a significant reduction in TLR4 gene expression at day 29 (p = 0.008) and day 
113 (p = 0.002). There was no significant difference between the study groups. The 
prednisolone group showed a significant decrease in TLR 4 gene expression at day 29         
(p = 0.013) compared to day 1. The methylprednisolone group did not (p = 0.173). At day 
113 the methylprednisolone group showed a significant reduction in TLR 4 gene expression 
compared to baseline (p = 0.009) but the prednisolone did not (p = 0.075). 
  
  **   ** 
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4.4.28 Toll-like receptor 9 gene expression during corticosteroid treatment 
Toll-like receptor 9
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Figure 4.20. TLR9 gene expression days 1, 4, 29 and 113 
There were no significant changes in TLR9 gene expression in the steroid treated group as a 
whole at any of the time points. However the methylprednisolone treated group showed a 
significant decrease in gene expression at day 113 (p = 0.018). 
4.4.29 The relationship between the clinical outcome and gene expression of         
toll-like receptors at day 113 compared to baseline 
There was no pattern observed in the level of gene expression of TLR1 and TLR9 for the 
various clinical outcomes. The only individual in the recovered category whose day 113 
sample cDNA amplified satisfactory had an eight fold reduction in TLR1 gene expression 
compared to day 1. 
TLR2 showed successive decreases in the median fold change of TLR2 gene expression as 
one moves from the individual who deteriorated to those who recovered. In the recovered 
group there was a median tenfold reduction in TLR2 gene expression compared to baseline. 
The individual who deteriorated had almost doubled the amount of TLR2 gene expression. 
There were no statistical differences between the groups but the pattern is striking. 
The pattern of TLR4 gene expression at day 113 compared to day 1 was similar to that of 
TLR2. The improved and unchanged groups had almost identical median fold changes in 
gene expression. There were no statistical differences between the clinical categories. 
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4.5 Discussion 
In this study individuals with T1R do not have levels of cellular infiltration in skin lesions 
that are significantly different to that in skin lesions from untreated non-reactional leprosy 
control subjects.  This is in contrast to the findings reported in the study by Andersson et al 
(Andersson et al., 2005) in which 30 patients with T1R had significantly increased levels of 
cellular infiltration and CD68 positive staining cells than untreated leprosy control patients. 
In this study Andersson used the same method for grading cellular infiltration as used for the 
current experiments. 
There are some differences between the current study and Andersson’s Indian cohort. 
Andersson only included individuals with T1R affecting the skin. The control groups 
differed in that 50% of Andersson’s 12 controls had BL leprosy or LL whereas only 33% did 
so in this study.   
The findings are broadly in agreement with the studies of both Andersson and Little (Little 
et al., 2001) in demonstrating a reduction in cellular infiltration and CD68 positive staining 
cells during corticosteroid therapy. 
              Figure 4.21. TLR gene expression by clinical outcome at day 113 compared to baseline  
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Andersson showed that both cellular infiltration and CD68 staining were significantly 
reduced at 28 days and 228 days after starting treatment with prednisolone 30 mg reduced by 
5mg every month.  
In this study cellular infiltration was significantly reduced at day 4 and day 113 compared to 
baseline. There was no significant difference in cellular infiltration between samples taken at 
baseline and those taken at day 29. The reduction seen at day 4 probably reflects the change 
in the MP treated group. The median cellular infiltration score of the corticosteroid group as 
a whole was two at baseline and that of the MP group was one at day 4, although the change 
of the median scores for the MP group went from 2.5 at baseline to one this was not 
statistically significant. The numbers in the day 4 group are small.  
CD68 staining in this study was reduced compared to baseline at days 29 and 113 as in 
Andersson’s study.  
Little and colleagues showed that cellular infiltration in skin lesions declined during 
treatment with prednisolone. Fifteen patients with T1R affecting the skin had biopsies 
performed at baseline and day 7, day 28 and day 180 after starting treatment. In this study, 
which used the same methodology as Andersson, there was a significant reduction in cellular 
infiltration at day 28 but not days 7 and 180. 
There is no consistent effect seen during the early stages of corticosteroid therapy and this 
may reflect the relatively smaller numbers compared to baseline and the final time point. 
T lymphocyte cells have been demonstrated in skin lesions in all forms of leprosy and form 
a cuff around dermal granulomas (Van Voorhis et al., 1982). CD3 positive cells have been 
demonstrated to be closely associated with macrophages and CD1a positive cells containing 
M. leprae antigen in both reactional and non-reactional skin lesions (Rambukkana et al., 
1992). The number of mature T-lymphocytes in skin lesions as indicated by those staining 
with anti-CD3 antibody were significantly reduced compared to controls and probably 
reflects the effect of individuals with nerve only involvement. The difference between 
controls and those with skin involvement was not significant. Narayanan et al reported an 
increase in CD2 T-lymphocytes in reactional skin lesions (using immunofluorescent 
technique with FITC labelled OKT11 monoclonal antibodies) from both BT (n=6) and BL 
leprosy (n=5) patients compared to matched controls (Narayanan et al., 1984).  
There were no statistical differences in the percentage of CD4 positive cells in skin biopsies 
of patients with T1R or TT or BT leprosy or LL in a study from Thailand (Mahaisavariya et 
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al., 1999). In the same study there was no significant difference in the CD4/CD8 ratio in 
skin biopsies from BT patients and leprosy patients with T1R.  
Dermal dendritic cells (CD1a positive staining cells) have been previously shown to be 
present in areas of granulomatous inflammation in leprosy. Sieling et al reported strong 
expression of CD1 proteins by dendritic cells in the skin of individuals with tuberculoid but 
not lepromatous leprosy (Sieling et al., 1999). This finding has been repeated recently by 
Brazilian workers (Simoes Quaresma et al., 2009). In a small series (n=7) from China the 
only comment concerning dermal OKT6 (CD1a) positive cells was that there was “no 
obvious change” seen in the dermis (Liu et al., 1984).  
In the two individuals reported by Sieling who were experiencing a T1R CD1 proteins were 
also strongly expressed. The authors suggest that the appearance of CD1 protein expressing 
cells is temporally related to the onset of a T1R.  
In the current study there was no significant difference in the expression of CD1a between 
the controls and study participants. This must be interpreted with caution because no internal 
controls were available (i.e. a patient who was biopsied before and at the time of reaction) 
and also the preponderance of BT control patients. 
It was interesting that the study participants showed a significant decrease in the expression 
of dermal CD1a at day 4 and day 29 but not day 113. In studies of the effect of topical 
corticosteroids on CD1a epidermal (Langerhans) cells ex vivo there was a significant 
reduction in the number of CD1a positive cells (Ashworth et al., 1988). The fact that oral 
prednisolone, albeit at a dose of 5mg per day, does not continue to suppress expression of 
CD1a by  dermal cells after four months of corticosteroid treatment may be an insight into 
the possible role of CD1a positive cells in individuals who deteriorate. 
TLR1 and TLR2 exist as heterodimers and one would expect their expression at different 
time points to be similar. In the current study both showed a reduction in median staining 
scores during corticosteroid therapy but this was only significant for both of them at day 
113. The reduction in the expression of both receptors is not mirrored in the two treatment 
groups. This is likely to be a reflection of the small numbers involved. 
The significant reduction in TLR2 gene expression at days 29 and 113 is accompanied by a 
significant reduction in the level of TLR2 protein expression in the skin lesions.  
The expression of TLR1 and TLR2 in the skin of patients with T-lep or L-lep leprosy has 
been demonstrated previously (Krutzik et al., 2003). The expression of both receptors was 
greater in tuberculoid patients compared to patients with lepromatous leprosy. This is not the 
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case with the control patients in this study. The BL/LL control group were small in number 
(n = 5) and so the current results need to be interpreted with caution. This group had 
significantly greater staining of TLR1 than the TT/BT control group and both study groups. 
The staining of TLR2 was significantly higher than that of the TT/BT study group. This is 
the opposite of the findings of Krutzik and colleagues for the non-reactional control patients. 
The patients in the study by Krutzik are likely to have been a genetically more 
heterogeneous group than the Nepali patients in the current study which might possibly 
explain the difference in the results. It is also possible that in the BL/LL control patients 
subclinical T1Rs were occurring which were not identified using standard histopathological 
techniques. This seems unlikely. A further more plausible explanation is that this group were 
very active immunologically and this accounts for the high levels of TLR expression. It is 
possible that the greater quantity of M. leprae antigen present in the skin of patients with BL 
leprosy and LL results in increased expression which by the time clinically evident T1R 
occurs TLR expression has down regulated. However the significantly different level of 
staining of TLR2 in individuals with T1R affecting the skin compared to those with isolated 
NFI is somewhat at variance with this argument but the groups were too small to further 
subdivide by Ridley-Jopling classification.  
TLR2 is highly expressed in the epidermis in normal skin and in non-lesional skin from 
individuals with psoriasis and from psoriatic lesions. Epidermal pathology results in 
different patterns of TLR2 staining. In cells obtained from patients with sarcoidosis using 
bronchoalveolar lavage there is reduced IFN-γ production following incubation with an anti-
TLR2 antibody (Oswald-Richter et al., 2009). Mycobacterium ulcerans significantly 
increases the cell surface expression of TLR2 and TLR4 by primary human keratinocytes 
(Lee et al., 2009a). Propionibacterium acnes activates TLR2 which may lead to 
inflammation in acne (Kim et al., 2002), interestingly Shibata and colleagues have shown 
that there is a four-fold increase in TLR2 gene expression in cultured keratinocytes 
incubated with P. acnes and dexamethasone compared to P. acnes alone (Shibata et al., 
2009).  
The corticosteroids dexamethasone, methylprednisolone and prednisone all resulted in an 
increase in gene expression of TLR2, TLR3 and TLR4 by dendritic cells. Despite this 
increased expression the dendritic cells produced significantly less TNFα and IL12 
(Rozkova et al., 2006). Prednisolone has also been shown to inhibit the function of 
plasmacytoid dendritic cells in liver transplant recipients.  
In Ethiopian patients with leprosy, polymorphisms in the TLR2 gene are associated with 
different frequencies of T1R. The polymorphisms were examined in stored samples taken 
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from the AMFES cohort (n=441) (Bochud et al., 2008; Saunderson et al., 2000b). The study 
reported that the single nucleotide polymorphism resulting in the substitution of thymidine 
for cytosine at position 597 was associated with a lower risk of T1R (OR, 0.34 95% CI, 
0.17-0.68). A 280 bp allelic length microsatellite was associated with an increased risk of 
T1R in this cohort (OR, 5.83 95% CI, 1.98-17.15). Sixty six patients had a T1R and only 
150 were reported as having no reaction and so 225 individuals were excluded from the 
analysis. The findings therefore should be interpreted with caution.  
A further finding supporting the role of TLR2 in T1R pathology is the lower gene expression 
in individuals with better clinical outcomes. In a study of 45 individuals with bacterial sepsis 
recurrence of disease was strongly associated with the level of monocyte expression of 
TLR2 at the time of discontinuation of antimicrobial therapy (Orihara et al., 2007). 
The three individuals (AN18, AN23 and AN29) who developed new skin inflammation at 
day 113 did not show a consistent pattern in the TLR2 gene expression or protein staining. 
AN23 had increased TLR2 gene expression compared to baseline whereas in AN29 it was 
decreased. AN29 had no TLR2 positive staining cells at any time point. Larger numbers of 
subjects with late skin deterioration would be required to investigate whether clinical 
deterioration in the skin is associated with increased TLR2 gene expression and TLR2 
staining cells. The confounding effect of paradoxical increase in TLR2 gene expression 
secondary to corticosteroid therapy would also need to be taken into account. 
Individuals with a SNP in TLR1 resulting in the substitution of thymidine with guanine at 
position 1805 may have a lower risk of T1R (Misch et al., 2008). Individuals who are 
homozygous for the guanine allele at this position do not express TLR1 (Johnson et al., 
2007). The study by Misch was conducted in Nepal in patients recruited from Anandaban 
Hospital. However the primary aim of the project was to investigate associations with the 
different clinical types of leprosy and not associations with T1R. A study of patients in 
Bangladesh did not show a significant association between the presence of the S248 allele in 
the TLR1 gene and having a T1R (Schuring et al., 2009). 
It is possible that TLR polymorphisms may have affected the effectiveness of the primers 
used to amplify these genes in the current experiments. Sequence polymorphisms in herpes 
simplex virus significantly affected the performance of real time PCR used to identify the 
presence of the virus in clinical samples (Stevenson et al., 2005). This problem has also been 
identified in diverse multicellular organisms such as the Pacific oyster (Taris et al., 2008). 
TLR4 staining was reduced during corticosteroid treatment and this was reflected in TLR4 
gene expression. However unlike TLR2 the significant reduction in TLR4 gene expression at 
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day 29 is not accompanied by a significant decrease in TLR4 positive staining cells. At day 
113 the reduction of both gene expression and protein staining are significant. At day 4 the 
reduced median fold change in TLR4 gene expression is not significant but it is associated 
with a significant reduction in positive staining cells. TLR4 gene expression also shows a 
similar pattern to that of TLR2 when individuals are categorised by clinical status at the end 
of corticosteroid treatment. The differences between the groups are not significant but there 
is a trend of increased gene expression in individuals who are unchanged or worse compared 
to those who have recovered. 
The TLR4 SNPs (TLR4 896GA and TLR4 1196CT) have been reported to protect 
against developing leprosy in the control subjects of the study of Ethiopian patients with 
leprosy (Bochud et al., 2009a). There have been no reported associations of TLR4 
polymorphisms with T1Rs. 
TLR9 is an intracellular molecule and this may make it more difficult to visualise using 
immunohistochemical techniques. There are few reports of TLR9 being successfully stained 
in human skin using immunohistochemistry. One study of Mycobacterium ulcerans disease 
used a mouse monoclonal antibody. Another study used a goat polyclonal in skin affected by 
viral warts or molluscum contagiosum. A third study used a rabbit polyclonal anti-human 
TLR9 antibody in skin biopsies from individuals with lichen planus. Jarrousse et al 
demonstrated TLR9 staining using a polyclonal donkey antibody in biopsies from patients 
with cutaneous T-cell lymphoma. The staining in all four studies was visualised using a 
biotin-streptavidin technique with either 3-amino-9-ethylcarbazole or DAB as the 
chromagen. In the current study positive controls were not used, however reliable TLR9 
staining was demonstrated in 18 out of 56 samples using a murine monoclonal primary 
antibody. The lack of a positive control means that the statistically significant difference 
between controls and study participants should be interpreted with caution. 
 All but one of the nine study participants had skin involvement. Six had BT leprosy but two 
had BL leprosy and one LL. The control patients had a similar distribution of Ridley-Jopling 
classifications. It is not possible to draw any firm conclusions from the 
immunohistochemical experiments of TLR9.  
The TLR9 gene expression did not significantly decrease during corticosteroid therapy but 
the smaller numbers compared to TLR2 and TLR4 may be responsible. The lack of robust 
TLR9 immunostaining data makes interpreting the gene expression data problematic. 
CD1a positive dermal dendritic cells did not express TLR2 nor did their epidermal 
counterparts. This is in keeping with the findings of Angel and colleagues who showed that 
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normal skin did not have dermal CD1a positive cells expressing TLR2 however some CD14 
positive dermal APCs did (Angel et al., 2007).  
The same workers also demonstrated that CD14 positive dermal APCs express CD68 in 
normal skin. CD68 is largely a macrophage marker but phenotypic heterogeneity has been 
reported in atopic dermatitis in which cells were CD68/CD1a positive (Kiekens et al., 2001).  
Ochoa and colleagues have used immunohistology to demonstrate that there are two distinct 
populations of cells in the dermis of normal human skin which have the morphology of 
dermal dendritic cells. One group of cells express CD1 proteins. The other group expressed 
CD209 (DC-SIGN) which is a macrophage marker. This latter group of cells also expressed 
CD68 (Ochoa et al., 2008). 
The activation of human monocytes with TLR ligands in vitro leads to differentiation into 
macrophages or dendritic cells (Krutzik et al., 2005). Different cell lineages express 
different TLRs. 
In the dermal granulomatous inflammation that characterises leprosy and leprosy T1Rs the 
proportion of CD68 positive cells greatly outweighs those that are CD1a positive but 
concomitant expression of both markers was not investigated.  
CD68 positive cells expressed TLR2 in the granulomas of individuals with T1R and BT and 
BL leprosy controls. This is in agreement with the findings of Krutzik et al in leprosy 
patients and also in individuals with acne inversa (Hunger et al., 2008). This demonstrates 
that the expression of TLR2 is closely associated with some of the abundant cells forming 
the inflammatory infiltrate in individuals with T1R. However in these double 
immunofluorescence experiments it was not possible to replicate the findings of Krutzik in 
which five percent of cells in the granuloma were CD1a positive and expressed TLR2. CD1c 
positive epidermal Langerhans cells have been shown to express TLR2 ex vivo (Peiser et al., 
2008). 
The CD3 positive lymphocytes were closely associated with TLR2 positive staining cells but 
did not appear to express TLR2 themselves. This too is in agreement with the work of 
Krutzik et al. 
Krutzik and colleagues were able to demonstrate colocalisation of TLR1 and TLR2. In the 
current experiment it is likely that there was insufficient anti-TLR1 antibody bound to be 
visualised with the goat anti-mouse fluorochrome conjugated secondary antibodies. These 
secondary antibodies do not provide the same degree of signal amplification as the biotin-
streptavidin method used in immunohistochemical techniques because they do not complex 
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with each other. There is less signal amplification when bound to small amounts of primary 
antibody compared to techniques based on biotin-streptavidin methods. The protocol using 
biotin-Alexa Fluor® 350 conjugated streptavidin may not have worked because the 
biotinylated secondary used was from the Dako K5001 kit which may have been 
incompatible with the fluorochrome labelled streptavidin used. 
It should be noted that in the experiment described by Krutzik both primary antibodies 
against TLR1 and TLR2 were of the IgG1 isotype which raises the possibility that each of the 
secondary fluorescent antibodies recognised the same primary antibody. This problem can 
complicate the method used by Krutzik in which each primary and secondary antibody pair 
are incubated sequentially (Jones and Westmacott, 2007). 
There are no reports of immunofluorescent studies of TLR4 and TLR9 in human skin. It is 
possible that other workers have experienced difficulties with fluorescent techniques 
involving these targets. 
4.6 Summary and conclusions 
 The small BL/LL control group had consistently higher staining of TLR1, TLR2 and 
TLR4 than TT/BT control groups and reactional study patients. 
 The findings of the immunohistochemical studies suggest that individuals with T1R 
have similar levels of cellular infiltration as non-reactional leprosy controls. There 
are no significant differences in the cells of the cellular infiltrate. The level of 
cellular infiltrate and the number of cells of each subtype studied falls during 
corticosteroid therapy. 
 TLR2 is highly expressed by cells in skin lesions of individuals with T1R. TLR2 is 
expressed by CD68 positive cells in these skin lesions but not CD1a positive dermal 
dendritic cells. 
 TLR2 expression in skin lesions of T1R is significantly higher than in the normal 
appearing skin of individuals with NFI.  
 Corticosteroid therapy is associated with a significant reduction in TLR2 expression 
in skin lesions.  
 hARP-P0 is a suitable control gene to use in MDT and corticosteroid treated 
individuals. 
 TLR2 gene expression is reduced during corticosteroid therapy. Individuals with a 
favourable clinical outcome have lower TLR2 gene expression at the end of 
corticosteroid treatment compared to baseline than those who do less well. 
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 TLR4 protein expression and TLR4 gene expression in the skin is reduced during 
corticosteroid therapy. 
 Individuals who received a higher dose of corticosteroid did have significantly 
different changes in TLR staining or TLR gene expression compared to those who 
received less.  
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5.1 Measuring the severity of Type 1 reactions and nerve function 
impairment 
The Clinical Severity Scale is the first validated scale for measuring leprosy T1R and NFI. It 
provides a means of assessing the severity of an individual’s reaction using clinical 
examination. The score generated by application of the scale allows the comparison of the 
severity of reaction between individuals and in a given individual during treatment. 
The score could be used to categorize participants in future clinical trials. This would enable 
investigators to determine whether there was any significant difference in the severity of 
T1R between individuals in the different arms of an intervention study. 
The Clinical Severity Scale does require the use of SWM and it is important that researchers 
using the scale ensure that adequate training in their use has been undertaken.  
The Global Strategy for Further Reducing the Leprosy Burden and Sustaining Leprosy 
Control Activities (2006-2010) (WHO, 2006) recommends that individuals with T1Rs 
and/or NFI should be managed in referral centres.  If staff in referral centres could be trained 
in the use of the SWM then the scale could be used to monitor an individual patients 
response to treatment.  
It would be important to ensure that the scale was validated in the particular setting in which 
it was being employed. The greatest burden of leprosy remains in India and Brazil from 
where 69.5% of cases are reported (WHO, 2009). It is likely that any large intervention 
studies of T1Rs are likely to include centres from these countries and so validation of the 
scale in India should be made a priority. A validation of the scale in India should also be 
designed so that the impact of NFI present for longer than six months could be assessed. 
This would require a larger number of people to be recruited. The scale is currently being 
tested in Ethiopia where it is being validated and the MID in Ethiopian patients is also being 
assessed. 
The change in score might be useful as an outcome measure in clinical trials. At present the 
range of scores that represent the clinical categories of mild or moderate or severe T1R have 
been determined using the receiver operating characteristic curves. Further work is needed to 
assess what a change in unit score represents in terms of clinical improvement or 
deterioration to someone affected by a T1R and/or NFI.  
The scale needs to be assessed in terms of MID which will allow any change in severity 
score to be interpreted in clinically meaningful ways. 
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There are various methods for determining MID of a clinical measurement device. A study 
could be designed to apply the Clinical Severity Scale to individuals presenting with T1R 
and/or NFI in a setting where the scale had already been validated. The scale is applied again 
after four weeks of treatment. The individual is asked whether their condition is: much 
better, somewhat better, the same, somewhat worse or worse (Coeytaux et al., 2006). It 
would be important to ensure that these terms were unambiguous in the first language of the 
participants in the study. The category “somewhat better” is assumed to be an improvement 
in clinical status which is discernible by the patient. 
One could then calculate the mean change in score for individuals in the “somewhat better” 
group. To allow for variation of the score with time the mean change in score of the group 
that report their symptoms as the “same” could be subtracted from that of the “somewhat 
better” group. An alternative method would be to compare the mean scores at the four week 
assessment between the groups “somewhat better” and “same”. The MID is calculated by 
subtracting one from the other. Another method assumes that the MID of “somewhat better” 
is the same as “somewhat worse” and the mean of the change in the scores of the two groups 
can be used to calculate MID. 
Calculating MID using all of these methods will provide a more accurate assessment of 
MID. 
A knowledge of the magnitude of the change in score required to achieve a MID would 
facilitate power calculations for clinical trials.  
The significant difference in the change in nerve score between individuals who were better 
or improved and those who were unchanged or worse in the Nepali cohort, although a 
preliminary finding, suggests that the scale reflects clinically relevant change. The small 
numbers in the cohort and the criterion used to determine improvement (post hoc physician 
assessment) make this finding less reliable than a study designed using the methodologies 
outlined above.  
It could be argued that the scale remains too complex. Studies could be undertaken to try and 
further reduce the number of items. However if neurological items (such as particular 
peripheral nerves) were removed then some other way of assessing the functional status of 
these nerves might be required. 
The demonstration that it is possible to develop a valid, reliable scale to measure the severity 
of T1R and NFI will encourage researchers to turn their attention to developing and 
validating a scale for ENL. ENL has more clinical components than T1Rs and a scale might 
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be somewhat more complex and require larger study populations. The development of a 
scale would help to monitor those individuals with chronic disease and those whose ENL 
was becoming corticosteroid resistant. The multisystem nature of ENL makes the design of 
clinical trials difficult and a valid reliable scale would be useful in defining outcomes.  
5.2 The treatment of Type 1 reactions 
This study is the first to systematically assess pulse IV methylprednisolone for the 
management of T1Rs. The rationale for this investigation was that administration of this 
drug has been associated with clinical improvement in MS and RA. The drug is also 
affordable and available in leprosy endemic settings. 
This study was too small to determine small differences in the effect of high dose pulse 
methylprednisolone and oral prednisolone compared to oral prednisolone alone. During the 
inception of this study the study by Rao and colleagues was published suggesting that the 
duration of treatment rather than total dose of corticosteroid used may be more beneficial in 
controlling the symptoms and signs of T1R (Rao et al., 2006).  
In the Rao double-blind placebo controlled study clinicians were less likely to prescribe 
additional prednisolone to individuals who received prednisolone for 20 weeks compared to 
those who received prednisolone for 12 weeks. In this study participants were treated with 
corticosteroids for 16 weeks despite this 47.6% of individuals required extra prednisolone. 
This is comparable to the 46% of individuals treated with the 12 week course of 
prednisolone by Rao. It should be noted that it is likely that the current study had a lower 
threshold for prescribing additional prednisolone than that of Rao. It is not clear from the 
Rao study how nerve function was assessed. Another difference between the studies is that 
the current study included individuals with NFI who did not have skin signs. The treatment 
of isolated NFI and T1R with NFI is the same and there is no evidence to suggest that the 
two syndromes differ in their response to treatment. 
It is likely that future clinical trials will be designed to examine the effect of longer courses 
(24-36 weeks) of corticosteroids on leprosy T1Rs and NFI rather than larger cumulative 
doses. This pilot study has provided reasonable evidence to suggest that pulse 
methylprednisolone treatment is not associated with significantly greater adverse events than 
oral prednisolone but I do not think this provides sufficient evidence for a larger study of 
pulsed methylprednisolone given the data from the Rao study. I would advocate the design 
of a large multi-centre study of three oral prednisolone regimens of 20, 28 and 36 weeks 
duration. It would be important to maintain follow up for 48 weeks after cessation of 
corticosteroid treatment. Other agents such as azathioprine and ciclosporin are currently 
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being studied in clinical trials and these too should be subjected to the same design standards 
as trials of corticosteroids. 
There are no agreed criteria for prescribing additional prednisolone to individuals in whom 
symptoms or NFI has deteriorated. This hampers the comparison of clinical trials. The 
development of the Clinical Severity Score should allow researchers to standardise criteria 
for clinical deterioration, particularly with respect to NFI, once the MID of the scale has 
been determined. An agreed standard is urgently needed to improve the design of future 
studies. 
The recruitment of participants was not as high as had been hoped. The alteration of the 
entry criteria after 9 months of the study is not ideal but should not have affected the primary 
objective of the study to determine the adverse effect profile in individuals who received 
methylprednisolone compared to individuals who were treated with prednisolone alone. 
The IV administration of methylprednisolone requires an individual to be hospitalised. This 
factor may have affected the willingness of potential participants to enrol as they have to be 
away from family and work for a greater period of time than would be the case with self-
administered oral therapy. 
Women are underrepresented in the studies of T1Rs. The under representation of certain 
groups affects many clinical trials worldwide (Bolen et al., 2006). The results of trials may 
not be applicable if the study population is not representative. The lack of recruitment of 
women is a cause for concern. Gender inequalities may be more significant in leprosy as it is 
a highly stigmatizing disease (Le Grand, 1997). 
All the prospective studies outlined in Tables 1.08 and 1.09 (Chapter 1) have recruited more 
men than women with rates of female recruitment varying from 13-36%. The rate of T1R in 
women with borderline forms of leprosy at Anadaban Hospital (where this study was 
performed) is 28.7% (Roche et al., 1991).  In this study 21.4% of the participants were 
female which makes this study reasonably representative. 
The methylprednisolone study has provided data which has some implications for future 
policy. It demonstrates that even using 16 weeks of prednisolone there is a large proportion 
of people who require further prednisolone. Until recently WHO advocated the use of a 12 
week standard tapering course of prednisolone for T1R and NFI. The current “The Global 
Strategy for Further Reducing the Leprosy Burden and Sustaining Leprosy Control 
Activities (2006–2010)” states that “Severe reversal reactions should be treated with a 
course of steroids, usually lasting 3–6 months” (WHO, 2006). This study and that of Rao 
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should be used by policy makers as evidence that 12 weeks oral prednisolone is insufficient 
treatment and the minimum should probably be 20 weeks. 
As we move towards longer courses of corticosteroids we need to consider ways of 
identifying those individuals at risk of deteriorating as the dose of prednisolone is reduced. 
Identifying risk factors might also minimise exposing individuals unnecessarily to prolonged 
courses of prednisolone and hopefully reduce the risk of them experiencing an adverse 
event. 
 
5.3 Toll-like receptors and Type 1 reactions 
The publication of the paper by Lockwood concerning the histological diagnosis of T1R has 
an impact on future studies in this area (Lockwood et al., 2008). The histological criteria 
including HLA-DR staining should be used to provide further support of the clinical 
diagnosis of T1R following enrolment. I think there are even grounds for arguing that two 
experienced histopathologists review all the skin biopsies from patients in clinical and 
immunological studies. 
The experiments performed in this research might be further strengthened by categorizing 
participants into two groups depending on whether their skin sections are positive for 
epidermal staining of HLA-DR. 
The results of semi-quantitative scales to assess the staining need to be interpreted 
cautiously. The expression of inflammatory cytokines and cell surface receptors in the skin 
does fall during corticosteroid therapy however it is not possible to determine whether 
subsequent staining is the result of identifying further antigen expression or a delay in 
clearance.  
The expression of the markers of interest may not be proportional to the level of 
inflammation observed clinically, itself a difficult factor to quantify. Many biological 
systems rely on cascade mechanisms and once a pathway has been activated the expression 
of individual receptors or mediators may be amplified to such an extent that it bears little 
relationship to the initial trigger. 
The main role of immunohistochemical techniques is to identify a target antigen in a tissue 
to show that it is being expressed and might be playing a role in the process being studied. It 
is of interest in studies in a chronological series of specimens to determine any change in 
expression but this does not necessarily reflect changes in level of function of the molecule 
of interest. The finding of increased TLR1, TLR2 and TLR4 in the skin of BL/LL control 
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patients is worthy of further research. The current findings are contrary to the existing 
concepts of TLR expression in skin lesions of a small number of leprosy patients. 
Gene expression is a fundamental indication of the processes involved in initiating or 
propagating a pathological process. The data in this study allowed the analysis of TLR gene 
expression during treatment with corticosteroids and also MDT. The identification of a 
suitable control gene for use in this group of patients is of great use for future gene 
expression studies. The expression of hARP-P0 was not significantly affected by MDT or 
corticosteroids. 
 The ΔΔCT method is an approximation method and only provides relative expression data 
compared to the baseline sample. One could use the absolute standard curve method to 
calculate the input copy number of the gene of interest. 
SYBR Green is a fluorescent dye that binds double-stranded DNA it is less specific than 
probe based technologies which employ oligonucleotides containing fluorescent reporter and 
quencher dyes. The quencher dye acts by the principle of Fluorescence (or Förster) 
Resonance Energy Transfer to inhibit fluorescence of bound reporter dye. Once the 
polymerase replicates a template the reporter dye of the probe is unbound and its 
fluorescence no longer inhibited by the quencher dye. The increased specificity makes the 
probe based approach more accurate. 
The data on both protein and gene expression was limited because a pre-reaction sample was 
not available. Ideally experiments such as these would be designed as part of a cohort study 
in which individuals were enrolled and specimens obtained prior to the onset of the problem 
under investigation. This was done in the INFIR Cohort study and 38% (115 out of 303) had 
either a reaction or new NFI at presentation which shows how large such studies would need 
to be. 
The data obtained from the current set of experiments is interesting in that it gives further in 
vivo evidence to the role of TLR2 in the pathophysiology of T1Rs. There have not been any 
reports of in vivo experiments of TLR4 in leprosy or T1R. The gene expression data for both 
demonstrated reduced expression during treatment but also suggested lower expression of 
these genes in individuals who had a better clinical outcome. This warrants further 
investigation with a larger sample of patients preferably nested within a cohort study. A 
cohort study of this nature would need to be large. The results of these studies should be 
widely disseminated and if possible repeated in other regions of the world. 
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The leprosy non-governmental organisations which support the care of leprosy patients and 
leprosy research should be encouraged to develop infrastructure within their organisations 
(particularly dedicated leprosy hospitals) so that an open-ended cohort study can operate 
where data and samples are collected prospectively and stored appropriately with relevant 
consent obtained. As leprosy services in endemic countries continue to be integrated into 
general health services leprosy research has a lower priority and this needs to be addressed. 
The results obtained for immunostaining of TLR9 were disappointing because staining 
occurred much less frequently than with the other anti-TLR antibodies. This receptor 
warrants further investigation. Adaptations to staining techniques should be explored such as 
alternative fixatives. The role of heat-induced antigen retrieval has been explored in frozen 
sections using other antibodies (Yamashita and Okada, 2005). The experiments should also 
be performed with positive control tissue. 
The experiments provide further evidence of the activation of the innate immune system 
during T1R and other receptors such as the nucleotide-binding oligomerization domain-like 
receptors warrant investigation in this condition.  
The functional role of TLRs in the immunopathology of leprosy and leprosy reactional states 
could be further investigated in vivo using TLR agonists and antagonists (Kanzler et al., 
2007). These agents could be injected intradermally into reactional and non-reactional 
leprosy skin lesions in a manner similar to that employed by Kaplan in her experiments with 
recombinant IFN-γ (Kaplan et al., 1989). Experiments such as this with suitable controls 
might provide functional data which would help in understanding the mechanisms of T1R 
and granulomatous inflammation in leprosy.  
The improved management of T1Rs requires larger robust clinical trials to provide more 
evidence on the most appropriate treatment. These trials need to be well designed with clear 
outcome measures. An improved understanding of the mechanisms underlying T1R may 
indicate the potential usefulness of other treatments to control this damaging complication of 
leprosy. 
The work in this thesis contributes to a better understanding of T1Rs by improving our 
ability to assess the severity of T1R and provide better outcome measures for clinical 
studies. This research has added to the evidence that the outcomes following prolonged 
systemic corticosteroid therapy for T1R are not satisfactory. This is the first study to 
examine TLR expression in leprosy T1Rs and has identified and validated a control gene for 
future gene expression studies of T1R. 
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5.4 Summary of future work 
 The severity scale should be validated and MID determined in other leprosy 
endemic settings particularly India and Brazil. 
 A more concise scale might be developed for use in descriptive studies of T1R 
severity. 
 A scale should be developed and validated for ENL. 
 The study has highlighted the need to agree criteria for the prescribing of additional 
corticosteroids to individuals who experience re-reaction. These criteria should be 
evidence based and evaluated in clinical studies. 
 Further clinical trials and cohort studies of corticosteroids and other 
immunosuppressants are urgently needed. 
 Data collection on the features and outcome of T1R in established leprosy centres 
should be improved to provide good cohort data. 
 Case-control studies to identify risk factors for re-reaction should be undertaken. 
 The mechanisms underlying the pathophysiology of T1R are difficult to determine 
without good control specimens. The best control specimens are provided by the 
individual experiencing T1R. This requires tissue to be collected and stored prior to 
reaction. A cutaneous (and neural) tissue biobank would facilitate current and future 
biological research. This could be established with suitable ethical oversight but 
would require financial support. 
 Experiments should pay close attention to the MDT status of the patient and the 
cutaneous and neural involvement at the time of onset of the reaction.  
 In vivo experiments with TLR agonists and antagonists might provide useful 
functional data. 
 Optimisation of TLR9 staining and dual immunofluorescent staining for bacterial 
DNA should be undertaken. 
 Microdissection of granulomas from reactional and non-reactional lesions may 
reduce the “background noise” of whole skin specimens in PCR assays. 
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Appendix 2.1 
 
Information for prospective participants in the clinical scale study 
 
A multicentre study to critically evaluate a clinical severity score for measuring the severity of skin and nerve signs in nerve 
function impairment and type 1 reactions in leprosy. 
Dr Ajit Barkataki 
Dr Ruth Butlin 
Dr Diana Lockwood 
Dr José Nery 
Dr Peter Nicholls 
Dr Samba Sow 
Dr Stephen Walker 
 
Clinical Research Unit, 2nd Floor 
Department of Infectious and Tropical Diseases 
London School of Hygiene and Tropical Medicine 
Keppel St 
London  
UK 
WC1E 7HT 
 
Email: steve.walker@lshtm.ac.uk 
drstevewalker@hotmail.com 
 
We would like to ask for your cooperation in a study that we are conducting. The study aims to improve our ability to measure skin and nerve 
damage that can be part of leprosy. 
Leprosy is a disease affecting the skin and nerves caused by a bacterium called Mycobacterium Leprae. Leprosy can be treated and 
completely cured with antibiotics, the so-called ‘multidrug therapy’ or MDT. One of the complications of leprosy is that the nerves in the face, 
the arms and the legs are at risk of getting damaged.  
The risk of nerve damage is highest during so-called ‘reactions’, which are like special attacks the body itself launches on the bacilli. These 
reactions can occur at any time. You may have experienced one already before and the doctor has diagnosed a reaction today. At the time of 
a reaction the skin patches on your body may become red and swollen. You may also get pain in your nerves, which may be like shooting 
pain in your arms or legs. At such times, you may feel that parts of the palms of your hands or the soles of your feet loose their feeling and 
become numb. There may also be a ‘pins and needles’ sensation in your face, hands or feet. These symptoms are caused by nerve damage. 
Another sign of nerve damage may be that muscles get weak. In that case you might experience weakness in your hands, have difficulty 
walking or have problems closing your eyes. Sometimes nerve damage also occurs without a reaction. 
People with leprosy may get reactions and nerve damage but we cannot predict who will get it and who won’t. As with many diseases, the 
earlier you treat reactions and nerve damage, the more chance you have to be completely healed. Despite this two fifths of people do not 
fully recover with the standard treatment of steroid tablets.  
In order to improve the diagnosis and treatment of reactions it is important to be able to measure them as accurately as possible. 
The Clinical Scale study 
To achieve these aims, we have set up a study. It is called the Clinical Scale study. Over the years researchers in leprosy have developed a 
scale to measure reactions. We now wish to test the reliability of this scale. 
If you are diagnosed as having a reaction you will be invited to take part in this study. You will be examined in the usual way. The testing of 
your sensation and strength will be measured and recorded on the scale. Once this has been done a doctor will also examine you and decide 
without using the scale the severity of the reaction affecting you. We will then use the results to compare the results from the scale with 
doctor to see if it is reliable. 
If you take part in the study there will be no more visits to the clinic than would have been required had you not taken part. No blood or skin 
tests are required for the study. The study will mean that your clinic visit will last thirty minutes longer than it would do if you do not take part. 
The information collected as part of this study will be kept secure and is entirely confidential. The results will be analysed in an anonymous 
fashion. This means that you can not be identified from the data we collect as part of the study or from the published results. 
This study has received approval from the Ethics Committee of the London School of Hygiene and Tropical Medicine and the committees of 
the collaborating centres. 
Your decision whether to take part or not will not affect the routine leprosy treatment you will receive. We would very much like you to take 
part and help us with this study, but you will not be penalised in any way if you refuse to take part. If, at any time after deciding to take part, 
you feel unhappy about continuing with the study, you have the freedom to come out of the study and do not have to give a reason for doing 
so. This will not negatively affect your leprosy treatment. 
Thank you for taking the time to consider participating in the Clinical Scale study. 
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Appendix 2.2 
 
Clinical Scale Study  
 
Informed Consent 
 
 
You should read the statement describing the project and explain the study to the patient so that s/he 
understands what is involved. The patient may choose to take part or not.   
 
If the patient does NOT consent to take part, s/he must NOT be entered into the Clinical Scale Study. DO 
NOT fill in any more Clinical Scale Study forms. Treat the patient according to the standard procedures in 
the clinic. 
 
If the patient agrees to participate s/he must sign the statement below. This form and a copy of the 
information leaflet about the study must be stored with Clinic Notes. The form must also be signed by the 
enrolling researcher. 
 
A multicentre study to critically evaluate a clinical severity score for measuring the severity of skin 
and nerve signs in nerve function impairment and type 1 reactions in leprosy. 
 
Dr Ajit Barkataki 
Dr Ruth Butlin 
Dr Loretta Das 
Prof JA Nery 
Dr Samba Sow    
 
 
 
 
 
  
Are you willing to take part in this study? 
Yes, I have understood the purpose of the Clinical Scale study and I am willing to take part.  The 
accompanying description of the project has been read to me. I understand what will be required of me and 
what will happen to me if I take part in it.  
 
My questions concerning this study have been answered by …………………………………… 
 
I understand that at any time I may withdraw from this study without giving a 
reason and without affecting my normal care and management. 
 
I agree to take part in this study 
 
 Name:    Signature:   Date: 
 
Consent obtained and witnessed by: 
 
 
Name:    Signature:   Date: 
(Enrolling researcher) 
 
Dr Diana Lockwood 
Dr Peter Nicholls 
Dr Stephen Walker 
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Appendix 2.3 
 
Information for prospective participants in the Methylprednisolone study 
 
A Phase 2 trial to investigate the safety of early intravenous high dose methylprednisolone in acute 
neuritis and type 1 reactions (T1R) with neuritis. 
 
Dr Rachel Hawksworth 
Dr Diana Lockwood 
Dr Murdo Macdonald 
Dr Peter Nicholls 
Dr Stephen Walker 
 
Anandaban Hospital 
PO Box 151 
Kathmandu 
Nepal 
 
Clinical Research Unit 
Department of Infectious and Tropical Diseases 
London School of Hygiene and Tropical Medicine 
Keppel St 
London  
UK 
WC1E 7HT 
 
Email: steve.walker@lshtm.ac.uk 
 
We would like to ask for your cooperation in a study that we are conducting. The study has two main aims: 
1. To improve our ability to treat the nerve damage that can be part of leprosy. 
2. To improve our understanding of the factors causing that nerve damage. 
 
Leprosy is a disease affecting the skin and nerves caused by a bacteria called Mycobacterium Leprae. Leprosy can 
be treated and completely cured with antibiotics, the so-called „multidrug therapy‟ or MDT. One of the complications 
of leprosy is that the nerves in the face, the arms and the legs are at risk of getting damaged.  
 
The risk of nerve damage is highest during so-called „reactions‟, which are like special attacks the body itself 
launches on the bacteria. These reactions can occur at any time. You may have experienced one already before 
and the doctor has diagnosed a reaction today. At the time of a reaction the skin patches on your body may 
become red and swollen. You may also get pain in your nerves, which may be like shooting pain in your arms or 
legs. At such times, you may feel that parts of the palms of your hands or the soles of your feet loose their feeling 
and become numb. There may also be a „pins and needles‟ sensation in your face, hands or feet. These symptoms 
are caused by nerve damage. Another sign of nerve damage may be that muscles get weak. In that case you might 
experience weakness in your hands, have difficulty walking or have problems closing your eyes. Sometimes nerve 
damage also occurs without a reaction. 
 
People with leprosy may get reactions and nerve damage but we cannot predict who will get it and who won‟t. As 
with many diseases, the earlier you treat reactions and nerve damage, the more chance you have to be completely 
healed. Despite this two fifths of people do not fully recover with the standard treatment of steroid tablets. We 
would therefore like to try and improve the treatment of reactions and our understanding of what causes them.  
 
The Methylprednisolone study 
 
To achieve these aims, we have set up a study. It is called the Methylprednisolone study. Methylprednisolone is 
another steroid medicine which we hope will improve reactions by using it at a high dose and by giving it 
intravenously rather than in tablet form for the first three days of reaction treatment. Participants in the study will 
then take the standard steroid tablet regime. Not everyone who takes part will receive the methylprednisolone, this 
is because people are assigned to the treatment using a process of random allocation. This helps to minimise bias 
which can result in erroneous conclusions. Half of the people in the study will receive a placebo (a simple salt water 
solution – still given into the vein) instead but they will still be given the standard steroid tablet treatment for 
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reactions. This means that neither you nor your doctors will know whether you have received methylprednisolone 
or the placebo. 
 
As the methylprednisolone or the placebo has to be given into a vein you will be admitted to hospital for a period of 
approximately four to seven days. You will also be taking steroid tablets afterwards which would have happened 
normally. You will have to have some blood tests, a chest x ray and provide a stool specimen to rule out certain 
health problems which the steroids could make worse. In addition to these as part of the study looking at the 
causes of the reaction we will want to take a small amount of blood (10ml) on three occasions during the 48 
weeks which people take part in the trial.  On three occasions during the trial we would take a small piece of skin, 
to be able to study the changes under the microscope. This is called a „skin biopsy‟. Before such a biopsy is taken, 
we would make the skin numb, so that you would have as little discomfort as possible. The removal of this small 
piece of skin will leave a wound which should heal in 7- 10 days. In order to record changes in the skin during the 
study we would also like to take photographs. These would be used to monitor progress. They would also be used 
to teach health care professionals about leprosy and when the results of the study are published. If you do not 
wish to have photographs taken you may still participate in the study. 
In addition to spending at least four days in Anandaban Hospital you will have to attend the clinic on 14 occasions 
to be examined for changes in the skin and nerves and have the tests performed. This is approximately three more 
than if you did not participate in the study. All the treatment you will need as part of this study is free. 
 
Methylprednisolone is a safe drug which has been available for many years. It has been used in high doses over a 
three day period in various diseases and is well tolerated. Like all steroids it can make certain conditions such as 
high blood pressure and diabetes worse but you will be tested for these and others. It can also cause weight gain, 
acne and mood disturbances just as other steroids can. 
 
If you do experience any problems as a result of the study the doctors at Anandaban Hospital will see and treat you 
for free. 
 
The information collected as part of this study will be entirely confidential and the results will be analysed in an 
anonymous fashion. This means that you can not be identified from the data we collect as part of the study or from 
the published results. The information and specimens will be kept secure. Some analysis of the information and 
specimens will take place in Nepal but the majority will be done in London, UK. 
 
This study has received approval from the Medical Research Council of Nepal and the Ethics Committee of the 
London School of Hygiene and Tropical Medicine. 
 
Your decision whether to take part or not will not affect the routine leprosy treatment you will receive. We would 
very much like you to take part and help us with this study, but you will not be penalised in any way if you refuse 
to take part. If, at any time after deciding to take part, you feel unhappy about continuing with the study, you have 
the freedom to come out of the study and do not have to give a reason for doing so. This will not negatively affect 
your leprosy treatment. 
 
Thank you for taking the time to consider participating in the Methylprednisolone study. 
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Appendix 2.4 
MP Study – Registration 
 
Informed Consent 
 
Completion of the consent procedure by PMW 
 
You should read the Nepali statement describing the project and explain the study to the patient so that 
s/he understands what is involved. The patient may choose to take part or not.   
 
If the patient does NOT consent to take part, s/he must NOT be entered into the MP Study. DO NOT fill in 
any more MP Study forms. Treat the patient according to the standard procedures in the clinic. 
 
If the patient agrees to participate s/he must sign the statement below. This form and a copy of the Nepali 
statement must be stored with Clinic Notes. The form must also be signed by the enrolling researcher. 
 
A Phase 2 trial to investigate the safety of early intravenous high dose methylprednisolone in acute neuritis 
and type 1 reactions with neuritis. 
Dr Rachel Hawksworth    
Dr Diana Lockwood 
Dr Murdo Macdonald 
Dr Peter Nicholls 
Dr Stephen Walker 
 
 
 
 
 
 
 
 
Form 2 
Are you willing to take part in this study? 
 
Yes, I have understood the purpose of the Methylprednisolone study and I am willing to take part.  The 
accompanying description of the project has been read to me in Nepali. I understand what will be required of 
me and what will happen to me if I take part in it. I am happy to attend the regular clinic appointments. 
My questions concerning this study have been answered by …………………………………… 
I understand that at any time I may withdraw from this study without giving a 
reason and without affecting my normal care and management. 
I agree to take part in this study 
 Name:    Signature:   Date: 
 
I hereby confirm that I give consent for the photographs  to be taken of me. I understand the material has 
educational value. I consent to the material being shown to appropriate professional staff and used in 
educational publications, journals, textbooks and used in any other form or medium including all forms of 
electronic publication or distribution anywhere in the world. As a result, I understand that the material may be 
seen by the general public. All or part of the material may be used in conjunction with other photographs, 
drawings, videotape images, sound recordings or other forms of illustration. Efforts will be made to conceal my 
identity but full confidentiality is not guaranteed. 
Name:    Signature:   Date: 
 
 Consent obtained and witnessed by: 
 
 
Name:    Signature:   Date: 
(Enrolling researcher) 
Anandaban Hospital 
PO Box 151 
Kathmandu 
Nepal 
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240 
 
Appendix 2.7  
Information for non-reactional controls in the Methylprednisolone study 
 
A Phase 2 trial to investigate the safety of early intravenous high dose methylprednisolone in acute 
neuritis and type 1 reactions (T1R) with neuritis. 
 
Dr Rachel Hawksworth 
Dr Diana Lockwood 
Dr Murdo Macdonald 
Dr Peter Nicholls 
Dr Stephen Walker 
 
Anandaban Hospital 
PO Box 151 
Kathmandu 
Nepal 
 
 
Email: steve.walker@lshtm.ac.uk 
 
We would like to ask for your cooperation in a study that we are conducting. The study has two main aims: 
3. To improve our ability to treat the nerve damage that can be part of leprosy. 
4. To improve our understanding of the factors causing that nerve damage. 
 
Leprosy is a disease affecting the skin and nerves caused by a bacteria called Mycobacterium Leprae. Leprosy can 
be treated and completely cured with antibiotics, the so-called „multidrug therapy‟ or MDT. One of the complications 
of leprosy is that the nerves in the face, the arms and the legs are at risk of getting damaged.  
 
The risk of nerve damage is highest during so-called „reactions‟, which are like special attacks the body itself 
launches on the bacteria. You are not having a reaction but the changes in your skin would be useful to compare 
with people in the study who are having a reaction. 
 
Your doctor has arranged for you to have a skin biopsy to help diagnose your condition. We would like to ask for 
your permission to take a small amount (6mm diameter circle) of extra skin that we can compare with the people in 
the study. The removal of this small amount of additional skin will not affect the healing of the biopsy wound. 
 
If you do experience any problems as a result of the biopsy the doctors at Anandaban Hospital will see and treat 
you for free. 
 
The information collected as part of this study will be entirely confidential and the results will be analysed in an 
anonymous fashion. This means that you can not be identified from the data we collect as part of the study or from 
the published results. The information and specimens will be kept secure. Some analysis of the information and 
specimens will take place in Nepal but the majority will be done in London, UK. 
 
This study has received approval from the Medical Research Council of Nepal and the Ethics Committee of the 
London School of Hygiene and Tropical Medicine. 
 
Your decision whether to take part or not will not affect the routine treatment you will receive. We would very 
much like you to take part and help us with this study, but you will not be penalised in any way if you refuse to 
take part. If, at any time after deciding to take part, you feel unhappy about continuing, you have the freedom to 
stop the biopsy and do not have to give a reason for doing so. This will not negatively affect your treatment. 
 
Thank you for taking the time to consider assisting in this study.  
 
 
  
 
Clinical Research Unit 
Department of Infectious and Tropical Diseases 
London School of Hygiene and Tropical Medicine 
Keppel St 
London, WC1E 7HT United Kingdom 
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Appendix 2.8 
 
Non reactional controls for the MP Study  
 
Informed Consent 
 
Completion of the consent procedure by PMW 
 
You should read the Nepali statement describing the reason for the biopsy and explain the study to the 
patient so that s/he understands what is involved. The patient may choose to take part or not.   
If the patient does NOT consent to take part, s/he must NOT have the additional biopsy performed. Treat the 
patient according to the standard procedures in the clinic. 
If the patient agrees to participate s/he must sign the statement below. This form and a copy of the Nepali 
statement must be stored with Clinic Notes. The form must also be signed by the enrolling researcher. 
A Phase 2 trial to investigate the safety of early intravenous high dose methylprednisolone in acute neuritis 
and type 1 reactions with neuritis. 
Dr Rachel Hawksworth   
Dr Diana Lockwood 
Dr Murdo Macdonald 
Dr Peter Nicholls 
Dr Stephen Walker 
 
 
 
 
 
 
 
 
 
 
Controls 
Are you willing to take part in this study? 
 
Yes, I have understood the purpose of the additional skin biopsy and I am willing to take part.  The 
accompanying description of the project has been read to me in Nepali. I understand what will be required of 
me and what will happen to me if I take part in it.  
My questions concerning this procedure  have been answered by ………………………………… 
 
I understand that at any time I may withdraw my consent  without giving a 
reason and without affecting my normal care and management. 
 
I agree to have an additional skin biopsy 
 
 Name:    Signature:   Date: 
 
 
 
Consent obtained and witnessed by: 
 
 
Name:    Signature:   Date: 
(Enrolling researcher) 
 
Anandaban Hospital 
PO Box 151 
Kathmandu 
Nepal 
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243 
 
Appendix 2.10 
 
  
244 
 
APPENDIX 3. Protocols and data collection forms 
3.1   Clinical Severity Scale protocol 245 
3.2   Clinical Severity Scale Form A 248 
3.3   Clinical Severity Scale Form B 251 
3.4   Methylprednisolone study protocol 252 
3.5   Methylprednisolone study Form 1 262 
3.6   Methylprednisolone study Form 3 264 
3.7   Methylprednisolone study Form 4 267 
3.8   Methylprednisolone study Form 5 268 
3.9   Methylprednisolone study Form 6 269 
3.10 Methylprednisolone study Form 7 273 
3.11 Methylprednisolone study Form 8 274 
3.12 Pharmacy protocol 275 
 
  
245 
 
Appendix 3.1 
PROTOCOL 
A multicentre study to critically evaluate a clinical severity score for measuring the severity of skin and nerve signs in nerve 
function impairment and type 1 reactions in leprosy. 
Dr A and P Barkatakis 
Dr CR Butlin 
Dr Diana Lockwood 
Dr JAC Nery 
Dr Peter Nicholls 
Dr Samba Sow 
Dr Stephen Walker 
 
Clinical Research Unit, 2nd Floor 
Department of Infectious and Tropical Diseases 
London School of Hygiene and Tropical Medicine 
Keppel St 
London  
UK 
WC1E 7HT 
 
Email: steve.walker@lshtm.ac.uk 
and 
   drstevewalker@hotmail.com 
Eligibility 
Entry criteria 
 All individuals presenting with a new Type 1 (reversal) reaction who have not received corticosteroids in the 
previous three months. Those who have experienced previous type 1 reactions are eligible. 
Exclusion criteria 
 Anyone unwilling to give consent. 
Informed consent 
Consent 
 Trial carefully explained by investigator. 
 Written explanatory note available in local language and English. 
 Individual’s signature or mark obtained as proof of consent to the take part in the trial. 
 Signature of enrolling researcher. 
Confidentiality 
 A trial database is to be kept at each participating centre by the lead investigator. 
 The database should record the date an individual took part in the trial. The participant’s unique clinic number 
should be recorded (but no other identifying details) alongside the generated “study number”. This will prevent 
inadvertently enrolling someone twice. 
 The database should be kept secure (ie locked in a safe) by the lead investigator 
 The “study number” will be the two letter code for each centre followed by the numerical order in which the 
individual was enrolled starting with 1 for the first participant at any given centre. 
 
History and examination at presentation on Form A 
 Examiner A 
      Record on Form A 
 Sex 
 Age 
 Type of leprosy (Ridley-Jopling) 
 Date of onset of T1R 
 Current treatment for reaction (Record none if treatment has yet to be started) 
 MDT start date 
 Number of previous type 1 reactions (record 0 if this first) 
 Time since previous type 1 reaction (record x if this is first) 
 Duration of leprosy 
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Using Form A record examination scores 
 Skin  
 Oedema 
 Nerves 
 Fever 
Using Form A record sensory testing scores 
 The trigeminal nerve is tested on each side using cotton wool.  
 The ulnar, median and posterior tibial nerves are tested on each side. Trigeminal sensation should be tested 
with cotton wool. 
 The 2g and 10g Semmes-Weinstein monofilaments are used at 3 sites for the ulnar and median. 
 The 10g and 300g monofilament at 3 sites for the posterior tibial nerves.  
 Record on the diagram of the hands and feet the result of the monofilament testing at each test site using the 
following symbols 
Purple 2g felt -   ▲ 
Orange 10g felt - ■ 
Pink 300g felt -    # 
Orange not felt on hands, Pink not felt on feet then mark an A at the site in question. 
 Record in the table the score for each nerve, determined by the results of the monofilament testing. 
     Using Form A record voluntary motor testing scores 
 The modified MRC grading for muscle power is used to assess the facial, ulnar, radial, median and lateral popliteal 
nerves on each side. 
Testing procedure for each movement 
The patient should be seated in comfortably. 
Facial nerve - Forced eye closure 
 The patient is asked to close the eyes as tight as (s)he can. 
 The tester tries to pull down the lower lid on both sides using    his/her thumbs 
 
Median nerve -Thumb abduction  
 The wrist is held in extension and the patient is asked to lift his thumb up.               
 Pressure is applied over the lateral side of the base of the proximal phalanx. 
 
Ulnar nerve - Little finger abduction 
 Ask the patient to abduct the little finger with MCP in slight flexion. 
 Pressure is applied over the base of the proximal phalanx. 
 
Radial nerve - Wrist extention 
 Ask the patient to make a fist and lift the wrist up. 
 Pressure is applied over the dorsum of hand. 
 
Lateral popliteal nerve - Foot dorsiflexion       
 Ask the patient to lift the foot up. 
 Pressure is applied over the dorsum of foot.      
 
 The score is derived for each as follows:  
 
 
 
 
 
THE SCORES NEED TO BE RECORDED ON FORM A ALONG WITH THE MONOFILAMENT RESULTS ON 
THE HANDS AND FEET DIAGRAM 
Add the three individual scores for the total severity score 
MRC = 5 scores 0 
MRC = 4 scores 1 
MRC = 3 scores 2 
MRC < 3 scores 3 
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Examiner B 
Record on Form B 
 The presence of signs of reaction 
 The treatment including any drug dosages that would best manage the reaction 
 The severity of the reaction – not present, mild, moderate or severe 
 Mark an X on the line to indicate the degree of severity, the further to the right end of the line (10) the more severe. 
 Free text box for any additional comments. 
 
PROTOCOL FOR ASSESSMENT OF TYPE 1 REACTION CLINICAL SEVERITY SCORE 
1) An individual who is eligible should be invited to take part in the study and be given the information about the trial 
verbally and in writing. 
2) If they consent to taking part then continue with steps 3 and on.  
3) Examiner A performs the initial examination including completing the assessment form A. 
4) Examiner B who is unaware of A’s findings then undertakes the assessment he/she would normally perform for an 
individual in reaction and then complete the form B.  
5) The treatment of the reaction is recorded 
6) The two sets of data are then placed together in an envelope without being compared.  
7) In a given centre an investigator who is designated the role of Examiner A can not subsequently perform Examiner 
B’s role and vice versa. 
8) Analysis of the data will be performed by Drs Lockwood, Nicholls and Walker at LSHTM.  
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Appendix 3.2 
Clinical Severity Scale Study    
 
Type 1 reaction Severity Assessment 
 
 
Criteria               0 1 2 3 Score 
A1 Degree of inflammation of skin 
lesions  
None 
Erythema   Erythema, 
raised 
 
Ulceration  
A2 Number of raised and/or 
inflamed lesions 
0 1-5 6-10 >10  
A3 
Peripheral oedema due to 
reaction 
None Minimal 
Visible, but 
not affecting 
function 
Oedema 
affecting 
function 
 
A4 Nerve pain and/or paraesthesia None 
Pain on 
activity 
Pain at rest 
Pain 
disturbing 
sleep 
 
A5 
Nerve tenderness (worst 
affected nerve only) 
None 
Mild 
tenderness 
Withdrawal or 
wincing 
Not 
allowing 
palpation 
 
A6 
Fever (°C) <37.5 37.5-38.5 38.6-40 >40  
TOTAL A SCORE   
 
  
Study Patient Number:  
Enter Study code ie BRAS1 
___________ 
Today’s Date: 
dd-mmm-yyyy ___/_____/______ 
Assessed by: 
Name 
Is this a presentation of a new Type 1  reaction? 
 
Yes/No 
Sex:  
(M/F) 
 
Age:  
(Yrs) 
 
Classification:  
BT/BB/BL/LL/PN./I 
 
MDT Start Date: 
dd-mmm-yyyy 
___/_____/______ 
Duration of Type1 reaction symptoms on this occasion 
 
 
Current treatment for reaction symptoms (including dose) 
 
 
Number of previous Type 1 reactions 
- if first record 0 
 
Time since last Type 1 reaction ( in months) 
- if first reaction then record X 
 
Duration of leprosy: 
Number of months since first sign               
 
SCORE 
DURATION 
 
 
Weeks 
Form A 
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Study Patient Number:  
Enter Study code ie BRAS1 
___________ 
 
Sensory Assessment by Monofilament 
 
 
       Right                        Left 
Mark the symbols clearly on the diagram above: 
2g – Purple - ▲ 
10g – Orange - ■ 
Not felt at 10g - A 
Missing/unable to test – Mark =U 
 
                          Right                    Left 
 
Mark the symbols clearly on the diagram above: 
10g – Orange ■ 
300g – Pink  # 
Not felt at 300g - A 
Missing/unable to test – Mark = U 
 
 
 
Hands Purple 2g Monofilament scores Orange 10g Monofilament 
scores Score 
Nerves 0 1 2 3 4 
 
5 6 
B1 RIGHT 
Trigeminal 
Felt 
 
Not felt  
B2 LEFT 
Trigeminal 
Felt 
Not felt  
B3 
RIGHT ulnar 
All 
sites 
felt 
1 site 
not 
felt 
2 sites 
not 
felt 
3 sites 
not 
felt 
1 site 
not 
felt 
2 sites 
not 
felt 
3 sites not 
felt 
 
B4 
LEFT ulnar 
All 
sites 
felt 
1 site 
not 
felt 
2 sites 
not 
felt 
3 sites 
not 
felt 
1 site 
not 
felt 
2 sites 
not 
felt 
3 sites not 
felt 
 
B5 
RIGHT 
median 
All 
sites 
felt 
1 site 
not 
felt 
2 sites 
not 
felt 
3 sites 
not 
felt 
1 site 
not 
felt 
2 sites 
not 
felt 
3 sites not 
felt 
 
B6 
LEFT 
median 
All 
sites 
felt 
1 site 
not 
felt 
2 sites 
not 
felt 
3 sites 
not 
felt 
1 site 
not 
felt 
2 sites 
not 
felt 
3 sites not 
felt 
 
 
Feet 
Orange 10g Monofilament scores Pink 300g Monofilament 
scores 
Score 
Nerves 
0 1 2 3 4 5 6 
B7 RIGHT 
posterior 
tibial 
All 
sites 
felt 
1 site 
not 
felt 
2 sites 
not 
felt 
3 sites 
not 
felt 
1 site 
not 
felt 
2 sites 
not 
felt 
3 sites not 
felt 
 
B8 
LEFT 
posterior 
tibial 
All 
sites 
felt 
1 site 
not 
felt 
2 sites 
not 
felt 
3 sites 
not 
felt 
1 site 
not 
felt 
2 sites 
not 
felt 
3 sites not 
felt 
 
TOTAL B SCORE  
  
 R   L
O
O
O  O
O
O
O
9
  O
O
O
O
9
 O
  O
  O
  O
 9
R L
SCORE 
250 
 
Study Patient Number:  
Enter Study code ie BRAS1 
___________ 
 
Motor Assessment by VMT 
 
 
 
 Nerve             0 1 2 3 Score 
C1 RIGHT Facial  MRC =5 MRC=4 
MRC=3 
 
MRC<3 
 
C2 LEFT Facial  MRC =5 MRC=4 
MRC=3 
 
MRC<3 
 
C3 RIGHT Ulnar  MRC =5 MRC=4 
MRC=3 
 
MRC<3 
 
C4 LEFT Ulnar  MRC =5 MRC=4 
MRC=3 
 
MRC<3 
 
C5 RIGHT Median  MRC =5 MRC=4 
MRC=3 
 
MRC<3 
 
C6 LEFT Median  MRC =5 MRC=4 
MRC=3 
 
MRC<3 
 
C7 RIGHT Radial  MRC =5 MRC=4 
MRC=3 
 
MRC<3 
 
C8 LEFT Radial  MRC =5 MRC=4 
MRC=3 
 
MRC<3 
 
C9 RIGHT Lateral Popliteal MRC =5 MRC=4 
MRC=3 
 
MRC<3 
 
C10 LEFT Lateral Popliteal  MRC =5 MRC=4 
MRC=3 
 
MRC<3 
 
TOTAL C SCORE 
 
 
 
CLINICAL SEVERITY SCORE = A + B +C 
 
 
  
SCORE 
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Appendix 3.3 
 
Clinical Severity Scale Study    
 
Study Patient Number:  
Enter Study code ie BRAS1 
____/_______ 
Today’s Date: 
dd-mmm-yyyy 
___/_____/______ 
Assessed by:Name 
Is this a new presentation of a Type 1 reaction? 
 
Yes/No 
 
Features of type 1 reaction    
Signs of reaction Present (Y/N) 
Skin involvement  
Nerve involvement  
Oedema  
Fever  
Treatment of type 1 reaction    
Treatment of reaction Drug including dose 
No treatment  
Paracetamol/ Non-steroidal anti-inflammatory drug  
Corticosteroids  
Other (please indicate reason below)  
Severity of type 1 reaction   (circle answer) 
 
No evidence of reaction Mild  Moderate Severe 
Please mark an X on the line below to indicate the severity of the reaction (10 = most severe) 
 
 
0        10 
 
 
 
  
Form B 
Additional comments (if any): 
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Appendix 3.4 
PROTOCOL 
 
A Phase 2 trial to investigate the safety of early intravenous high dose methylprednisolone in acute neuritis and type 1 
reactions (T1R) with neuritis. 
 
Dr Rachel Hawksworth 
Dr Diana Lockwood 
Dr Murdo Macdonald 
Dr Peter Nicholls 
Dr Stephen Walker 
 
Anandaban Hospital 
PO Box 151 
Kathmandu 
Nepal 
 
Clinical Research Unit, 2nd Floor 
Department of Infectious and Tropical Diseases 
London School of Hygiene and Tropical Medicine 
Keppel St 
London  
UK 
WC1E 7HT 
 
Email: steve.walker@lshtm.ac.uk 
  
  drstevewalker@hotmail.com 
Form 1- Eligibility 
 
Entry criteria 
 
 Individuals with clinical evidence of T1R with new nerve function impairment (NFI). A T1R is clinically defined 
by the acute development of erythema and oedema of skin lesions, often accompanied by neuritis and oedema of the 
hands, feet and face. New NFI is defined as less than 6 months duration of reduction in sensory, motor or 
autonomic function on history or examination.  
 
OR 
 
Individuals with new nerve function impairment without inflammation of skin lesions (if skin lesions are present) 
 
 Aged 16-65  
 Weigh more than 30Kg 
 
 Exclusion criteria 
 
 Anyone unwilling to give consent. 
 T1R without  new NFI.  
 Individuals with severe active infection such as tuberculosis. 
 Individuals with severe intercurrent disease (cardiac, hepatic or renal disorder) 
 Contraindications to high dose methylprednisolone such as peptic ulcer disease, diabetes mellitus, glaucoma and 
uncontrolled hypertension or known allergy to methylprednisolone.  
 Pregnant women and those females of child bearing capacity without at least one month of adequate contraception.  
 Individuals who have taken systemic steroids or thalidomide within 3 months.  
 Anyone unwilling to be admitted or return for follow-up. 
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Form 2 – Informed consent 
Consent 
 
 Trial carefully explained by investigator. 
 Written explanatory note available in Nepali and English. 
 Individual’s signature or mark obtained as proof of consent to take part in the trial. 
 Individual’s signature or mark obtained as proof of consent to photography (participation in the trial is not 
dependent on giving consent for photography). 
 Signature of enrolling researcher. 
 Attach adhesive label stating MP Study and the patient’s STUDY number to front of clinic notes. 
 
 RECORD DATE, NAME ,CLINIC NUMBER, STUDY NUMBER AND CATEGORY (SEVERE OR MILD) 
IN THE METHYLPREDNISOLONE STUDY RECORD BOOK IN STUDY BOX 
 
Form 3 - History and examination at registration 
Pre-treatment assessment 
 
2. History 
 Date of onset of T1R 
 Symptoms of T1R  (with particular attention to date of onset) 
 Leprosy classification and date of diagnosis 
 Leprosy treatment (type, starting and completion dates) 
 Time since completion of leprosy treatment 
 Previous history of T1R 
 
3. Clinical Examination  
 Full general clinical examination including T , blood pressure      and weight 
 Leprosy clinical examination 
 
i. Nerves  - signs and symptoms of neuritis  
         (pain, tenderness, enlargement)                                                                                                                              
 
ii.  Skin      - location of lesions (body chart) 
                                    - type of lesions  
         (patches, plaques, papules, nodules) 
- signs of inflammation in lesions 
- oedema of the hands and/or feet 
 
   Form 4 - Sensory testing (ST) 
 
 Trigeminal*, ulnar, median and posterior tibial nerves on each side. The Purple 2g and Orange 10g Semmes-
Weinstein monofilaments are used at 3 sites for each nerve on the hand (median and ulnar). The Orange 10g and 
Pink 300g monofilament at 3 sites for the posterior tibial nerves. (* cotton wool is used) 
 
 Record on the diagram of the hands and feet the result of the monofilament testing at each test site using the 
following symbols 
Purple 2g felt -   ▲ 
Orange 10g felt - ■ 
Pink 300g felt -    # 
Neither monofilament felt – A  
(Orange not felt on hands, Pink not felt on feet then mark an A at the site in question). 
 
      Form 5 - Voluntary motor testing (VMT) 
i. Facial, ulnar, radial, median and lateral popliteal nerves on each side. Using the modified MRC 
grading for muscle power. 
Facial nerve - Forced eye closure (orbicularis oculi) 
Median nerve - Thumb abduction (abductor pollicis brevis) 
Ulnar nerve - Little finger abduction (abductor digiti minimi) 
Radial nerve - Wrist extension (extensor muscles) 
Lateral popliteal nerve- Foot dorsiflexion (tibialis anterior,                 peroneus longus and brevis) 
 
Testing procedure for each movement 
 
The patient should be seated comfortably. 
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Facial nerve - Forced eye closure 
 The patient is asked to close the eyes as tight as (s)he can. 
 The tester tries to pull down the lower lid on both sides using his/her thumbs 
 
Median nerve -Thumb abduction  
 The wrist is held in extension and the patient is asked to lift his thumb up.               
 Pressure is applied over the lateral side of the base of the proximal phalanx. 
 
Ulnar nerve - Little finger abduction 
 Ask the patient to abduct the little finger with MCP in slight flexion. 
 Pressure is applied over the base of the proximal phalanx. 
 
Radial nerve - Wrist extention 
 Ask the patient to make a fist and lift the wrist up. 
 Pressure is applied over the dorsum of hand. 
 
Lateral popliteal nerve - Foot dorsiflexion       
 Ask the patient to lift the foot up. 
 Pressure is applied over the dorsum of foot.      
 
 
ii. Score is derived for each nerve.   
    MRC = 5 scores 0   
   MRC = 4 scores 1 
                                                   MRC = 3 scores 2 
                                                   MRC < 3 scores 3 
 
If there is evidence of NFI for a given nerve then confirmation of the duration of the NFI should be sought from the affected 
individual to determine whether or not this is new. 
 
MRC modified grading of muscle power 
 Severity 
Scale Score 
Score  Muscle response 
5 Full range of movement (FROM) 0 
4 
FROM but less than normal 
resistance 
1 
3 FROM but no resistance 2 
2 
Partial range of movement with no 
resistance 
3 
1 
Perceptible contraction of the muscle 
not resulting in joint movement 
3 
0 Complete paralysis 3 
 
Form 7 
Pre-enrolment Screening Tests 
 Full clinical examination. 
 Full blood count, creatinine, random blood sugar. 
 Stool specimen will be examined for ova, cysts and parasites 
 Chest radiograph  
 Sputum examination for AFB 
 Pregnancy test 
Staging and initial trial investigations 
 Skin smears from four sites including both ear lobes and two active skin lesions (the elbow or thigh should be used 
if there is only one skin lesion and both should be used if there are none).Smears are unnecessary if they have been 
done within 3 months of enrolment into the trial. 
 6mm punch biopsy of skin for Ridley Jopling classification if not already done. 
 6mm punch biopsy of skin at baseline. The site of biopsy should be clearly documented on FORM 8 to enable 
subsequent biopsies to be taken from an adjacent site. Ulcerated lesions should be avoided if possible. USE 
PLAIN 1 0R 2% LIGNOCAINE DO NOT USE LIGNOCAINE WITH ADRENALINE. The skin biopsy 
should be halved lengthwise. Place half in the test vials with RNAlater, the other half should be placed in a dry 
test vial. A yellow top should be placed in the cap of the vial containing the RNAlater. These should be taken 
by the doctor to the laboratory and handed to the member of laboratory staff responsible 
 5 ml heparinised venous blood specimen for trial at baseline. 
 
Subsequent trial investigations 
 5ml heparinised venous blood specimens at days 3, 14, 28 and weeks 16 and 24. 
 6mm punch  biopsy of skin at day 4 and week 16 taken from same site as baseline specimen.  
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Admission 
 All those enrolled in the trial will be admitted for the infusions (either methylprednisolone or placebo) 
 Period of admission is 7-14 days for uncomplicated cases 
 
Allocation of treatment  
 
Preparatory actions. 
 
A Randomisation Table has been prepared specifying the order in which individuals recruited to the study are to be allocated to 
MP and P arms.  This lists allocations within two separate lists, one for individuals with severe reactions and one for 
individuals with mild reactions, as clinically assessed at intake. Each list has been generated using random numbers in an Excel 
spreadsheet and includes a sequence number.  In each, the randomisation is organised so that, among each block of four 
individuals recruited to the study, there are two allocations to the MP arm and two the P arm.  Example(not the actual 
allocations): 
 
 
Seq No. Severe Reaction List Seq No. Mild Reaction List 
1 MP 1  MP 
2 MP 2 Placebo 
3 Placebo 3 Placebo 
4 Placebo 4 MP 
    
5 Placebo 5 MP 
 Etc.  Etc. 
 
 
If this were the true allocation, the first recruited individual with a severe reaction would be allocated to the MP arm, the 
second also to the MP arm, the third to the Placebo arm etc.  
 
The randomisation allows for up to 40 allocations of individuals with severe reactions and up to 40 individuals with mild 
reactions.  The total recruitment to the study will be 60, 30 in each arm.   
 
At this stage, the relative frequency of mild and severe reactions is unknown and no target has been set for the numbers of mild 
or severe reactions. 
Allocation process 
To ensure blinding of clinicians to allocation to treatment arms, the following procedure is to be followed.   
 
Two designated individuals in the hospital pharmacy will need to provide prednisolone or placebo tablets and normal saline or 
methylprednisolone infusions during the first three days after enrolment to the trial.  We propose this be the responsibility of 
just one senior pharmacist and that this individual alone have access to information about the allocation to treatment arms.  It 
should be the responsibility of this individual to maintain a record of recruitment and to deliver appropriate tablets and 
infusions to individual patients in the hospital ward.  This will be achieved as follows: 
 
From the lists in the Randomisation Table we have prepared duplicate sets of 80 labelled and sealed envelopes containing the 
details of how each individual recruited to the study is to be allocated to Placebo and MP arms.  Each envelope and its contents 
will be linked to the Randomisation Table by the details of reaction severity and sequence number.   
 
The labelling on each envelope will identify the reaction severity group – Mild or Severe – and the sequence number within the 
group – 1 to 40.  The labelling will NOT specify the treatment allocation (See Appendix One).   
 
Inside the sealed envelopes will be placed a one page form with three sections with contents as follows (See Appendix Two): 
 
Part One describes the allocated treatment arm, either methyl prednisolone or placebo. 
Part Two provides space for the pharmacist to record the patients details. 
Part Three guides the pharmacist as to the tablets and infusion to be collected from pharmacy and delivered to the patient in the 
ward on each of the first three days from intake. 
 
The full set of sealed envelopes will be handed to the designated pharmacist at the start of the study.  They are to be kept in a 
secure place.  No other staff should have access to the envelopes.  Only the pharmacist is permitted to open the envelopes. 
 
When a clinician identifies an individual to be enrolled in the study he will request the pharmacist to register this individual and 
identify the reaction group as mild or severe.  The pharmacist will then take the following actions: 
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Register the new case on a master list held in the pharmacy, recording details of hospital card number, name and registration 
date.  This list will have the format following:  
 
Severe Reaction Group Mild Reaction Group 
Envelope 
Number 
Hospital 
Number 
Patient Name  
Date 
Envelope 
Number 
Hospital 
Number 
Patient Name  
Date 
1    1    
2    2    
3    3    
4    4    
5    5    
Etc    Etc    
 
The pharmacist will then give the sequence number/envelope number to the clinician so that this information can be recorded 
on the appropriate data form – FORM 3 and ultimately be entered onto computer (e.g. Severe Reaction Group #1).   
This is an essential action that will ensure that the treatment arm can be identified on the computerized database. 
The pharmacist will then retrieve the envelope containing the form specifying the treatment arm for the designated sequence 
number and reaction severity group.   He/she will open the envelope, note the allocation to a treatment arm and file the form in 
a temporary location designated for individuals under process (i.e. covering the first three days from admission when MP/saline 
is being given). 
He/she will then proceed to pharmacy, collect the appropriate infusion and tablets and deliver them to the patient in the hospital 
ward.  The labelling on both tablets and infusion should NOT specify contents other than “Treatments relating to MP study”. 
The pharmacist will repeat these actions on the second and third days. 
After the third day he/she will record the delivery of tablets and infusion as completed and transfer the form to a permanent file 
held in a secure place. 
Access to files or forms by any of the clinical staff during the course of the study is denied. 
Other points 
The pharmacists must be absolutely certain to assign the correct envelope number and to provide the specified tablets and 
infusion on each of the first days following registration.  This is fundamental to the success of the research. 
A second person from the pharmacy should be involved to try and ensure that no mistakes are made. 
In the event of some clinical emergency during the first 96 hours after registration of each new patient it may be necessary to 
ascertain if the patient concerned received MP.  To provide access to this information, a second set of sealed envelopes, 
identical to the first, will be provided.  These will be in the safe-keeping of the project director.  Should the need arise, he may 
open the envelope relating to the individual concerned. 
Treatment 
 All individuals will receive albendazole 400mg daily for three days at enrolment. 
 All individuals will receive famotidine 40mg daily for whilst on steroids. 
 If the stool sample demonstrates Entamoeba histolytica then Metronidazole/Diloxanide furoate  (Metrin DF) should 
be prescribed for 5 days 
 Steroid protocol: 
 
Methylprednisolone/prednisolone arm  6.15g of prednisolone    
 
Assessment 1 Day 1 IV methylprednisolone 1g (in 100ml Normal Saline)  
 + placebo tablets    
Day 2 IV methylprednisolone 1g (in 100ml Normal Saline) + placebo tablets 
Day 3 IV methylprednisolone 1g (in 100ml Normal Saline) + placebo tablets 
Assessment 2 Day 4-7  prednisolone 40mg 
Assessment 3 Week 2   prednisolone 40mg 
Assessment 4 Week 3   prednisolone 35mg 
Week 4   prednisolone 35mg 
Assessment 5 Week 5   prednisolone 30mg 
Week 6   prednisolone 30mg 
Week 7   prednisolone 25mg 
Week 8   prednisolone 25mg 
Assessment 6 Week 9   prednisolone 20mg 
Week 10 prednisolone 20mg 
Week 11 prednisolone 15mg 
Week 12 prednisolone 15mg 
Assessment 7 Week 13 prednisolone 10mg 
Week 14 prednisolone 10mg 
Week 15 prednisolone 5mg 
Week 16 prednisolone 5mg 
Assessment 8 Week 17 Off steroids 
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Prednisolone alone arm = 2.52g of prednisolone 
  
Assessment 1 Day 1 IV placebo (100ml Normal Saline) + prednisolone 40mg  
Day 2 IV placebo (100ml Normal Saline)+ prednisolone 40mg 
Day 3 IV placebo (100ml Normal Saline)+ prednisolone 40mg  
Assessment 2        Day 4-7  prednisolone 40mg 
Assessment 3 Week 2   prednisolone 40mg 
Assessment 4 Week 3   prednisolone 35mg 
Week 4   prednisolone 35mg 
Assessment 5 Week 5   prednisolone 30mg 
Week 6   prednisolone 30mg 
Week 7   prednisolone 25mg 
Week 8   prednisolone 25mg 
Assessment 6 Week 9   prednisolone 20mg 
Week 10 prednisolone 20mg 
Week 11 prednisolone 15mg 
Week 12 prednisolone 15mg 
Assessment 7 Week 13 prednisolone 10mg 
Week 14 prednisolone 10mg 
Week 15 prednisolone 5mg 
Week 16 prednisolone 5mg 
Assessment 8  Week 17 Off steroids 
 
Form 6 - Assessment during study and after finishing prednisolone 
 
 Full general clinical assessment (including temperature, blood pressure and weight) at days 4, 8, 15, 29 and 4 
weekly thereafter for 48 weeks. 
 Leprosy clinical examination at days 4, 8, 15, 29 and 4 weekly thereafter for 48 weeks. 
 Nerve function tests (ST and VMT) at days 4, 8, 15, 29 and 4 weekly thereafter for 48 weeks.  
 Severity score at days 4, 8, 15, 29 and 4 weekly thereafter for 48 weeks. 
 Any clinical examinations that are not part of the trial schedule should be recorded on a separate form – Form 8. 
Additional forms are kept in the protocol file in the study box. 
 The date, reason and outcome of any additional examinations should also be recorded. 
 RECORD THE DATE AND NUMBER OF PATIENT’S NEXT ASSESSMENT IN THE DIARY IN THE 
STUDY BOX  
 
Safety monitoring 
 Specific questioning at each visit with respect to adverse events or new symptoms possibly related to trial 
interventions. 
 Major adverse events 
i. Gastrointestinal bleeding 
ii. Nocturia, polyuria, polydipsia 
iii. Diabetes mellitus 
iv. Psychosis or other mental health problems 
v. Weight loss >5kg 
vi. Weight gain 
vii. Glaucoma 
viii. Cataract 
ix. Hypertension >160/90 on two separate readings at least one week apart 
x. Infections 
xi. Infected ulcers 
xii. Corneal ulcer  
xiii. Tuberculosis 
xiv. Night sweats 
 Minor adverse events  
i. Moon face 
ii. Acne 
iii. Cutaneous (including nails)fungal infections 
iv. Gastric pain requiring antacids 
 
Criteria for unblinding 
 In the event of a major adverse event in the first 96 hours which is felt could be related to methylprednisolone then 
the code can be broken for that individual in order to aid management of the problem. 
 
Recurrence of T1R OR neuritis 
 Criteria for using additional prednisolone 
 
i. Sustained deterioration for a period of at least two weeks of: 
a. Deterioration in nerve function 
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b. Nerve pain unresponsive to analgesics  
c. Palpable swelling of skin patches 
d. New erythematous and raised skin patches 
 
ii. Deterioration in nerve function which the study doctors believe requires immediate additional 
prednisolone 
 
 The patient must be examined by at least two of the study doctors and they should be in agreement about giving the 
patient additional prednisolone. 
 The reasons for the additional prednisolone and the date started should be recorded. 
Regimen for additional prednisolone 
 If there is recurrence of T1R with NFI (or nerve pain unresponsive to analgesics) on treatment then add extra 
prednisolone to make up a total of 40mg and then taper according to the original regimen. 
 
 If there is recurrence of T1R with skin signs but no NFI then: 
 
i. If recurrence within the first ten weeks of treatment or there is facial involvement then add extra 
prednisolone to make up a total of 40mg and then taper according to the original regimen. 
ii. If recurrence after ten weeks of treatment then add extra prednisolone to make up a total of 20mg and 
then taper according to the original regimen. 
Monitoring the trial 
 
 Drs KV Krishna Moorthy and PS S Sundar Rao who are  independent of the conception, design and management of 
the trial have agreed to act as trial monitors.  
 
Data entry 
 Each subject enrolled into the study will have an individual case booklet for recording of all clinical and laboratory 
data. 
 An anonymised Access database will be created for storage of trial data which will subsequently be analysed using 
standard statistical packages. 
 
Late Clinic Attendances 
 
If a trial subject does not attend a scheduled assessment then they will be contacted and asked to come to the next clinic for 
their assessment. It is essential that the date of the attendance is recorded. The number of the Assessment should not be 
changed regardless of how late the assessment is carried out.  
The next assessment after this should be scheduled as though the original assessment had been performed as planned.  If the 
assessment is so late that the following assessment has also been missed then the next assessment should be scheduled for 28 
days (four weeks) later. 
If a participant  has missed certain trial investigations then these should be performed when they next attend. 
Unscheduled Clinic Attendances/examinations 
 All unscheduled examinations (if an inpatient) or clinic attendances should be recorded on Form 8. 
 If the reason for the attendance/examination is related to their leprosy diagnosis then Forms 4,5 and 6 should also be 
completed. 
 All Forms should be completed in red ink or clearly marked at the top UNSCHEDULED. 
 The next assessment number should be used for unscheduled visits/examinations. 
 It should be documented if the clinician feels the attendance is related to corticosteroids. 
Non reactional controls 
Borderline patients who are undergoing a diagnostic skin biopsy should be approached to see if they would consent to a 6mm 
skin punch biopsy done at the same time as their diagnostic one. 
They should be guided through the specific information leaflet and if agreeable asked to sign the consent form for the 
additional biopsy. The aim is to recruit 10 controls. 
THESE CONTROLS MUST NOT BE IN REACTION. 
CHECKLIST ON ADMISSION 
Type 1 reaction with nerve function impairment or neuritis less than 6 months duration. 
Reaction mild or severe 
Inform pharmacy of admission and reaction type 
Physical examination 
FBC, creatinine, random glucose 
Stool sample 
Chest Xray 
Sputum 
Pregnancy test females with childbearing capacity 
Appropriate contraception in females with childbearing capacity 
Prescribe albendazole and famotidine 
Intravenous  access 
REQUIREMENTS AT EACH VISIT 
Assessment 1 (Enrolment/Admission) 
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Form 1 Eligibility 
Form 2 Consent 
Form 3 History and examination 
Form 4 Sensory testing 
Form 5 Motor testing 
Form 7 Investigations 
FBC, Creatinine, random blood glucose 
5ml of venous blood collected in heparin (for whole blood assay and Luminex) 
Stool specimen 
Chest Xray 
Sputum 
Pregnancy test 
Contraception 
Albendazole and famotidine 
Skin smears if not done in previous 3 months 
Skin biopsy for Ridley Jopling classification if not done at a previous attendance 
Skin biopsy from the edge of an area of reactional (non-ulcerated) skin  
Inform pharmacy of clinical categorisation of the reaction – severe or not severe 
Intravenous access 
Infusion duration 1 hour 
Take oral prednisolone or placebo at same time 
Assessment 2 (Day 4- the day after the last infusion) 
Form 4 
Form 5 
Form 6 
Form 7 
5ml of venous blood collected in heparin (for whole blood assay and Luminex) 
Skin biopsy from the edge of an area of reactional (non-ulcerated) skin 
Assessment 3 (Day 8 after one week of steroids) 
Form 4 
Form 5 
Form 6 
Assessment 4 (Day 15 after two weeks of steroids) 
Form 4 
Form 5 
Form 6 
Form 7 
5ml of venous blood collected in heparin (for whole blood assay and Luminex) 
**REMOVE BIOPSY SUTURES** 
Assessment 5 (Day 29 after four weeks of steroids) 
Form 4 
Form 5 
Form 6 
Form 7 
5ml of venous blood collected in heparin (for whole blood assay and Luminex) 
Assessment 6 (Day 57 after eight weeks steroids) 
Form 4 
Form 5 
Form 6 
Assessment 7 (Day 85 after 12 weeks steroids) 
Form 4 
Form 5 
Form 6 
Assessment 8 (Day 113 after 16 weeks steroids) 
Form 4 
Form 5 
Form 6 
Form 7 
5ml of venous blood collected in heparin (for whole blood assay and Luminex) 
Skin biopsy from an area of reactional (non-ulcerated) or previously reactional skin 
STOP STEROIDS IF NO DETERIORATION 
Assessment 9 (Day 141 after 20 weeks in trial) 
Form 4 
Form 5 
Form 6 
Assessment 10 (Day 169 after 24 weeks in trial) 
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Form 4 
Form 5 
Form 6 
Form 7 
5ml of venous blood collected in heparin (for whole blood assay and Luminex) 
Assessment 11 (Day 197 after 28 weeks in trial) 
Form 4 
Form 5 
Form 6 
Assessment 12 (Day 225 after 32 weeks in trial) 
Form 4 
Form 5 
Form 6 
Assessment 13 (Day 253 after 36 weeks in trial) 
Form 4 
Form 5 
Form 6 
Assessment 14 (Day 281 after 40 weeks in trial) 
Form 4 
Form 5 
Form 6 
Assessment 15 (Day 309 after 44 weeks in trial) 
Form 4 
Form 5 
Form 6 
Assessment 16 (Day 337 after 48 weeks in trial) 
Form 4 
Form 5 
Form 6 
USE OF THE TRIAL FORMS 
Form 1 
Used to screen and register patients at the first visit 
Form 2 
Consent form for the MP study. 
Form 3 
Initial history and examination for admission 
Form 4 
Monofilament sensory testing 
Form 5 
Voluntary motor testing 
Form 6 
Follow up assessments including documentation of the current prednisolone dose and any additional prednisolone that 
may be required. 
Form 7 
Recording any investigations performed at an assessment. 
Form 8  
Information that might need to be recorded but is not covered by the other trial documentation. It should also be used to 
document skin biopsy procedure and site. 
It should also be used if a participant withdraws and wishes to give a reason. 
TRIAL SPECIMENS 
Skin biopsies 
 
 6mm punch biopsies taken from the edge of an active non–ulcerated skin lesion should be bisected. 
 Half is to be placed in a cryogenic vial with a WHITE cap and snap frozen in liquid nitrogen. 
 The other half is to be placed together with RNAlater in a cryogenic vial with a YELLOW cap.  This should be 
stored overnight at 4°C to allow penetration of the RNAlater. The excess should be removed the following day and 
the specimen in the vial stored at -80°C. 
 Each vial should be clearly labelled with the participants unique study code and the date. 
 
Venous blood samples 
 
 These should be collected into heparin. 5ml is required. 
 The stimulation is undertaken and the supernatant removed and frozen at -70°C after 24 hours with the exception of 
the DAY 4 (if taken on a Saturday) sample which will be stimulated for 48 hours. 
Appendix One 
Envelope labelling 
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Methyl Prednisolone Study 
 
Reaction type: 
 
Sequence Number: 
 
Appendix Two 
Form enclosed in Envelope 
Version One – for Methylprednisolone arm 
 Severity Group:  
 Sequence Number  
 
 
Part One  
 
 
Study Arm 
 
 
Methylprednisolone  
Part Two  Patient details: 
 
Name 
Clinic Card 
Study Number 
Enrolment date: 
 
 
Part Three   
Day 1 8 placebo tablets 
1 g Methylprednisolone IV 
Completed by: 
Day 2 8 placebo tablets 
1g Methylprednisolone IV 
Completed by: 
Day 3 8 placebo tablet 
1 g Methylprednisolone IV 
Completed by: 
Version Two – for Placebo arm 
 Severity Group:  
 Sequence Number  
 
 
Part One  
 
 
Study Arm 
 
 
Placebo  
Part Two  Patient details: 
 
Name 
Clinic Card 
Study Number 
Enrolment date: 
 
 
Part Three   
Day 1 40mg prednisolone tablets 
IV Normal Saline 
Completed by: 
Day 2 40mg prednisolone tablets 
IV Normal Saline 
Completed by: 
Day 3 40mg prednisolone tablets 
IV Normal Saline 
Completed by: 
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Appendix 3.5 
 
 
 
 Ask questions 1-4 of each patient who has evidence of a Type 1 reaction and new nerve function impairment.  
Mark each answer Yes or No 
Patient Screening – Part One – Demographics 
1. Is the patient below 16 years of age? Yes No 
2. Is the patient above 65 years of age? Yes No 
3. Is the patient unable to come regularly for follow up? Yes No 
4. Is the urine sugar test positive ? Yes No 
If you answered YES to any of these questions, the patient must NOT be entered into the MP Study.  You 
should place this form with clinic records and treat the patient according to the standard procedures in 
your clinic.  
If the answer to each question was NO you should explain to the patient why special screening is needed: 
1) Need to enrol patients to participate in the MP research project  
2) Need to meet MP MO to see if qualify for inclusion in the study 
 
Take the patient to the MP Medical Officer with this Form 
MP  MO - Ask the patient the following questions. Mark each answer Yes or No 
Patient Screening – Part Two – History and Current Condition 
5. Is there any reason why the patient should not start reaction treatment? Yes No 
6. Is there evidence that the patient will be irregular in attending the clinic for regular visits? Yes No 
7. Does the patient have a history or clinical signs of non-leprosy-related  neurological 
conditions or of psychosis/abnormal behaviour? 
Yes No 
8. Does the patient have any history of mental incapacity? Yes No 
9. Does the patient have any evidence of TB? Yes No 
10. Does the patient have any history of diabetes mellitus? Yes No 
11. Does the patient have any history of alcohol abuse? Yes No 
12. Does the patient have any current illness or taking any long-term treatment? Yes No 
13. Does the patient have any severe infection? Yes No 
14. Is the patient taking steroids or has taken steroids in the last three months for any 
reason? 
Yes No 
15. Is there any other reason for exclusion? ie pregnancy Yes No 
If you answered YES to any of these questions, the patient must NOT be entered into the MP Cohort Study. 
You should: 
1. Place this form with clinic notes 
2. Explain to the patient that they do not qualify for inclusion in the MP study 
3. Treat the patient according to the standard procedures in your clinic. 
 
Only if you answered NO to all the questions 5 to 15 should  you continue with the neurological 
examination. 
 
  
Form 1 MP Study – Patient Screening and registration 
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Part Two – Personal Details, Leprosy Type and WHO Grading 
 
 
Patient’s Name: 
 
From the Register of patients enrolled in the study assign the next available number 
 
Study Patient Number:  
Enter AN1,AN2 etc 
__________ 
Enrolment Card Number:   
 
Study Enrolment Date: 
dd-mmm-yyyy 
___/_____/______ 
Enrolled by:   
 
Sex:  
(M/F) 
 
Age:  
(Yrs) 
 
Occupation 
 
Primary Secondary 
Reading and writing ability (Y/N) 
 
Reading Writing 
Classification:  
TT/BT/BB/BL/LL/PN/I 
 
Type of MDT?  
PB/MB 
 
MDT Start Date: 
dd-mmm-yyyy 
___/_____/______ 
MDT CompletionDate: 
dd-mmm-yyyy                         (X if still taking MDT) 
 
Duration of leprosy: 
Number of months since first sign              (missing value = 999) 
 
 
REACTION TYPE (CIRCLE) SKIN AND NERVES SKIN ONLY NERVES ONLY 
PREVIOUS STEROIDS  
CURRENT DOSE OF 
PREDNISOLONE 
 
DOSE WHEN SYMPTOMS 
DETERIORATED 
 
TOTAL AMOUNT OF STEROIDS IN 
LAST 12 MONTHS 
 
Longstanding Nerve Status – Record the details of the history/ examination of nerve status 6 months prior to 
enrolment date  
Record of sensory or motor impairment LONGER than six months  duration at the time of enrolment  
Nerve Facial Ulnar Median Radial Lat Pop Pos Tib Sural 
Side R L R L R L R L R L R L R L 
Sensory 
(Y/N) 
              
Motor 
(Y/N) 
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Appendix 3.6 
 
MP Study –  History and Examination  
Study Patient Number:  
Enter AN1,AN2 etc 
___________ 
Registration Card Number:  
 
 
Today’s Date: 
dd-mmm-yyyy 
___/_____/____
__ 
Assessment Number: 
(1  for newly registered cases) 
 
Assessed by: 
Name 
TOTAL REACTION SCORE A+B+C  
 
Part A – Patient History 
Ask the patient if s/he has experienced any of the following symptoms in the last 6 months: 
Patient‟s report of new symptoms (<6 months old) 
 RIGHT LEFT  
E 
L 
B
O
W 
H 
A 
N 
D 
 
K 
N 
E 
E 
F 
O 
O 
T 
E 
L 
B
O
W 
H 
A 
N 
D 
 
K 
N 
E 
E 
F 
O 
O 
T 
O 
T 
H 
E 
R 
Diminished sensation – eg unable to feel hot or 
cold, numbness (Y/N) 
         
New Weakness (Y/N) 
 
         
Paraesthesia - eg pins and needles, insects 
crawling 
  (y/n) 
         
Nerve Pain eg burning sensation, shooting pain 
(Y/)  
 
         
Patient‟s report of skin lesions and extent of disease 
How long have they had inflamed skin patches? 
 
 
Have they developed new skin patches recently? (Y/N) 
 
 
How many new skin patches have developed recently?  
Facial patch? (Y/N)  
Facial patch inflammation. (Circle) 
NONE ERYTHEMA 
ERYTHEMA 
AND RAISED 
ULCER-
ATED 
Have they had a reaction in the past? (Y/N)  
Previous reaction documented in notes? (Y/N)  
Previous reaction confirmed by patient? (Y/N)  
 
Form 3 
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Form 3 
Study Patient Number:  
Enter AN1,AN2 etc 
_____________ 
Registration Card Number:  
 
 
Visit Number: 
(1  for newly registered cases) 
 
Today’s Date: 
dd-mmm-yyyy 
___/_____/______ 
 Does the patient have any current illnesses or drug treatment (other than MDT)?  If yes, please describe 
 
 
 
 
 
Part B – Clinical Assessment 
Weight (Kg) Height (cm) Temperature (°C) 
Blood pressure 
(mmHg) 
 
 
   
Part C – Details of Reaction and Neuritis  
Reaction Severity Assessment 
Score reaction signs and symptoms in the right hand column: 
  
 
Criteria               0 1 2 3 Score 
A1 Degree of inflammation of 
skin lesions  
None 
Erythema   Erythema, 
raised 
 
Ulceration  
A2 Number of raised and/or 
inflamed lesions 
0 1-5 6-10 >10  
A3 
Peripheral oedema due to 
reaction 
None Minimal 
Visible, but 
not affecting 
function 
Oedema 
affecting 
function 
 
A4 
Nerve pain and/or 
paraesthesia 
None 
Pain on 
activity 
Pain at rest 
Pain 
disturbing 
sleep 
 
A5 
Nerve tenderness (worse 
affected nerve only) 
None 
Mild 
tenderness 
Withdrawal or 
wincing 
Not 
allowing 
palpation 
 
TOTAL A SCORE  
 
 
 
 
SCORE 
DURATION 
 
 
Weeks 
266 
 
Form 3 
 Any Mild Severe 
Reactional skin lesions?  
(Y/N) 
   
Type 1 reaction? 
(Y/N)                    
   
Neuritis – New nerve function impairment according to the monofilament or 
voluntary muscle test? (Y/N) 
  
 Neuritis – other evidence?  
(Y/N)                    
 
Mixed-signs neuritis? 
(Y/N)             
 
 
Record here any problem with the patient affecting the completion of the assessment: 
 
 
 
 
Record details of any eye problems: 
Eye Problems 
Right  Left 
 Cataract  
(Y/N) 
 
 Visual Acuity 
 
 
 
Part D– Admission 
 
Study Patient Number:  
Enter AN1,AN2 etc 
__________ 
Registration Card Number:  
 
 
Today’s Date: 
dd-mmm-yyyy 
___/_____/______ 
Randomisation Envelope Number 
 (to be done by pharmacist) 
 
 
Inform ward staff of admission of trial patient 
Inform pharmacy of admission of trial patient and category ie severe or not severe 
Request the baseline and trial investigations 
Ensure that all the necessary medication including albendazole is prescribed 
 
MP  Data Entry:   
 
Entered by:                                    
 
 
Entered on: 
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Appendix 3.7 
Form 4 
Sensory Assessment by Monofilament 
Study Patient Number:  
Enter AN1,AN2 etc 
_____________
_ 
Registration Card Number:  
 
 
Today’s Date: 
dd-mmm-yyyy 
____/____/____
___ 
Assessment Number: 
(1  for newly registered cases) 
 
Assessed by: 
Name 
Other Anandaban Tests points affected?    Y/N 
 
       Right                 Left 
      
Mark the symbols clearly on the diagram above: 
2g – Purple - ▲ 
10g – Orange - ■ 
Not felt at 10g - A 
Missing/unable to test – Mark =U 
 
                         Right           Left 
Mark the symbols clearly on the diagram above: 
2g – Purple - ▲ 
10g – Orange - ■ 
Not felt at 10g - A 
Missing/unable to test – Mark =U 
 
 
Hands 
Purple 2g Monofilament scores Orange 10g Monofilament scores 
Score 
Nerves 
0 1 2 3 
4 
 
5 6 
B1 
RIGHT Trigeminal 
Felt 
 
Not felt  
B2 
LEFT Trigeminal 
Felt Not felt  
B3 
RIGHT ulnar 
All sites 
felt 
1 site 
not felt 
2 sites 
not felt 
3 sites 
not felt 
1 site 
not felt 
2 sites 
not felt 
3 sites not felt  
B4 
LEFT ulnar 
All sites 
felt 
1 site 
not felt 
2 sites 
not felt 
3 sites 
not felt 
1 site 
not felt 
2 sites 
not felt 
3 sites not felt  
B5 
RIGHT median 
All sites 
felt 
1 site 
not felt 
2 sites 
not felt 
3 sites 
not felt 
1 site 
not felt 
2 sites 
not felt 
3 sites not felt  
B6 
LEFT median 
All sites 
felt 
1 site 
not felt 
2 sites 
not felt 
3 sites 
not felt 
1 site 
not felt 
2 sites 
not felt 
3 sites not felt  
 Feet 
Orange 10g Monofilament scores Pink 300g Monofilament scores 
Score 
Nerves 
0 1 2 3 4 5 6 
B7 
RIGHT posterior tibial 
All sites 
felt 
1 site 
not felt 
2 sites 
not felt 
3 sites 
not felt 
1 site 
not felt 
2 sites 
not felt 
3 sites not felt  
B8 
LEFT posterior tibial 
All sites 
felt 
1 site 
not felt 
2 sites 
not felt 
3 sites 
not felt 
1 site 
not felt 
2 sites 
not felt 
3 sites not felt  
TOTAL B SCORE 
 
 R   L
O
O
O  O
O
O
O
9
  O
O
O
O
9
 O
  O
  O
  O
 9
R L
SCORE 
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Appendix 3.8 
 
Motor Assessment by VMT 
Study Patient Number:  
Enter AN1,AN2 etc 
 
Registration Card Number:   
 
Today’s Date: 
dd-mmm-yyyy 
 
Assessment Number: 
(1  for newly registered cases) 
 
Assessed by: 
Name 
 
 
 
Nerve             0 1 2 3 Score 
C1 RIGHT Facial  MRC =5 MRC=4 
MRC=3 
 
MRC<3 
 
C2 LEFT Facial  MRC =5 MRC=4 
MRC=3 
 
MRC<3 
 
C3 RIGHT Ulnar  MRC =5 MRC=4 
MRC=3 
 
MRC<3 
 
C4 LEFT Ulnar  MRC =5 MRC=4 
MRC=3 
 
MRC<3 
 
C5 RIGHT Median  MRC =5 MRC=4 
MRC=3 
 
MRC<3 
 
C6 LEFT Median  MRC =5 MRC=4 
MRC=3 
 
MRC<3 
 
C7 RIGHT Radial  MRC =5 MRC=4 
MRC=3 
 
MRC<3 
 
C8 LEFT Radial  MRC =5 MRC=4 
MRC=3 
 
MRC<3 
 
C9 RIGHT Lateral Popliteal MRC =5 MRC=4 
MRC=3 
 
MRC<3 
 
C10 LEFT Lateral Popliteal  MRC =5 MRC=4 
MRC=3 
 
MRC<3 
 
TOTAL C SCORE 
 
 
Comment:  Record here any problem with the patient affecting the completion of the test: 
 
 
 
 
  
Form 5 MP Study – Regular Assessments 
SCORE 
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Appendix 3.9 
Form 6 
Study Patient Number:  
Enter AN1,AN2 etc 
___________ 
Registration Card Number:  
 
 
Today’s Date: 
dd-mmm-yyyy ___/_____/______ 
Assessment Number: 
(1  for newly registered cases) 
 
Assessed by: 
Name 
TOTAL REACTION SCORE A+B+C  
Part A – Patient History 
Ask the patient if s/he has experienced any of the following symptoms since the last assessment: 
 
Patient‟s report of new symptoms since last assessment 
 RIGHT LEFT  
E 
L 
B 
O
W 
H 
A 
N 
D 
 
K 
N 
E 
E 
F 
O 
O 
T 
E 
L 
B 
O
W 
H 
A 
N 
D 
 
K 
N 
E 
E 
F 
O 
O 
T 
O 
T 
H 
E 
R 
Diminished sensation – eg unable to feel hot or cold, 
numbness (Y/N) 
         
New Weakness (Y/N) 
 
         
Paraesthesia - eg pins and needles, insects crawling 
  (Y/N) 
         
Nerve Pain eg burning sensation, shooting pain  
(Y/N) 
         
Patient‟s report of skin lesions since last assessment 
Have the inflamed skin patches improved? 
(Y/N/STABLE) 
 
 
How many skin patches have improved since last 
visit? 
 
Have they developed new skin patches recently? (Y/N) 
 
 
How many new skin patches have developed 
recently? 
 
Do you feel your skin is worse, the same or better?  
Facial patch? (Y/N)  
Facial patch inflammation. (Circle) NONE ERYTHEMA ERYTHEMA 
AND RAISED 
ULCER-
ATED 
 
 
  
MP Study –  Follow up assessments  
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Study Patient Number:  
Enter AN1,AN2 etc 
___________ 
Registration Card Number:  
 
 
Today’s Date: 
dd-mmm-yyyy  
Has the patient had any problems with the reaction treatment or any of the following symptoms or 
conditions diagnosed since starting the reaction treatment?(Please tick) 
Moon face □ 
Acne □ 
Cutaneous (including nails) fungal infections □ 
Gastric pain requiring antacid □ 
Gastrointestinal bleeding □ 
Nocturia, polyuria, polydipsia □ 
Diabetes mellitus □ 
Psychosis or other mental health problems □ 
Weight loss >5kg □ 
Weight gain □ 
Glaucoma □ 
Cataract □ 
Hypertension BP > 160/90 on two separate readings at least one week apart □ 
Infections □ 
Infected ulcers □ 
Corneal ulcer  □ 
Tuberculosis □ 
Night sweats □ 
If yes, please describe: 
 
 
 
 
Does the patient have any current illnesses or drug treatment (other than MDT and/or prednisolone)?  If 
yes, please describe: 
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Study Patient Number:  
Enter AN1,AN2 etc ___________ 
Registration Card Number:  
 
 
Today’s Date: 
dd-mmm-yyyy 
___/_____/______ 
 
Part B – Clinical Assessment 
Weight (kg) Temperature (°C) Blood pressure (mmHg) 
   
 
Part C – Details of Reaction and Neuritis  
Reaction Severity Assessment 
Score reaction signs and symptoms in the right hand column: 
 
 
Criteria               0 1 2 3 Score 
A1 Degree of inflammation of 
skin lesions  
None 
Erythema   Erythema, 
raised 
 
Ulceration  
A2 Number of raised and/or 
inflamed lesions 
0 1-5 6-10 >10  
A3 
Peripheral oedema due to 
reaction 
None Minimal 
Visible, but 
not affecting 
function 
Oedema 
affecting 
function 
 
A4 
Nerve pain and/or 
paraesthesia 
None 
Pain on 
activity 
Pain at rest 
Pain 
disturbing 
sleep 
 
A5 
Nerve tenderness (worse 
affected nerve only) 
None 
Mild 
tenderness 
Withdrawal or 
wincing 
Not 
allowing 
palpation 
 
TOTAL A SCORE  
 
 
  
SCORE 
DURATION 
 
 
Weeks 
272 
 
Study Patient Number: Enter AN1,AN2 etc ___________ 
Registration Card Number:  
 
 
Today’s Date:dd-mmm-yyyy ___/_____/______ 
Current dose of prednisolone?  
How much prednisolone is left from the last 
assessment? 
 
Is there any evidence of recurrence or 
deterioration? (Y/N) 
 
Does the patient require additional 
prednisolone?(Y/N) 
 
 
Nature of problem Action 
Recur
rence 
(Y/N) 
 
If there is recurrence of T1R with NFI (or nerve 
pain unresponsive to analgesics) on treatment  
 
add extra prednisolone to make up a total of 
40mg and then taper according to the 
original regimen. 
 
 
 
 
 
 
If there is recurrence of T1R with skin signs but 
no NFI then 
 
 
 
 
If recurrence is within the first ten weeks of 
enrolling or the face is affected then add 
extra prednisolone to make up a total of 
40mg and taper according to the original 
regimen. 
 
 
If recurrence after ten weeks of treatment 
then add extra prednisolone to make up a 
total of 20mg and then taper according to 
the original regimen. 
 
Dose of prednisolone for the next week? 
 
Total dose of prednisolone dispensed? 
 
Record details of any eye problems: 
Eye Problems 
Right  Left 
 Cataract  
(Y/N) 
 
 Visual Acuity 
(Days 113 and 337 ONLY) 
 
 
 
Part D – Next Appointment 
Check the Appointments Diary and set a date for the next visit. 
Date of next visit: 
dd-mmm-yyyy 
___ / ___ / 
_____ 
Write the date on the patient’s Next Visit Card 
Remaining actions: 
1. Request the prescribed tests from the laboratory and send patient to physiotherapists  
2. According to the prescribed list, request biopsies and specimens. 
To complete the full assessment: 
1. Update the Study Register with the patient name, study number, Registration Card number and 
registration date 
2. Check all tasks identified on the Checklist held by the patient have been completed. 
3. Send the patient to the assigned PMW to take address details. 
 
MP Data Entry:   
 
Entered by:                                    
 
 
Entered on: 
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Appendix 3.10 
Form 7 
 
MP Study – Regular Assessments 
Results of local laboratory tests and recording of trial investigations 
Study Patient Number: Enter AN1,AN2 etc 
___________ 
Registration Card Number:  
 
 
Today’s Date:dd-mmm-yyyy 
___/___/____
__ 
Assessment Number: 
(1  for newly registered cases) 
 
Available tests: 
Code Name of test Code Name of test 
A Smear BI I Skin biopsy stored 
B Smear MI J Stool specimen 
C1 Blood Hct K Chest X-ray 
C2 Blood Hb L Sputum 
D Blood White cell count M Pregnancy test 
E Platelets N Urinalysis 
F Blood sugar O  
G Blood creatinine P  
H Serum separated and stored Q  
Use the table below to record the results of tests, using as many lines as necessary.  If a test is not listed 
above write its name in the appropriate column 
Ite
m 
Test Letter 
(from table above) 
Result: Comments/Sites: 
1         
2         
3         
4         
5         
6         
7         
8         
9         
10 
 
        
11         
12         
13         
Comment:  Record here any problem with the patient affecting the completion of the test or additional 
relevant information: 
 
 
 
 
MP Data Entry:   
 
Entered by:                                    
 
 
Entered on: 
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Appendix 3.11 
Form 8 
 
MP Study – Miscellaneous 
 
Record any information not covered by the trial forms or protocol that is felt to be relevant 
Study Patient Number:  
Enter AN1,AN2 etc 
___________ 
Registration Card Number:  
 
 
Today’s Date: 
dd-mmm-yyyy 
___/___/______ 
Assessment Number: 
(1  for newly registered cases) 
 
 
Problem 
 
 
 
Examination 
Investigations 
Treatment 
 
MP Data Entry:   
 
Entered by:                                    
 
 
Entered on: 
 
275 
 
Appendix 3.12 
METHYLPREDNISOLONE STUDY 
 
PHARMACY PROCEDURES FOR MOHAN AND RAM KUMAR 
 
 PATIENT ENROLLED IN STUDY 
 
 DOCTOR INFORMS PHARMACY – MILD OR SEVERE 
 
 IF MILD – NEXT WHITE ENVELOPE OPENED 
 IF SEVERE – NEXT BROWN ENVELOPE OPENED 
 
 INSTRUCTION SHEET IN ENVELOPE : 
 
 RECORD ON SHEET SEVERITY GROUP IE MILD OR SEVERE 
 ENVELOPE NUMBER 
 PATIENT DETAILS: NAME,CLINIC AND STUDY 
NUMBERS 
 DATE 
 
 METHYLPREDNISOLONE 1g IN 500ML NORMAL SALINE IV + PLACEBO 
TABLETS ORALLY 
OR 
 
 500ML NORMAL SALINE IV + PREDNISOLONE 40MG ORALLY 
 
 ALL PREPARATIONS  BOTH IV AND ORAL SHOULD BE LABELLED WITH THE 
PATIENT NAME, STUDY NUMBER AND DATE. 
 
 NONE OF THIS INFORMATION IS TO BE PASSED ON TO MEDICAL OR 
NURSING STAFF 
 
 SIGN EACH DAY IN THE “COMPLETED” SECTION 
 
 THIS IS FOR 3 CONSECUTIVE DAYS 
 
 THE COMPLETED INSTRUCTION SHEET SHOULD BE FILED AND KEPT 
LOCKED IN PHARMACY 
 
 AFTER THIS DOCTORS WILL PRESCRIBE ORAL PREDNISOLONE AS PER THE 
PROTOCOL AND THE USUSAL PREDNISOLONE CAN BE GIVEN 
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APPENDIX  4. Final Clinical Severity Scale 
 
4.1 Final Scale 277 
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4.1 The Final Scale 
 
 
Criteria               0 1 2 3 Score 
A1 
Degree of inflammation of skin 
lesions  
None 
Erythema   
Erythema and 
raised 
 
Ulceration 
 
A2 
Number of raised and/or inflamed 
lesions 
0 1-5 6-10 >10 
 
A3 
Peripheral oedema due to reaction 
None Minimal 
Visible, but not 
affecting 
function 
Oedema 
affecting 
function 
 
A SCORE  
 
 
 
 
HANDS Purple 2g Monofilament scores 
Orange 10g Monofilament 
scores 
Score 
Nerves 0 0.5 1 1.5 
2 
 
2.5 3 
B1 
RIGHT 
Trigeminal 
Felt 
 
Not felt  
B2 
LEFT 
Trigeminal 
Felt 
Not felt  
B3 
RIGHT ulnar 
All 
sites 
felt 
1 site 
not 
felt 
2 sites 
not 
felt 
3 sites 
not 
felt 
1 site 
not 
felt 
2 sites 
not 
felt 
3 sites not 
felt 
 
B4 
LEFT ulnar 
All 
sites 
felt 
1 site 
not 
felt 
2 sites 
not 
felt 
3 sites 
not 
felt 
1 site 
not 
felt 
2 sites 
not 
felt 
3 sites not 
felt 
 
B5 RIGHT 
median 
All 
sites 
felt 
1 site 
not 
felt 
2 sites 
not 
felt 
3 sites 
not 
felt 
1 site 
not 
felt 
2 sites 
not 
felt 
3 sites not 
felt 
 
B6 
LEFT median 
All 
sites 
felt 
1 site 
not 
felt 
2 sites 
not 
felt 
3 sites 
not 
felt 
1 site 
not 
felt 
2 sites 
not 
felt 
3 sites not 
felt 
 
 
FEET 
Orange 10g Monofilament scores 
Pink 300g Monofilament 
scores 
Score 
Nerves 
0 0.5 1 1.5 
2 
 
2.5 3 
B7 RIGHT 
posterior tibial 
All 
sites 
felt 
1 site 
not 
felt 
2 sites 
not 
felt 
3 sites 
not 
felt 
1 site 
not 
felt 
2 sites 
not 
felt 
3 sites not 
felt 
 
B8 LEFT 
posterior tibial 
All 
sites 
felt 
1 site 
not 
felt 
2 sites 
not 
felt 
3 sites 
not 
felt 
1 site 
not 
felt 
2 sites 
not 
felt 
3 sites not 
felt 
 
B SCORE  
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NERVE           0 1 2 3 Score 
C1 RIGHT Facial  
MRC =5 
MRC=4 
MRC=3 
 
MRC<3 
 
C2 LEFT Facial  
MRC =5 
MRC=4 MRC=3 
 
MRC<3 
 
C3 RIGHT Ulnar  
MRC =5 
MRC=4 MRC=3 
 
MRC<3 
 
C4 LEFT Ulnar  
MRC =5 
MRC=4 MRC=3 
 
MRC<3 
 
C5 RIGHT Median  
MRC =5 
MRC=4 MRC=3 
 
MRC<3 
 
C6 LEFT Median  
MRC =5 
MRC=4 MRC=3 
 
MRC<3 
 
C7 RIGHT Radial  
MRC =5 
MRC=4 MRC=3 
 
MRC<3 
 
C8 LEFT Radial  
MRC =5 
MRC=4 MRC=3 
 
MRC<3 
 
C9 RIGHT Lateral Popliteal 
MRC =5 
MRC=4 MRC=3 
 
MRC<3 
 
C10 LEFT Lateral Popliteal  
MRC =5 
MRC=4 MRC=3 
 
MRC<3 
 
C SCORE 
 
 
Total score Scores of A+B+C  
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Appendix 5.1 Melt Report 
Table A5.1 Thermal cycler conditions 
Cycle Cycle Point 
Hold @ 95°c, 15 min 0 secs  
Cycling (50 repeats) Step 1 @ 95°c, hold 10 secs 
 Step 2 @ 60°c, hold 15 secs 
 Step 3 @ 72°c, hold 20 secs, acquiring 
to Cycling A(FAM) 
Melt (72-95°c) , hold 45 secs on the 1st step, hold 5 
secs on next steps, Melt A(FAM) 
 
Fig A5.1 Representative Melt data for Melt A.FAM 
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No. Colour Name Peak 1 No. Colour Name Peak 1 
A1 
 
TLR4 27A 77.7 C7 
 
TLR4 30C 77.7 
A2 
 
TLR4 27A 77.5 C8 
 
TLR4 30C 77.7 
A3 
 
TLR4 27B 77.7 D1 
 
TLR4 31A 77.7 
A4 
 
TLR4 27B 77.5 D2 
 
TLR4 31A 77.7 
A5 
 
TLR4 27C 77.5 D3 
 
TLR4 31B 77.7 
A6 
 
TLR4 27C 77.7 D4 
 
TLR4 31B 77.7 
A7 
 
TLR4 28A 77.7 D5 
 
TLR4 31C 77.7 
A8 
 
TLR4 28A 77.7 D6 
 
TLR4 31C 77.7 
B1 
 
TLR4 28B 77.7 D7 
 
TLR4 32A 77.7 
B2 
 
TLR4 28B 77.7 D8 
 
TLR4 32A 77.7 
B3 
 
TLR4 28C 77.5 E1 
 
TLR4 32B 77.7 
B4 
 
TLR4 28C 77.7 E2 
 
TLR4 32B 77.7 
B5 
 
TLR4 29A 77.8 E3 
 
TLR4 NC 73.7 
B6 
 
TLR4 29A 77.8 E4 
 
TLR4 NTC 76.7 
B7 
 
TLR4 29B 77.7     
B8 
 
TLR4 29B 77.7     
C1 
 
TLR4 29C 77.7     
C2 
 
TLR4 29C 77.7     
C3 
 
TLR430A 77.7     
C4 
 
TLR4 30A 77.7     
C5 
 
TLR4 30B 77.8     
C6 
 
TLR4 30B 77.7     
Table A5.2 Representative Tm TLR4  
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Appendix 5.2 Electrophoresis of real-time PCR products 
 
 
 
 
Figure A5.2.  Representative 3% Agarose gel of PCR products. EasyLadder I (Bioline, London, 
UK). 
 
 
  
2000bp 
1000bp 
 500bp 
 250bp 
 100bp 
283 
 
Appendix 5.3 hARP-P0 and toll-like receptor efficiency testing data 
 
TLR1 
dilution Ct 
TLR1 
MEAN Ct hARP-P0 dilution Ct 
hARP-P0 
MEAN Ct 
TLR1 -hARP-P0 
(delta Ct) 
tlr1_1/ 1 28.09  hARP-P0 1/1 18.12  
 tlr1_1/ 1 27.84  hARP-P0 1/1 18.23  
 tlr1_1/ 1 28 27.97667 hARP-P0 1/1 18.18 18.17667 9.8 
tlr1_1/ 2 29.09  hARP-P0 1/2 20.05  
 tlr1_1/ 2 29.23  hARP-P0 1/2 20.12  
 tlr1_1/ 2 29.38 29.23333 hARP-P0 1/2 20.21 20.12667 9.106667 
tlr1_1/ 4 29.27  hARP-P0 1/4 20.77  
 tlr1_1/ 4 29.79  hARP-P0 1/4 20.82  
 tlr1_1/ 4 29.63 29.56333 hARP-P0 1/4 21.6 21.06333 8.5 
tlr1_1/ 8 30.72  hARP-P0 1/8 21.88  
 tlr1_1/ 8 30.79  hARP-P0 1/8 22.18  
 tlr1_1/ 8 30.44 30.65 hARP-P0 1/8 22.06 22.04 8.61 
tlr1_1/ 16 31.84  hARP-P0 1/16 23.34  
 tlr1_1/ 16 32.43  hARP-P0 1/16 23.27  
 tlr1_1/ 16 31.96 32.07667 hARP-P0 1/16 23.16 23.25667 8.82 
tlr1_1/ 32 32.62  hARP-P0 1/32 23.52  
 tlr1_1/ 32 32.7  hARP-P0 1/32 23.55  
 tlr1_1/ 32 33.38 32.9 hARP-P0 1/32 23.58 23.55 9.35 
tlr1_1/ 64 33.84  hARP-P0 1/64 24.8  
 tlr1_1/ 64 34.2  hARP-P0 1/64 24.97  
 tlr1_1/ 64 34.59 34.21 hARP-P0 1/64 24.64 24.80333 9.406667 
tlr1_1/ 128 34.9  hARP-P0 1/128 25.91  
 tlr1_1/ 128 35 34.95 hARP-P0 1/128 25.78 25.81667 9.133333 
   
hARP-P0 1/128 25.76  
  Table A5.3 Ct TLR1 and hARP-P0 
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TLR2 
dilution Ct 
TLR2 
MEAN Ct 
hARP-P0 
dilution Ct 
hARP-P0 
MEAN Ct 
TLR2 -hARP-P0 
(delta Ct) 
tlr2_1/1 30.06  hARP-P0 
1/1 
21.4  
 tlr2_1/1 30.91  hARP-P0 
1/1 
20.04  
tlr2_1/1 30.39 30.45333 hARP-P0 
1/1 
19.51 20.31667 10.13667 
tlr2_1/2 31.03  hARP-P0 
1/2 
21.09   
tlr2_1/2 32.65  hARP-P0 
1/2 
20.76   
tlr2_1/2 31.48 31.72 hARP-P0 
1/2 
20.34 20.73 10.99 
tlr2_1/4 32.4  hARP-P0 
1/4 
22.06   
tlr2_1/4 32.11  hARP-P0 
1/4 
21.51   
tlr2_1/4 33.84 32.78333 hARP-P0 
1/4 
21.14 21.57 11.21333 
tlr2_1/8 33.26  hARP-P0 
1/8 
23.01   
tlr2_1/8 33.64  hARP-P0 
1/8 
22.37   
tlr2_1/8 32.92 33.27333 hARP-P0 
1/8 
22.07 22.48333 10.79 
tlr2_1/16 34.31  hARP-P0 
1/16 
23.86   
tlr2_1/16 35.39  hARP-P0 
1/16 
23.74   
tlr2_1/16 34.46 34.72 hARP-P0 
1/16 
22.96 23.52 11.2 
tlr2_1/32 35.82  hARP-P0 
1/32 
24.99   
tlr2_1/32 34.68  hARP-P0 
1/32 
24.34   
tlr2_1/32 35.42 35.30667 hARP-P0 
1/32 
24.46 24.59667 10.71 
tlr2_1/64 37.06  hARP-P0 
1/64 
25.69   
tlr2_1/64 35.68  hARP-P0 
1/64 
25.41   
tlr2_1/64 36.82 36.52 hARP-P0 
1/64 
25.2 25.43333 11.08667 
tlr2_1/128 36.01  hARP-P0 
1/128 
26.96   
tlr2_1/128 36.46  hARP-P0 
1/128 
26.43   
tlr2_1/128  
36.235 
hARP-P0 
1/128 
26.35 26.58 9.655 
Table A5.4 Ct TLR2 and hARP-P0 
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TLR4 Ct 
TLR4 
MEAN Ct hARP-P0 Ct 
hARP-P0 
MEAN Ct 
TLR4 -hARP-P0 
(delta Ct) 
tlr4_1/ 1 33.99  hARP-P0 1/1 18.12  
 tlr4_1/ 1 34.49  hARP-P0 1/1 18.23  
 tlr4_1/ 1 34.47 34.31667 hARP-P0 1/1 18.18 18.17667 16.14 
tlr4_1/ 2 36.64  hARP-P0 1/2 20.05  
 tlr4_1/ 2 35.93  hARP-P0 1/2 20.12  
 tlr4_1/ 2 36.54 36.37 hARP-P0 1/2 20.21 20.12667 16.24333 
tlr4_1/ 4 37.58  hARP-P0 1/4 20.77  
 tlr4_1/ 4 38.1  hARP-P0 1/4 20.82  
 tlr4_1/ 4 37.37 37.68333 hARP-P0 1/4 21.6 21.06333 16.62 
tlr4_1/ 8 38.3  hARP-P0 1/8 21.88  
 tlr4_1/ 8 37.6  hARP-P0 1/8 22.18  
 tlr4_1/ 8 37.01 37.63667 hARP-P0 1/8 22.06 22.04 15.59667 
tlr4_1/ 16 39.24  hARP-P0 1/16 23.34  
 tlr4_1/ 16 39.29  hARP-P0 1/16 23.27  
 tlr4_1/ 16 38.49 39.00667 hARP-P0 1/16 23.16 23.25667 15.75 
tlr4_1/ 32 39.25  hARP-P0 1/32 23.52  
 tlr4_1/ 32 39.29  hARP-P0 1/32 23.55  
 tlr4_1/ 32 39.47 39.33667 hARP-P0 1/32 23.58 23.55 15.78667 
tlr4_1/ 64 40.91  hARP-P0 1/64 24.8  
 tlr4_1/ 64 40.24  hARP-P0 1/64 24.97  
 tlr4_1/ 64 40.77 40.64 hARP-P0 1/64 24.64 24.80333 15.83667 
tlr4_1/ 128 41.48  hARP-P0 1/128 25.91  
 tlr4_1/ 128 42.34 41.83333 hARP-P0 1/128 25.78 25.81667 16.01667 
tlr4_1/ 128 41.68 
 
hARP-P0 1/128 25.76  
  Table A5.5 Ct TLR4 and hARP-P0 
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TLR9 dilution Ct 
TLR9 
MEAN Ct 
hARP-P0 
dilution Ct 
hARP-P0 
MEAN Ct 
TLR4 -hARP-P0 
(delta Ct) 
tlr9_1/ 1 28.89  hARP-P0 
1/1 
18.12  
 tlr9_1/ 1 29.03  hARP-P0 
1/1 
18.23  
 tlr9_1/ 1 29.26 29.06 hARP-P0 
1/1 
18.18 18.17667 
10.88 
tlr9_1/ 2 30.55  hARP-P0 
1/2 
20.05  
 tlr9_1/ 2 30.68  hARP-P0 
1/2 
20.12  
 tlr9_1/ 2 30.59 30.60667 hARP-P0 
1/2 
20.21 20.12667 
10.48 
tlr9_1/ 4 31.3  hARP-P0 
1/4 
20.77  
 tlr9_1/ 4 30.91  hARP-P0 
1/4 
20.82  
   31.105 hARP-P0 
1/4 
21.6 21.06333 
10.04167 
tlr9_1/ 8 31.85  hARP-P0 
1/8 
21.88  
 tlr9_1/ 8 32.66  hARP-P0 
1/8 
22.18  
 tlr9_1/ 8 31.57 32.02667 hARP-P0 
1/8 
22.06 22.04 
9.986667 
tlr9_1/ 16 34.19  hARP-P0 
1/16 
23.34  
 tlr9_1/ 16 34.54  hARP-P0 
1/16 
23.27  
 tlr9_1/ 16 33.33 34.02 hARP-P0 
1/16 
23.16 23.25667 
10.76333 
tlr9_1/ 32 33.83  hARP-P0 
1/32 
23.52  
 tlr9_1/ 32 33.55  hARP-P0 
1/32 
23.55  
   33.69 hARP-P0 
1/32 
23.58 23.55 
10.14 
tlr9_1/ 64   hARP-P0 
1/64 
24.8  
 tlr9_1/ 64   hARP-P0 
1/64 
24.97  
 tlr9_1/ 64 36.61 36.61 hARP-P0 
1/64 
24.64 24.80333 
11.80667 
tlr9_1/ 128 35.5  hARP-P0 
1/128 
25.91  
 tlr9_1/ 128  35.5 hARP-P0 
1/128 
25.78 25.81667 
9.683333 
   
hARP-P0 
1/128 
25.76  
 Table A5.6 Ct TLR9 and hARP-P0 
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Introduction
Results
Scale adjustments
Leprosy type 1 reactions are an important 
complication of borderline leprosy. They occur 
before, during or after multi-drug therapy. They may 
affect the skin, nerves or both and are a significant 
cause of nerve function impairment. Nerve function 
impairment leads to the disability and deformity 
associated with leprosy.
Approximately 40% of individuals with nerve function 
impairment will have some residual impairment 
despite treatment with oral corticosteroids. 
Studies to optimise treatment are needed.
Participants:
•81 enrolled (79% male) 
•Mean age 39.5 (11-86)
•Bangladesh 56, Brazil 25
•64.2% experiencing 1st reaction
•56 skin and nerve involvement
•18 skin only
•7 nerve only
Adjustments to the scale were made and the 
analysis repeated.
•The maximum sensory test score possible for 
each nerve was changed to 3 rather than 6.
•The components fever, nerve pain and nerve 
tenderness were removed.
• The reliability of the scale was maintained.
• The differences between the median scores 
of each severity category became significant.
•An examiner applied the scale to an 
individual diagnosed as having a type 1 
reaction.
•The individual was then examined by an 
“expert” who categorised the reaction as mild 
or moderate or severe.
•Assessments were performed independently 
in a blinded manner.
The development and validation of a severity scale for 
leprosy type 1 reactions
SL Walker (1), PG Nicholls (2), CR Butlin (3), JAC Nery (4), HK Roy(3), E Rangel (4), AM Sales (4), DNJ Lockwood (1)
1.London School of Hygiene and Tropical Medicine, UK, 2. University of Southampton, UK, 3. DBLM Hospital, Nilphamari, Bangladesh, 4. Oswaldo Cruz Institute, Rio de Janeiro, Brazil
Median scores:
•Mild=5.0 (IQR= 11.0)
•Moderate=10.5 (IQR = 13.0)
•Severe= 18.0  (IQR = 29)
Why is a Severity Scale needed?
Methods – Step 1
A scale would:
• allow the combining of cutaneous and neurological 
signs. 
•facilitate the development of treatment guidelines.
•aid the comparability of clinical trials.
•possibly help to determine prognosis.
Methods – Step 2
•Two examiners independently applied the scale 
to patients diagnosed with type 1 reaction.
•Performed using 4 pairs of examiners on  
individuals with type 1 reaction.
Conclusions and further work
•This is the first prospective validation of a 
severity scale for leprosy type 1 reactions.
•The scale is valid, reliable and has good inter-
observer agreement.
•The impact of nerve function impairment greater 
than 6 months on severity needs to be assessed.
•Further testing of the modified scale in other 
settings is warranted.
The Severity Scale
Bland Altman plot of the difference between the scores of the 
two examiners and the mean of those scores (n=39)
Internal Consistency (Reliability)
•Cronbach’s alpha = 0.828 
•This measures how well a set of items (the 
scale components) measure a single 
construct, namely type 1 reaction severity. 
An alpha of >0.7 is considered desirable.
•Criteria that performed less well were
–Inflammation of skin lesions
–Number of skin lesions
–Nerve pain 
–Nerve tenderness
–Fever
The current scale was developed from previously 
used scales which had not been validated, following 
consultation with leprologists independent of the 
scale developers.
It is a clinical tool in which fixed criteria are 
assigned a score. The higher the total score the 
worse the reaction. It is a measure of severity and 
not a diagnostic tool.
The score for each item is  recorded on a standard 
form divided into sections to permit different staff 
members to complete the part relevant to them.
The score for each section is added together to give 
a  total.
The scale is made up of 24 items:
•Inflammation of skin lesions
•Number of raised or inflamed skin lesions
•Peripheral oedema due to reaction
•Nerve pain and/or paraesthesia
•Nerve tenderness
•Degree of fever (°C)
•Graded monofilament sensory testing using 2 and 
10g on the hands and 10 and 300g on the feet
•Voluntary Motor Testing of muscles supplied by 10 
nerves.
Range of scores possible 0-96
Leprosy type 1 reaction
Voluntary Motor 
Testing
Sensory testing using 
graded monofilaments
Using one-way ANOVA did not demonstrate a  
statistically significant difference (p= 0.053).
Lagophthalmos due to nerve damage following a type 1 
reaction. This may lead to blindness.
40.0020.000.00
Mean of the two scores for each patient
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17
th 
International Leprosy Congress, Hyderabad, India.  
 
30
th
 January – 4th February 2008 
 
ABS163ILC - The validation of a severity scale for leprosy type 1 reactions 
 
SL Walker (1), PG Nicholls (2), CR Butlin (3), JAC Nery (4), HK Roy (3), E Rangel (4), 
DNJ Lockwood (1) 
1. London School of Hygiene and Tropical Medicine, UK 
2. University of Southampton, UK 
3. DBLM Hospital, Nilphamari, Bangladesh 
4. Oswaldo Cruz Institute, Rio de Janeiro, Brazil. 
 
Type 1 reactions are an important complication of borderline leprosy and are a significant 
cause of disability. A validated tool providing a standard measure of disease severity would 
aid the development of treatment guidelines and clinical trials. 
 
Methodology: Leprosy patients in Bangladesh and Brazil diagnosed with type 1 reaction 
were assessed using a modified version of the INFIR reaction severity scale which 
incorporates signs of cutaneous involvement, neuritis and nerve function impairment. The 
scale was administered independently of an examination performed by an experienced 
leprologist who categorized the reaction as mild, moderate or severe prior to treatment.  
 
Results: 81 patients (64 male) were recruited. 70 had complete data. 18 were diagnosed as 
having a mild type 1 reaction, 40 moderate and 12 severe. The median scores for reactions 
categorized as mild were 6.0 (Range 2-30), moderate 10.5 (3-57) and severe 18.0 (4-61).  
Comparing the scores (Mann-Whitney test) of the categories of severity: mild and moderate 
and moderate and severe showed significant differences between the mild and moderate 
groups (p=0.03) and the moderate and severe groups (p=0.015) 
 
Discussion: This type 1 reaction severity scale is a valid measure of disease severity. Further 
work is underway to measure inter-observer reliability and to determine the weighting of 
individual items in the scale. The ability of the scale to reflect changes in disease severity 
over time and with treatment is also being assessed. 
 
Key words: Leprosy, type 1 reactions, severity scale 
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6
th
 South Asian Regional Congress of Dermatology, Kathmandu, Nepal. 
13
th
 -15
th
 November 2009 
Topic : A randomized double blind controlled phase 2 study of methylprednisolone in the 
management of leprosy Type 1 reactions and nerve function impairment; 
 
Authors : SL Walker, RA Hawksworth, S Dhakal, K Mahat, PG Nicholls, DN 
Lockwood; 
 
Introduction : Leprosy Type 1 reactions are a significant cause of nerve function impairment 
in people affected by leprosy. Treatment with oral prednisolone is not always effective. 
Leprosy Type 1 reactions are a significant cause of nerve function impairment in people 
affected by leprosy. Treatment with oral prednisolone is not always effective. 
The optimal dose and duration of corticosteroid therapy for Type 1 reactions needs 
clarification. High dose intravenous methylprednisolone has not been used previously in a 
trial of treatment of leprosy Type 1 reactions.  
 
Objectives : We wished to assess the safety and tolerability of high dose methylprednisolone 
in leprosy patients in Nepal. 
 
Methodology : A randomized double blind controlled trial comparing intravenous high dose 
methylprednisolone and oral prednisolone with prednisolone alone was used. 
The primary outcome measure was the frequency of adverse events in the two treatment 
arms.  
Secondary outcomes measures were:  
• change in clinical nerve function impairment and Clinical Severity Score at days 4, 29, 113 
and 337. • time to the next steroid requiring reactional episode or acute nerve function 
impairment  
• the amount of supplementary prednisolone required in addition to the reducing 16 week 
regimen. A post-hoc physician assessment of neurological outcome was determined in those 
individuals who had nerve function impairment and had completed the course of treatment.  
 
Results : Forty two individuals were recruited. Twenty-three participants experienced at 
least one adverse event, twelve (54.5%) in the prednisolone arm and 11 (55%) in the 
methylprednisolone arm. Seven individuals experienced more than one adverse event. There 
were no statistically significant differences in the number of individuals experiencing a 
given adverse event between the two groups of the study. Two individuals (one from each 
arm of the study) experienced a major adverse event. The risk ratio of having an adverse 
event (of any type; major or minor) given that the participant received methylprednisolone 
was 1.0083 (95% CI: 0.5817 to 1.7480; p=0.9764) compared to prednisolone. The physician 
assessment of neurological outcome demonstrated that 7 (20.6%) individuals who had nerve 
damage at baseline (of less than six months duration) recovered. Seventeen individuals of 34 
(50%) had an improvement in their nerve function. However nine participants (26.5%) had 
nerve function that was unchanged and one individual’s nerve function had deteriorated. 
The clinical outcome of patients in the two arms of this study was not significantly different 
in terms of the validated clinical severity scale or a global assessment of neurological 
examination. The methylprednisolone treated group had significantly less deterioration in 
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sensory function during the 16 weeks of corticosteroid therapy but this was not maintained 
to the end of the 48 week follow up period.; 
 
Conclusion : Methylprednisolone appears to no more likely to cause adverse events than 
prednisolone. The study highlighted that corticosteroid treatment for Type 1 reactions and 
NFI is sub-optimal even when given in large doses for 16 weeks. ; 
 
Keywords : leprosy reactions corticosteroids; 
 
Category of Presentation: Free Paper 
Topic : In leprosy Type 1 reactions changes in severity score are significantly different in 
treated patients who recover or improve compared to those who do not. 
 
Authors : SL Walker, RA Hawksworth, S Dhakal, K Mahat, PG Nicholls, DN 
Lockwood; 
Introduction : Leprosy Type 1 reactions are a significant cause of nerve function impairment 
in people affected by leprosy. A severity scale for leprosy Type 1 reactions was developed 
and validated. It can discriminate between mild, moderate and severe disease. It also has 
good inter-observer reliability.; 
 
Objectives : We wished to assess the ability of a validated severity scale for leprosy Type 1 
reactions to differentiate the level of improvement following corticosteroid treatment of 
Nepali patients with Type 1 reactions. 
 
Methodology : A randomized double blind controlled trial comparing intravenous high dose 
methylprednisolone and oral prednisolone with prednisolone alone was used. Patients were 
assessed over 48 weeks on 16 occasions. The clinical severity scale was applied at each 
assessment and a severity score calculated. 
A post-hoc physician assessment of neurological outcome was determined in those 
individuals who had nerve function impairment and had completed the course of treatment.  
 
Results : Forty two individuals were recruited. Individuals were grouped according to their 
status with respect to the physician assessment of neurological outcome.  
Individuals were grouped into two categories improved and recovered or unchanged and 
worse.  
The median change in nerve score between the baseline and the final recorded assessments 
were significantly different (Mann Whitney p=0.003).  
 
Conclusion : These results lend further weight to the validity of the severity scale for leprosy 
Type 1 reactions and support its use in future clinical studies in which improvement in 
clinical status needs to be quantified. 
 
Keywords : leprosy reactions measurement scale; 
 
Category of Presentation: Free Paper 
